GPCR/G Protein

G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na^+/H^+ exchanger in the plasma membrane, and the lowering of intracellular Ca^{2+} levels.
Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system.
A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs.

References:

[1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
[2] Tuteja N. Plant Signal Behav. 2009 Oct;4(10):942-7.
[3] Williams C, et al. Methods Mol Biol. 2009;552:39-50.
[4] Schiöth HB, et al. Gen Comp Endocrinol. 2005 May 15;142(1-2):94-101.



Target List in GPCR/G Protein

Target List in GPCR/G Protein

5-HT Receptor

Serotonin Receptor;5-hydroxytryptamine Receptor



5-HT receptors (Serotonin receptors) are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. Type: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7. They mediate both excitatory and inhibitory neurotransmission. The serotonin receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand. The serotonin receptors modulate the release of many neurotransmitters, as well as many hormones. The serotonin receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics,antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.

(4E)-SUN9221

Cat. No.: HY-U00367

Bioactivity: (4E)-SUN9221 is a potent antagonist of **α1-adrenergic receptor** and **5-HT2 receptor**, with antihypertensive and anti-platelet aggregation activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



(R,R)-Palonosetron Hydrochloride

Cat. No.: HY-A0021C

Bioactivity: (R,R)-Palonosetron Hydrochloride is the active enantiomer of Palonosetron.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg



(Z)-Thiothixene

Cat. No.: HY-108324

Bioactivity: (Z)-Thiothixene is an antagonist of **serotonergic receptor** extracted from patent US 20150141345 A1.

Purity: 99.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



5-HT1A modulator 1

Cat. No.: HY-100290

Bioactivity: 5-HT1A modulator 1 displays very high affinities for the **$5HT_{1A}$**, **adrenergic α_1** and **dopamine D_2 receptor** with **IC_{50}**s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



5-HT2 antagonist 1

Cat. No.: HY-U00365

Bioactivity: 5-HT2 antagonist 1 is a potent antagonist of **5-HT2 receptor**, with weak **α1 adrenoceptor** blocking activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



5-HT2A antagonist 1

Cat. No.: HY-U00286

Bioactivity: 5-HT2A antagonist 1 is a **5-HT2A** antagonist extracted from patent US5728835A and JP 1007727. 5-HT2A antagonist 1 may be useful in treatment of gastrointestinal disorders circulatory disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



5-HT3 antagonist 1

Cat. No.: HY-U00368

Bioactivity: 5-HT3 antagonist 1 is a potent and selective antagonist of **serotonin 3 (5-HT3) receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



5-HT3 antagonist 2

Cat. No.: HY-U00408

Bioactivity: 5-HT3 antagonist 2 is a **5-HT3** receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



5-HT3-In-1

Cat. No.: HY-U00413

Bioactivity: 5-HT3-In-1 is extracted from patent EP0748807A1, compound example 8. It shows **5-HT3** inhibition activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



5-HT4 antagonist 1

Cat. No.: HY-100170

Bioactivity: 5-HT4 antagonist 1 is a **$5\text{-}HT_4$ receptor** antagonist with a **pK_i** of 9.6.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



5-HT6/7 antagonist 1

Cat. No.: HY-101622

Bioactivity: 5-HT6/7 antagonist 1 is a multifunctional ligand that antagonizes **5-HT6/7/2A** and **D2** receptors, without interacting with M1 receptors and hERG channels.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



5-HT7 agonist 1

Cat. No.: HY-109527

Bioactivity: 5-HT7 agonist 1 is a selective **5-HT7 receptor** agonist, with an **IC_{50}** of 222.93 nM, can be used for the 5-HT7 receptor related disease, such as CNS disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



5HT6-ligand-1

Cat. No.: HY-U00126

Bioactivity: 5HT6-ligand-1 is a potent **5-HT6** receptor ligand with a **K_i** of 1.43 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



8-OH-DPAT

(8-Hydroxy-DPAT)

Cat. No.: HY-112061

Bioactivity: 8-OH-DPAT is a potent and selective **5-HT** agonist, with a **pIC_{50}** of 8.19 for 5-HT1A and a **K_i** of 466 nM for 5-HT7; 8-OH-DPAT weakly binds to 5-HT1B (pIC_{50}, 5.42), 5-HT (pIC_{50} <5).

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Abaperidone

Cat. No.: HY-101619

Bioactivity: Abaperidone is a potent antagonist of **5-HT_{2A} receptor** and **dopamine D_2 receptor** with **IC_{50}**s of 6.2 and 17 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Adoprazine

(SLV313)

Cat. No.: HY-14782

Bioactivity: Adoprazine, a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.

Purity: 98.13%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Agomelatine

(S-20098)

Cat. No.: HY-17038

Bioactivity: Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2c); 6.6 (pKi, 5-HT2b) Target: 5-HT2C Receptor; 5-HT2B receptor It is classified as a norepinephrine-dopamine...

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Agomelatine hydrochloride

(S-20098 hydrochloride)

Cat. No.: HY-17038A

Bioactivity: Agomelatine hydrochloride is a antidepressant, which is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor.

Purity: 99.49%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Agomelatine L(+)-Tartaric acid

(S-20098 L(+)-Tartaric acid)

Cat. No.: HY-17038B

Bioactivity: Agomelatine (L(+)-Tartaric acid) is a antidepressant, which is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor.

Purity: >98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Alniditan

(Alnitidan)

Cat. No.: HY-101698

Bioactivity: Alniditan is a potent **5-$HT_{1B/1D}$ receptors** agonist, with **IC_{50}** of 1.7 and 1.3 nM in HEK293 cells, and **pK_i** value of 8.96 and 9.40 for 5-$HT_{1B/1D}$ receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Alosetron

(GR 68755; GR 68755X) Cat. No.: HY-70050A

Bioactivity: Alosetron (GR 68755) is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome. IC50 Value: Target: 5-HT Receptor Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT3 antagonist...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Alosetron ((Z)-2-butenedioate) (GR 68755

((Z)-2-butenedioate); GR 68755X ((Z)-2-butenedioate)) Cat. No.: HY-70050B

Bioactivity: Alosetron (Z)-2-butenedioate (GR 68755 (Z)-2-butenedioate) is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome. IC50 Value: N/A Target: 5-HT Receptor Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Alosetron (Hydrochloride(1:X)) (GR 68755

(Hydrochloride(1:X)); GR 68755X (Hydrochloride(1:X))) Cat. No.: HY-70050

Bioactivity: Alosetron Hydrochloride(1:X) (GR 68755 Hydrochloride(1:X)) is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome. IC50 Value: N/A Target: 5-HT3 Receptor Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Alosetron D3 Hydrochloride

(GR-68755C D3) Cat. No.: HY-70050CS

Bioactivity: Alosetron D3 Hydrochloride (GR-68755C D3) is deuterium labeled Alosetron, which is a serotonin 5HT3-receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Alosetron Hydrochloride (GR 68755C; GR 68755 (Hydrochloride);

GR 68755X (Hydrochloride)) Cat. No.: HY-70050C

Bioactivity: Alosetron Hydrochloride (GR 68755 Hydrochloride) is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome. IC50 Value: Target: 5-HT Receptor Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract....

Purity: 99.72%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Alprenolol

((RS)-Alprenolol; dl-Alprenolol) Cat. No.: HY-B1517

Bioactivity: Alprenolol is a non-selective beta blocker as well as 5-HT1A receptor antagonist.

Purity: 99.87%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Alprenolol hydrochloride ((RS)-Alprenolol hydrochloride;

dl-Alprenolol hydrochloride) Cat. No.: HY-B1517A

Bioactivity: Alprenolol (hydrochloride) is a non-selective beta blocker as well as 5-HT1A receptor antagonist.

Purity: 98.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Alverine citrate

(NSC 35459) Cat. No.: HY-B0500

Bioactivity: Alverine citrate is a **5-HT$_{1A}$** receptor antagonist, with an **IC$_{50}$** of 101 nM.

Purity: 98.71%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g



AM9405

Cat. No.: HY-112707

Bioactivity: AM9405 is a novel peripherally active **cannabinoid type 1 (CB1)** and **serotonin type 3 receptor** agonist. AM9405 inhibits twitch contraction of the ileum and the colon with **IC$_{50}$**s of 45.71 and 0.076 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Ansofaxine hydrochloride

(LY03005; LPM570065) Cat. No.: HY-U00096

Bioactivity: Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits **serotonin**, **dopamine** and **norepinephrine** reuptake with **IC$_{50}$** values of 723, 491 and 763 nM, respectively.

Purity: >98%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg



AP521

Cat. No.: HY-100166

Bioactivity: AP521 is an agonist of human **5-HT$_{1A}$ receptor** with an **IC$_{50}$** of 94 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



AR-A 2

(AR-A 000002)

Cat. No.: HY-107018

Bioactivity: AR-A 2 is a selective **5-HT$_{1B}$ receptor** antagonist, with high affinity to guinea pig cortex **5HT$_{1B/1D}$** and recombinant guinea pig **5-HT$_{1B}$ receptors** (**K$_i$**=0.24 and 0.47 nM) and with 10-fold lower affinity to guinea pig **5-HT$_{1D}$ receptor** (**K$_i$**

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Aripiprazole

(OPC-14597)

Cat. No.: HY-14546

Bioactivity: Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg, 200 mg, 500 mg, 1 g



Aripiprazole D8

(OPC-14597 D8)

Cat. No.: HY-14546S

Bioactivity: Aripiprazole D8 (OPC-14597 D8) is the deuterium labeled Aripiprazole, which is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Asenapine

(Org 5222)

Cat. No.: HY-10121

Bioactivity: Asenapine(Org 5222) inhibits adrenergic receptor (α1, α2A, α2B, α2C) with Ki of 0.25-1.2 nM and also inhibits 5-HT receptor (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) with Ki of 0.03-4.0 nM. IC50 Value: 0.25-1.2 nM(Ki for adrenergic receptor); 0.03-4.0 nM(Ki for 5-HT receptor) Target: 5-HT Receptor;...

Purity: >98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



Asenapine hydrochloride

Cat. No.: HY-16567

Bioactivity: Asenapine maleate, an antipsychotic, is a **5-HT** (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and **Dopamine (D$_2$, D$_3$, D$_4$)** receptor antagonist with **K$_i$** values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively.

Purity: 99.39%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



Asenapine maleate

(Org 5222 maleate)

Cat. No.: HY-11100

Bioactivity: Asenapine maleate is a **5-HT** (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and **D2** antagonist with **K$_i$** values of 0.03-4.0 nM, 1.3nM, respectively, and an antipsychotic.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg



AVN-492

Cat. No.: HY-101924

Bioactivity: AVN-492 is a very specific and highly-selective antagonist with picomolar affinity to **5-HT6R** (**K$_i$**=91 pM).

Purity: 99.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Azasetron hydrochloride

(Y-25130 hydrochloride)

Cat. No.: HY-B0068

Bioactivity: Azasetron HCl is a selective 5-HT3 receptor antagonist with IC50 of 0.33 nM used in the management of nausea and vomiting induced by cancer chemotherapy.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
10 mg, 50 mg, 100 mg, 200 mg



Befiradol

(NLX-112; F13640)

Cat. No.: HY-14785

Bioactivity: Befiradol (NLX-112) is a selective **5-HT1A** receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Befiradol hydrochloride

(NLX-112 (hydrochloride); F 13640 (hydrochloride)) Cat. No.: HY-14785A

Bioactivity: Befiradol hydrochloride (NLX-112 hydrochloride) is a selective **5-HT$_{1A}$** receptor agonist.

Purity: 99.22%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Bemesetron

(MDL 72222) Cat. No.: HY-B1541

Bioactivity: Bemesetron (MDL 72222) is a selective **5-HT$_3$ receptor** antagonist with an **IC$_{50}$** of 0.33 nM [1]. Neuroprotective effect [2].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg



Blonanserin

(AD-5423) Cat. No.: HY-13575

Bioactivity: Blonanserin(AD-5423) is a D2/5-HT2 receptor antagonist, atypical antipsychotic. Target: D2 receptor; 5-HT2 receptor Blonanserin(AD-5423) is a relatively new atypical antipsychotic for the treatment of schizophrenia. Blonanserin belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and...

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 25 mg, 100 mg



Brexpiprazole

(OPC-34712) Cat. No.: HY-15780

Bioactivity: Brexpiprazole is a partial agonist of human **5-HT1A** and **dopamine receptor** with **K$_i$**s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a **5-HT2A** receptor antagonist with a **K$_i$** of 0.47 nM.

Purity: 99.38%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

BRL 54443

Cat. No.: HY-13221

Bioactivity: BRL 54443 is a potent 5-HT1E/1F receptor agonist (pKi values are 8.7 and 8.9 respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors.

Purity: 98.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



BRL-15572 dihydrochloride

(BRL-15572) Cat. No.: HY-13200

Bioactivity: BRL-15572 2Hcl is a 5-HT1D receptor antagonist with pKi of 7.9, also shows a considerable affinity at 5-HT1A and 5-HT2B receptors, exhibiting 60-fold selectivity over 5-HT1B receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



Bromperidol

(R-11333) Cat. No.: HY-B0901

Bioactivity: Bromperidol is a butyrophenone derivative, is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia.

Purity: 96.36%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
50 mg, 100 mg



Buspirone hydrochloride

Cat. No.: HY-B1115

Bioactivity: Buspirone hydrochloride is an anxiolytic psychotropic drug, is used to treat generalized anxiety disorder (GAD).

Purity: 99.64%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg



Cariprazine

(RGH-188) Cat. No.: HY-14763

Bioactivity: Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the **D$_3$** (**K$_i$**=0.085 nM) and **D$_2$** (**K$_i$**=0.49 nM) receptors, and moderate affinity for the **5-HT$_{1A}$** receptor (**K$_i$**=2.6 nM).

Purity: 99.35%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Cariprazine hydrochloride

(RGH188 hydrochloride) Cat. No.: HY-14763A

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the **D$_3$** (**K$_i$**=0.085 nM) and **D$_2$** (**K$_i$**=0.49 nM) receptors, and moderate affinity for the **5-HT$_{1A}$** receptor (**K$_i$**=2.6 nM).

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Chlorpromazine D6 hydrochloride

Cat. No.: HY-B0407AS

Bioactivity: Chlorpromazine D6 hydrochloride is the deuterium labeled Chlorpromazine. Chlorpromazine is an inhibitor of dopamine receptor, 5-HT receptor, potassium channel, sodium channel.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



Chlorpromazine hydrochloride

Cat. No.: HY-B0407A

Bioactivity: Chlorpromazine Hydrochloride is an antagonist of the **dopamine D2**, **5HT2A**, **potassium channel** and **sodium channel**. Chlorpromazine binds with D2 and 5HT2A with K_is of 363 nM and 8.3 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 1 g, 5 g



Cisapride

(R 51619; (±)-Cisaprid)

Cat. No.: HY-14149

Bioactivity: Cisapride(R 51619) is a nonselective 5-HT4 receptor agonist, it is also a potent hERG potassium channel inhibitor. IC50 Value: 0.14 μM(EC50 for 5-HT4 receptor) [1]; 9.8 μM (Kv4.3) [2] Target: 5-HT4 Receptor in vitro: Cisapride showed higher inhibitory effects on a hERG current, as indicated by its IC50...

Purity: 99.72%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg



Clocapramine

(Clocarpramine; 3-Chlorocarpipramine)

Cat. No.: HY-B2073

Bioactivity: Clocapramine is an antagonist of the **D_2**, **5-HT_{2A} receptors**.

Purity: >98%
Clinical Data: Launched
Size: 1 mg



Clocapramine hydrochloride hydrate

(3-Chlorocarpipramine hydrochloride hydrate)

Cat. No.: HY-B2073A

Bioactivity: Clocapramine hydrochloride hydrate is an antagonist of the **D_2** and **5-HT_{2A} receptors**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Clozapine N-oxide

Cat. No.: HY-17366

Bioactivity: Clozapine N-oxide (CNO) is a major metabolite of the anti-psychotic drug clozapine. Clozapine N-oxide is a agonist for the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (**DREADD**) system.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CP-809101

Cat. No.: HY-15543

Bioactivity: CP-809101 is a potent and selective 5-HT2C receptor agonist with pEC50 of 9.96/7.19/6.81 for human 5-HT2C/5-HT2B/5-HT2A receptors respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



CP-809101 hydrochloride

Cat. No.: HY-15543A

Bioactivity: CP-809101 Hcl is a potent and selective 5-HT2C receptor agonist with pEC50 of 9.96/7.19/6.81 for human 5-HT2C/5-HT2B/5-HT2A receptors respectively.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 50 mg



Cyclobenzaprine hydrochloride

(MK130 hydrochloride)

Cat. No.: HY-B0740

Bioactivity: Cyclobenzaprine Hcl is a skeletal muscle relaxant and a central nervous system (CNS) depressant.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Cyproheptadine hydrochloride

Cat. No.: HY-B0366A

Bioactivity: Cyproheptadine is a histamine receptor antagonist for 5-HT2 receptor with IC50 of 0.6 nM.

Purity: 98.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g



Cyproheptadine hydrochloride sesquihydrate

Cat. No.: HY-B1165

Bioactivity: Cyproheptadine hydrochloride sesquihydrate is an antihistamine and is an antagonist of serotonin and histamine2.

Purity: 99.20%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Deramciclane

(EGIS-3886)

Cat. No.: HY-101630

Bioactivity: Deramciclane has a high affinity for **5-HT$_{2A}$** and **5-HT$_{2C}$** receptors; it acts as an antagonist at both receptor subtypes and has inverse agonist properties at the 5-HT $_{2C}$ receptors without direct stimulatory agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Desipramine hydrochloride

Cat. No.: HY-B1272

Bioactivity: Desipramine hydrochloride is an inhibitor of **norepinephrine transporter** (**NET**), **5-HT transporter** (**SERT**) and **dopamine transporter** (**DAT**) with **K$_i$**s of 4, 61 and 78,720 nM, respectively.

Purity: 99.68%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Dihydroergotamine mesylate

Cat. No.: HY-B0670A

Bioactivity: Dihydroergotamine mesylate is an ergot alkaloid used to treat migraines.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Dolasetron

(MDL-73147)

Cat. No.: HY-B0750

Bioactivity: Dolasetron(MDL-73147) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Dolasetron Mesylate

(MDL-73147EF)

Cat. No.: HY-B0750A

Bioactivity: Dolasetron Mesylate (MDL-73147EF) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Dolasetron Mesylate hydrate

(MDL-73147EF (hydrate))

Cat. No.: HY-B0750B

Bioactivity: Dolasetron(MDL-73147) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg



Eletriptan hydrobromide

(Eletriptan HBr)

Cat. No.: HY-A0010

Bioactivity: Eletriptan HBr is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively. IC50 value: 0.82 nM/3.14 nM (5-HT1B/5-HT1D, Ki) [1] Target: 5-HT1B/5-HT1D in vitro: [3H]Eletriptan has a total number of binding sites (Bmax) of 2478 fmol/mg and 1576 fmol/mg for...

Purity: 95.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Eltoprazine

(DU 28853)

Cat. No.: HY-16687

Bioactivity: Eltoprazine(DU28853) is a serenic or antiaggressive agent which as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.

Purity: 95.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Eltoprazine hydrochloride

(DU 28853 hydrochloride)

Cat. No.: HY-16687A

Bioactivity: Eltoprazine(DU28853) is a serenic or antiaggressive agent which as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.

Purity: 99.35%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Eplivanserin

(SR-46349) Cat. No.: HY-10792

Bioactivity: Eplivanserin is a potent, selective and orally available **5-HT$_2$ receptor** antagonist, with an **IC$_{50}$** of 5.8 nM in rat cortical membrane, and a **K$_d$** of 1.14 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Eplivanserin mixture

(SR-46349 (mixture)) Cat. No.: HY-10792A

Bioactivity: Eplivanserin mixture is a selective **serotonin reuptake** inhibitor and a **5-HT$_{2A}$ receptor** antagonist, extracted from patent WO 2005/002578 A1 [1].

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Eptapirone

(F 11440) Cat. No.: HY-19946

Bioactivity: Eptapirone (F11440) is a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Eucalyptol

(1,8-Cineole) Cat. No.: HY-N0066

Bioactivity: Eucalyptol is an inhibitor of **5-HT$_3$ receptor** , **potassium channel**, **TNF-α** and **IL-1β**.

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 50 mg



F-15599

Cat. No.: HY-19863

Bioactivity: F-15599 is a highly selective G-protein biased **5-HT1A receptor** agonist, with **K$_i$** of 3.4 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Ferulic acid sodium

(Sodium ferulate) Cat. No.: HY-N0060A

Bioactivity: Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic compound present in several plants with claimed beneficial effects in prevention and treatment of disorders linked to oxidative stress and inflammation. IC50 value: Target: 5-HT Receptor In vitro: In the present study we have showed that...

Purity: 99.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g, 5 g



FK1052 hydrochloride

Cat. No.: HY-101638

Bioactivity: FK1052 hydrochloride is a potent **5-HT3** and **5-HT4** receptor dual antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Flibanserin

(BIMT-17; BIMT-17BS) Cat. No.: HY-A0095

Bioactivity: Flibanserin is a novel multifunctional serotonin agonist and antagonist (MSAA) that improves sexual functioning in premenopausal women who suffer from reduced sexual interest and desire.

Purity: 99.31%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Flopropione

Cat. No.: HY-100562

Bioactivity: Flopropione is a **5-HT$_{1A}$ receptor** antagonist and also a **catechol-o-methyltransferase** (**COMT**) inhibitor.

Purity: 98.37%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Granisetron

(BRL 43694) Cat. No.: HY-B0071

Bioactivity: Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.

Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg



Granisetron Hydrochloride

(BRL 43694A) Cat. No.: HY-B0071A

Bioactivity: Granisetron Hcl(BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.

Purity: 99.69%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



GSK163090

Cat. No.: HY-14348

Bioactivity: GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively.

Purity: 99.95%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Harmine

(Telepathine) Cat. No.: HY-N0737A

Bioactivity: Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (**(DYRK)**) inhibitor with anticancer and anti-inflammatory activities.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 500 mg



Idalopirdine

(Lu AE58054) Cat. No.: HY-14338

Bioactivity: Idalopirdine (Lu AE58054) is a potent and selective **5-HT6 receptor** antagonist with a K_i of 0.83 nM.

Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg



Idalopirdine Hydrochloride

(Lu AE58054 (Hydrochloride)) Cat. No.: HY-14338A

Bioactivity: Idalopirdine Hydrochloride (Lu AE58054 Hydrochloride) is a potent and selective **5-HT6 receptor** antagonist with a K_i of 0.83 nM.

Purity: 99.17%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Iloperidone

(HP 873) Cat. No.: HY-17410

Bioactivity: Iloperidone(HP 873) is a D2/5-HT2 receptor antagonist, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Iloperidone hydrochloride

(HP 873 hydrochloride) Cat. No.: HY-17410A

Bioactivity: Iloperidone (hydrochloride) is a D(2)/5-HT(2) receptor antagonistis, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Intepirdine

(SB-742457; GSK-742457; RVT-101) Cat. No.: HY-14339

Bioactivity: Intepirdine (SB742457) is a highly selective 5-HT6 receptor antagonist with pKi of 9.63; exhibits >100-fold selectivity over other receptors.

Purity: 98.92%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Irindalone

(Lu 21-098) Cat. No.: HY-101632

Bioactivity: Irindalone is a novel serotonin **5-HT$_2$** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Isocorynoxeine

(7-Isocorynoxeine) Cat. No.: HY-N0775

Bioactivity: Isocorynoxeine, an isorhynchophylline-related alkaloid, exhibits a dose-dependent inhibition of **5-HT$_{2A}$** receptor-mediated current response with an **IC$_{50}$** of 72.4 μM.

Purity: 99.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



JNJ-18038683

Cat. No.: HY-19889

Bioactivity: JNJ-18038683 is a 5-Hydroxytryptamine Type 7 (**5-HT$_7$**) receptor antagonist, with **pK$_i$s** of 8.19, 8.20 for rat and human 5-HT $_7$ in HEK293 cells, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Ketanserin

(R41468)

Cat. No.: HY-10562

Bioactivity: Ketanserin is a selective **5-HT receptor** antagonist. Ketanserin also blocks hERG current (**I$_{hERG}$**) in a concentration-dependent manner (**IC$_{50}$**=0.11 μM).

Purity: 98.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Ketanserin tartrate

(R41468 tartrate)

Cat. No.: HY-10562A

Bioactivity: Ketanserin tartrate is a selective **5-HT receptor** antagonist. Ketanserin tartrate also blocks hERG current (**I$_{hERG}$**) in a concentration-dependent manner (**IC$_{50}$**=0.11 μM).

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Lasmiditan

(COL-144; LY573144)

Cat. No.: HY-14861

Bioactivity: Lasmiditan (COL-144; LY573144) is a high-affinity, highly selective 5-HT1F receptor agonist(Ki=2.1 nM), compared with Ki of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively.

Purity: >98%
Clinical Data: Phase 3
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Latrepirdine dihydrochloride

(Dimebolin dihydrochloride)

Cat. No.: HY-14537

Bioactivity: Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and **amyloid-β** (**Aβ**) secretion.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



Lesopitron dihydrochloride

(E4424)

Cat. No.: HY-101609

Bioactivity: Lesopitron dihydrochloride is a full and selective **5-HT$_{1A}$** receptor agonist with **IC$_{50}$** of 125 nM in rat hippocampal membranes.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Lidanserin

(ZK-33839)

Cat. No.: HY-101815

Bioactivity: Lidanserin is a drug which acts as a combined **5-HT$_{2A}$** and **α$_1$-adrenergic receptor** antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Lintopride

Cat. No.: HY-U00121

Bioactivity: Lintopride is a **5HT4** antagonist with moderate 5HT3 antagonist properties.

Purity: 96.38%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Loxapine

Cat. No.: HY-17390

Bioactivity: Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.

Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Loxapine succinate

Cat. No.: HY-17390A

Bioactivity: Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



LP-211

Cat. No.: HY-111455

Bioactivity: LP-211 is a selective and blood–brain barrier penetrant **5-HT$_7$ receptor** agonist, with a **K$_i$** of 0.58 nM, with high selectivity over 5-HT $_{1A}$ receptor (K $_i$, 188 nM) and D $_2$ receptor (K $_i$, 142 nM).

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



lumateperone Tosylate

(ITI-007)

Cat. No.: HY-19733

Bioactivity: Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). IC50 value: 0.54 nM (Ki, for 5-HT2A receptor) Target: 5-HT2A receptor Lumateperone also possesses...

Purity: 99.21%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Lurasidone

(SM-13496)

Cat. No.: HY-B0032A

Bioactivity: Lurasidone (SM-13496) is an antagonist of both **dopamine D$_2$** and **5-HT$_7$** with **IC$_{50}$**s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of **5-HT$_{1A}$** receptor with an **IC$_{50}$** of 6.75 nM.

Purity: 99.33%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Lurasidone Hydrochloride

(SM-13496 (Hydrochloride))

Cat. No.: HY-B0032

Bioactivity: Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both **dopamine D$_2$** and **5-HT$_7$** with **IC$_{50}$**s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist...

Purity: 99.87%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



LY 344864

Cat. No.: HY-13788

Bioactivity: LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. IC50 Value: 6 nM (Ki) [1] Target: 5-HT1F LY344864 possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined [1]. in vitro: he 5-HT1A, 5-HT1B and...

Purity: 99.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



LY 344864 hydrochloride

Cat. No.: HY-13788B

Bioactivity: LY 344864 hydrochloride is a selective **5-HT1F** agonist with a **K$_i$** of 6 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



LY 344864 racemate

Cat. No.: HY-13788C

Bioactivity: LY 344864 racemate is a **5-HT$_{1F}$ receptor** agonist extracted from patent US 5708187 A.

Purity: 98.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



LY 344864 S-enantiomer

Cat. No.: HY-13788A

Bioactivity: LY 344864 S-enantiomer is the S-enantiomer of LY344864. LY344864 is a 5-HT1F receptor agonist.

Purity: 99.62%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg



LY310762

Cat. No.: HY-13527

Bioactivity: LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM, having a weaker affinity for 5-HT1B receptor.

Purity: 98.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



LY334370

Cat. No.: HY-103107

Bioactivity: LY334370 is a selective **5-HT$_{1F}$** receptor agonist with a **K$_i$** of 1.6 nM.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Metergoline

Cat. No.: HY-B1033

Bioactivity: Metergoline is a psychoactive drug of the ergoline chemical class which acts as a ligand for various serotonin and dopamine receptors.

Purity: 99.74%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Methiothepin mesylate

(Metitepine mesylate; Ro 8-6837 mesylate)

Cat. No.: HY-107836

Bioactivity: Methiothepin mesylate is a potent and non-selective **5-HT$_2$ receptor** antagonist, with p **K$_d$**s of 7.10 (5-HT $_{1A}$), 7.28 (5HT $_{1B}$), 7.56 (5HT $_{1C}$), 6.99 (5HT $_{1D}$), 7.0 (5-HT $_{5A}$), 7.8 (5-HT $_{5B}$), 8.74 (5-HT $_6$), and 8.99 (5-HT $_7$), and p **K$_i$**s...

Purity: 99.32%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg



MHP 133

Cat. No.: HY-101653

Bioactivity: MHP 133 is a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with **K$_i$** of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Mirtazapine

(Org3770; 6-Azamianserin)

Cat. No.: HY-B0352

Bioactivity: Mirtazapine is a potent tetracyclic antidepressant.

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Mosapride

(TAK-370; AS-4370)

Cat. No.: HY-B0189

Bioactivity: Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Mosapride citrate

(TAK-370 citrate; AS-4370 citrate)

Cat. No.: HY-B0189A

Bioactivity: Mosapride citrate is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Purity: 99.74%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Naftidrofuryl oxalate

(Nafronyl oxalate salt)

Cat. No.: HY-B1107

Bioactivity: Naftidrofuryl is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.

Purity: 97.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Naluzotan

(PRX 00023)

Cat. No.: HY-14848

Bioactivity: Naluzotan is a novel, potent, and selective amidosulfonamide **5-HT1A** agonist with **IC$_{50}$** and **K$_i$** of appr 20 nM and 5.1 nM, used for the treatment of anxiety and depression; Also a weak **hERG K$^+$ channel** blocker, with IC $_{50}$ of 3800 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



NAN-190 hydrobromide

Cat. No.: HY-19818A

Bioactivity: NAN-190 hydrobromide is a serotonin receptor 5-HT antagonist. NAN-190 is a selective antagonist of 5-HT1A.

Purity: 99.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Naratriptan

(GR-85548A)

Cat. No.: HY-B0197

Bioactivity: Naratriptan is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Naratriptan D3 Hydrochloride

(GR-85548A D3) Cat. No.: HY-B0197AS

Bioactivity: Naratriptan D3 Hydrochloride is the deuterium labeled Naratriptan, which is a selective 5-HT1 receptor subtype agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Naratriptan hydrochloride

(GR-85548A hydrochloride) Cat. No.: HY-B0197A

Bioactivity: Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Nefazodone hydrochloride

(BMY-13754; MJ-13754-1) Cat. No.: HY-B1396

Bioactivity: Nefazodone hydrochloride is an antidepressant drug.

Purity: 99.71%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Nelotanserin

(APD125) Cat. No.: HY-10559

Bioactivity: Nelotanserin is a potent **5-HT$_{2A}$** inverse agonist, a moderately potent **5-HT$_{2C}$** partial inverse agonist and a weak **5-HT$_{2B}$** inverse agonist, with **IC$_{50}$s** of 1.7, 79, 791 nM in IP accumulation assays, respectively.

Purity: 99.59%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



NEO 376

(SPI-376) Cat. No.: HY-101583

Bioactivity: NEO 376 is a selective modulator of **5-HT1 receptor**, **GABA receptor** and **dopamine receptor**, with anti-psychotic actively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Nexopamil racemate

Cat. No.: HY-101727

Bioactivity: Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined **Ca^{2+}/ 5-HT$_2$** antagonist on thrombus formation in vivo and on platelet aggregation in vitro.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



NPS ALX Compound 4a

Cat. No.: HY-103090

Bioactivity: NPS ALX Compound 4a is a potent and selective **5-hydroxytryptamine$_6$ (5-HT$_6$) receptor** antagonist with an **IC$_{50}$** of 7.2 nM, which also has a great binding affinity with **K$_i$** of 0.2 nM [1].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg



NRA-0160

Cat. No.: HY-101641

Bioactivity: NRA-0160 is a selective **dopamine D4 receptor** antagonist, with a **K$_i$** value of 0.48 nM and with negligible affinity for **dopamine D2 receptor** (**K$_i$**: >10000 nM), **D3 receptor** (**K$_i$**: 39 nM), rat **5-HT2A receptor** (**K$_i$**: 180 nM) and rat

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Nuciferine

Cat. No.: HY-N0049

Bioactivity: Nuciferine is an antagonist at **5-HT$_{2A}$** (**IC$_{50}$**=478 nM), **5-HT$_{2C}$** (**IC$_{50}$**=131 nM), and **5-HT$_{2B}$** (**IC$_{50}$**=1 μM), an inverse agonist at **5-HT$_7$** (**IC$_{50}$**=150 nM), a partial agonist at **D$_2$** (**EC$_{50}$**=64 nM), **D$_5$** (**EC$_{50}$**=2.6 μM) and **5-HT$_6$** (**EC$_{50}$**=...

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Ocaperidone

(R79598) Cat. No.: HY-101094

Bioactivity: Ocaperidone is an effective antipsychotic agent, acting as a potent **5-HT$_2$** and **dopamine D$_2$** antagonist, and a **5-HT$_{1A}$** agonist, with **K$_i$**s of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT $_2$, a $_1$-adrenergic receptor, dopamine D $_2$

Purity: 98.55%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Olanzapine

(LY170053) Cat. No.: HY-14541

Bioactivity: Olanzapine(LY170053) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist. IC50 Value: Target: 5-HT Receptor Olanzapine is a thienobenzodiazepine that blocks especially the serontonin (5-hydroxytryptamine [5-HT]) 5-HT2A and the dopamine D2 receptors (Ki values are 4 and 11 nM...

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Ondansetron

(GR 38032; SN 307) Cat. No.: HY-B0002B

Bioactivity: Ondansetron(GR 38032; SN 307) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy. IC50 Value: Target: 5- HT3 Receptor in vitro: 5-HT evoked transient inward currents (EC50 = 3.4 microM; Hill coefficient = 1.8) that were...

Purity: 98.55%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Ondansetron hydrochloride

(GR 38032 (hydrochloride); SN 307 (hydrochloride)) Cat. No.: HY-B0002

Bioactivity: Ondansetron hydrochloride (GR 38032 hydrochloride; SN 307 hydrochloride) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy. Target: 5- HT Receptor IC50 Value: in vitro: 5-HT evoked transient inward currents (EC50 = 3.4...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Ondansetron hydrochloride dihydrate (GR 38032 (hydrochloride dihydrate); SN 307 (hydrochloride dihydrate))

Cat. No.: HY-B0002A

Bioactivity: Ondansetron hydrochloride dihydrate (GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy. Target: 5- HT3 Receptor IC50 Value: in vitro: 5-HT evoked...

Purity: 99.56%
Clinical Data: Launched
Size: 50 mg, 100 mg, 1 g, 5 g



Palonosetron

Cat. No.: HY-A0018

Bioactivity: Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 100 mg



Palonosetron Hydrochloride

Cat. No.: HY-A0021

Bioactivity: Palonosetron Hcl is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Pancopride

(LAS 30451) Cat. No.: HY-19684

Bioactivity: Pancopride is a new potent and selective **5-HT$_3$ receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Pardoprunox

(SLV-308; DU-126891) Cat. No.: HY-14958

Bioactivity: Pardoprunox(SLV-308) is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist; D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%); also binds to D4 (pKi = 7.8),...

Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Pardoprunox hydrochloride

(SLV-308 hydrochloride; DU-126891 hydrochloride) Cat. No.: HY-14958A

Bioactivity: Pardoprunox hydrochloride is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist, D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist and 5-HT1A receptor (pKi = 8.5) full agonist.

Purity: 98.89%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Peptide 401

Cat. No.: HY-12537

Bioactivity: Peptide 401, a potent mast cell degranulating factor from bee venom, suppresses the increased vascular permeability due to intradermal injection of various smooth muscle spasmogens (**histamine**, and **5-HT**).

Purity: 98.29%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Perphenazine

Cat. No.: HY-A0077

Bioactivity: Perphenazine is a typical antipsychotic drug, inhibits **5-HT$_{2A}$receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor**, and **Histamine H1 receptor**, with **K$_i$** values of 5.6, 10, 0.765/0.13, 3.4, and 8 ...

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Perphenazine D8 Dihydrochloride

Cat. No.: HY-A0077AS

Bioactivity: Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Phenylbiguanide

(N-Phenylbiguanide; PBG; 1-Phenylbiguanide)

Cat. No.: HY-101331

Bioactivity: Phenylbiguanide is a **5-HT$_3$ receptor** selective agonist with an **EC$_{50}$** of 3.0±0.1 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Piboserod

(SB-207266)

Cat. No.: HY-15574

Bioactivity: Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

Purity: 98.85%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Piboserod hydrochloride

(SB-207266 hydrochloride)

Cat. No.: HY-15574A

Bioactivity: Piboserod (SB 207266) Hcl is a selective 5-HT(4) receptor antagonist.

Purity: >98%
Clinical Data: Phase 2
Size: 10 mg, 50 mg



Pimavanserin

(ACP-103)

Cat. No.: HY-14557

Bioactivity: Pimavanserin is a selective inverse agonist of the **5-HT2A** receptor with **pIC$_{50}$** and **pK$_d$** of 8.73 and 9.3, respectively.

Purity: 99.73%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Pimavanserin tartrate

(ACP-103 tartrate)

Cat. No.: HY-14557A

Bioactivity: Pimavanserin tartrate (ACP-103) is a potent **5-HT 2A** receptor inverse agonist with **pIC$_{50}$** and **pK$_i$** of 8.73 and 9.3, respectively.

Purity: 99.50%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Pimethixene

(Pimetixene)

Cat. No.: HY-B1101

Bioactivity: Pimethixene is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene is a highly potent antagonist of 5-HT $_{1A}$, 5-HT $_{2A}$, 5-HT $_{2B}$, 5-HT $_{2C}$, histamine H $_1$, dopamine D $_2$ and D $_{4.4}$ as well as muscari...

Purity: >98%
Clinical Data: Launched
Size: 10 mg



Pimethixene maleate

(Pimetixene maleate)

Cat. No.: HY-B1101A

Bioactivity: Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene maleate is a highly potent antagonist of 5-HT $_{1A}$, 5-HT $_{2A}$, 5-HT $_{2B}$, 5-HT $_{2C}$, histamine H $_1$, dopamine D $_2$ and D $_{4.4}$ as well...

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg



Pindolol

(LB-46)

Cat. No.: HY-B0982

Bioactivity: Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial agonist / antagonist (Ki=33nM).

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Pizotifen

(BC-105; Pizotyline) Cat. No.: HY-B0115

Bioactivity: Pizotifen (BC-105) is a potent **5-HT$_2$** receptor antagonist, with a high affinity for **5-HT$_{1C}$** binding site.

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Pizotifen malate

(BC-105 (malate); Pizotyline (malate)) Cat. No.: HY-B0115A

Bioactivity: Pizotifen (malate) (BC-105 (malate)) is a potent **5-HT$_2$** receptor antagonist, with a high affinity for **5-HT$_{1C}$** binding site.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Prucalopride

Cat. No.: HY-14151

Bioactivity: Prucalopride (R093877) is a drug acting as a selective, high affinity 5-HT4 receptor agonist(pKi=8.6/8.1 for 5-HT4a/4b); >150-fold higher affinity for 5-HT4 receptors than for other receptors. IC50 value: 8.6/8.1 for 5-HT4a/4b(pKi) Target: 5-HT4 receptor Prucalopride is a novel enterokinetic...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Prucalopride succinate

(R-108512) Cat. No.: HY-12694

Bioactivity: Prucalopride succinate is a selective, high affinity 5-HT4 receptor agonist with pKi of 8.6/8.1 for 5-HT4a/4b.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



PRX-08066

Cat. No.: HY-15472

Bioactivity: PRX-08066 is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR, IC50= 3.4 nM) antagonist that causes selective vasodilation of pulmonary arteries.

Purity: 97.04%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



PRX933 hydrochloride

(GW876167 hydrochloride; BVT-933 hydrochloride) Cat. No.: HY-100171

Bioactivity: PRX933 hydrochloride is a **5-HT$_{2c}$ receptor** agonist extracted from patent WO 2014140631 A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Puerarin

Cat. No.: HY-N0145

Bioactivity: Puerarin, an isoflavone extracted from Radix puerariae, is a **5-HT2C** receptor antagonist.

Purity: 98.14%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Pumosetrag Hydrochloride

(MKC-733; DDP-733) Cat. No.: HY-19650

Bioactivity: Pumosetrag Hydrochloride (MKC-733; DDP-733) is an orally available **5-HT3** partial agonist developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Quetiapine

(ICI204636) Cat. No.: HY-14544

Bioactivity: Quetiapine (ICI204636) is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.

Purity: 99.83%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Quetiapine D4 fumarate

Cat. No.: HY-B0031S

Bioactivity: Quetiapine D4 fumarate is the deuterium labeled Quetiapine, which is an atypical antipsychotic.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Quetiapine fumarate

Cat. No.: HY-B0031

Bioactivity: Quetiapine fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.

Purity: 99.54
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Ramosetron Hydrochloride

(YM060)

Cat. No.: HY-B0595

Bioactivity: Ramosetron Hydrochloride(YM060 Hydrochloride) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting. Target: 5-HT3 Receptor Ramosetron hydrochloride selectively blocks serotonin receptors (5-HT3). Serotonin plays a vital role in vomiting, serotonin-induced bradycardic...

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Revexepride

Cat. No.: HY-U00373

Bioactivity: Revexepride is a highly selective **5-HT4 receptor** agonist, and a potential inducer of **CYP3A4 enzyme**, used for the treatment of gastroesophageal reflux disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



RG-12915

Cat. No.: HY-19110

Bioactivity: RG-12915 is a selective **5-HT3** antagonist, with **IC_{50}** value of 0.16 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Risperidone

(R 64 766)

Cat. No.: HY-11018

Bioactivity: Risperidone is a serotonin **5-HT_2 receptor** blocker, **P-Glycoprotein** inhibitor and potent **dopamine D_2 receptor** antagonist, with **K_is** of 4.8, 5.9 nM for 5-HT_{2A} and dopamine D_2 receptor, respectively.

Purity: 99.16%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Risperidone hydrochloride

(R 64 766 hydrochloride)

Cat. No.: HY-11018A

Bioactivity: Risperidone hydrochloride is a serotonin **5-HT_2** receptor blocker and a potent **dopamine D_2** receptor antagonist, with **K_is** of 0.16, 1.4 nM for 5-HT_2 and D_2 receptor, respectively.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Risperidone mesylate

(R 64 766 mesylate)

Cat. No.: HY-11018B

Bioactivity: Risperidone mesylate(R 64 766 mesylate) is a serotonin 5-HT2 receptor blocker(Ki= 0.16 nM) and a potent dopamine D2 receptor antagonist(Ki= 1.4 nM).

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Roluperidone

(CYR-101; MIN-101; MT-210)

Cat. No.: HY-19469

Bioactivity: Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for **5-HT_{2A}** and **sigma-2** receptors (**K_i** of 7.53 nM and 8.19 nM for 5-HT_{2A} and sigma-2, respectively).

Purity: 98.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Rotigotine

(N-0437; N-0923)

Cat. No.: HY-75502

Bioactivity: Rotigotine is a full agonist of **dopamine receptor**, a partial agonist of the **5-HT1A receptor**, and an antagonist of the **α2B-adrenergic receptor**, with **K_i**s of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Rotundine

((-)-Tetrahydropalmatine; L-Tetrahydropalmatine)

Cat. No.: HY-N0096

Bioactivity: Rotundine is an antagonist of **dopamine D1**, **D2** and **D3 receptors** with **IC_{50}**s of 166 nM, 1.4 μM and 3.3 μM, respectively. Rotundine is also an antagonist of **5-HT_{1A}** with an **IC_{50}** of 370 nM.

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



RS 127445

(MT 500)

Cat. No.: HY-15419

Bioactivity: RS 127445 is a novel high affinity, selective **5-HT$_{2B}$** receptor antagonist with **pK$_i$** of 9.5.

Purity: 99.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



RU 24969

Cat. No.: HY-16688

Bioactivity: RU 24969 is a selective agonist at the 5-HT1A and 5-HT1B receptors.

Purity: 99.77%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



Rupatadine

(UR-12592)

Cat. No.: HY-13511

Bioactivity: Rupatadine (UR-12592) is a potent dual PAF/H1 antagonist with Ki of 0.55/0.1 uM(rabbit platelet membranes/guinea pig cerebellum membranes). IC50 value: Target: PAF/H1 antagonist in vitro: Rupatadine competitively inhibited histamine-induced guinea pig ileum contraction (pA2 = 9.29 +/- 0.06) without...

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Rupatadine Fumarate

(UR-12592 (Fumarate))

Cat. No.: HY-13511A

Bioactivity: Rupatadine Fumarate (UR-12592 Fumarate) is a potent dual PAF/H1 antagonist with Ki of 0.55/0.1 uM(rabbit platelet membranes/guinea pig cerebellum membranes). IC50 value: Target: PAF/H1 antagonist in vitro: Rupatadine competitively inhibited histamine-induced guinea pig ileum contraction (pA2...

Purity: 99.34%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg, 500 mg



Sarpogrelate hydrochloride

(MCI-9042)

Cat. No.: HY-10564

Bioactivity: Sarpogrelate hydrochloride (MCI-9042), a selective 5-HT2 antagonist, has been widely used as an anti-platelet agent for the treatment of PAD. Target: 5-HT2 Recepter Sarpogrelate is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. Sarpogrelate was shown to have the same affinity as...

Purity: 98.39%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



SB 242084

Cat. No.: HY-13409

Bioactivity: SB 242084 is a 5-HT2C receptor antagonist(pKi=9.0) that displays 158- and 100-fold selectivity over 5-HT2A and 5-HT2B receptors respectively.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



SB 242084 hydrochloride

Cat. No.: HY-13409A

Bioactivity: SB 242084 hydrochloride is a 5-HT2C receptor antagonist(pKi=9.0) that displays 158- and 100-fold selectivity over 5-HT2A and 5-HT2B receptors respectively. IC50 value: 9.0(pKi) [1] Target: 5-HT2C antagonist in vitro: SB 242084 had over 100-fold selectivity over a range of other...

Purity: 98.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



SB 258719

Cat. No.: HY-U00443

Bioactivity: SB 258719 is a selective **5-HT$_7$ receptor** antagonist with a **pK$_i$** of 7.5.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



SB 271046 Hydrochloride

(SB 271046A)

Cat. No.: HY-14336A

Bioactivity: SB271046 Hcl is a potent, selective and orally active 5-HT6 receptor antagonist with pKi of 8.9.

Purity: 99.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



SB-224289 hydrochloride

(SB-224289A)

Cat. No.: HY-101105A

Bioactivity: SB-224289 hydrochloride is a selective **5-HT1B receptor** antagonist, with anxiolytic effect.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg



SB-269970

Cat. No.: HY-15370

Bioactivity: SB269970 is a **5-HT7 receptor** antagonist with **pKi** of 8.3, exhibits >50-fold selectivity against other receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



SB-269970 hydrochloride

(SB-269970A)

Cat. No.: HY-15370A

Bioactivity: SB269970 hydrochloride is a hydrochloride salt form of SB-269970, which is a **5-HT7 receptor** antagonist with **pKi** of 8.3, exhibits >50-fold selectivity against other receptors.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



SB-399885 hydrochloride

Cat. No.: HY-103099

Bioactivity: SB-399885 hydrochloride is a **5-HT$_6$ receptor** antagonist.

Purity: 98.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



SB-616234A

Cat. No.: HY-19477

Bioactivity: SB-616234A is a selective and orally bioavailable **5-HT1B receptor** antagonist, with anxiolytic and antidepressant activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Scopolamine

(Hyoscine; Scopine (-)-tropate; Scopine tropate)

Cat. No.: HY-N0296

Bioactivity: Scopolamine is a high affinity (nM) **muscarinic** antagonist. **5-HT$_3$** receptor-responses are reversibly inhibited by Scopolamine with an **IC$_{50}$** of 2.09 μM.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Scopolamine hydrobromide ((-)-Scopolamine hydrobromide; Hyoscine hydrobromide; Scopine hydrobromide)

Cat. No.: HY-N0296A

Bioactivity: Scopolamine hydrobromide is a high affinity (nM) **muscarinic** antagonist. **5-HT$_3$** receptor-responses are reversibly inhibited by Scopolamine with an **IC$_{50}$** of 2.09 μM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Serotonin hydrochloride

(5-Hydroxytryptamine hydrochloride; 5-HT hydrochloride)

Cat. No.: HY-B1473

Bioactivity: Serotonin hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous **5-HT receptor** agonist. Serotonin hydrochloride is also a **catechol O-methyltransferase** (**COMT**) inhibitor with a **K$_i$** of 44 μM.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Sertindole

(Lu 23-174)

Cat. No.: HY-14543

Bioactivity: Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Target: Multi-target In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors. Sertindole offers an alternative treatment option for...

Purity: 96.14%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Setiptiline

(Org-8282)

Cat. No.: HY-32329

Bioactivity: Setiptiline(Org-8282) is a serotonin receptor antagonist.

Purity: 96.00%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Setiptiline maleate

(MO-8282)

Cat. No.: HY-32329A

Bioactivity: Setiptiline is a serotonin receptor antagonist.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Sulamserod

(RS-100302) Cat. No.: HY-101668

Bioactivity: Sulamserod is a **5-HT4 receptor** antagonist, with antiarrhythmic activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



T 82

Cat. No.: HY-U00028

Bioactivity: T 82 is a potent **5-HT3** antagonist and **acetylcholinesterase (AChE)** inhibitor, used for treatment of Alzheimer's Disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Talipexole dihydrochloride

(B-HT 920 (dihydrochloride)) Cat. No.: HY-A0008

Bioactivity: Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Tandospirone

(SM-3997) Cat. No.: HY-14558

Bioactivity: Tandospirone(SM-3997) is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over SR-2, SR-1C, α1, α2, D1 and D2 receptors (Ki values ranging from 1300-41000 nM).

Purity: 96.81%
Clinical Data: Launched
Size: 10 mg, 50 mg



Tandospirone citrate

(SM-3997 citrate) Cat. No.: HY-B0061

Bioactivity: Tandospirone citrate is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over SR-2, SR-1C, α1, α2, D1 and D2 receptors (Ki values ranging from 1300-41000 nM). IC50 Value: 27±5 nM(Ki) [1] Target: 5-HT1A in vitro: Tandospirone is most potent at the 5-HT1A...

Purity: 98.87%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg



Tedatioxetine hydrobromide

(Lu AA 24530 hydrobromide) Cat. No.: HY-101755

Bioactivity: Tedatioxetine hydrobromide acts as a triple reuptake inhibitor and **5-HT$_{2A}$**, **5-HT$_{2C}$**, **5-HT$_3$** and **α$_{1A}$-adrenergic receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Tegaserod maleate

(SDZ-HTF-919; HTF-919) Cat. No.: HY-14153A

Bioactivity: Tegaserod maleate is a partial agonist of the 5-HT4 receptor; stimulates the peristaltic reflex and accelerates gastrointestinal transit.

Purity: 99.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Temanogrel

(APD791) Cat. No.: HY-10560

Bioactivity: Temanogrel is a highly selective **5-HT$_{2A}$ receptor** antagonist with a **K$_i$** of 4.9 nM.

Purity: 98.14%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



Tertatolol

((±)-Tertatolol; Racemic Tertatolol; dl-Tertatolol) Cat. No.: HY-U00356

Bioactivity: Tertatolol is a potent antagonist of **beta-adrenoceptor** and **5-HT receptor**, with unique renal vasodilatatory effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



TG6-10-1

Cat. No.: HY-16978

Bioactivity: TG6-10-1 is an **EP2** antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors [1].

Purity: 99.28%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Thioridazine hydrochloride

Cat. No.: HY-B0965

Bioactivity: Thioridazine is an antipsychotic drug, used in the treatment of schizophrenia and psychosis, shows D4 selectivity or serotonin antagonism.

Purity: 99.93%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Tianeptine

Cat. No.: HY-90003

Bioactivity: Tianeptine is a selective facilitator of 5-HT uptake in vitro and in vivo. IC50 Value: N/A Target: 5-HT Receptor Tianeptine has no affinity for a wide range of receptors, including 5-HT and dopamine (IC50 > 10 μM) and has no effect on noradrenalin or dopamine uptake. Antidepressant, analgesic and...

Purity: 99.69%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Tianeptine sodium salt

Cat. No.: HY-90003A

Bioactivity: Tianeptine sodium salt is a selective facilitator of 5-HT uptake in vitro and in vivo. IC50 Value: Target: 5-HT Receptor Tianeptine has no affinity for a wide range of receptors, including 5-HT and dopamine (IC50 > 10 μM) and has no effect on noradrenalin or dopamine uptake. Antidepressant,...

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Trazodone hydrochloride

(AF-1161)

Cat. No.: HY-B0478

Bioactivity: Trazodone (hydrochloride) (AF-1161) is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Trimipramine maleate

Cat. No.: HY-B1213

Bioactivity: Trimipramine maleate is a 5-HT receptor antagonist, with pK_is of 6.39, 8.10, 4.66 for 5-HT $_{1C}$, 5-HT $_2$ and 5-HT $_{1A}$, respectively.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Tropisetron

(SDZ-ICS-930 (free base))

Cat. No.: HY-B0072

Bioactivity: Tropisetron (SDZ-ICS-930 free base) is a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor. IC50 value: 70.1 ± 0.9 nM [1] Target: 5-HT3 receptor in vitro: Tropisetron specifically inhibited both IL-2 gene transcription and IL-2...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Tropisetron Hydrochloride

(SDZ-ICS-930)

Cat. No.: HY-B0020

Bioactivity: Tropisetron Hydrochloride (SDZ-ICS-930) is a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor. IC50 value: 70.1 ± 0.9 nM Target: 5-HT3 receptor; α7-nicotinic receptor in vitro: Retinal ganglion cells(RGCs) pretreated with 100 nM...

Purity: 99.64%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Urapidil

Cat. No.: HY-B0716

Bioactivity: Urapidil is an **α1 adrenoreceptor** antagonist and a **5-HT$_{1A}$ receptor** agonist.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 50 mg



Urapidil hydrochloride

Cat. No.: HY-B0354A

Bioactivity: Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Vabicaserin hydrochloride

(SCA 136)

Cat. No.: HY-111200

Bioactivity: Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (**5-HT$_{2C}$**) **receptor**-selective agonist with an **EC$_{50}$** of 8 nM.

Purity: 98.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Vilazodone
(EMD 68843; SB659746A) Cat. No.: HY-14262

Bioactivity: Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Vilazodone D8
Cat. No.: HY-14261S

Bioactivity: Vilazodone D8 is the a deuterium labeled vilazodone, which is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Vilazodone Hydrochloride
(EMD 68843 (Hydrochloride); SB659746A (Hydrochloride)) Cat. No.: HY-14261

Bioactivity: Vilazodone Hydrochloride (EMD 68843 Hydrochloride; SB659746A Hydrochloride) is a **serotonin** transporter (SER) inhibitor and **5-HT$_{1A}$** receptor partial agonist.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Volinanserin
(MDL100907; M 100907) Cat. No.: HY-14940

Bioactivity: Volinanserin is a potent and selective antagonist of **5-HT$_2$ receptor**, with a **K$_i$** of 0.36 nM, and shows 300-fold selectivity for 5-HT $_2$ receptor over 5-HT $_{1c}$, alpha-1 and DA D $_2$ receptors. Volinanserin has antipsychotic activity.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Vortioxetine
(Lu AA 21004) Cat. No.: HY-15414

Bioactivity: Vortioxetine is a inhibitor of **5-HT$_{1A}$**, **5-HT$_{1B}$**, **5-HT$_{3A}$**, **5-HT$_7$** receptor and **SERT**, with **K$_i$** values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.

Purity: 98.81%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Vortioxetine hydrobromide
(Lu AA21004 hydrobromide) Cat. No.: HY-15414A

Bioactivity: Vortioxetine hydrobromide is a multimodal serotonergic agent, inhibits **5-HT$_{1A}$**, **5-HT$_{1B}$**, **5-HT$_{3A}$**, **5-HT$_7$** receptor and **SERT** with **K$_i$** values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.

Purity: 99.54%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



WAY 163909
Cat. No.: HY-15401

Bioactivity: WAY 163909 is a potent and selective **5-HT(2C) receptor** agonist with a **K$_i$** of 10.5±1.1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



WAY-100635
Cat. No.: HY-10349

Bioactivity: WAY-100635 is a potent and selective 5-HT $_{1A}$ Receptor antagonist with a pIC $_{50}$ of 8.87, an apparent pA $_2$ of 9.71.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



WAY-100635 Maleate
Cat. No.: HY-10349A

Bioactivity: WAY-100635 Maleate is a potent and selective 5-HT $_{1A}$ Receptor antagonist with a pIC $_{50}$ of 8.87, an apparent pA $_2$ of 9.71.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



WAY-100635 maleate salt
Cat. No.: HY-13105

Bioactivity: WAY-100635 maleate salt is a potent and selective 5-hydroxytryptamine1A antagonist with an IC50 of 0.95 ± 0.12 nM for 5-HT. IC50 Value: 0.95 nM Target: 5-HT Receptor in vitro: WAY 100635 has an IC50 of 1.35 nM and is > 100-fold selective for the 5-HT1A site relative to a range of other CNS...

Purity: 99.77%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Wf-516

Cat. No.: HY-19417A

Bioactivity: Wf-516 is an inhibitor of **5-HT reuptake**, and an antagonist of **5-HT1A** and **5-HT2A** receptors, with K_i of 5 nM and 40 nM for 5-HT1A receptor and 5-HT2A receptor in humans, respectively, and has potent antidepressant activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Xanthotoxol

(8-Hydroxypsoralen) Cat. No.: HY-30152

Bioactivity: Xanthotoxol is a biologically active linear furocoumarin, shows strong pharmacological activities as anti-inflammatory, antioxidant, **5-HT** antagonistic, and neuroprotective effects.

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



YL0919

Cat. No.: HY-100769

Bioactivity: YL0919, a novel antidepressant candidate with dual activity as a 5-HT1A receptor agonist and a selective serotonin reuptake inhibitor,the IC50 values of YL-0919 inhibiting the uptake of 5-HT into rat cerebral cortical synaptosomes and human recombinant cells were 1.78±0.34 nM and 1.93±0.18 nM...

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



YM348

Cat. No.: HY-100330

Bioactivity: YM348 is a potent and orally active **5-HT$_{2C}$ receptor** agonist, which shows a high affinity for cloned human **5-HT$_{2C}$ receptor** (K_i: 0.89 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Zatosetron maleate

(LY 277359 maleate) Cat. No.: HY-U00234

Bioactivity: Zatosetron maleate is a potent and selective **5HT3 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Ziprasidone

(CP-88059) Cat. No.: HY-14542

Bioactivity: Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Purity: 98.69%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Ziprasidone D8

(CP-88059 D8) Cat. No.: HY-14542S

Bioactivity: Ziprasidone D8 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Ziprasidone hydrochloride

(CP-88059 hydrochloride) Cat. No.: HY-14542A

Bioactivity: Ziprasidone Hcl(CP-88059 Hcl) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Ziprasidone hydrochloride monohydrate

(CP 88059 (hydrochloride monohydrate)) Cat. No.: HY-17407

Bioactivity: Ziprasidone hydrochloride monohydrate (CP 88059 hydrochloride monohydrate) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity. Target: 5-HT receptor; Dopamine receptor Ziprasidone hydrochloride monohydrate is the salt...

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Adenosine Receptor

P1 receptor



Adenosine receptors (ARs) comprise a group of G protein-coupled receptors (GPCR) which mediate the physiological actions of adenosine. To date, four AR subtypes have been cloned and identified in different tissues. These receptors have distinct localization, signal transduction pathways and different means of regulation upon exposure to agonists. A key property of some of Adenosine receptors is their ability to serve as sensors of cellular oxidative stress, which is transmitted by transcription factors, such as NF-κB, to regulate the expression of ARs. The importance of Adenosine receptors in the regulation of normal and pathological processes such as sleep, the development of cancers and in protection against hearing loss will be examined.

5'-N-Ethylcarboxamidoadenosine

(NECA)

Cat. No.: HY-103173

Bioactivity: 5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective **adenosine receptor** agonist.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



A2A receptor antagonist 1

Cat. No.: HY-102024

Bioactivity: A2A receptor antagonist 1 is an antagonist of both **adenosine A_{2A} receptor** and **A_1 receptor** with **K_i**s of 4 and 264 nM, respectively.

Purity: 98.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



A2AR-agonist-1

Cat. No.: HY-18776

Bioactivity: A2AR-agonist-1 is a potent A2AR and ENT1 agonist with Ki of 4.39 and 3.47 for A2AR and ENT1.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



A2B receptor antagonist 1

Cat. No.: HY-U00321

Bioactivity: A2B receptor antagonist 1 is a potent **A2B adenosine receptor** antagonist extracted from patent WO 2009157938 A1 EXAMPLE 9B.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



AB-MECA

Cat. No.: HY-19365

Bioactivity: AB-MECA is a high affinity A3 adenosine receptor agonist, has high affinity for recombinant A1 and A3 receptors.

Purity: 99.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Acefylline

(Theophyllineacetic acid; Theophylline-7-acetic acid)

Cat. No.: HY-B1505

Bioactivity: Acefylline is an **adenosine receptor** antagonist.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Adenosine 5'-monophosphate monohydrate

(5'-AMP monohydrate)

Cat. No.: HY-A0181A

Bioactivity: Adenosine 5'-monophosphate monohydrate is an **adenosine A_1 receptor** agonist.

Purity: 99.07%
Clinical Data: Phase 4
Size: 10mM x 1mL in Water, 1 g



Adenosine antagonist-1

Cat. No.: HY-100274

Bioactivity: Adenosine antagonist-1 is an **adenosine A3 receptor** (**AA3R**) antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



APNEA

(N6-[2-(4-Aminophenyl)ethyl]adenosine)

Cat. No.: HY-18687

Bioactivity: APNEA is a potent, non-selective A3 adenosine receptor agonist.

Purity: 97.19%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



AZD4635

(HTL1071)

Cat. No.: HY-101980

Bioactivity: AZD4635 is a novel **adenosine 2A receptor** (**A2AR**) inhibitor with a **K_i** of 1.7 nM.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BAY-545

Cat. No.: HY-111767

Bioactivity: BAY-545 is a potent and selective **A_{2B} adenosine receptor** antagonist, with an **IC_{50}** of 59 nM. BAY-545 also exhibits **IC_{50}**s of 66, 400, 280 nM for human, mouse, rat A $_{2B}$ adenosine receptor in cells, respectively, and a **K_i** of 97 nM for huma...

Purity: 97.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Capadenoson

(BAY 68-4986)

Cat. No.: HY-14917

Bioactivity: Capadenoson is a selective agonist of **adenosine-A1 receptor**.

Purity: 98.43%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



CGS 21680

Cat. No.: HY-13201

Bioactivity: CGS 21680 is a selective **adenosine A2A receptor** agonist, with a **K_i** of 27 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



CGS 21680 Hydrochloride

Cat. No.: HY-13201A

Bioactivity: CGS 21680 Hydrochloride is a selective **adenosine A2A receptor** agonist with a **K_i** of 27 nM.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



CPI-444

(V81444; ciforadenant)

Cat. No.: HY-101978

Bioactivity: CPI-444 is a potent and selective inhibitor of **A2A receptor** (**A2AR**) induces antitumor responses.

Purity: 99.94%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Diphylline

(Diprophylline)

Cat. No.: HY-B0128

Bioactivity: Dyphylline acts as an adenosine receptor antagonist and phosphodiesterase inhibitor, which is used in the treatment of respiratory disorders.

Purity: 99.28%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg, 500 mg



Doxofylline

Cat. No.: HY-B0004

Bioactivity: Doxofylline is an antagonist of **adenosine A1 receptor** which also inhibits **phosphodiesterase IV**.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
100 mg



GP531

Cat. No.: HY-U00116

Bioactivity: GP531 is a potent, second-generation **adenosine** regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



GR79236

Cat. No.: HY-18978

Bioactivity: GR79236 is a highly potent and selective adenosine A1 receptor agonist (Ki = 3.1 nM) that has analgesic and anti-inflammatory actions in humans and animals. IC50 value: 3.1 nM(Ki) Target: adenosine A1 receptor in vitro: GR79236 is a highly potent and selective A1-receptor agonist that is originally developed for...

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg



Istradefylline

(KW-6002)

Cat. No.: HY-10888

Bioactivity: Istradefylline is a very potent, selective and orally active **adenosine A2A receptor** antagonist with **K_i** of 2.2 nM in experimental models of Parkinson's disease.

Purity: 99.42%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg



KF21213

Cat. No.: HY-U00180

Bioactivity: KF21213 is a highly selective ligand for mapping CNS adenosine **A_{2A}** receptors. KF21213 shows a high affinity for the adenosine **A_{2A}** receptors (**K_i**=3.0 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



KFM19

Cat. No.: HY-U00251

Bioactivity: KFM19 is a potent, selective **Adenosine receptor** (**A1-receptor**) antagonist, with an **IC_{50}** of 50 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



LAS101057

Cat. No.: HY-14390

Bioactivity: LAS101057 is a potent, selective, and orally efficacious **A2B receptor** antagonist.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 20 mg



LUF6000

Cat. No.: HY-13236

Bioactivity: LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR).

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



MRE3008F20

Cat. No.: HY-103178

Bioactivity: MRE3008F20 is a highly potent and selective antagonistic of **adenosine A3 receptor (AA3R)**, inhibits agonist-induced cAMP elevation in resting T lymphocytes with an **IC_{50}** of 5 nM [1].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 5 mg



MRS 1754

Cat. No.: HY-14121

Bioactivity: MRS 1754 is a selective antagonist radioligand for **A_{2B} adenosine receptor** with very low affinity for A_1 and A_3 receptors of both humans and rats [1].

Purity: 98.31%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg



MRS-1706

Cat. No.: HY-103186

Bioactivity: MRS-1706 is a potent and selective **adenosine A_{2B} receptor** inverse agonist. MRS-1706 has **K_i** values of 1.39, 112, 157, and 230 nM for human A_{2B}, A_{2A}, A_1 and A_3 receptors respectively [1] [2].

Purity: 98.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



MRS1177

Cat. No.: HY-120090

Bioactivity: MRS1177 is a potent and selective human Adenosine A3 receptor **(hA_3AR)** antagonist, with a **K_i** of 0.3 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



MRS1186

Cat. No.: HY-118678

Bioactivity: MRS1186 is a potent and selective human Adenosine A3 receptor **(hA_3AR)** antagonist, with a **K_i** of 7.66 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



N-0861 racemate

Cat. No.: HY-U00143

Bioactivity: N-0861 racemate is the racemate of N-0861. N-0861 is a selective adenosine A1 receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



N-[(4-Aminophenyl)methyl]adenosine

Cat. No.: HY-100130

Bioactivity: N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor, with Ki of 29 nM for Rat ecto-5′-Nucleotidase.

Purity: 98.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



N6-(2-Phenylethyl)adenosine

(N6-Phenethyladenosine; N6-Phenylethyladenosine)

Cat. No.: HY-101854

Bioactivity: N6-(2-Phenylethyl)adenosine is a selective **A1** adenosine receptor agonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 200 mg



N6-Cyclohexyladenosine

(CHA)

Cat. No.: HY-18939

Bioactivity: N6-Cyclohexyladenosine is a selective A1 receptor agonist (EC50 = 8.2 nM).

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



N6-Cyclopentyladenosine

(CPA; UK-80882)

Cat. No.: HY-103181

Bioactivity: N6-Cyclopentyladenosine (CPA) is a selective **Adenosine A_1 receptor** agonist, with **K_i** values of 2.3 nM, 790 nM and 43 nM for human A_1, A_{2A} and A_3 receptors, respectively [1] [2]

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



N6-Ethyladenosine

Cat. No.: HY-111809

Bioactivity: N6-Ethyladenosine is an adenosine derivative, acts as a **Adenosine receptor** agonist, with **K_i**s of 4.9 and 4.7 nM for hA $_1$AR and hA $_3$AR, respectively [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



Namodenoson

(CF-102; 2-Cl-IB-MECA)

Cat. No.: HY-12365

Bioactivity: Namodenoson (CF-102) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PD 117519

(CI947)

Cat. No.: HY-100032

Bioactivity: PD 117519 is an adenosine agonist.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Piclidenoson

(IB-MECA; CF-101)

Cat. No.: HY-13591

Bioactivity: Piclidenoson (IB-MECA) is an agonist of the adenosine A3 receptor with EC50 values of 0.11 μM. IC50 value: 0.11 μM (EC50) [3] Target: adenosine A3 receptor in vitro: Piclidenoson has been shown to play important roles in cell proliferation and apoptosis in a variety of cancer cell lines....

Purity: 98.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



Preladenant

(SCH-420814)

Cat. No.: HY-10889

Bioactivity: Preladenant is a potent and competitive antagonist of the human **adenosine A2A** receptor with a **K_i** of 1.1 nM and has over 1000-fold selectivity over other adenosine receptors.

Purity: 99.08%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Proxyphylline

Cat. No.: HY-B1742

Bioactivity: Proxyphylline is a methylxanthine derivative clinical used as cardiac stimulant, vasodilator and bronchodilator.

Purity: 99.46%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg



Regadenoson

(CVT-3146)

Cat. No.: HY-A0168

Bioactivity: Regadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing.

Purity: 99.59%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg



SCH 58261

Cat. No.: HY-19533

Bioactivity: SCH 58261 is the adenosine A2A receptor competitive antagonist. Displays 323-, 53- and 100-fold selectivity over A1, A2B and A3 receptors, respectively.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Sch412348

Cat. No.: HY-U00189

Bioactivity: Sch412348 is a potent competitive antagonist of the human **adenosine A_{2A}** receptor (**K_i**=0.6 nM) and has >1000-fold selectivity over all other adenosine receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



ST3932

Cat. No.: HY-112840

Bioactivity: ST3932 is a metabolite of ST1535, acts as an antagonist of **adenosine A_{2A} receptor**, with **K_i**s of 8 nM and 33 nM for A_{2A} and A_1 receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



ST4206

Cat. No.: HY-U00341

Bioactivity: ST4206 is a potent **adenosine A2A** antagonist, with **K_i**s of 12 nM and 197 nM for adenosine A2A receptor and adenosine A1 receptor, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Taminadenant

Cat. No.: HY-109139

Bioactivity: Taminadenant is an antagonist of **adenosine receptor** [1].

Purity: 99.13%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Tecadenoson

(CVT-510)

Cat. No.: HY-19661

Bioactivity: Tecadenoson (CVT-510) is a selective **A1 adenosine receptor** agonist.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Theobromine

(3,7-Dimethylxanthine)

Cat. No.: HY-N0138

Bioactivity: Theobromine is a methylxanthine found in cacao beans which can inhibit **adenosine receptor A1** (**AR1**) signaling.

Purity: 99.65%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
100 mg

Theophylline

(1,3-Dimethylxanthine; Theo-24)

Cat. No.: HY-B0809

Bioactivity: Theophylline is a nonselective **phosphodiesterase (PDE)** inhibitor, **adenosine receptor** blocker, and **histone deacetylase (HDAC)** activator.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 g



Ticlopidine hydrochloride

Cat. No.: HY-B0153A

Bioactivity: Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM. Target: Adenosine diphosphate (ADP) Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Ticlopidine hydrochloride inhibits platelet...

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
1 g, 5 g



Tozadenant

(SYN115)

Cat. No.: HY-10995

Bioactivity: Tozadenant is an **adenosine A_{2A}** receptor antagonist, with **K_i** of 11.5 nM on human A_{2A} and 6 nM on rhesus A_{2A}.

Purity: 98.06%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



UP202-56

Cat. No.: HY-U00226

Bioactivity: UP202-56 is an adenosine analogue, which is an adenosinergic agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Vipadenant

(BIIB-014; CEB-4520)

Cat. No.: HY-10857

Bioactivity: Vipadenant (BIIB-014; CEB-4520) is an **adenosine receptor** antagonist, with **K_i**s of 1.3 nM and 68 nM for A_{2A} and A_{1}, respectively.

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



ZM241385

Cat. No.: HY-19532

Bioactivity: ZM 241385 is a selective and high affinity **A2A adenosine receptor** antagonist.

Purity: 98.55%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Adenylate Cyclase

Adenylyl cyclase



cAMP is produced by adenylatecyclase (AC), a 12-transmembrane-spanning enzyme that catalyzes the conversion of ATP to 3′,5′-cAMP and pyrophosphate.

In neuronal and neuroendocrine cells, a variety of ligands, such as neurotransmitters and hormones, signal via activation of G protein coupled receptors (GPCRs) coupled to $G_S\alpha$. These receptors activate adenylatecyclases (ACs), the family of enzymes that generate cAMP.

cAMP is synthesized by adenylatecyclases (ACs) and degraded by phosphodiesterases (PDEs). Local cAMP signaling is achieved by targeting of signaling components to subcellular compartments and assembly of signaling complexes. Primary cilia also host several cAMP-signaling components: the somatostatin 3 receptor (SSTR3), various adenylatecyclases (AC3, AC4, AC6, AC8), PKA, and Epac2 (exchange protein directly activated by cAMP).

Adenylate Cyclase Inhibitors & Modulators

CB-7921220

Cat. No.: HY-101862

Bioactivity: CB-7921220 is an **adenylate cyclase** inhibitor.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



Forskolin

(Coleonol; Colforsin)

Cat. No.: HY-15371

Bioactivity: Forskolin is a potent **adenylate cyclase** activator, with **IC_{50}** and **EC_{50}** of 41 nM and 0.5 μM for **type I adenylyl cyclase**, respectively.

Purity: 98.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg



LRE1

Cat. No.: HY-100524

Bioactivity: LRE1 is a specific and allosteric inhibitor of soluble **adenylyl cyclase**.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Small Cardioactive Peptide B SCPB

Cat. No.: HY-P1495

Bioactivity: Small Cardioactive Peptide B (SCP_B), a neurally active peptide, stimulates **adenylate cyclase** activity in particulate fractions of both heart and gill tissues with **EC_{50}**s of 0.1 and 1.0 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



SQ22536

Cat. No.: HY-100396

Bioactivity: SQ22536 is an effective **adenylate cyclase** (**AC**) inhibitor.

Purity: 98.43%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



ST034307

Cat. No.: HY-101279

Bioactivity: ST034307 is a potent and selective **adenylyl cyclase 1 (AC1)** inhibitor, with IC_{50} of 2.3 μM.

Purity: 98.11%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



TIP 39, Tuberoinfundibular Neuropeptide

Cat. No.: HY-P1852

Bioactivity: TIP 39, Tuberoinfundibular Neuropeptide is a neuropeptide and parathyroid hormone 2 receptor (PTH2R) agonist. TIP 39 is highly conserved among species. TIP39 from all species activates adenylyl cyclase and elevates intracellular calcium levels through parathyroid hormone 2 receptor (PTH2R) [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

α-Melanocyte-Stimulating Hormone (MSH), amide

Cat. No.: HY-P0252

Bioactivity: α-Melanocyte-Stimulating Hormone (MSH), amide stimulates melanocortin 1 receptor that results in the activation of **adenylyl cyclase**.

Purity: 98.55%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Adiponectin Receptor

AdipoRs



Adiponectin is a protein which in humans is encoded by the ADIPOQ gene. It is involved in regulating glucose levels as well as fatty acid breakdown. The hormone plays a role in the suppression of the metabolic derangements that may result intype 2 diabetes, obesity, atherosclerosis, non-alcoholic fatty liver disease and an independent risk factor for metabolic syndrome. Adiponectin binds to a number of receptors. Two receptors have been identified with homology to G protein-coupled receptors, and one receptor similar to the cadherin family: adiponectin receptor 1 and adiponectin receptor 2.

Adiponectin Receptor Inhibitors & Modulators

AdipoRon

Cat. No.: HY-15848

Bioactivity: AdipoRon is an orally active **adiponectin receptor (AdipoR)** agonist, binding to AdipoR1 and AdipoR2 with $\mathbf{K_d}$s of 1.8 and 3.1 μM, respectively.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



AdipoRon hydrochloride

Cat. No.: HY-110164

Bioactivity: AdipoRon hydrochloride is an orally active and specific **AdipoR** agonist, binding to AdipoR1 and AdipoR2, with $\mathbf{K_d}$s of 1.8 and 3.1 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Gramine

(Donaxine)

Cat. No.: HY-N0166

Bioactivity: Gramine (Donaxine) is a natural alkaloid isolated from giant reed [2], acts as an active **adiponectin receptor (AdipoR)** agonist, with $\mathbf{IC_{50}}$s of 3.2 and 4.2 μM for AdipoR2 and AdipoR1, respectively [1]. Gramine is also a human and mo...

Purity: 99.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg



Adrenergic Receptor

Beta Receptor



Adrenergic receptors are a class of G protein-coupled receptors that are targets of the catecholamines, especially norepinephrine and epinephrine. Many cells possess these receptors, and the binding of a catecholamine to the receptor will generally stimulate the sympathetic nervous system. The sympathetic nervous system is responsible for the fight-or-flight response, which includes widening the pupils of the eye, mobilizing energy, and diverting blood flow from non-essential organs to skeletal muscle. There are two main groups of adrenergic receptors, α and β, with several subtypes. α receptors have the subtypes α1 and α2. β receptors have the subtypes β1, β2 and β3. All three are linked to Gs proteins, which in turn are linked to adenylate cyclase. Agonist binding thus causes a rise in the intracellular concentration of the second messenger cAMP. Downstream effectors of cAMP include cAMP-dependent protein kinase (PKA), which mediates some of the intracellular events following hormone binding.

(+)-Penbutolol

((R)-Penbutolol; (+)-Isopenbutolol) Cat. No.: HY-116790A

Bioactivity: (+)-Penbutolol is a β-adrenoceptor antagonist, with an IC_{50} of 0.74 μM [1]. (+)-Penbutolol is an optical isomer of l-penbutolol with Na^+ channel-blocking action [2].

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



(4E)-SUN9221

Cat. No.: HY-U00367

Bioactivity: (4E)-SUN9221 is a potent antagonist of **α1-adrenergic receptor** and **5-HT2 receptor**, with antihypertensive and anti-platelet aggregation activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



(R)-(-)-Phenylephrine

(Phenylephrine) Cat. No.: HY-B0769

Bioactivity: (R)-(-)-Phenylephrine is a selective **$α_1$-adrenoceptor** agonist primarily used as a decongestant.

Purity: >98%
Clinical Data: Launched
Size: 200 mg



(R)-(-)-Phenylephrine hydrochloride

(Phenylephrine hydrochloride) Cat. No.: HY-B0471

Bioactivity: (R)-(-)-Phenylephrine hydrochloride is a selective **$α_1$-adrenoceptor** agonist with **pK_is** of 5.86, 4.87 and 4.70 for $α_{1D}$, $α_{1B}$ and $α_{1A}$ receptors respectively.

Purity: 98.10%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



(RS)-Butyryltimolol

Cat. No.: HY-102032A

Bioactivity: (RS)-Butyryltimolol is the racemate of Butyryltimolol. Butyryltimolol is the butyryl ester of Timolol. Timolol is in the non-selective **β** blocker family of medication.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



(S)-Timolol Maleate

(L-714,465 (Maleate); MK 950) Cat. No.: HY-17380

Bioactivity: (S)-Timolol maleate, is a potent non-selective β-adrenergic receptor antagonist (Ki values are 1.97 and 2.0 nM for β1 and β2 receptor subtypes respectively). IC50 Value: 1.97 nM(Ki for β1); 2.0 nM(Ki for β2) Target: β-adrenergic receptor (S)-Timolol, 50% bioavailability following oral...

Purity: 99.87%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg



(±)-Befunolol

Cat. No.: HY-101752

Bioactivity: (±)-Befunolol is a **β-adrenoceptor** blocking agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



(±)-Bisoprolol (hemifumarate)

(Bisoprolol hemifumarate salt) Cat. No.: HY-B0076

Bioactivity: Bisoprolol is a selective type β1 adrenergic receptor blocker.

Purity: 98.41%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 200 mg, 500 mg



3-Hydroxy-4-methoxycinnamic acid

(Isoferulic acid) Cat. No.: HY-N0761

Bioactivity: 3-Hydroxy-4-methoxycinnamic acid (Isoferulic acid) is a cinnamic acid derivative that has antidiabetic activity. 3-Hydroxy-4-methoxycinnamic acid binds to and activates α1-adrenergic receptors (IC_{50}=1.4 μM) to enhance secret...

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



5-HT2 antagonist 1

Cat. No.: HY-U00365

Bioactivity: 5-HT2 antagonist 1 is a potent antagonist of **5-HT2 receptor**, with weak **α1 adrenoceptor** blocking activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Acebutolol hydrochloride

Cat. No.: HY-17497A

Bioactivity: Acebutolol Hydrochloride is a β-adrenergic receptors antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 5 g, 10 g



Adrenalone hydrochloride

Cat. No.: HY-B1308

Bioactivity: Adrenalone hydrochloride is a selective α1-adrenoceptor agonist, used as a topical vasoconstrictor and hemostatic, used to prolong the action of local anesthetics.

Purity: 98.0%
Clinical Data: Launched
Size: 100 mg



AGN 192836

Cat. No.: HY-100300

Bioactivity: AGN 192836 is a potent and selective **α2 adrenergic** agonist with **EC_{50}**s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Alfuzosin

(SL 77499)

Cat. No.: HY-B0192

Bioactivity: Alfuzosin is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

Purity: 99.81%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Alfuzosin hydrochloride

(SL 77499-10)

Cat. No.: HY-B0192A

Bioactivity: Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Amezinium methylsulfate

(Amezinium metilsulfate; Lu-1631)

Cat. No.: HY-A0275

Bioactivity: Amezinium metilsulfate has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition ofnoradrenaline and tyramine uptake.

Purity: 99.51%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g



Amibegron hydrochloride

(SR 58611A)

Cat. No.: HY-103207

Bioactivity: Amibegron hydrochloride is a selective **β3-adrenoceptor** agonist, with an **EC_{50}** of 3.5 nM for **β-adrenoceptor** in rat colon; Amibegron hydrochloride has anxiolytic and antidepressant activity.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg



Amitraz

(BTS-27419)

Cat. No.: HY-B1111

Bioactivity: Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Ancarolol

Cat. No.: HY-100141

Bioactivity: Ancarolol is a **beta-adrenergic** blocking agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



AR-08

Cat. No.: HY-U00371

Bioactivity: AR-08 is an agonist of **α2-adrenergic receptor**, used for the treatment of attention deficit hyperactivety disorder (ADHD).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Asenapine

(Org 5222)

Cat. No.: HY-10121

Bioactivity: Asenapine(Org 5222) inhibits adrenergic receptor (α1, α2A, α2B, α2C) with Ki of 0.25-1.2 nM and also inhibits 5-HT receptor (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) with Ki of 0.03-4.0 nM. IC50 Value: 0.25-1.2 nM(Ki for adrenergic receptor); 0.03-4.0 nM(Ki for 5-HT receptor) Target: 5-HT Receptor;...

Purity: >98%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Atenolol

((RS)-Atenolol)

Cat. No.: HY-17498

Bioactivity: Atenolol is a selective β1 receptor antagonist.

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 1 g, 5 g



Atipamezole

(MPV 1248)

Cat. No.: HY-12380A

Bioactivity: Atipamezole is a synthetic **α_2-adrenoceptor antagonist** with a **K_i** of 1.6 nM.

Purity: 99.07%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Atipamezole hydrochloride

(MPV-1248 hydrochloride)

Cat. No.: HY-12380

Bioactivity: Atipamezole hydrochloride is a synthetic **α_2-adrenoceptor antagonist** with a **K_i** of 1.6 nM.

Purity: 99.96%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Bambuterol

(KWD-2183; (±)-Bambuterol)

Cat. No.: HY-17501

Bioactivity: Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. IC50 value: Target: beta-adrenoceptor agonist Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people...

Purity: >98%

Clinical Data: Launched

Size: 10 mg, 50 mg, 100 mg



Bambuterol hydrochloride

(KWD-2183 hydrochloride; (±)-Bambuterol hydrochloride)

Cat. No.: HY-17501A

Bioactivity: Bambuterol Hcl is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. IC50 value: Target: beta-adrenoceptor agonist Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people...

Purity: 99.57%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Batefenterol

(GSK961081; TD-5959)

Cat. No.: HY-12980

Bioactivity: Batefenterol (GSK961081;TD-5959) is a novel **muscarinic** receptor antagonist and **β_2-adrenoceptor** agonist; displays high affinity for hM2, hM3 muscarinic and hβ $_2$-adrenoceptor with **K_i** values of 1.4, 1.3 and 3.7 nM, respectively.

Purity: 98.30%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Benzquinamide

(P2647; BZQ; Benzoquinamide)

Cat. No.: HY-U00244

Bioactivity: Benzquinamide (P2647) is an antiemetic which can bind to the **α_{2A}**, **α_{2B}**, and **α_{2C} adrenergic receptors** (α2-AR) with K_i values of 1,365, 691, and 545 nM, respectively.

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg, 10 mg, 20 mg



Betaxolol

Cat. No.: HY-B0381

Bioactivity: Betaxolol is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.

Purity: 96.95%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Betaxolol hydrochloride

(SL75212)

Cat. No.: HY-B0381A

Bioactivity: Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.

Purity: 98.94%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Bometolol Hydrochloride

Cat. No.: HY-U00386

Bioactivity: Bometolol Hydrochloride is a **beta-adrenergic** blocking agent, used for the research of cardiovascular disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Brimonidine

(UK 14304; AGN190342)

Cat. No.: HY-B0659

Bioactivity: Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Brimonidine tartrate

(UK 14304 (tartrate); AGN190342 (tartrate))

Cat. No.: HY-B0659A

Bioactivity: Brimonidine tartrate (UK 14304 tartrate) is a full α2-adrenergic receptor (α2-AR) agonist.

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Carbazochrome sodium sulfonate

(AC-17)

Cat. No.: HY-B0491A

Bioactivity: Carbazochrome (sodium sulfonate) (AC-17) is an antihemorrhagic agent. Target: Others Carbazochrome is an antihemorrhagic agent that will cease blood flow by causing the aggregation and adhesion of platelets in the blood to form a platelet plug, ceasing blood flow from an open wound. It is hoped that...

Purity: 99.51%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Carteolol hydrochloride

(OPC-1085 hydrochloride)

Cat. No.: HY-17495A

Bioactivity: Carteolol HCl is a non-selective beta blocker used to treat glaucoma. Target: Beta adrenergic Receptor Carteolol HCl is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol hydrochloride at 1 mmol/L...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Carvedilol

(BM 14190)

Cat. No.: HY-B0006

Bioactivity: Carvedilol(BM14190) is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 μM for inhibition of LDL oxidation. IC50 Value: 3.8 μM (inhibition of LDL oxidation) Target: beta Adrenergic Receptor Carvedilol is a nonselective-blocking agent and is used in the treatment of...

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Carvedilol phosphate hemihydrate

(BM 14190 (phosphate hemihydrate))

Cat. No.: HY-B0006A

Bioactivity: Carvedilol (phosphate hemihydrate) (BM 14190 (phosphate hemihydrate)) is a non-selective beta blocker/alpha-1 blocker with an IC_{50} of 3.8 μM for inhibition of LDL oxidation.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Centanafadine

(EB-1020)

Cat. No.: HY-16736

Bioactivity: Centanafadine is dual **norepinephrine (NE)/dopamine (DA)** transporter inhibitor, also inhibits serotonin transporter, with **IC_{50}s** of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Centanafadine hydrochloride

(EB-1020 (hydrochloride))

Cat. No.: HY-16736A

Bioactivity: Centanafadine (hydrochloride) is dual **norepinephrine (NE)/dopamine (DA)** transporter inhibitor, also inhibits serotonin transporter, with **IC_{50}s** of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Cicloprolol hydrochloride

Cat. No.: HY-U00066

Bioactivity: Cicloprolol is a partial **β 1-adrenoceptor** agonist .

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Clonidine hydrochloride

Cat. No.: HY-B0409A

Bioactivity: Clonidine hydrochloride is an agonist of **α2-adrenoceptor** and potent antihypertensive agent.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Clorprenaline hydrochloride

Cat. No.: HY-B1347

Bioactivity: Clorprenaline hydrochloride is a **β_2-adrenergic receptor** agonist.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



D2343

Cat. No.: HY-U00206

Bioactivity: D2343 is a **β2-adrenoceptor** agonist and also is an **α1-adrenoceptor** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Dapiprazole hydrochloride

Cat. No.: HY-A0142A

Bioactivity: Dapiprazole hydrochloride is a potent α-adrenergic blocking drug, which is used to reverse mydriasis after eye examination.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Deriglidole

(SL 86-0715)

Cat. No.: HY-101683

Bioactivity: Deriglidole is a peripheral **adrenoceptor** antagonist with a high affinity for α $_2$-adrenoceptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Detomidine

Cat. No.: HY-B0163

Bioactivity: Detomidine produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Detomidine hydrochloride

Cat. No.: HY-B0163A

Bioactivity: Detomidine hydrochloride produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride)

Cat. No.: HY-17034A

Bioactivity: Dexmedetomidine Hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties. Target: Adrenergic alpha-2 Receptor Dexmedetomidine, acting at alpha(2A) adrenoceptors, must be present during the encoding process to decrease...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



DL-Epinephrine

((±)-Epinephrine; (±)-Adrenaline; DL-Adrenali)

Cat. No.: HY-B0447

Bioactivity: DL-Epinephrine is the racemate of epinephrine. L-Epinephrine is a hormone secreted by the medulla of the adrenal glands. L-Epinephrine is an **α-adrenergic** and **β-adrenergic** receptor agonist.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 1 g, 5 g



Dobutamine hydrochloride

Cat. No.: HY-15746

Bioactivity: Dobutamine Hcl(Dobutrex) is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Its primary mechanism is direct stimulation of β1 receptors of the sympathetic nervous system.

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Dopexamine hydrochloride

(FPL60278AR) Cat. No.: HY-U00205

Bioactivity: Dopexamine hydrochloride is a **β2 adrenergic receptor** agonist.

Purity: >98%
Clinical Data: Launched
Size: 1 mg



Doxazosin

(UK 33274) Cat. No.: HY-B0098

Bioactivity: Doxazosin(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Doxazosin mesylate

(UK 33274 mesylate) Cat. No.: HY-B0098A

Bioactivity: Doxazosin mesylate(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. Target: α1-adrenergic receptor Doxazosin (mesylate) is the mesylate salt form of doxazosin, which is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat...

Purity: 98.60%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g



Ecastolol

Cat. No.: HY-101691

Bioactivity: Ecastolol is a **beta adrenergic receptor** antagonist, with antianginal activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Epanolol

(Visacor; ICI141292) Cat. No.: HY-U00183

Bioactivity: Epanolol (Visacor; ICI141292) is a potent **β-adrenoceptor** partial agonist with a greater affinity for **β1**- than β2-adrenoceptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Esmolol hydrochloride

Cat. No.: HY-B1392

Bioactivity: Esmolol Hydrochloride is a beta adrenergic receptor blocker. Target: Adrenergic receptor Esmolol Hydrochloride is the hydrochloride salt form of Esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic...

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Falintolol, (Z)-

Cat. No.: HY-U00283

Bioactivity: Falintolol, (Z)-, a new **β-adrenergic** antagonist, is characterized by the presence of an oxime function.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Fenmetozole Tosylate

Cat. No.: HY-U00402

Bioactivity: Fenmetozole Tosylate is an antagonist of the actions of ethanol, also antagonizes **α2-adrenergic receptor**, and acts as an antidepressant drug.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Fenspiride Hydrochloride

Cat. No.: HY-A0027

Bioactivity: Fenspiride Hcl is an α adrenergic and H1 histamine receptor antagonist.

Purity: 99.03%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Fiduxosin

Cat. No.: HY-U00399

Bioactivity: Fiduxosin is a potent **α1-adrenoceptor** antagonist, with K_i of 0.160 nM, 24.9 nM, and 0.920 nM for α1a-, α1b-, and α1d-adrenoceptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Gramine
(Donaxine) Cat. No.: HY-N0166

Bioactivity: Gramine (Donaxine) is a natural alkaloid isolated from giant reed [2], acts as an active **adiponectin receptor (AdipoR)** agonist, with **IC_{50}**s of 3.2 and 4.2 μM for AdipoR2 and AdipoR1, respectively [1]. Gramine is also a human and mo...

Purity: 99.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg



Guanabenz Acetate
(BR-750; Wy8678 acetate) Cat. No.: HY-B0566

Bioactivity: Guanabenz (Acetate) (BR-750) is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.

Purity: 98.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Guanfacine
Cat. No.: HY-17416A

Bioactivity: Guanfacine is a selective α2A receptor agonist. Target: α2A Receptor Guanfacine is a sympatholytic. It is a selective α2A receptor agonist. These receptors are concentrated heavily in the prefrontal cortex and the locus coeruleus, with the potential to improve attention resulting from interaction with...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Guanfacine hydrochloride
Cat. No.: HY-17416

Bioactivity: Guanfacine Hcl, an anti-hypertensive agent, is a selective α2A-adrenoceptor agonist with Kd of 31 nM and displays 60-fold selectivity over α2B-adrenoceptors. IC50 Value: 31 nM(Kd) Target: Adrenergic Receptor Guanfacine is a sympatholytic. It is a selective α2A receptor agonist. These receptors are...

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Guanoxabenz
(Hydroxyguanabenz) Cat. No.: HY-U00123

Bioactivity: Guanoxabenz is an **α2 adrenergic receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



HOKU-81
(4-Hydroxytulobuterol) Cat. No.: HY-50291

Bioactivity: HOKU-81, a new bronchodilator, is one of the metabolites of tulobuterol.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 25 mg



Hydrocortisone 17-butyrate
(Cortisol 17-butyrate; Hydrocortisone butyrate) Cat. No.: HY-B0983

Bioactivity: Hydrocortisone 17-butyrate is an adrenocortico hormone.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg



ICI 118,551 hydrochloride
(ICI 118551 hydrochloride) Cat. No.: HY-13951

Bioactivity: ICI 118,551 (hydrochloride) is a highly selective **β2 adrenergic receptor** antagonist, with **K_i**s of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.

Purity: 98.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Imoxiterol
(RP 58802B) Cat. No.: HY-101585

Bioactivity: Imoxiterol is a **β-adrenergic** agonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Indacaterol
Cat. No.: HY-14299

Bioactivity: Indacaterol(Onbrez; Arcapta) is an ultra-long-acting β-adrenoceptor agonist.

Purity: 96.17%
Clinical Data: Launched
Size: 100 mg, 500 mg



Indacaterol maleate

(QAB149) Cat. No.: HY-14299A

Bioactivity: Indacaterol (QAB149) maleate is an ultra-long-acting β-adrenoceptor agonist.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Indanidine

Cat. No.: HY-101717

Bioactivity: Indanidine is an **alpha-adrenergic** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Indoramin D5

(Indoramine D5; Wy-21901 D5) Cat. No.: HY-12760S

Bioactivity: Indoramin D5 is deuterium labeled Indoramin, which is a piperidine antiadrenergic agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Isoprenaline hydrochloride

(Isoproterenol hydrochloride) Cat. No.: HY-B0468

Bioactivity: Isoprenaline hydrochloride is a non-selective **beta-adrenergic receptor** agonist with potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities.

Purity: 99.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 200 mg, 1 g



Ivabradine D3 Hydrochloride

Cat. No.: HY-B0162AS1

Bioactivity: Ivabradine D3 Hydrochloride is the deuterium labeled Ivabradine hydrochloride. Ivabradine hydrochloride is a new I_f inhibitor with IC_{50} of 2.9 μM, and used as a pure heart rate lowering agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Ivabradine D6 hydrochloride

Cat. No.: HY-B0162AS

Bioactivity: Ivabradine D6 hydrochloride is the deuterium labeled Ivabradine hydrochloride. Ivabradine hydrochloride is a new I_f inhibitor with IC_{50} of 2.9 μM, and used as a pure heart rate lowering agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Ivabradine hydrochloride

Cat. No.: HY-B0162A

Bioactivity: Ivabradine is an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (**HCN**) channel blocker.

Purity: 98.39%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



JP1302 dihydrochloride

Cat. No.: HY-103213

Bioactivity: JP1302 dihydrochloride is a selective, high affinity antagonist of the **alpha2C-adrenoceptor (α_{2C}-adrenoceptor)**, with a K_b value (antagonist activity) of 16 nM and a K_i (binding affinity) value of 28 nM [1] [2].

Purity: >98%
Clinical Data: No Development Reported
Size:



Ko-3290

Cat. No.: HY-101721

Bioactivity: Ko-3290 is an antagonist of **β-adrenoceptor**, with cardioselectivity and antilipolytic effects in animals.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



L-(-)-α-Methyldopa

(MK-351; Methyldopa) Cat. No.: HY-B0225

Bioactivity: Methyldopa is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive. Target: alpha-adrenergic agonist Methyldopa is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a...

Purity: >98%
Clinical Data: Launched
Size: 1 g



L-(-)-α-Methyldopa hydrate

(MK-351 hydrate; Methyldopa hydrate) Cat. No.: HY-B0225B

Bioactivity: L-(-)-α-Methyldopa hydrate is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive. Target: alpha-adrenergic agonist Methyldopa is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive...
Purity: 98.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



L-(-)-α-Methyldopa hydrochloride

(MK-351 hydrochloride; Methyldopa hydrochloride) Cat. No.: HY-B0225A

Bioactivity: L-(-)-α-Methyldopa hydrochloride is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive. Target: alpha-adrenergic agonist Methyldopa is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive...
Purity: >98%
Clinical Data: Launched
Size: 1 g



L-765314

Cat. No.: HY-101385

Bioactivity: L-765314 is a potent and selective **α1b adrenergic receptor** antagonist with **K_i**s of 5.4 nM and 2.0 nM for rat and human α1b adrenergic receptor, respectively.
Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



L-771688

Cat. No.: HY-U00237

Bioactivity: L-771688 is a highly selective **α1A-Adrenoceptor** antagonist with a **K_i** of 0.43±0.02 nM.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



L-Epinephrine

((-)-Epinephrine; L-Adrenaline; (-)-Adrenalin) Cat. No.: HY-B0447B

Bioactivity: L-Epinephrine is a hormone secreted by the medulla of the adrenal glands. L-Epinephrine is an **α-adrenergic** and **β-adrenergic** receptor agonist.
Purity: 99.0%
Clinical Data: Launched
Size: 1 g, 5 g, 25 g



L-Epinephrine Bitartrate ((-)-Epinephrine (+)-bitartrate salt; L-Adrenaline (+)-bitartrate salt)

Cat. No.: HY-B0447A

Bioactivity: L-Epinephrine bitartrate is an **α-adrenergic** and **β-adrenergic** receptor agonist. L-Epinephrine is a hormone secreted by the medulla of the adrenal glands.
Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



L755507

Cat. No.: HY-19334

Bioactivity: L755507 is a potent, selective agonist of **β_3-AR** with an **IC_{50}** of 35 nM.
Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg

Labetalol hydrochloride

(AH-5158 hydrochloride; Sch-15719W) Cat. No.: HY-B1108

Bioactivity: Labetalol hydrochloride is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Latrepirdine dihydrochloride

(Dimebolin dihydrochloride) Cat. No.: HY-14537

Bioactivity: Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and **amyloid-β** (**Aβ**) secretion.
Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



Levalbuterol tartrate

(Levosalbutamol tartrate) Cat. No.: HY-17457

Bioactivity: Levosalbutamol tartrate(levalbuterol) is the R-enantiomer of the short-acting β2-adrenergic receptor agonist salbutamol.
Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Levobetaxolol hydrochloride

((S)-Betaxolol hydrochloride; AL-1577A) Cat. No.: HY-B0381B

Bioactivity: Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker), used to lower the pressure in the eye in treating conditions such as glaucoma.

Purity: 98.11%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Lidanserin

(ZK-33839) Cat. No.: HY-101815

Bioactivity: Lidanserin is a drug which acts as a combined **5-HT$_{2A}$** and **α_1-adrenergic receptor** antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Lofexidine

Cat. No.: HY-B1052A

Bioactivity: Lofexidine is a selective **α2-receptor** agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal [1] [2].

Purity: 99.08%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



Lofexidine hydrochloride

(Baq-168; MDL-14042) Cat. No.: HY-B1052

Bioactivity: Lofexidine (hydrochloride) is a selective **α2-receptor** agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal [1] [2].

Purity: >98%
Clinical Data: Launched
Size: 50 mg



Lusaperidone

(R107474) Cat. No.: HY-U00117

Bioactivity: Lusaperidone (R107474) is an α2 **adrenergic receptor** antagonist with **K_i**s of 0.13 and 0.15 nM for α2A and α2C, respectively.

Purity: 97.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Medetomidine

Cat. No.: HY-17034

Bioactivity: Medetomidine(Domtor) is a potent, highly selective α2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively).

Purity: 99.88%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Medetomidine hydrochloride

(MPV785) Cat. No.: HY-17034B

Bioactivity: Medetomidine Hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties. Target: Adrenergic alpha-2 Receptor Medetomidine, acting at alpha(2A) adrenoceptors, must be present during the encoding process to decrease discrete...

Purity: 99.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 50 mg



Metipranolol hydrochloride

Cat. No.: HY-16316

Bioactivity: Metipranolol is a non-selective **β adrenergic receptor** blocking agent.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Metoprolol

Cat. No.: HY-17503

Bioactivity: Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: β1 receptor

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Metoprolol Succinate

Cat. No.: HY-17503A

Bioactivity: Metoprolol Succinate (Toprol XL) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: β1 receptor

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Metoprolol Tartrate

Cat. No.: HY-17503B

Bioactivity: Metoprolol is a cardioselective β1-adrenergic blocking agent.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



MG 1

Cat. No.: HY-U00110

Bioactivity: MG 1 is an α1 **adrenergic receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Midaglizole hydrochloride

((±)-DG5128; DG5128)

Cat. No.: HY-U00165

Bioactivity: Midaglizole hydrochloride (DG5128) is a preferential **α2-adrenoceptor** antagonist. Midaglizole hydrochloride (DG5128) exhibits 7.4 times higher affinity (**pK_i**=6.28) toward α2-adrenoceptor than α1-adrenoceptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Mirabegron

(YM178)

Cat. No.: HY-14773

Bioactivity: Mirabegron is a selective **β_3-adrenoceptor** agonist with **EC_{50}** of 22.4 nM.

Purity: 99.08%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Moxisylyte hydrochloride

(Thymoxamine hydrochloride)

Cat. No.: HY-B1435

Bioactivity: Moxisylyte (hydrochloride) is (alpha 1-blocker) antagonist, it can vasodilates cerebral vessels without reducing blood pressure. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. [1][2]

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 1 g



Nadolol D9

(SQ-11725 D9)

Cat. No.: HY-B0804S

Bioactivity: Nadolol D9 is the deuterium labeled Nadolol(SQ-11725), which is a non-selective beta blocker.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Naftopidil

(KT-611; BM-15275)

Cat. No.: HY-B0391

Bioactivity: Naftopidil (Flivas), a selective α1-adrenergic receptor antagonist or alpha blocker, is an antihypertensive drug.

Purity: 98.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g



Naphazoline hydrochloride

Cat. No.: HY-B0446

Bioactivity: Naphazoline HCl is an ocular vasoconstrictor and imidazoline derivative sympathomimetic amine.

Purity: 96.55%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g, 10 g

Nebivolol

(R 065824)

Cat. No.: HY-B0203

Bioactivity: Nebivolol selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Nebivolol hydrochloride

(R 065824 hydrochloride)

Cat. No.: HY-B0203A

Bioactivity: Nebivolol hydrochloride selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Nefazodone hydrochloride

(BMY-13754; MJ-13754-1) Cat. No.: HY-B1396

Bioactivity: Nefazodone hydrochloride is an antidepressant drug.

Purity: 99.71%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Nicergoline

Cat. No.: HY-B0702

Bioactivity: Nicergoline is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Target: Alpha-1A adrenergic receptor Nicergoline acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of...

Purity: 99.06%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Norepinephrine

(Levarterenol; L-Noradrenaline) Cat. No.: HY-13715

Bioactivity: Norepinephrine (Levarterenol; L-Noradrenaline) is a β_1-selective **adrenergic receptor** agonist with **EC_{50}** of 5.37 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg



Norepinephrine bitartrate monohydrate (Levarterenol

(bitartrate monohydrate); ...) Cat. No.: HY-13715B

Bioactivity: Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate) is a β_1-selective **adrenergic receptor** agonist with **EC_{50}** of 5.37 μM.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g, 5 g



Norepinephrine hydrochloride (Levarterenol (hydrochloride);

L-Noradrenaline (hydrochloride)) Cat. No.: HY-13715A

Bioactivity: Norepinephrine hydrochloride (Levarterenol hydrochloride; L-Noradrenaline hydrochloride) is a β_1-selective **adrenergic receptor** agonist with **EC_{50}** of 5.37 μM.

Purity: >98%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g



NRA-0160

Cat. No.: HY-101641

Bioactivity: NRA-0160 is a selective **dopamine D4 receptor** antagonist, with a **K_i** value of 0.48 nM and with negligible affinity for **dopamine D2 receptor** (**K_i**: >10000 nM), **D3 receptor** (**K_i**: 39 nM), rat **5-HT2A receptor** (**K_i**: 180 nM) and rat

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Octopamine hydrochloride

((±)-p-Octopamine hydrochlorid) Cat. No.: HY-B0528A

Bioactivity: Octopamine Hydrochloride is an endogenous biogenic amine that is closely related to norepinephrine, and has effects on the adrenergic and dopaminergic systems.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 1 g, 5 g



OPC-28326

Cat. No.: HY-101610

Bioactivity: OPC-28326 is a selective peripheral vasodilator and an angatonist of **α2-adrenergic receptor**, with **K_i** of 2040, 285, and 55nM for α2A-, α2B- and α2C-adrenoceptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Pamatolol

Cat. No.: HY-U00019

Bioactivity: Pamatolol is a cardioselective **beta-adrenoceptor** antagonist without sympathomimetic activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Pardoprunox

(SLV-308; DU-126891) Cat. No.: HY-14958

Bioactivity: Pardoprunox(SLV-308) is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist; D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%); also binds to D4 (pKi = 7.8),...

Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Pardoprunox hydrochloride

(SLV-308 hydrochloride; DU-126891 hydrochloride) Cat. No.: HY-14958A

Bioactivity: Pardoprunox hydrochloride is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist, D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist and 5-HT1A receptor (pKi = 8.5) full agonist.

Purity: 98.89%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Pargolol hydrochloride

(Ko 1400 hydrochloride) Cat. No.: HY-101658

Bioactivity: Pargolol hydrochloride is a **β adrenergic receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Penbutolol sulfate

((-)-Terbuclomine) Cat. No.: HY-B1154

Bioactivity: Penbutolol sulfate is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker. Penbutolol is a sympathomimetic drugused in the treatment of high blood pressure.

Purity: 99.62%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg



Perphenazine

Cat. No.: HY-A0077

Bioactivity: Perphenazine is a typical antipsychotic drug, inhibits **5-HT$_{2A}$receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor**, and **Histamine H1 receptor**, with **K$_i$** values of 5.6, 10, 0.765/0.13, 3.4, and 8 ...

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Perphenazine D8 Dihydrochloride

Cat. No.: HY-A0077AS

Bioactivity: Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Phenoxybenzamine hydrochloride

Cat. No.: HY-B0431A

Bioactivity: Phenoxybenzamine hydrochloride is a selective antagonist of both **α-adrenoceptor** and **calmodulin** that is commonly used for the treatment of hypertension, specifically caused by pheochromocytoma.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg, 1 g



Phentolamine mesylate

(Phentolamine methanesulfonate) Cat. No.: HY-B0362A

Bioactivity: Phentolamine mesylate is a competitive, reversible **α-adrenoceptor** antagonist with an **IC$_{50}$** between 5 and 30 nM.

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Pimozide

(R6238) Cat. No.: HY-12987

Bioactivity: Pimozide is a **dopamine receptor** antagonist, with **K$_i$**s of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at **α1-adrenoceptor**, with a **K$_i$** of 39 nM; Pimozide also inhib...

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



Pindolol

(LB-46) Cat. No.: HY-B0982

Bioactivity: Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial agonist / antagonist (Ki=33nM).

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Piperoxan hydrochloride

(Benodaine hydrochloride) Cat. No.: HY-100850

Bioactivity: Piperoxan hydrochloride is an α $_2$ adrenoceptor antagonist.

Purity: 99.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Piribedil

Cat. No.: HY-12707

Bioactivity: Piribedil is a **dopamine D_2 receptor** (**D_2R**) agonist which also displays antagonist property at **hα_{1A}-adrenoceptor** (**hα_{1A}-AR**).

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Piribedil D8

(ET-495 D8)

Cat. No.: HY-12707S

Bioactivity: Piribedil D8 is the deuterium labeled Piribedil, which is an antiparkinsonian agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Prazosin

Cat. No.: HY-B0193

Bioactivity: Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder.

Purity: >98%
Clinical Data: Launched
Size: 10 mg



Prazosin hydrochloride

Cat. No.: HY-B0193A

Bioactivity: Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic...

Purity: 99.73%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Pronethalol

((±)-Pronethalo)

Cat. No.: HY-B1238

Bioactivity: Pronethalol is a non-selective beta-adrenergic blocking agent, protect against and to reverse Digitalis-induced ventricular arrhythmias. Target: beta-adrenergic receptor

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg



Propranolol hydrochloride

Cat. No.: HY-B0573

Bioactivity: Propranolol hydrochloride is a nonselective β-adrenergic receptor (**βAR**) antagonist with an **IC_{50}** of 12 nM.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g



QF0301B

Cat. No.: HY-101690

Bioactivity: QF0301B is an **α1 adrenergic receptor** antagonist and a low α2 adrenoceptor, 5-HT2A, and histamine H1 receptor blocker.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Rauwolscine hydrochloride (α-Yohimbine hydrochloride; Corynanthidine hydrochloride; Isoyohimbine hydrochloride)

Cat. No.: HY-12710A

Bioactivity: Rauwolscine hydrochloride is a potent and specific **α2 adrenergic** receptor antagonist with a **K_i** of 12 nM.

Purity: 99.16%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Rotigotine

(N-0437; N-0923)

Cat. No.: HY-75502

Bioactivity: Rotigotine is a full agonist of **dopamine receptor**, a partial agonist of the **5-HT1A receptor**, and an antagonist of the **α2B-adrenergic receptor**, with **K_i**s of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



RS 17053 hydrochloride

(RS-17053)

Cat. No.: HY-101336

Bioactivity: RS 17053 hydrochloride is a potent and selective **α1$_A$ adrenoceptor** antagonist, with a **pK_i** value of 9.1 in native cell membrane and a **pA_2** value of 9.8 in functional assays.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Salbutamol

(Albuterol; AH-3365) Cat. No.: HY-B1037

Bioactivity: Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Salbutamol hemisulfate

(Albuterol (hemisulfate); AH-3365 (hemisulfate)) Cat. No.: HY-B0436

Bioactivity: Salbutamol Hemisulfate is a short-acting β2 adrenergic receptor agonist Target: β2 Adrenergic Receptor Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. All the effects of R,S-salbutamol on guinea-pig skeletal muscles are due to the...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Salmeterol

(GR33343X) Cat. No.: HY-14302

Bioactivity: Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma.

Purity: 99.68%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Salmeterol xinafoate

(GR 33343X xinafoate) Cat. No.: HY-17453

Bioactivity: Salmeterol xinafoate is a long-acting beta-2 adrenergic receptor (**β_2AR**) agonist, with **K_i** of 1.5 nM for WT β_2AR, and used for asthma treatment.

Purity: 97.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Scopine

(6,7-Epoxytropine) Cat. No.: HY-B0459

Bioactivity: Scopine is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg



Scopine hydrochloride

(6,7-Epoxytropine hydrochloride) Cat. No.: HY-B0459A

Bioactivity: Scopine Hcl salt is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Silodosin

(KAD 3213; KMD 3213) Cat. No.: HY-10122

Bioactivity: Silodosin (Rapaflo; KMD-3213) is an α1-adrenoceptor antagonist with high uroselectivity; In treatment of dysuria.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Solabegron

(GW 427353) Cat. No.: HY-19436

Bioactivity: Solabegron (GW 427353) is a selective **β_3-adrenergic receptor** agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β_3-AR, with an **EC_{50}** value of 22 nM [1]. Solabegron (GW 427353) is being developed ...

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Sotalol hydrochloride

(MJ-1999) Cat. No.: HY-B0437

Bioactivity: Sotalol Hydrochloride is an adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. Target: Adrenergic Receptor Sotalol is a non-selective competitive β-adrenergic receptor blocker that also exhibits Class III antiarrhythmic properties by its inhibition of potassium...

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Spirendolol

(Li 32-468; S 32-468; Substance 32468) Cat. No.: HY-101817

Bioactivity: Spirendolol is a **β adrenergic receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Synephrine hydrochloride

(Oxedrine hydrochloride) Cat. No.: HY-N0132A

Bioactivity: Synephrine Hcl(Oxedrine) is an alkaloid; synephrine produces most of its biological effects by acting as an agonist at adrenergic receptors.

Purity: 99.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Talipexole dihydrochloride

(B-HT 920 (dihydrochloride)) Cat. No.: HY-A0008

Bioactivity: Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



TD-5471 hydrochloride

Cat. No.: HY-19942A

Bioactivity: TD-5471 hydrochloride is a potent and selective full agonist of the human **β_2-adrenoceptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Tedatioxetine hydrobromide

(Lu AA 24530 hydrobromide) Cat. No.: HY-101755

Bioactivity: Tedatioxetine hydrobromide acts as a triple reuptake inhibitor and **5-HT_{2A}**, **5-HT_{2C}**, **5-HT_3** and **α_{1A}-adrenergic receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Teoprolol

Cat. No.: HY-U00016

Bioactivity: Teoprolol is a **β-adrenergic receptor** blocker.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Terazosin

Cat. No.: HY-B0371

Bioactivity: Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Terazosin hydrochloride dihydrate

Cat. No.: HY-B0371A

Bioactivity: Terazosin Hydrochloride dihydrate is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Terbutaline sulfate

(Terbutaline hemisulfate) Cat. No.: HY-B0802

Bioactivity: Terbutaline sulfate is a β2-adrenergic receptor agonist; a fast-acting bronchodilator and a tocolytic to delay premature labor.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g, 5 g



Tertatolol

((±)-Tertatolol; Racemic Tertatolol; dl-Tertatolol) Cat. No.: HY-U00356

Bioactivity: Tertatolol is a potent antagonist of **beta-adrenoceptor** and **5-HT receptor**, with unique renal vasodilatatory effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Tetrahydrozoline hydrochloride

(Tetryzoline hydrochloride) Cat. No.: HY-B0556A

Bioactivity: Tetrahydrozoline (hydrochloride) is a α-adrenoceptor agonist.

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Tiodazosin

(BL-5111)

Cat. No.: HY-100255

Bioactivity: Tiodazosin is a potent competitive postsynaptic **alpha adrenergic receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Tizanidine

Cat. No.: HY-B0194

Bioactivity: Tizanidine is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Tizanidine hydrochloride

Cat. No.: HY-B0194A

Bioactivity: Tizanidine hydrochloride is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons. Target: α2-adrenergic receptor Tizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist. It is used to treat the spasms, cramping,...

Purity: 99.48%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Tolazoline

(Imidaline; NSC35110)

Cat. No.: HY-A0066

Bioactivity: Tolazoline(Imidaline) is a non-selective competitive α-adrenergic receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g



Tolazoline hydrochloride

(Imidaline (hydrochloride); NSC35110 (hydrochloride))

Cat. No.: HY-A0066A

Bioactivity: Tolazoline (hydrochloride)(Imidaline (hydrochloride)) Hcl is a non-selective competitive α-adrenergic receptor antagonist. IC50 value: Target: α-adrenoceptor antagonist Tolazoline can be synthesized by the heterocyclation of the ethyl ester of iminophenzylacetic acid with ethylene diamine, which forms the...

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Tropodifene

(Tropaphen)

Cat. No.: HY-U00313

Bioactivity: Tropodifene (Tropaphen) is an **α-Adrenergic receptor** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Tulobuterol hydrochloride

Cat. No.: HY-W011733

Bioactivity: Tulobuterol hydrochloride is a **β2-adrenoceptor** agonist.

Purity: 99.82%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Urapidil

Cat. No.: HY-B0716

Bioactivity: Urapidil is an **α1 adrenoreceptor** antagonist and a **5-HT$_{1A}$ receptor** agonist.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 50 mg



Urapidil hydrochloride

Cat. No.: HY-B0354A

Bioactivity: Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Vanilpyruvic acid

(Vanylpyruvic acid)

Cat. No.: HY-101416

Bioactivity: Vanilpyruvic acid is a catecholamine metabolite and precursor to vanillactic acid.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg



Vatinoxan hydrochloride

(MK-467 hydrochloride; L-659066 hydrochloride) Cat. No.: HY-19057A

Bioactivity: Vatinoxan hydrochloride (MK-467 hydrochloride;L-659066 hydrochloride) is a peripheral **α2 adrenergic receptor** antagonist.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg



Vilanterol

(GW642444X; GW642444) Cat. No.: HY-14300

Bioactivity: Vilanterol is a long-acting **β_2-adrenoceptor** (β_2-AR) agonist with 24 h activity. The **pEC_{50}**s for β_2-AR,β_1-AR and β_3-AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.

Purity: 95.06%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Vilanterol trifenatate

(GW642444M) Cat. No.: HY-14300A

Bioactivity: Vilanterol trifenatate is a long-acting **β_2-adrenoceptor** (β_2-AR) agonist with inherent 24-hour activity. The **pEC_{50}**s for β_2-AR, β_1-AR and β_3-AR are 10.37, 6.98 and 7.36, respectively.

Purity: 99.02%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Xylazine

(BAY 1470) Cat. No.: HY-B0443

Bioactivity: Xylazine is α2 class of adrenergic receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg



Xylazine hydrochloride

(BAY 1470 hydrochloride) Cat. No.: HY-B0443A

Bioactivity: Xylazine Hydrochloride is α2 class of adrenergic receptor agonist.

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Xylometazoline hydrochloride

Cat. No.: HY-B0475

Bioactivity: Xylometazoline Hydrochloride is an α-adrenoceptor agonist commonly used as nasal decongestant.

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



Yohimbine

Cat. No.: HY-12715

Bioactivity: Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 μM. IC50 value: 0.6 uM [1] Target: alpha 2-adrenergic receptor in vitro: Yohimbine inhibits alpha2-receptor antagonist with Ki of 1.05 nM, 1.19 nM, and 1.19 nM for α2A, α2B, α2C,...

Purity: >98%
Clinical Data: Phase 4
Size: 1 g



Yohimbine Hydrochloride

Cat. No.: HY-N0127

Bioactivity: Yohimbine hydrochloride is an alpha 2-adrenoreceptor antagonist, blocking the pre- and postsynaptic alpha-2 adrenoreceptors and causing an increased release of noradrenaline and dopamine. IC50 value: Target: In vitro: In vivo: Yohimbine hydrochloride (0.2 mg/kg, i.p.) was...

Purity: 99.85%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 1 g



ZK-90055 hydrochloride

Cat. No.: HY-U00293

Bioactivity: ZK-90055 hydrochloride is a **β2 adrenergic receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



α1 adrenoceptor-MO-1

Cat. No.: HY-U00333

Bioactivity: α1 adrenoceptor-MO-1, an S enantiomer, has affinity at **alpha 1 adrenergic receptor**, shows alphalytic activity, and possesses analgesic action; more active than R enantiomer.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



β3-AR agonist 2

Cat. No.: HY-U00391

Bioactivity: β $_3$-AR agonist 2 is a potent and selective **β_3-adrenergic receptor** (**β_3-AR**) agonist with an **EC_{50}** of 8 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Angiotensin Receptor



Angiotensin receptors are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. AT2 receptors are more plentiful in the fetus and neonate. Other poorly characterized subtypes include the AT3 and AT4 receptors.

A 779

Cat. No.: HY-P0216

Bioactivity: A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an **Ang1-7 receptor** distinct from the classical AngII.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 1 mg, 5 mg



A81988

(Abbott81988) Cat. No.: HY-U00188

Bioactivity: A81988 is a potent, competitive, non-peptidic antagonist of **angiotensin AT_1** receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Angiotensin 1-7

(Angiotensin-(1-7); Ang-(1-7)) Cat. No.: HY-12403

Bioactivity: Angiotensin (1-7) inhibits purified canine angiotensin converting enzyme (**ACE**) activity with an **IC_{50}** of 0.65 μM.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg



Angiotensin II (1-4), human

Cat. No.: HY-P1792

Bioactivity: Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca $^{2+}$ levels. Angiotensin II also acts at the Na $^{+}$/H $^{+}$...

Purity: >98%
Clinical Data: No Development Reported
Size:



Angiotensin II (3-8), human

Cat. No.: HY-P1515

Bioactivity: Angiotensin II (3-8), human is a less effective agonist at the **angiotensin AT_1 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Angiotensin II (3-8), human TFA

Cat. No.: HY-P1515A

Bioactivity: Angiotensin II (3-8), human (TFA) is a less effective agonist at the **angiotensin AT_1 receptor**.

Purity: 98.99%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Angiotensin II (5-8), human

Cat. No.: HY-P1769

Bioactivity: Angiotensin II (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II [1]. Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells ...

Purity: >98%
Clinical Data: No Development Reported
Size:



Angiotensin II 5-valine

(Valine angiotensin II; 5-L-Valine angiotensin II) Cat. No.: HY-P0108

Bioactivity: Angiotensin II 5-valine is an agonist of **angiotensin receptor**.

Purity: 95.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Angiotensin II human

(Angiotensin II; Hypertensin II; Ang II; DRVYIHPF) Cat. No.: HY-13948

Bioactivity: Angiotensin II human is a vasoconstrictor that acts on the **AT1** and the **AT2** receptor.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Angiotensin III

Cat. No.: HY-113035

Bioactivity: Angiotensin III is an **angiotensin 1 (AT1)** and **AT2** receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Angiotensin III

Angiotensin III TFA

Cat. No.: HY-113035A

Bioactivity: Angiotensin III (TFA) is an **angiotensin 1 (AT1)** and **AT2** receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg

Angiotensin III, human, mouse

Cat. No.: HY-P1540

Bioactivity: Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous **angiotensin type 2 receptor (AT_2R)** agonist, with **IC_{50}**s of 0.648 nM and 21.1 nM for AT_2R and AT_1R, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



AVE 0991

Cat. No.: HY-15778

Bioactivity: AVE 0991 is a nonpeptide and orally active **angiotensin-(1-7) receptor** agonist with an **IC_{50}** of 21 nM.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AVE 0991 sodium salt

Cat. No.: HY-15778A

Bioactivity: AVE 0991 sodium salt is a nonpeptide and orally active **Ang-(1-7) receptor Mas** agonist. AVE 0991 competes for high-affinity binding of [^{125}I]-Ang-(1-7) to bovine aortic endothelial cell membranes with **IC_{50}** of 21±35 nM.

Purity: 99.32%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Azilsartan

(TAK-536)

Cat. No.: HY-14914

Bioactivity: Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Azilsartan D5

(TAK-536 D5)

Cat. No.: HY-14914S

Bioactivity: Azilsartan D5 is the deuterium labeled Azilsartan(TAK-536), which is a specific and potent angiotensin II type 1 receptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



Azilsartan medoxomil

(TAK-491)

Cat. No.: HY-14736

Bioactivity: Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Azilsartan medoxomil monopotassium

(Azilsartan kamedoxomil; TAK 491 monopotassium)

Cat. No.: HY-17458

Bioactivity: Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

Purity: 95.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BIBS 39

Cat. No.: HY-19732

Bioactivity: BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



C-Type Natriuretic Peptide (1-53), human

Cat. No.: HY-P1815

Bioactivity: C-Type Natriuretic Peptide (1-53), human is the 1-53 fragment of C-Type Natriuretic Peptide. C-Type Natriuretic Peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

C-Type Natriuretic Peptide (CNP) (1-22), human

Cat. No.: HY-P1237

Bioactivity: C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide. C-type natriuretic peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone.
Purity: 96.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 500u g, 1 mg, 5 mg

Candesartan

(CV 11974)

Cat. No.: HY-B0205

Bioactivity: Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
Purity: 98.34%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Candesartan Cilexetil

(TCV-116)

Cat. No.: HY-17505

Bioactivity: Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g



Candesartan D4

(CV-11974 D4)

Cat. No.: HY-B0205S

Bioactivity: Candesartan D4 is the deuterium labeled Candesartan, which is an angiotensin II receptor antagonist.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



CGP-42112

(CGP42112A)

Cat. No.: HY-12405

Bioactivity: CGP-42112(CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist. IC50 value: Target: AT2 R agonist in vitro: CGP42112 (>==1 nM) significantly inhibited cGMP production from the basal value. CGP42112 (>==1 nM) significantly inhibited TH-enzyme activity from the basal...
Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



CGP48369

Cat. No.: HY-101706

Bioactivity: CGP48369 is a nonpeptidic **angiotensin II receptor** antagonist, used for anti-hypertensive research.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Elisartan

(HN 65021)

Cat. No.: HY-19214

Bioactivity: Elisartan is an orally active non-peptide pro-drug of **angiotensin II AT1 receptor** antagonist HN-12206, and shows anti-hypertension activities.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Eprosartan mesylate

(SKF-108566J)

Cat. No.: HY-15834A

Bioactivity: Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.
Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Fimasartan

(BR-A-657)

Cat. No.: HY-B0780

Bioactivity: Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.
Purity: 98.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



H-Val-Pro-Pro-OH

Cat. No.: HY-114161

Bioactivity: H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme **(ACE)**, with an $\mathbf{IC_{50}}$ of 9 μM.
Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



H-Val-Pro-Pro-OH TFA

Cat. No.: HY-114161A

Bioactivity: H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme **(ACE)**, with an **IC_{50}** of 9 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 25 mg, 50 mg



Irbesartan

(SR-47436; BMS-186295)

Cat. No.: HY-B0202

Bioactivity: Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.

Purity: 99.79%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Irbesartan D4

(SR-47436 D4; BMS-186295 D4)

Cat. No.: HY-B0202S

Bioactivity: Irbesartan D4 is the deuterium labeled Irbesartan, which is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



L-159282

(MK 996)

Cat. No.: HY-19191

Bioactivity: L-159282 is a highly potent, orally active, nonpeptide **angiotensin II receptor** antagonist, with anti-hypertensive activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



L162389

Cat. No.: HY-101618

Bioactivity: L162389 is a potent antagonist of **angiotensin AT1 receptor** with **K_i** of 28 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



L162441

Cat. No.: HY-U00245

Bioactivity: L162441 is an **Angiotensin type 1 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



LCZ696

(Sacubitril mixture with Valsartan)

Cat. No.: HY-18204A

Bioactivity: LCZ696 is a dual **angiotensin II** receptor and **neprilysin** inhibitor.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg



Losartan

(DuP-753)

Cat. No.: HY-17512

Bioactivity: Losartan is an **angiotensin II receptor** antagonist, competing with the binding of angiotensin II to AT1 receptors with **IC_{50}** of 20 nM.

Purity: 99.24%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
1 g, 5 g



Losartan D4

(DuP-753 D4)

Cat. No.: HY-17512S

Bioactivity: Losartan D4 is the deuterium labeled Losartan. Losartan is an **angiotensin II receptor** antagonist, competing with the binding of angiotensin II to AT1 receptors with **IC_{50}** of 20 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Losartan D4 Carboxylic Acid

(E-3174 D4; EXP-3174 D4)

Cat. No.: HY-12765S

Bioactivity: Losartan D4 Carboxylic Acid is the deuterium labeled Losartan(EXP-3174), which is an angiotensin II receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Losartan potassium

(DuP-753 potassium)

Cat. No.: HY-17512A

Bioactivity: Losartan (potassium) is an **angiotensin II receptor type 1 (AT1)** antagonist, competing with the binding of angiotensin II to AT1 with an **IC_{50}** of 20 nM.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



LY285434

Cat. No.: HY-U00202

Bioactivity: LY285434 is a suitable **angiotensin II receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Olmesartan

(RNH 6270; CS 088)

Cat. No.: HY-17004

Bioactivity: Olmesartan is an **angiotensin II receptor (AT1R)** antagonist used to treat high blood pressure.

Purity: 99.01%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Olmesartan D4

(RNH-6270 D4; CS-088 D4)

Cat. No.: HY-17004S

Bioactivity: Olmesartan D4 is the deuterium labeled Olmesartan. Olmesartan is an **angiotensin II receptor (AT1R)** antagonist used to treat high blood pressure.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Olmesartan medoxomil

(CS 866)

Cat. No.: HY-17005

Bioactivity: Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with **IC_{50}** of 66.2 μM.

Purity: 99.03%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Olodanrigan

(EMA401; PD-126055)

Cat. No.: HY-13106

Bioactivity: Olodanrigan (EMA401), a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.

Purity: 99.29%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



PD 123319

((S)-(+)-PD 123319)

Cat. No.: HY-10259

Bioactivity: PD 123319 (ditrifluoroacetate) is a potent, selective **AT2 angiotensin II receptor** antagonist with **IC_{50}** of 34 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



PD 123319 ditrifluoroacetate

Cat. No.: HY-10259A

Bioactivity: PD 123319 (ditrifluoroacetate) is a potent, selective **AT2 angiotensin II receptor** antagonist with **IC_{50}** of 34 nM.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



Pratosartan

(FW 7203; KD 3-671; KT 3671)

Cat. No.: HY-101574

Bioactivity: Pratosartan is a selective **angiotensin II receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



SL910102

Cat. No.: HY-100292

Bioactivity: SL910102 is a nonpeptide **angiotensin AT_1 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Sparsentan

(RE-021; DARA-a)

Cat. No.: HY-17621

Bioactivity: Sparsentan (RE-021; BMS-346567; PS433540; DARA-a) is a highly potent dual **angiotensin II** and **endothelin A** receptor antagonist with $\mathbf{K_i}$s of 0.8 and 9.3 nM, respectively.

Purity: 99.08%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Tasosartan

(WAY-ANA 756)

Cat. No.: HY-A0250

Bioactivity: Tasosartan is a long-acting **angiotensin II** (**AngII**) **receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg



TD-0212

Cat. No.: HY-114412

Bioactivity: TD-0212 (compound 35) is an orally active dual pharmacology **angiotensin II type 1 receptor ($\mathbf{AT_1}$)** antagonist and **neprilysin (NEP)** inhibitor, with a $\mathbf{pK_i}$ of 8.9 for AT_1 and a $\mathbf{pIC_{50}}$ of 9.2 for NEP [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 100 mg, 250 mg



Telmisartan

(BIBR 277)

Cat. No.: HY-13955

Bioactivity: Telmisartan is a potent, long lasting antagonist of **angiotensin II type 1 receptor (AT1)**, selectively inhibiting the binding of ^{125}I-AngII to AT1 receptors with $\mathbf{IC_{50}}$ of 9.2 nM.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
50 mg, 100 mg, 500 mg, 1 g



Tranilast

(MK 341; SB 252218)

Cat. No.: HY-B0195

Bioactivity: Tranilast is an antiallergic agent. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases,...

Purity: 99.60%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



Tranilast Sodium

(Sodium Tranilast; MK 341 Sodium; SB 252218 Sodium)

Cat. No.: HY-B0195A

Bioactivity: Tranilast is an antiallergic agent. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases,...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Tranilast trans-

(trans-Tranilast)

Cat. No.: HY-18706

Bioactivity: Trans-Tranilast is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



Valsartan

(CGP 48933)

Cat. No.: HY-18204

Bioactivity: Valsartan (CGP-48933) is an **angiotensin II** receptor antagonist for the treatment of high blood pressure and heart failure.

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



Valsartan D9

(CGP-48933 D9)

Cat. No.: HY-18204S

Bioactivity: Valsartan D9 (CGP-48933 D9) is deuterium labeled valsartan. Valsartan is an **angiotensin II** receptor antagonist for treatment of high blood pressure and heart failure.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



ZD 7155(hydrochloride)

Cat. No.: HY-102093

Bioactivity: ZD 7155 hydrochloride is an angiotensin II receptor type 1 (**AT1 receptor**) antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



[Sar1, Ile8]-Angiotensin II

Cat. No.: HY-P1564

Bioactivity: [Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Bombesin Receptor



Bombesin, a peptide of 14 amino acids, is an amphibian homolog to the mammalian gastrin-releasing peptide (GRP), that has been extensively studied as a targeting ligand for diagnosis and therapy of GRP positive tumors, such as breast, pancreas, lungs and prostate cancers. Bombesin binds to and activates G-protein coupled receptors, known as gastrin releasing peptide receptor (GRPR).

Bombesin, a tetradecapeptide isolated from the skin of the frog Bombina bombina, have shown broad spectrum of biological activities. The BBS activates three G protein-coupled receptors: bombesin receptor 1 (BB_1), bombesin receptor 2 (BB_2), and bombesin receptor 3 (BB_3). BBS-like peptides-Neuromedin B (NB) and gastrin releasing peptide (GRP) are natural ligand of the BB1 and BB2 receptors, respectively.

In mammals, BBS receptors and BBS-like peptides are distributed in the Central Nervous System (CNS) including regions involved in the cardiorespiratory control.

The mammalian bombesin G-protein-coupled receptor subfamily comprises three structurally related members, the receptors for neuromedin B (NMBR or BB1), gastrin-releasing peptide (GRPR or BB2), and bombesin receptor subtype-3 (BRS-3 or BB3).

Bombesin receptor subtype-3 (BRS-3) is an orphan G protein-coupled receptor implicated in the regulation of energy homeostasis.

Bombesin Receptor Inhibitors & Modulators

Bombesin

Cat. No.: HY-P0195

Bioactivity: Bombesin is a tetradecapeptide originally isolated from frog skin; plays an important role in the release of gastrin and the activation of G-protein receptors.

Purity: 99.69%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg

MK-5046

Cat. No.: HY-14342

Bioactivity: MK-5046 is a novel BRS-3 agonist, binds to BRS-3 with high affinity (mouse Ki = 1.6 nM, human Ki = 25 nM).

Purity: 99.67%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



ML-18

Cat. No.: HY-101844

Bioactivity: ML-18 is a non-peptide bombesin receptor subtype-3 (**BRS-3**) antagonist with an $\mathbf{IC_{50}}$ of 4.8 μM.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PD176252

Cat. No.: HY-103286

Bioactivity: PD176252 is a potent antagonist of neuromedin-B preferring ($\mathbf{BB_1}$) and gastrin-releasing peptide-preferring ($\mathbf{BB_2}$) receptor with $\mathbf{K_i}$s of 0.17 nM and 1 nM for human BB_1 and BB_2 receptors, and 0.66 nM, 16 nM for Rat BB_1 and BB_2

Purity: 99.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg



Bradykinin Receptor



Bradykinin is a potent vasodilator peptide that exerts its vasodilatory action through stimulation of specific endothelial B_2 receptors, thereby causing the release of prostacyclin, NO, and EDHF.

Bradykinin (BK) has been reported to be involved in the progression of many types of cancer. Two bradykinin receptors, bradykinin B1 receptor (B1R) and bradykinin B2 receptor (B2R), are significantly expressed in all the tested colorectal cancer cells. Repression of B2R, but not B1R, attenuates the BK-mediated invasion and migration, and inhibits ERK1/2 activation and IL-6 production. Moreover, blocking of the ERK pathway decreases the BK-mediated IL-6 production. In addition, IL-6 repression suppresses the effects of BK on colorectal cancer cell invasion and migration.

Bradykinin, the enzymatic product of kallikrein-kinin system (KKS), is a major modulator of Ang II actions on blood volume, vascular reactivity and salt sensitivity.

Bradykinin Receptor Inhibitors & Modulators

Bradykinin

Cat. No.: HY-P0206

Bioactivity: Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.

Purity: 98.97%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RPPGFSPFR

Bradykinin 1-3

Cat. No.: HY-P1497

Bioactivity: Bradykinin (1-3) is a 3-amino acid residue peptide. Bradykinin (1-3) is an amino-truncated Bradykinin peptide, cleaved by Prolyl endopeptidase.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Bradykinin 1-5

Cat. No.: HY-P1488

Bioactivity: Bradykinin (1-5) is a major stable metabolite of Bradykinin, formed by the proteolytic action of angiotensin-converting enzyme (ACE).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Bradykinin 1-6

Cat. No.: HY-P1469

Bioactivity: Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Bradykinin 1-7

(Bradykinin Fragment 1-7)

Cat. No.: HY-P1484

Bioactivity: Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Bradykinin 2-9

(Des-Arg1-bradykinin)

Cat. No.: HY-P1490

Bioactivity: Bradykinin (2-9) is an amino-truncated Bradykinin peptide. Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



ELN-441958

Cat. No.: HY-15043

Bioactivity: ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.

Purity: 98.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



FR167344 free base

Cat. No.: HY-100301

Bioactivity: FR167344 free base is an orally active, nonpeptide **bradykinin receptor B2** antagonist. FR167344 free base shows a high affinity binding to the B2 receptor with an IC_{50} value of 65 nM and no binding affinity for the B1 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Icatibant

(HOE 140)

Cat. No.: HY-17446

Bioactivity: Icatibant (HOE-140) is a selective and specific antagonist of bradykinin B2 receptor with IC_{50} and K_i of 1.07 nM and 0.798 nM respectively.

Purity: 97.19%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
1 mg, 5 mg, 10 mg



SSR240612

Cat. No.: HY-15039

Bioactivity: SSR240612 is a potent, and orally active specific non-peptide **bradykinin B1 receptor** antagonist, with K_is of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells...

Purity: 99.19%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



[Des-Arg9]-Bradykinin

Cat. No.: HY-P0298

Bioactivity: [Des-Arg9]-Bradykinin is a **Bradykinin (B_1)** receptor agonist that displays selectivity for B_1 over B_2 receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



[Des-Arg9]-Bradykinin acetate

Cat. No.: HY-P0298A

Bioactivity: [Des-Arg9]-Bradykinin acetate is a **Bradykinin B_1 receptor** agonist that displays selectivity for B_1 over B_2 receptors.

Purity: 99.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 25 mg



Cannabinoid Receptor

Cannabinoid Receptor



Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

(±)-Ibipinabant

((±)-SLV319; (±)-BMS6462) Cat. No.: HY-14791A

Bioactivity: (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (**CB-1**) receptor antagonist with an IC_{50} of 22 nM.

Purity: 99.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



2-Arachidonoylglycerol

Cat. No.: HY-W011051

Bioactivity: 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.

Purity: 97.0%
Clinical Data: No Development Reported
Size: 1 mg



A-836339

Cat. No.: HY-12761

Bioactivity: A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg



AM251

Cat. No.: HY-15443

Bioactivity: AM251 is a selective **cannabinoid 1** (**CB1**) receptor antagonist with an IC_{50} of 8 nM, also acts as a potent **GPR55** agonist with an EC_{50} of 39 nM.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AM9405

Cat. No.: HY-112707

Bioactivity: AM9405 is a novel peripherally active **cannabinoid type 1 (CB1)** and **serotonin type 3 receptor** agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC_{50}s of 45.71 and 0.076 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Anandamide

Cat. No.: HY-10863

Bioactivity: Anandamide is an immune modulator in the central nervous system acts via not only **cannabinoid receptors** (**CB1** and **CB2**) but also other targets (e.g., **GPR18**/ **GPR55**).

Purity: 99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Bay 59-3074

Cat. No.: HY-100488

Bioactivity: Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively . Orally active CB1 agonist in vivo.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



BML-190

(Indomethacin morpholinylamide; IMMA) Cat. No.: HY-15420

Bioactivity: BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



CB1 antagonist 1

Cat. No.: HY-U00397

Bioactivity: CB1 antagonist 1 is an antagonist of **CB1 receptor**, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



CB1-IN-1

Cat. No.: HY-12790

Bioactivity: CB1-IN-1 is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CB2R-IN-1

Cat. No.: HY-100328

Bioactivity: CB2R-IN-1 is a potent **cannabinoid CB_2** receptor inverse agonist with a **K_i** of 0.9 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



GW842166X

Cat. No.: HY-14167

Bioactivity: GW842166X is a potent and selective **cannabinoid receptor 2** (CB2) agonist with **IC_{50}** values of 63 and 91 nM for human and rat CB2, respectively.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg



JD-5037

Cat. No.: HY-18697

Bioactivity: JD-5037 is a novel, peripherally restricted **CB_1R** antagonist with an **IC_{50}** of 1.5 nM.

Purity: 98.05%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



LY2828360

Cat. No.: HY-16642A

Bioactivity: LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid **(CB_2)** agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.

Purity: 98.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



MDA 19

Cat. No.: HY-15451

Bioactivity: MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



N-Oleoyl glycine

Cat. No.: HY-113204

Bioactivity: N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of **CB1 receptor** and **Akt** signaling pathway in 3T3-L1 adipocyte.

Purity: >98%
Clinical Data:
Size: 10 mg

Olivetol

Cat. No.: HY-W008364

Bioactivity: Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors **CB1** and **CB2** [3]. Olivetol also inhibits **CYP2C19** and **CYP2D6** activity, with IC_{50}s of 1...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Olorinab

(APD 371)

Cat. No.: HY-111110

Bioactivity: Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 **(CB_2)** agonist, with an **EC_{50}** of 6.2 nM for hCB $_2$.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Org 27569

Cat. No.: HY-13288

Bioactivity: Org 27569 is a potent **CB1 receptor** allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.

Purity: 98.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Otenabant

(CP-945598)

Cat. No.: HY-10871

Bioactivity: Otenabant is a potent and selective **cannabinoid receptor CB1** antagonist with **K_i** of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

Purity: 99.65%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Otenabant Hydrochloride

(CP 945598 Hydrochloride) Cat. No.: HY-10871A

Bioactivity: Otenabant Hydrochloride is a potent and selective **cannabinoid receptor CB1** antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



Pregnenolone

(Arthenolone; 3β-Hydroxy-5-pregnen-20-one) Cat. No.: HY-B0151

Bioactivity: Pregnenolone acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor**, reduces several effects of tetrahydrocannabinol (THC).

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 1 g, 5 g

Pregnenolone monosulfate

(Pregn-5-en-20-on-3β-yl sulfuric acid) Cat. No.: HY-B1739

Bioactivity: Pregnenolone monosulfate acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor**, reduces several effects of tetrahydrocannabinol (THC).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg



Rimonabant

(SR141716) Cat. No.: HY-14136

Bioactivity: Rimonabant (SR141716) is a highly potent and selective central **cannabinoid receptor (CB1)** antagonist with a K_i of 1.8 nM.

Rimonabant (SR141716) also inhibits **Mycobacterial membrane protein Large 3 (MMPL3)**.

Purity: >98%
Clinical Data: Phase 4
Size: 10 mg, 50 mg, 100 mg



Rimonabant Hydrochloride

(SR 141716A; SR 151716A) Cat. No.: HY-14137

Bioactivity: Rimonabant hydrochloride is a highly potent and selective central **cannabinoid receptor (CB1)** antagonist with an K_i of 1.8 nM. Rimonabant hydrochloride also inhibits **Mycobacterial membrane protein Large 3 (MMPL3)**.

Purity: 99.08%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



SR144528

Cat. No.: HY-13439

Bioactivity: SR144528 is a potent and selective **CB2 receptor** antagonist with a K_i of 0.6 nM.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Taranabant

(MK-0364) Cat. No.: HY-10013

Bioactivity: Taranabant is a highly potent and selective **cannabinoid 1** (**CB1**) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.

Purity: 99.28%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg



Taranabant ((1R,2R)stereoisomer)

(MK0364 (1R,2R)stereoisomer) Cat. No.: HY-10013B

Bioactivity: Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant. Taranabant is a highly potent and selective **cannabinoid 1** (**CB1**) receptor inverse agonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg



Taranabant racemate

(MK-0364 racemate) Cat. No.: HY-10013A

Bioactivity: Taranabant racemate is an antagonist and/or inverse agonist of the **Cannabinoid-1** (**CB1**) **receptor** extracted from patent WO 2004048317 A1.

Purity: 99.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg



WIN 55,212-2 Mesylate

((R)-(+)-WIN 55212) Cat. No.: HY-13291

Bioactivity: WIN 55,212-2 Mesylate is a potent aminoalkylindole **cannabinoid (CB) receptor** agonist with K_is of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.

Purity: 99.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Yangonin

Cat. No.: HY-N0919

Bioactivity: Yangonin exhibits affinity for the human recombinant cannabinoid **CB1 receptor** with an IC_{50} and a K_i of 1.79 ± 0.53 μM and 0.72±0.21 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



β-Caryophyllene ((−)-trans-Caryophyllene; (−)-β-caryophyllene; (-)-(E)-Caryophyllene)

Cat. No.: HY-N1415

Bioactivity: β-Caryophyllene is a **CB2 receptor** agonist.

Purity: 94.40%
Clinical Data: No Development Reported
Size: 500 mg



CaSR

Calcium-sensing receptor



CaSR (calcium-sensing receptor) is a Class C G-protein coupled receptor which senses extracellular levels of calcium ion. In theparathyroid gland, the calcium-sensing receptor controls calcium homeostasis by regulating the release of parathyroid hormone (PTH). The release of PTH is inhibited in response to elevations in plasma calcium concentrations and activation of the calcium receptor. Increased calcium binding on the extracellular side gives a conformational change in the receptor, which, on the intracellular side, initiates the phospholipase C pathway, presumably through a Gqα type of G protein, which ultimately increases intracellular concentration of calcium, which inhibits vesicle fusion and exocytosis of parathyroid hormone. It also inhibits the cAMP dependent pathway.

CaSR Inhibitors & Modulators

Calcium-Sensing Receptor Antagonists I

Cat. No.: HY-50713

Bioactivity: Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.

Purity: 99.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 100 mg



Cinacalcet

(AMG 073)

Cat. No.: HY-70037

Bioactivity: Cinacalcet (AMG 073) is an orally active, allosteric agonist of **Ca receptor (CaR)**, used for cardiovascular disease treatment.

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Cinacalcet hydrochloride

(AMG-073 (hydrochloride))

Cat. No.: HY-70037A

Bioactivity: Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of **Ca receptor (CaR)**, used for cardiovascular disease treatment.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Evocalcet

(KHK7580)

Cat. No.: HY-17613

Bioactivity: Evocalcet has an activating effect on **calcium sensing receptor** (**CaSR**) extracted from patent WO 2017061621 A1, compound A.

Purity: 98.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



GSK3004774

Cat. No.: HY-107773

Bioactivity: GSK3004774 is a potent, nonabsorbable agonist of **CaSR**, with an **pEC_{50}** of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an **EC_{50}** of 50 nM for human CaSR [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



Ligustroflavone

(Nuezhenoside)

Cat. No.: HY-N0546

Bioactivity: Ligustroflavone, extracted from Ligustrum lucidum, is a potential candidate as **calcium-sensing receptor (CaSR)** antagonist. Ligustroflavone exhibits protective effects against diabetic osteoporosis in mice [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



NPS-2143

(SB 262470A)

Cat. No.: HY-10007

Bioactivity: NPS-2143 is a selective antagonist of **calcium-sensing receptor (CaSR)** with an **IC_{50}** of 43 nM.

Purity: 99.42%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



NPS-2143 hydrochloride

Cat. No.: HY-10171

Bioactivity: NPS-2143 hydrochloride is a selective potent calcium ion-sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroid hormone secretion, respectively. IC50 value: 43 nM(for Ca2+ receptor) [1] Target: CaSR in vitro: NPS-2143, even when tested at much...

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



SB-423562

Cat. No.: HY-15105

Bioactivity: SB-423562 is a short-acting calcium-sensing receptor **(CaR)** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Strontium Ranelate

(Distrontium renelate; S12911)

Cat. No.: HY-17397

Bioactivity: Strontium ranelate(S12911) stimulates the calcium sensing receptors (CaSR) and leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation.

Purity: 99.16%
Clinical Data: Launched
Size: 100 mg, 500 mg



CCR

CC chemokine receptor



CCR (Chemokine receptors) are cytokine receptors found on the surface of certain cells that interact with a type of cytokine called achemokine. There have been 19 distinct chemokine receptors described in mammals. Each has a 7-transmembrane (7TM) structure and couples to G-protein for signal transduction within a cell, making them members of a large protein family of G protein-coupled receptors. Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca^{2+}) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism. Chemokine receptors are divided into different families, CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct subfamilies of chemokines they bind. Specific chemokine receptors provide the portals for HIV to get into cells, and others contribute to inflammatory diseases and cancer.

CCR Inhibitors & Modulators

Aplaviroc
(AK 602; GSK 873140; GW 873140)

Cat. No.: HY-17450

Bioactivity: Aplaviroc, a SDP derivative, is a **CCR5** antagonist, with **IC_{50}s** of 0.1-0.4 nM for HIV-1 $_{Ba-L}$, HIV-1 $_{JRFL}$ and HIV-1 $_{MOKW}$.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AZ084

Cat. No.: HY-119217

Bioactivity: AZ084 is a potent, selective, allosteric and oral active **CCR8** antagonist, with a **K_i** of 0.9 nM. Has potential to treat asthma [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AZD2098

Cat. No.: HY-U00064

Bioactivity: AZD2098 is a potent and selective **CC-chemokine receptor 4 (CCR4)** inhibitor with **pIC_{50}**s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research [1] [2].

Purity: 99.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg



BMS-813160

Cat. No.: HY-109593

Bioactivity: BMS-813160 is the first dual **CCR2/CCR5** antagonist to enter clinical development for cardiovascular.

Purity: 99.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



BX471
(ZK-811752)

Cat. No.: HY-12080

Bioactivity: BX471 (ZK-811752) is a potent and selective non-peptide **CCR1** antagonist with a **K_i** of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

Purity: 95.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



BX471 hydrochloride
(ZK-811752 (hydrochloride))

Cat. No.: HY-12080A

Bioactivity: BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide **CCR1** antagonist with **K_i** of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



CCR1 antagonist 1

Cat. No.: HY-U00350

Bioactivity: CCR1 antagonist 1 is an antagonist of **CCR1**, with anti-inflammatory activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



CCR1 antagonist 6

Cat. No.: HY-114193

Bioactivity: CCR1 antagonist 6 (compound 16q) is a **chemokine receptor 1 (CCR1)** antagonist, with an **IC_{50}** of 3 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 250 mg



CCR1 antagonist 7

Cat. No.: HY-114194

Bioactivity: CCR1 antagonist 7 (compound 16r) is a **chemokine receptor 1 (CCR1)** antagonist, with an **IC_{50}** of 4 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



CCR1 antagonist 8

Cat. No.: HY-120588

Bioactivity: CCR1 antagonist 8 (compound 19n), a third azaindazole series compound, is a **CCR1** antagonist clinical candidate, with an **IC_{50}** of 1.8 nM in Ca $^{2+}$ flux assay [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



CCR2 antagonist 1

Cat. No.: HY-112792

Bioactivity: CCR2 antagonist 1 is a high-affinity and long-residence-time **CCR2** antagonist, with a K_i of 2.4 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



CCR2-RA-[R]

Cat. No.: HY-50081

Bioactivity: CCR2-RA-[R] is an allosteric antagonist of the **C-C chemokine receptor type 2 (CCR2)** with an IC_{50} of 103 nM.

Purity: 99.36%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CCR3 antagonist 1

Cat. No.: HY-U00331

Bioactivity: CCR3 antagonist 1 is a potent antagonist of **CCR3**, used for the research of immunologic and inflammatory diseases.

Purity: >98%
Clinical Data: No Development Reported
Size: 20 mg



CCR5 antagonist 1

Cat. No.: HY-100261

Bioactivity: CCR5 antagonist 1 is a **CCR5** antagonist which can inhibit **HIV** replication extracted from WO 2004054974 A2.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



CCR6 inhibitor 1

Cat. No.: HY-112701

Bioactivity: CCR6 inhibitor 1 is a potent and selective **CCR6** inhibitor, with IC_{50}s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC_{50}, > 30000 nM), and CCR7 (IC_{50}, 9400 nM). CCR6 inhibitor 1 marke...

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Cenicriviroc

(TAK-652; TBR-652)

Cat. No.: HY-14882

Bioactivity: Cenicriviroc is an orally active, dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

Purity: 97.09%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Cenicriviroc Mesylate

(TAK-652 Mesylate; TBR-652 Mesylate)

Cat. No.: HY-14882A

Bioactivity: Cenicriviroc is a dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

Purity: 98.23%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg



DAPTA

(D-Ala-peptide T-amide; Adaptavir)

Cat. No.: HY-P1034

Bioactivity: DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively **CCR5**, and shows potent anti-HIV activities.

Purity: 98.73%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg



GSK2239633A

Cat. No.: HY-100183

Bioactivity: GSK2239633A is a CC-chemokine receptor 4 (**CCR4**) antagonist, which inhibits the binding of [^{125}I]-TARC to human CCR4 with a pIC_{50} of 7.96±0.11.

Purity: 98.05%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg



GW 766994

(GW 994)

Cat. No.: HY-107051

Bioactivity: GW 766994 is a specific and oral **chemokine receptor-3 (CCR3)** antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.

Purity: 99.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



INCB 3284

Cat. No.: HY-15450A

Bioactivity: INCB 3284 is a potent, selective and orally bioavailable human **CCR2** antagonist, inhibiting monocyte chemoattractant protein-1 binding to **hCCR2**, with an **IC_{50}** of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.

Purity: 99.30%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



INCB 3284 dimesylate

Cat. No.: HY-15450

Bioactivity: INCB 3284 dimesylate is a potent, selective and orally bioavailable human **CCR2** antagonist, inhibiting monocyte chemoattractant protein-1 binding to **hCCR2**, with an **IC_{50}** of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



INCB3344

Cat. No.: HY-50674

Bioactivity: INCB3344 is a potent, selective and orally bioavailable **CCR2** antagonist with **IC_{50}** values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Maraviroc

(UK-427857)

Cat. No.: HY-13004

Bioactivity: Maraviroc is a selective **CCR5** antagonist with activity against human **HIV**.

Purity: 99.71%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



MK-0812

Cat. No.: HY-50669

Bioactivity: MK-0812 is a potent and selective **CCR2** antagonist with low nM affinity for CCR2.

Purity: 99.75%
Clinical Data: Phase 2
Size: 5 mg, 10 mg



MK-0812 Succinate

Cat. No.: HY-50669A

Bioactivity: MK-0812 Succinate is a potent and selective **CCR2** antagonist with high affinity at CCR2.

Purity: 99.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PF-4136309

(INCB8761)

Cat. No.: HY-13245

Bioactivity: PF-4136309 is a potent, selective, and orally bioavailable **CCR2** antagonist, with **IC_{50}**s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.

Purity: 99.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



RS 504393

Cat. No.: HY-15418

Bioactivity: RS 504393 is a selective **CCR2** chemokine receptor antagonist (**IC_{50}** values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).

Purity: 99.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



RS102895

Cat. No.: HY-18611A

Bioactivity: RS102895 is a potent **CCR2** antagonist, with an **IC_{50}** of 360 nM, and shows no effect on CCR1.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



RS102895 hydrochloride

Cat. No.: HY-18611

Bioactivity: RS102895 hydrochloride is a potent **CCR2** antagonist, with an **IC_{50}** of 360 nM, and shows no effect on CCR1.

Purity: 98.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



SB297006

Cat. No.: HY-103361

Bioactivity: SB297006 is a **CCR3** antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.

Purity: 99.77%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



TAK-220

Cat. No.: HY-19974

Bioactivity: TAK-220 is a selective and orally bioavailable **CCR5** antagonist, with **IC_{50}**s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4,...

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



TAK-779

(Takeda 779)

Cat. No.: HY-13406

Bioactivity: TAK-779 is a potent and selective nonpeptide antagonist of **CCR5** and **CXCR3**, with a **K_i** of 1.1 nM for CCR5, and effectively and selectively inhibits **R5 HIV-1**, with **EC_{50}** ...

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg



Teijin compound 1

Cat. No.: HY-108323

Bioactivity: Teijin compound 1 is a specific **CCR 2** antagonist with **IC_{50}**s of 24 and 180 nM in chemotaxis and binding assay, respectively.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg



Vercirnon

(GSK-1605786; CCX282-B; Traficet-EN)

Cat. No.: HY-15724

Bioactivity: Vercirnon is an orally bioavailable, selective, and potent antagonist of **CCR9**, with an **IC_{50}** of 10 nM, used in the research of inflammatory bowel diseases.

Purity: 98.04%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Vicriviroc maleate

(SCH-417690 (maleate); SCH-D (maleate))

Cat. No.: HY-17377

Bioactivity: Vicriviroc maleate is a potent, selective, oral bioavailable and CNS penetrated antagonist of **CCR5**, with a **K_i** of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with **IC_{90}**s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) ...

Purity: 99.41%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg



ZK756326 dihydrochloride

Cat. No.: HY-101038A

Bioactivity: ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor **CCR8**.

Purity: 99.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CGRP Receptor

Calcitonin gene-related peptide receptor



CGRP receptor is a heterotrimer: a large peptide with 7 transmembrane domains, named calcitonin receptor-like receptor (CLR or CRLR), is supplemented by a small single transmembrane peptide, named receptor activity-modifying protein (RAMP1) that forms the CGRP-specific ligand binding site. CGRP receptors are expressed by multiple different cell types within the nervous, cardiovascular and immune systems that are thought to play important roles in migraine pathology: on cerebral vascular smooth muscle, where they cause vasodilation, on dural mast cells triggering their degranulation, at the central terminals of the trigeminal nerve, where CGRP is a neuromodulator at second-order nociceptive neurons in the spinal trigeminal nucleus caudalis and in the dorsal horn of the spinal cord, where CGRP has a similar role in inducing central sensitisation to tactile stimuli. CGRP is produced in both peripheral and central neurons. It is a potent peptide vasodilator and can function in the transmission of pain.

Adrenomedullin (1-50), rat

Cat. No.: HY-P1534

Bioactivity: Adrenomedullin (1-50), rat is a 50 amino acid peptide, which induces a selective arterial vasodilation via activation of **CGRP1 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Adrenomedullin (11-50), rat

Cat. No.: HY-P1766

Bioactivity: Adrenomedullin (11-50), rat is the C-terminal fragment (11-50) of rat adrenomedullin. Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

Adrenomedullin (16-31), human

Cat. No.: HY-P1770

Bioactivity: Adrenomedullin (16-31), human is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human possesses pressor activity in the systemic vascular bed of the rat, but not the cat [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

CRFGTCTVQKLAHQIY-NH2

Adrenomedullin (AM) (22-52), human

(22-52-Adrenomedullin (human))

Cat. No.: HY-P1471

Bioactivity: Adrenomedullin (AM) (22-52), human is an **adrenomedullin receptor** antagonist, and also antagonizes the calcitonin generelated peptide (**CGRP**) receptor in the hindlimb vascular bed of the cat.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Calcitonin Gene Related Peptide (CGRP) (83-119), rat

Cat. No.: HY-P1462

Bioactivity: Calcitonin Gene Related Peptide (CGRP) (83-119), rat is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor (**CRLR**).

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Calcitonin Gene Related Peptide (CGRP) (83-119), rat TFA

Cat. No.: HY-P1462A

Bioactivity: Calcitonin Gene Related Peptide (CGRP) (83-119), rat (TFA) is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor (**CRLR**).

Purity: 96.21%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

CGRP antagonist 1

Cat. No.: HY-112262

Bioactivity: CGRP antagonist 1 is a highly potent **CGRP receptor** antagonist with a K_i and IC_{50} of 35 and 57 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

HCGRP-(8-37)

(Human α-CGRP (8-37))

Cat. No.: HY-P1014

Bioactivity: HCGRP-(8-37) is a human calcitonin gene-related peptide (hCGRP) fragment and also an antagonist of **CGRP receptor**.

Purity: 98.28%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

MK-3207

Cat. No.: HY-10301

Bioactivity: MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3. IC50 Value: 0.024 nM (Ki, Human CGRP) [1] In common with other CGRP receptor antagonists, MK-3207 displays lower affinity for...

Purity: 98.76%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



MK-3207 Hydrochloride

Cat. No.: HY-10302

Bioactivity: MK-3207 (Hydrochloride) is a potent and orally bioavailable **CGRP receptor** antagonist with IC_{50} of 0.12 nM and K_i of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.

Purity: 98.07%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Olcegepant

(BIBN-4096; BIBN 4096BS) Cat. No.: HY-10095

Bioactivity: Olcegepant is a potent and selective non-peptide antagonist of the **calcitonin gene-related peptide 1 (CGRP1) receptor** with **IC_{50}** of 0.03 nM and **K_i** of 14.4 pM for human CGRP.

Purity: 99.32%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



Olcegepant hydrochloride

(BIBN-4096 hydrochloride; BIBN4096BS hydrochloride) Cat. No.: HY-10095A

Bioactivity: Olcegepant hydrochloride is the first potent and selective non-peptide antagonist of the **calcitonin gene-related peptide 1 (CGRP1) receptor** with **IC_{50}** of 0.03 nM and with a **K_i** of 14.4 pM for human CGRP.

Purity: 99.31%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg



Rat CGRP-(8-37)

Cat. No.: HY-P0209

Bioactivity: Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective **CGRP receptor** antagonist.

Purity: 98.29%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Rimegepant

(BMS-927711) Cat. No.: HY-15498

Bioactivity: Rimegepant (BMS-927711) is a highly potent, oral calcitonin gene-related peptide (**CGRP**) receptor antagonist with a **K_i** value of 0.027 nM.

Purity: 99.08%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Telcagepant

(MK-0974) Cat. No.: HY-32709

Bioactivity: Telcagepant (MK-0974) is a **calcitonin gene-related peptide (CGRP) receptor** antagonist with **K_i**s of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.

Purity: 99.07%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Ubrogepant

(MK-1602) Cat. No.: HY-12366

Bioactivity: Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (**CGRP**) antagonist in development for acute treatment of migraine [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



β-CGRP, human

(Human β-CGRP; CGRP-II (Human)) Cat. No.: HY-P1548

Bioactivity: β-CGRP, human is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with **IC_{50}**s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

β-CGRP, human TFA

(Human β-CGRP (TFA); CGRP-II (Human) (TFA)) Cat. No.: HY-P1548A

Bioactivity: β-CGRP, human TFA is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with **IC_{50}**s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells [1].

Purity: 98.82%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Cholecystokinin Receptor

CCK Receptor



Cholecystokinin (CCK) is a neuropeptide that affects growth rate in chickens by regulating appetite. CCK peptides exert their function by binding to two identified receptors, CCKAR and CCKBR in the GI tract and the brain, respectively, as well as in other organs. In mammals, CCK/CCKAR interactions affect a number of immunological parameters, including regulation of lymphocytes and functioning of monocytes.

CCK, also known as pancreozymin, is synthesized and secreted by enteroendocrine cells in the duodenum. The main function of CCK is to cause the release of digestive enzymes and bile from the pancreas and gallbladder, respectively. It also induces drug tolerance to opioids like morphine and heroin. Cholecystokinin (CCK) has strong bioactivity in the regulation of a number of cell activities.

Cholecystokinin Receptor Inhibitors & Modulators

CCK-A receptor inhibitor 1

Cat. No.: HY-U00387

Bioactivity: CCK-A receptor inhibitor 1 is a **cholecystokinin A** (**CCK-A**) **receptor** inhibitor with a binging **IC_{50}** of 340 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



CCK-B Receptor Antagonist 1

Cat. No.: HY-U00360

Bioactivity: CCK-B Receptor Antagonist 1 is an antagonist of cholecystokinin B **(CCK-B) receptor**, and has the potential of reducing the secretion of gastric acid.

Purity: 99.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Ceruletide

(Caerulein; Cerulein; FI-6934)

Cat. No.: HY-A0190

Bioactivity: Ceruletide, a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, is a potent cholecystokinetic agent, and acts as a **cholecystokinin receptor** agonist.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



CHEMBL333994

(FK-480)

Cat. No.: HY-U00363

Bioactivity: CHEMBL333994 is a potent and orally effective Cholecystokinin A **(CCK-A)** antagonist, with an **IC_{50}** of 0.67 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Gastrin-1, human

Cat. No.: HY-P1097

Bioactivity: Gastrin-1, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via **cholecystokinin 2 (CCK2)** receptor.

Purity: 98.41%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gastrin/CCK antagonist 1

Cat. No.: HY-U00375

Bioactivity: Gastrin/CCK antagonist 1 is an antagonist of **gastrin/CCK**, used for the research of gastrointestinal disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



GI 181771

Cat. No.: HY-11076

Bioactivity: GI 181771 is a **cholecystokinin 1** receptor agonist investigated for the treatment of obesity.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Lorglumide sodium salt

(CR-1409 (sodium salt))

Cat. No.: HY-B1439B

Bioactivity: Lorglumide sodium salt (CR-1409 sodium salt) is a potent **cholecystokinin** (**CCK**) **receptor** antagonist [1].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Loxiglumide

(CR-1505)

Cat. No.: HY-B2154

Bioactivity: Loxiglumide is a cholecystokinin (**CCK-1**) receptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Mini Gastrin I, human

Cat. No.: HY-P1593

Bioactivity: Mini Gastrin I, human is a shorter version of human gastrin 1, consists of amino acids 5-17 of the parent peptide, and binds with the **CCK2i4svR**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nastorazepide

(Z-360)

Cat. No.: HY-17617

Bioactivity: Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity.

Purity: 99.89%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Proglumide

Cat. No.: HY-B1330

Bioactivity: Proglumide is a known **cholecystokinin** (**CCK**) antagonist.

Purity: 99.74%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Sograzepide

(Netazepide; YF 476; YM-220)

Cat. No.: HY-14850

Bioactivity: Sograzepide (Netazepide;YF476) is a **gastrin/cholecystokinin 2 receptor (CCK2)** antagonist.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



SR 146131

Cat. No.: HY-11077

Bioactivity: SR 146131 is a potent, orally available, and selective nonpeptide (**cholecystokinin 1**) receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Tarazepide

Cat. No.: HY-U00062

Bioactivity: Tarazepide is a potent and specific **CCK-A** receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



CRFR

Corticotropin-releasing Factor Receptor



CRFR (Corticotropin-releasing Factor Receptor), also known as corticotropin-releasing hormone receptor (CRHR), belongs to the G protein-coupled receptor family. There are 3 types of this recetpor, CRF_1, CRF_2 and CRF_3 receptor. CRF_1 receptor (CRF_1 or $CRF_{1\alpha}$) is functionally coupled to adenylate cyclase and it belongs to the secretin-like, family B of GPCRs. CRF_1 receptor has several splice variants (CRF_{1c}-CRF_{1m}) including $CRF_{1\beta}$. CRF_2 receptor is a 411-amino acid protein with approximately 70% identity to the known CRF_1 and it is functionally coupled to adenylate cyclase. The CRF_2 receptor has been shown to be expressed as three functional splice variants, the $CRF_{2\alpha}$ (411-413 amino acids), the $CRF_{2\beta}$ (431-438 amino acids) and the $CRF_{2\gamma}$ (397 amino acids). CRF_3 receptor is a 428-amino acid protein, which binds CRF with a 5-fold higher affinity than URO and SVG and is expressed in the pituitary gland, urophysis, and brain.

CRFR subserves central functions related to stress physiology, and also exerts peripheral actions relevant to cardiovascular, muscular, gastrointestinal, pancreatic, inflammatory, and neoplastic diseases.

CP 316311

Cat. No.: HY-14129

Bioactivity: CP 316311 is a potent and selective **CRF1 receptor** antagonist with an **IC_{50}** value of 6.8 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



CP 376395

Cat. No.: HY-14130

Bioactivity: CP 376395 is a potent and selective **Corticotropin releasing factor 1 (CRF1)** receptor antagonist.

Purity: 99.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CRF, bovine

(Corticotropin Releasing Factor bovine)

Cat. No.: HY-P1533

Bioactivity: CRF, bovine is a potent agonist of **CRF receptor**, and displaces [^{125}I-Tyr]ovine CRF with a **K_i** of 3.52 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

CRF, bovine TFA

(Corticotropin Releasing Factor bovine (TFA))

Cat. No.: HY-P1533A

Bioactivity: CRF, bovine (TFA) is a potent agonist of **CRF receptor**, and displaces [^{125}I-Tyr]ovine CRF with a **K_i** of 3.52 nM [1].

Purity: 96.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
500u g, 1 mg, 5 mg

Emicerfont

(GW876008)

Cat. No.: HY-14367

Bioactivity: Emicerfont is a corticotropin-releasing factor type 1 (**CRF_1**) receptor antagonist with an **IC_{50}** of 66 nM.

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg



NVS-CRF38

Cat. No.: HY-12339

Bioactivity: NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility. IC50 value:
Target: CRF1 antagonist

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



Pexacerfont

(BMS-562086)

Cat. No.: HY-12127

Bioactivity: Pexacerfont is a selective corticotropin-releasing factor (**CRF_1**) receptor antagonist with **IC_{50}** of 6.1±0.6 nM for human CRF $_1$ receptor.

Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 20 mg



R121919

(NBI30775)

Cat. No.: HY-14127

Bioactivity: R121919 is a potent small-molecule **CRF1** receptor antagonist with a **K_i** of 2 to 5 nM for the CRF1 receptor and over 1000-fold weaker activity at the CRF2 receptor, CRF-binding protein, or 70 other receptor types.

Purity: 99.46%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Urocortin II, human

Cat. No.: HY-P1752

Bioactivity: Urocortin II (human) is a selective endogenous peptide agonist of **type-2 corticotropin-releasing factor (CRF2) receptor**. For investigating the role of the CRF (2) receptor in ingestive behavior [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

Urocortin III, mouse

Cat. No.: HY-P1858

Bioactivity: Urocortin III, mouse is a corticotropin-releasing factor (**CRF**)-related peptide. Urocortin III preferentially binds and activates **CRF-R2** [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

Urocortin, human (Urocortin (human); Human urocortin; Human urocortin 1; Human urocortin I)

Cat. No.: HY-P1295

Bioactivity: Urocortin, human, a 40-aa neuropeptide, acts as a selective agonist of endogenous **CRF_2 receptor**, with **K_i**s of 0.4, 0.3, and 0.5 nM for hCRF $_{1}$, rCRF $_{2\alpha}$ and mCRF $_{2\beta}$, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Urocortin, rat

(Urocortin (Rattus norvegicus); Rat urocortin;)

Cat. No.: HY-P1296

Bioactivity: Urocortin, rat is a selective agonist of **CRF receptor**, with **K_i**s of 0.32, 2.2, and 0.62 nM for hCRF $_{1}$, rCRF $_{2\alpha}$ and mCRF $_{2\beta}$, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Urotensin I

(Catostomus urotensin I)

Cat. No.: HY-P1542

Bioactivity: Urotensin I is, 41-aa neuropeptide, acts as an agonist of **CRF receptor** with **pEC_{50}**s of 11.46, 9.36 and 9.85 for human CRF $_{1}$, human CRF $_{2}$ and rat CRF $_{2\alpha}$ receptors in CHO cells, and **K_i**s of 0.4, 1.8, and 5.7 nM for hCRF $_{1}$, rCRF $_{2\alpha}$ and mCRF $_{2\beta}$

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Verucerfont

(GSK561679)

Cat. No.: HY-14875

Bioactivity: Verucerfont is a **corticotropin-releasing factor receptor 1** (**CRF1**) antagonist with **IC_{50}**s of ~6.1, >1000 and >1000nM for CRF1, CRF2, and CRF-BP, respectively.

Purity: 99.94%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



CXCR

CXC chemokine receptors;C-X-C motif chemokine receptors



CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells. The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.

ALX 40-4C

Cat. No.: HY-P7061

Bioactivity: ALX 40-4C is a small peptide inhibitor of the **chemokine receptor CXCR4**, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagon...

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



ALX 40-4C Trifluoroacetate

Cat. No.: HY-P7061A

Bioactivity: ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the **chemokine receptor CXCR4**, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as...

Purity: 98.15%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



AMD 3465

(GENZ-644494)

Cat. No.: HY-15971A

Bioactivity: AMD 3465 is a potent antagonist of **CXCR4**, inhibits binding of 12G5 mAb and CXCL12 ^{AF647} to **CXCR4**, with **IC_{50}**s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of **X4 HIV** strains (**IC_{50}**: 1-10 nM), but has...

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



AMD 3465 hexahydrobromide

(GENZ-644494 hexahydrobromide)

Cat. No.: HY-15971

Bioactivity: AMD 3465 hexahydrobromide is a potent antagonist of **CXCR4**, inhibits binding of 12G5 mAb and CXCL12 ^{AF647} to **CXCR4**, with **IC_{50}**s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of **X4 HIV** strains (**IC_{50}**

Purity: 98.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg, 100 mg



AMG 487

Cat. No.: HY-15319

Bioactivity: AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 **(CXCR3)** which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with **IC_{50}**s of 8.0 and 8.2 nM, respectively.

Purity: 99.65%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



ATI-2341

Cat. No.: HY-P0172

Bioactivity: ATI-2341 is a **CXCR4** agonist, induces CXCR4-dependent calcium flux, with an **EC_{50}** of 194 nM in CCRF-CEM cells. ATI-2341 is also a potent and efficacious mobilizer of bone marrow hematopoietic cells [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AZD-5069

Cat. No.: HY-19855

Bioactivity: AZD-5069 is a potent **CXCR2 chemokine receptor** antagonist, used for caner treatment.

Purity: 99.92%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AZD8797

Cat. No.: HY-13848

Bioactivity: AZD8797 is an allosteric non-competitive modulator of the human **CX3CR1** receptor; antagonizes CX3CR1 and CXCR2 with **K_i**s of 3.9 and 2800 nM, respectively.

Purity: 98.22%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Baohuoside I

(Icariin-II; Icariside-II)

Cat. No.: HY-N0011

Bioactivity: Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of **CXCR4**, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.

Purity: 98.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



Burixafor hydrobromide

(TG-0054 hydrobromide)

Cat. No.: HY-19867A

Bioactivity: Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of **CXCR4** and a well water soluble anti-angiogenic drug that is of potential value in treating choroid neovascularization [1]. Burixafor hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal stem...

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



CXCR2-IN-1

Cat. No.: HY-101022

Bioactivity: CXCR2-IN-1 is a central nervous system penetrant **CXCR2** antagonists with a **pIC$_{50}$** of 9.3.

Purity: 98.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CXCR7 modulator 2

Cat. No.: HY-112154

Bioactivity: CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (**CXCR7**), with a **K$_i$** of 13 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Danirixin

(GSK1325756)

Cat. No.: HY-19768

Bioactivity: Danirixin is a selective, and reversible **CXCR2** antagonist, with **IC$_{50}$**of12.5 nM for CXCL8.

Purity: 98.21%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



E6130

Cat. No.: HY-107456

Bioactivity: E6130 is an orally available and highly selective **CX3CR1** modulator, that may be effective for treatment of inflammatory bowel disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

IT1t

Cat. No.: HY-101458

Bioactivity: IT1t is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an **IC$_{50}$** of 2.1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



IT1t dihydrochloride

Cat. No.: HY-101458A

Bioactivity: IT1t dihydrochloride is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an **IC$_{50}$** of 2.1 nM.

Purity: 98.09%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



JMS-17-2

Cat. No.: HY-123918

Bioactivity: JMS-17-2 is a potent and selective **CX3CR1** antagonist with an **IC$_{50}$** of 0.32 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg



LIT-927

Cat. No.: HY-112709

Bioactivity: LIT-927 is a locally and orally active **CXCL12** neutraligand with anti-inflammatory effect, with a **K$_i$** of 267 nM for CXCL12 binding to its specific receptor CXCR4 [1] .

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



LY2510924

Cat. No.: HY-12488

Bioactivity: LY2510924 is a potent and selective **CXCR4** antagonist that blocks SDF-1 binding to CXCR4 with an **IC$_{50}$** of 0.079 nM.

Purity: 99.91%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Mavorixafor

(AMD-070)

Cat. No.: HY-50101

Bioactivity: Mavorixafor (AMD-070) is a potent, selective and orally available **CXCR4** antagonist, with an **IC$_{50}$** value of 13 nM against CXCR4 ^{125}I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells ...

Purity: >98%
Clinical Data: Phase 1
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Mavorixafor trihydrochloride

(AMD-070 (trihydrochloride)) Cat. No.: HY-50101A

Bioactivity: Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available **CXCR4** antagonist, with an IC_{50} value of 13 nM against CXCR4 ^{125}I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain)...

Purity: 99.14%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Motixafortide

(BKT140 (4-fluorobenzoyl); BL-8040; TF14016) Cat. No.: HY-P0171

Bioactivity: Motixafortide (BKT140 4-fluorobenzoyl) is a novel **CXCR4** antagonist with an IC_{50} vakue of 1 nM.

Purity: 99.19%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 25 mg

MSX-122

Cat. No.: HY-13696

Bioactivity: MSX-122 is a partial antagonist of **CXCR4**, inhibiting **CXCR4/CXCL12** actions, with an IC_{50} of 10 nM; MSX-122 has anti-inflammatory and anti-metastatic activity.

Purity: 98.29%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Navarixin

(SCH 527123; MK-7123) Cat. No.: HY-10198

Bioactivity: Navarixin is a potent, allosteric antagonist of both **CXCR1** and **CXCR2**, with K_d values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.

Purity: 98.62%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



NBI-74330

Cat. No.: HY-15320

Bioactivity: NBI-74330 is a potent antagonist for **CXCR3**, and exhibits potent inhibition of (^{125}I)CXCL10 and (^{125}I)CXCL11 specific binding with K_i of 1.5 and 3.2 nM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Nicotinamide N-oxide

Cat. No.: HY-101407

Bioactivity: Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the **CXCR2** receptor.

Purity: 99.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
100 mg

Plerixafor

(AMD 3100; JM3100; SID791) Cat. No.: HY-10046

Bioactivity: Plerixafor (AMD 3100) is a selective **CXCR4** antagonist with an IC_{50} of 44 nM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Ethanol,
10 mg, 50 mg, 100 mg



Plerixafor octahydrochloride (AMD3100 (octahydrochloride); JM3100 (octahydrochloride); SID791 (octahydrochloride))

Cat. No.: HY-50912

Bioactivity: Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective **CXCR4** antagonist with an IC_{50} of 44 nM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
10 mg, 50 mg, 100 mg



Reparixin

(Repertaxin; DF 1681Y) Cat. No.: HY-15251

Bioactivity: Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors **CXCR1** and **CXCR2** activation with IC_{50}s of 1 and 100 nM, respectively.

Purity: 99.98%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



Reparixin L-lysine salt

(Repertaxin L-lysine salt) Cat. No.: HY-15252

Bioactivity: Reparixin L-lysine salt is an allosteric inhibitor of **chemokine receptor 1/2 (CXCR1/2)** activation.

Purity: 99.97%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg



SB225002

Cat. No.: HY-16711

Bioactivity: SB225002 is a potent and selective **CXCR2** antagonist with an **IC_{50}** of 22 nM.

Purity: 99.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



SCH 546738

Cat. No.: HY-10017

Bioactivity: SCH 546738 is a novel, potent and non-competitive **CXCR3** antagonist, the affinity constant (**K_i**) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



SCH 563705

Cat. No.: HY-10011

Bioactivity: SCH 563705 is a potent and orally available **CXCR2** and **CXCR1** antagonist, with **IC_{50}**s of 1.3 nM, 7.3 nM and **K_i**s of 1 and 3 nM, respectively.

Purity: 95.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg



SRT3109

Cat. No.: HY-15462

Bioactivity: SRT3109 is an antagonist of **CXCR2**, with a **pIC_{50}** of 8.2, and used in the research of chemokine mediated diseases.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg



SRT3190

Cat. No.: HY-13021

Bioactivity: SRT3190 is an antagonist of **CXCR2**, used in the research of chemokine mediated diseases.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



TAK-779

(Takeda 779)

Cat. No.: HY-13406

Bioactivity: TAK-779 is a potent and selective nonpeptide antagonist of **CCR5** and **CXCR3**, with a **K_i** of 1.1 nM for CCR5, and effectively and selectively inhibits **R5 HIV-1**, with **EC_{50}** ...

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



UNBS5162

Cat. No.: HY-16509

Bioactivity: UNBS5162 is a pan-antagonist of **CXCL chemokine** expression, with anti-tumor activity.

Purity: 99.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



USL311

Cat. No.: HY-114244

Bioactivity: USL311 is a selective **CXCR4** antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 [1].

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



WZ811

Cat. No.: HY-15478

Bioactivity: WZ811 is a potent **CXCR4** antagonist, effectively inhibits TN14003 binding to **CXCR4**, with an **EC_{50}** of 0.3 nM.

Purity: 99.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Dopamine Receptor



Dopamine Receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. Dopamine receptors are implicated in many neurological processes, including motivation, pleasure, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. Thus, dopamine receptors are common neurologic drug targets; antipsychotics are often dopamine receptor antagonists while psychostimulants are typically indirect agonists of dopamine receptors. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4receptors are members of the D2-like family.

(+)-Dihydrexidine hydrochloride

(DAR-0100 hydrochloride)

Cat. No.: HY-101299

Bioactivity: (+)-Dihydrexidine hydrochloride is a **dopamine D1 receptor** agonist with an **EC_{50}** of 72± 21 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



(+)-PD 128907 hydrochloride

Cat. No.: HY-110000

Bioactivity: (+)-PD 128907 hydrochloride is a selective dopamine **D_2/D_3** receptor agonist, with **K_is** of 1.7, 0.84 nM for human and rat D 3 receptors, 179, 770 n M for human and rat D 3 receptors, respectively.

Purity: 98.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



(±)-Methotrimeprazine (D6)

(dl-Methotrimeprazine D6)

Cat. No.: HY-19489S

Bioactivity: (±)-Methotrimeprazine (D6) is the deuterium labeled Methotrimeprazine, which is a D3 dopamine and Histamine H1 receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



5-HT6/7 antagonist 1

Cat. No.: HY-101622

Bioactivity: 5-HT6/7 antagonist 1 is a multifunctional ligand that antagonizes **5-HT6/7/2A** and **D2** receptors, without interacting with M1 receptors and hERG channels.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



A-381393

Cat. No.: HY-116941

Bioactivity: A-381393 is a potent, selective, brain penetrate **dopamine D_4 receptor** antagonist, with **K_i**s of 1.5, 1.9 and 1.6 nM for human dopamine D 4.4, D 4.2, and D 4.7 receptor, respectively, >2700-fold selectivity over D 1, D 2, D 3

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



A-437203

(Lu201640; A37203)

Cat. No.: HY-U00185

Bioactivity: A-437203 is a selective **D_3** receptor antagonist with **K_i** of 71, 1.6, and 6220 nM for D 2, D 3, and D 4 receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Abaperidone

Cat. No.: HY-101619

Bioactivity: Abaperidone is a potent antagonist of **5-HT_{2A}receptor** and **dopamine D_2 receptor** with **IC_{50}**s of 6.2 and 17 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



ABT-670

Cat. No.: HY-19483

Bioactivity: ABT-670 is a selective, oral bioavailable agonist of **dopamine D_4 receptor**, with **EC_{50}** of 89 nM, 160 nM, and 93 nM for humanD 4, ferretD 4, and ratD 4, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Adoprazine

(SLV313)

Cat. No.: HY-14782

Bioactivity: Adoprazine, a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.

Purity: 98.13%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Alizapride hydrochloride

Cat. No.: HY-A0125A

Bioactivity: Alizapride hydrochloride is a **dopamine receptor** antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Amisulpride
(DAN 2163) Cat. No.: HY-14545

Bioactivity: Amisulpride is a **dopamine D_2/D_3 receptor** antagonist with **K_i**s of 2.8 and 3.2 nM for human **dopamine D_2** and **D_3**, respectively.

Purity: 98.0%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Amisulpride hydrochloride
(DAN 2163 hydrochloride) Cat. No.: HY-14545A

Bioactivity: Amisulpride hydrochloride is a dopamine **D_2/D_3 receptor** antagonist with **K_i**s of 2.8 and 3.2 nM for human **dopamine D_2** and **D_3**, respectively.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Asenapine hydrochloride
Cat. No.: HY-16567

Bioactivity: Asenapine maleate, an antipsychotic, is a **5-HT** (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and **Dopamine (D_2, D_3, D_4)** receptor antagonist with **K_i** values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively.

Purity: 99.39%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Azaperone
(R-1929) Cat. No.: HY-B1470

Bioactivity: Azaperone (R-1929) acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used mainly as a tranquilizer in veterinary medicine.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Benzamide Derivative 1
Cat. No.: HY-U00415

Bioactivity: Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Blonanserin
(AD-5423) Cat. No.: HY-13575

Bioactivity: Blonanserin(AD-5423) is a D2/5-HT2 receptor antagonist, atypical antipsychotic. Target: D2 receptor; 5-HT2 receptor Blonanserin(AD-5423) is a relatively new atypical antipsychotic for the treatment of schizophrenia. Blonanserin belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and...

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 100 mg



BP 897
Cat. No.: HY-106660

Bioactivity: BP 897 is a potent and selective **dopamine D3 receptor** agonist, and a weak **dopamine D2 receptor** antagonist, with **K_i**s of 0.92 nM and 61 nM for D3 and D2 receptors, and shows low affinities at D1 and D4 receptors (**K_i**s, 3 and 0.3...

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Brexpiprazole
(OPC-34712) Cat. No.: HY-15780

Bioactivity: Brexpiprazole is a partial agonist of human **5-HT1A** and **dopamine receptor** with **K_i**s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a **5-HT2A** receptor antagonist with a **K_i** of 0.47 nM.

Purity: 99.38%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Bromocriptine mesylate
(CB-154) Cat. No.: HY-12705A

Bioactivity: Bromocriptine mesylate is a potent **dopamine D2/D3 receptor** agonist, which binds D2 dopamine receptor with **pK_i** of 8.05±0.2.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Bromopride
Cat. No.: HY-B1164

Bioactivity: Bromopride is a dopamine antagonist with prokinetic properties widely used as an antiemetic.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Cabergoline

(FCE-21336)

Cat. No.: HY-15296

Bioactivity: Cabergoline is an ergot derived-dopamine D $_2$-like receptor agonist that has high affinity for **D_2**, **D_3**, and **5-HT_{2B}** receptors (**K_i**=0.7, 1.5, and 1.2, respectively).

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Cariprazine

(RGH-188)

Cat. No.: HY-14763

Bioactivity: Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the **D_3** (**K_i**=0.085 nM) and **D_2** (**K_i**=0.49 nM) receptors, and moderate affinity for the **5-HT_{1A}** receptor (**K_i**=2.6 nM).

Purity: 99.35%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Cariprazine hydrochloride

(RGH188 hydrochloride)

Cat. No.: HY-14763A

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the **D_3** (**K_i**=0.085 nM) and **D_2** (**K_i**=0.49 nM) receptors, and moderate affinity for the **5-HT_{1A}** receptor (**K_i**=2.6 nM).

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CGP 25454A

Cat. No.: HY-100454

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Chlorpromazine D6 hydrochloride

Cat. No.: HY-B0407AS

Bioactivity: Chlorpromazine D6 hydrochloride is the deuterium labeled Chlorpromazine. Chlorpromazine is an inhibitor of dopamine receptor, 5-HT receptor, potassium channel, sodium channel.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



Chlorpromazine hydrochloride

Cat. No.: HY-B0407A

Bioactivity: Chlorpromazine Hydrochloride is an antagonist of the **dopamine D2**, **5HT2A**, **potassium channel** and **sodium channel**. Chlorpromazine binds with D2 and 5HT2A with **K_i**s of 363 nM and 8.3 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 1 g, 5 g



Chlorprothixene

Cat. No.: HY-B0274

Bioactivity: Chlorprothixene has strong binding affinities to dopamine and histamine receptors, such as D1, D2, D3, D5, H1, 5-HT2, 5-HT6 and 5-HT7, with Ki of 18 nM, 2.96 nM, 4.56 nM, 9 nM, 3.75 nM, 9.4 nM, 3 nM and 5.6 nM, respectively.

Purity: 99.52%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Clebopride malate

Cat. No.: HY-B1613A

Bioactivity: Clebopride malate is a dopamine antagonist drug with antiemetic and prokinetic properties used to treat functional gastrointestinal disorders.

Purity: 99.46%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Clocapramine

(Clocarpramine; 3-Chlorocarpipramine)

Cat. No.: HY-B2073

Bioactivity: Clocapramine is an antagonist of the **D_2**, **5-HT_{2A} receptors**.

Purity: >98%
Clinical Data: Launched
Size: 1 mg



Clocapramine hydrochloride hydrate

(3-Chlorocarpipramine hydrochloride hydrate)

Cat. No.: HY-B2073A

Bioactivity: Clocapramine hydrochloride hydrate is an antagonist of the **D_2** and **5-HT_{2A} receptors**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Clomipramine hydrochloride

Cat. No.: HY-B0457

Bioactivity: Clomipramine HCl is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively. Target: 5-HT Receptor Clomipramine hydrochloride (Anafranil) is a hydrochloride salt of clomipramine which is a serotonin...

Purity: 99.72%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Clozapine

(HF 1854)

Cat. No.: HY-14539

Bioactivity: Clozapine (HF 1854) is an antipsychotic used to treat schizophrenia. Clozapine is a potent antagonist of dopamine and a number of other receptors, with a K_i of 9.5 nM for **M1** receptor.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 5 g



Dexpramipexole

((R)-Pramipexole; R-(+)-Pramipexole; KNS-760704)

Cat. No.: HY-17355B

Bioactivity: Dexpramipexole(KNS-760704), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist. IC50 Value:

Purity: >98%
Clinical Data: Phase 3
Size: 10 mg, 50 mg



Dexpramipexole dihydrochloride ((R)-Pramipexole (dihydrochloride); ...)

Cat. No.: HY-17355A

Bioactivity: Dexpramipexole dihydrochloride, also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist. IC50 Value: Target: Dopamine Receptor Dexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic...

Purity: 98.01%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Dicarbine

Cat. No.: HY-127086

Bioactivity: Dicarbine blocks **dopamine receptors** in various brain parts and prevents the depression of the conditioned defence reflexes caused by stimulation of the mesencephalic portion of the reticular formation. Dicarbine could be used to treat patients with schizophrenia and alcoholic psychosis in...

Purity: >98%
Clinical Data: No Development Reported
Size:



Domperidone

(R33812)

Cat. No.: HY-B0411

Bioactivity: Domperidone is a dopamine blocker and an antidopaminergic reagent.

Purity: 99.52%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Dopamine hydrochloride

(ASL279)

Cat. No.: HY-B0451A

Bioactivity: Dopamine HCl is a catecholamine neurotransmitter present in a wide variety of animals,And a dopamine D1-5 receptors agonist. Target: Dopamine Receptor Dopamine (or 3,4-dihydroxyphenethylamine) is a neuroendocrine transmitter in the catecholamine and phenethylamine families that plays a...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg

Dopamine serotonin antagonist-1

Cat. No.: HY-42110

Bioactivity: Dopamine serotonin antagonist-1 is a dual **dopamine** and **serotonin** receptor antagonist with K_is of 200, 2500, 420, 39, 84, 40 nM for dopamine D1, D2,D4, and serotonin S2A, S2C, S3, respectively.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Droperidol

(Dehydrobenzperidol)

Cat. No.: HY-B1240

Bioactivity: Droperidol is a Dopamine-2 Receptor Antagonist.

Purity: 99.29%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Fenoldopam

(SKF 82526)

Cat. No.: HY-B0735

Bioactivity: Fenoldopam(SKF 82526) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.

Purity: >98%
Clinical Data: Launched
Size: 10 mg



Fenoldopam mesylate

(Fenoldopam methanesulfonate; SKF-82526 mesylate) Cat. No.: HY-B0735A

Bioactivity: Fenoldopam(SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Fluphenazine dihydrochloride

Cat. No.: HY-A0081

Bioactivity: Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor; used to deliver Fluphenazine to biological systems in studies probing the effects and metabolic fates of this commonly used dopamine antagonist.

Purity: 99.96%
Clinical Data: Launched
Size: 100 mg



Foscarbidopa

(Carbidopa 4'-monophosphate) Cat. No.: HY-109131

Bioactivity: Foscarbidopa (Carbidopa 4'-monophosphate) is a prodrug of Carbidopa, acts as a **dopamine receptor** agonist [1] [2].

Purity: >98%
Clinical Data: No Development Reported
Size:



Foslevodopa

(Dopa 4-Phosphate; 3-Hydroxy-O-phosphono-L-tyrosine) Cat. No.: HY-109132

Bioactivity: Foslevodopa is a **dopamine receptor** agonist [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



GSK163090

Cat. No.: HY-14348

Bioactivity: GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively.

Purity: 99.95%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GSK598809

Cat. No.: HY-19654

Bioactivity: GSK598809 is a potent and selective dopamine D3 Receptor **(DRD3)** antagonist, with a **pK_i** of 8.9.

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Haloperidol

Cat. No.: HY-14538

Bioactivity: Haloperidol is a potent **dopamine D2 receptor** antagonist, widely used as an antipsychotic.

Purity: 99.72%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Haloperidol D4

Cat. No.: HY-14538S

Bioactivity: Haloperidol D4 is deuterium labeled haloperidol, and the latter is a potent **dopamine D2 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Haloperidol D4'

Cat. No.: HY-14538S1

Bioactivity: Haloperidol D4' is deuterium labeled haloperidol, and the latter is a potent **dopamine D2 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Haloperidol hydrochloride

Cat. No.: HY-14538A

Bioactivity: Haloperidol hydrochloride is a potent **dopamine D2 receptor** antagonist, widely used as an antipsychotic.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Iloperidone

(HP 873) Cat. No.: HY-17410

Bioactivity: Iloperidone(HP 873) is a D2/5-HT2 receptor antagonist, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Iloperidone hydrochloride

(HP 873 hydrochloride) Cat. No.: HY-17410A

Bioactivity: Iloperidone (hydrochloride) is a D(2)/5-HT(2) receptor antagonistis, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



L-DOPA

(Levodopa; 3,4-Dihydroxyphenylalanine) Cat. No.: HY-N0304

Bioactivity: L-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease. L-DOPA is the precursor of dopamine and product of tyrosine hydroxylase. Target: Dopamine Receptor L-DOPA (L-3,4-dihydroxyphenylalanine) is a chemical that is made and used as part of the normal biology of humans, some...

Purity: >98%
Clinical Data: Launched
Size: 200 mg, 1 g



Levosulpiride

(RV-12309; S-(-)-Sulpiride) Cat. No.: HY-B1059

Bioactivity: Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



lumateperone Tosylate

(ITI-007) Cat. No.: HY-19733

Bioactivity: Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). IC50 value: 0.54 nM (Ki, for 5-HT2A receptor) Target: 5-HT2A receptor Lumateperone also possesses...

Purity: 99.21%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Lurasidone

(SM-13496) Cat. No.: HY-B0032A

Bioactivity: Lurasidone (SM-13496) is an antagonist of both **dopamine D_2** and **5-HT_7** with **IC_{50}**s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of **5-HT_{1A}** receptor with an **IC_{50}** of 6.75 nM.

Purity: 99.33%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Lurasidone Hydrochloride

(SM-13496 (Hydrochloride)) Cat. No.: HY-B0032

Bioactivity: Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both **dopamine D_2** and **5-HT_7** with **IC_{50}**s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist...

Purity: 99.87%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Metoclopramide

Cat. No.: HY-17382

Bioactivity: Metoclopramide is a dopamine D2 antagonist that is used as an antiemetic. IC50 Value: Target: D2 Receptor Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In various countries, metoclopramide is the...

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Metoclopramide hydrochloride hydrate

(Metoclopramide monohydrochloride monohydrate) Cat. No.: HY-17382A

Bioactivity: Metoclopramide hydrochloride hydrate is a dopamine D2 antagonist that is used as an antiemetic. IC50 Value: Target: D2 Receptor Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In...

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Molindone hydrochloride

(EN-1733A) Cat. No.: HY-B1017

Bioactivity: Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



NEO 376

(SPI-376) Cat. No.: HY-101583

Bioactivity: NEO 376 is a selective modulator of **5-HT1 receptor**, **GABA receptor** and **dopamine receptor**, with anti-psychotic actively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Neuromedin N

(Neuromedin N (rat, mouse, porcine, canine)) Cat. No.: HY-P0079

Bioactivity: Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg



NMI 8739

Cat. No.: HY-101540

Bioactivity: NMI 8739 is a **dopamine D_2 autoreceptor** agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg

Nomifensine

((±)-Nomifensin) Cat. No.: HY-B1110

Bioactivity: Nomifensine is a norepinephrine-dopamine reuptake inhibitor, increases the amount of synaptic norepinephrine and dopamine available to receptors by blocking the dopamine and norepinephrine reuptake transporters.

Purity: 99.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Nomifensine maleate

((±)-Nomifensine maleat) Cat. No.: HY-B1110A

Bioactivity: Nomifensine maleate is a selective inhibitor of dopamine uptake, used in adult attention deficit disorder.

Purity: 98.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



NRA-0160

Cat. No.: HY-101641

Bioactivity: NRA-0160 is a selective **dopamine D4 receptor** antagonist, with a K_i value of 0.48 nM and with negligible affinity for **dopamine D2 receptor** (K_i: >10000 nM), **D3 receptor** (K_i: 39 nM), rat **5-HT2A receptor** (K_i: 180 nM) and rat

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Nuciferine

Cat. No.: HY-N0049

Bioactivity: Nuciferine is an antagonist at **5-HT_{2A}** (**IC_{50}**=478 nM), **5-HT_{2C}** (**IC_{50}**=131 nM), and **5-HT_{2B}** (**IC_{50}**=1 μM), an inverse agonist at **5-HT_7** (**IC_{50}**=150 nM), a partial agonist at **D_2** (**EC_{50}**=64 nM), **D_5** (**EC_{50}**=2.6 μM) and **5-HT_6** (**EC_{50}**=...

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Ocaperidone

(R79598) Cat. No.: HY-101094

Bioactivity: Ocaperidone is an effective antipsychotic agent, acting as a potent **5-HT_2** and **dopamine D_2** antagonist, and a **5-HT_{1A}** agonist, with **K_i**s of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT $_2$, a $_1$-adrenergic receptor, dopamine D $_2$

Purity: 98.55%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Org-10490

Cat. No.: HY-U00077

Bioactivity: Org-10490 is an antagonist of **dopamine D1 receptor** and **dopamine D2 receptor**, used for the treatment for psychiatric disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Oxidopamine hydrobromide

(6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide) Cat. No.: HY-B1081A

Bioactivity: Oxidopamine (hydrobromide), an antagonist of the **neurotransmitter dopamine**, is a widely used neurotoxin that selectively destroys dopaminergic neurons.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Paliperidone

(9-hydroxyrisperidone) Cat. No.: HY-A0019

Bioactivity: Paliperidone (9-hydroxyrisperidone is a dopamine antagonist of the atypical antipsychotic class of medications.

Purity: 99.09%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Pardoprunox

(SLV-308; DU-126891) Cat. No.: HY-14958

Bioactivity: Pardoprunox(SLV-308) is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist; D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%); also binds to D4 (pKi = 7.8),...

Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Pardoprunox hydrochloride

(SLV-308 hydrochloride; DU-126891 hydrochloride) Cat. No.: HY-14958A

Bioactivity: Pardoprunox hydrochloride is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist, D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist and 5-HT1A receptor (pKi = 8.5) full agonist.

Purity: 98.89%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



PD-168077 maleate

Cat. No.: HY-21098A

Bioactivity: PD-168077 maleate is a selective dopamine **D_4** receptor agonist, with a **K_i** of 9 nM.

Purity: 98.44%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Pentiapine

(CGS 10746) Cat. No.: HY-100143

Bioactivity: Pentiapine is a novel **dopamine release** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Pergolide mesylate

(Pergolide methanesulfonate; LY127809) Cat. No.: HY-13720A

Bioactivity: Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist. Target: Dopamine Receptor Pergolide mesylate (trade name Permax) is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Pergolide mesylate functions...

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Perphenazine

Cat. No.: HY-A0077

Bioactivity: Perphenazine is a typical antipsychotic drug, inhibits **5-HT_{2A} receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor**, and **Histamine H1 receptor**, with **K_i** values of 5.6, 10, 0.765/0.13, 3.4, and 8 ...

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Perphenazine D8 Dihydrochloride

Cat. No.: HY-A0077AS

Bioactivity: Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



PF-592379

Cat. No.: HY-U00400

Bioactivity: PF-592379 is a potent **dopamine D_3 receptor** agonist with an **EC_{50}** of 21 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Pimethixene

(Pimetixene) Cat. No.: HY-B1101

Bioactivity: Pimethixene is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene is a highly potent antagonist of 5-HT_{1A}, 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, histamine H_1, dopamine D_2 and $D_{4.4}$ as well as muscari...

Purity: >98%
Clinical Data: Launched
Size: 10 mg



Pimethixene maleate

(Pimetixene maleate)

Cat. No.: HY-B1101A

Bioactivity: Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene maleate is a highly potent antagonist of 5-HT $_{1A}$, 5-HT $_{2A}$, 5-HT $_{2B}$, 5-HT $_{2C}$, histamine H $_{1}$, dopamine D $_{2}$ and D $_{4.4}$ as well...

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg



Pimozide

(R6238)

Cat. No.: HY-12987

Bioactivity: Pimozide is a **dopamine receptor** antagonist, with **K_i**s of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at **α1-adrenoceptor**, with a **K_i** of 39 nM; Pimozide also inhib...

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



Piperidine-MO-1

Cat. No.: HY-19845A

Bioactivity: Piperidine-MO-1 is a modulator of **dopamine receptor** extracted from patent WO/2005/121087A1, compound example 2; exhibits an **ED_{50}** of 68 μmol/kg on increase of DOPAC in the rat striatum.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Piribedil

Cat. No.: HY-12707

Bioactivity: Piribedil is a **dopamine D_2 receptor** (**D_2R**) agonist which also displays antagonist property at **$hα_{1A}$-adrenoceptor** (**$hα_{1A}$-AR**).

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Piribedil D8

(ET-495 D8)

Cat. No.: HY-12707S

Bioactivity: Piribedil D8 is the deuterium labeled Piribedil, which is an antiparkinsonian agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Pramipexole

Cat. No.: HY-B0410

Bioactivity: Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).

Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg



Pramipexole dihydrochloride

Cat. No.: HY-17355

Bioactivity: Pramipexole 2Hcl is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. IC50 Value: 3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4) Target: Dopamine Receptor Pramipexole dihydrochloride is a dopamine receptor agonist...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg



Pridopidine

(ACR16; ASP2314; FR310826)

Cat. No.: HY-10684

Bioactivity: Pridopidine, a **dopamine** (**DA**) stabilizer, acts as a low affinity **dopamine D2 receptor** (**D2R**) antagonist. Pridopidine exerts high affinity towards **sigma 1 receptor** (**S1R**) with **K_i** between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Prochlorperazine D8

Cat. No.: HY-B0807S

Bioactivity: Prochlorperazine D8 is the deuterium labeled Prochlorperazine, which is a dopamine (D2) receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Prochlorperazine D8 dimeleate

Cat. No.: HY-B0807S1

Bioactivity: Prochlorperazine D8 dimeleate is the deuterium labeled Prochlorperazine, which is a dopamine (D2) receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Promazine hydrochloride

Cat. No.: HY-B1225

Bioactivity: Promazine (hydrochloride) is a D2 dopamine receptor antagonist, belongs to the phenothiazine class of antipsychotics, used to treat schizophrenia.

Purity: 99.72%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg



Quetiapine D4 fumarate

Cat. No.: HY-B0031S

Bioactivity: Quetiapine D4 fumarate is the deuterium labeled Quetiapine, which is an atypical antipsychotic.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Quetiapine fumarate

Cat. No.: HY-B0031

Bioactivity: Quetiapine fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.

Purity: 99.54
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Quinagolide hydrochloride

(CV205-502 hydrochloride)

Cat. No.: HY-13736A

Bioactivity: Quinagolide hydrochloride is a selective dopamine D2 receptor agonist, also is a prolactin inhibitor. Target: dopamine D2 receptor, prolactin Quinagolide is a selective, D2 receptor agonist (or prolactin-release inhibitor) that is used for the treatment of elevated levels of prolactin. Quinagolide is...

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Quinpirole Hydrochloride

((-)-LY 171555)

Cat. No.: HY-B1752A

Bioactivity: Quinpirole (Hydrochloride) is a high-affinity agonist **dopamine D2/D3** receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



rac-Rotigotine Hydrochloride

Cat. No.: HY-15394

Bioactivity: rac-Rotigotine Hcl is a high potency and selectivity agonist for D-2 receptor with Ki of 0.69 nM.

Purity: 97.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Raclopride

Cat. No.: HY-103414

Bioactivity: Raclopride is a **dopamine D_2/ D_3 receptor** antagonist, which binds to **D_2** and **D_3 receptor**s with dissociation constants (**K_i**s) of 1.8 nM and 3.5 nM, respectively, but has a very low affinity for D_1 and D_4 receptors with K_is...

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Risperidone

(R 64 766)

Cat. No.: HY-11018

Bioactivity: Risperidone is a serotonin **5-HT_2 receptor** blocker, **P-Glycoprotein** inhibitor and potent **dopamine D_2 receptor** antagonist, with **K_is** of 4.8, 5.9 nM for 5-HT_{2A} and dopamine D_2 receptor, respectively.

Purity: 99.16%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Risperidone hydrochloride

(R 64 766 hydrochloride)

Cat. No.: HY-11018A

Bioactivity: Risperidone hydrochloride is a serotonin **5-HT_2** receptor blocker and a potent **dopamine D_2** receptor antagonist, with **K_is** of 0.16, 1.4 nM for 5-HT_2 and D_2 receptor, respectively.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Risperidone mesylate

(R 64 766 mesylate)

Cat. No.: HY-11018B

Bioactivity: Risperidone mesylate(R 64 766 mesylate) is a serotonin 5-HT2 receptor blocker(Ki= 0.16 nM) and a potent dopamine D2 receptor antagonist(Ki= 1.4 nM).

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Ro 10-5824 dihydrochloride

Cat. No.: HY-101384A

Bioactivity: Ro 10-5824 dihydrochloride is a selective **dopamine D4 receptor** partial agonist, with K_i of 5.2 nM.

Purity: 98.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Ropinirole hydrochloride

(SKF 101468 hydrochloride)

Cat. No.: HY-B0623A

Bioactivity: Ropinirole hydrochloride(SKF101468 hydrochloride) a selective dopamine D2 receptor inhibitor with IC50 of 29 nM.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Rotigotine

(N-0437; N-0923)

Cat. No.: HY-75502

Bioactivity: Rotigotine is a full agonist of **dopamine receptor**, a partial agonist of the **5-HT1A receptor**, and an antagonist of the **α2B-adrenergic receptor**, with K_is of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Rotigotine D7 Hydrochloride

(N-0923 D7 Hydrochloride)

Cat. No.: HY-A0007S

Bioactivity: Rotigotine D7 Hydrochloride is the deuterium labeled Rotigotine(N-0923), which is a dopamine D2 and D3 receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Rotundine

((-)-Tetrahydropalmatine; L-Tetrahydropalmatine)

Cat. No.: HY-N0096

Bioactivity: Rotundine is an antagonist of **dopamine D1**, **D2** and **D3 receptors** with IC_{50}s of 166 nM, 1.4 μM and 3.3 μM, respectively. Rotundine is also an antagonist of **5-HT$_{1A}$** with an IC_{50} of 370 nM.

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



SB-277011

(SB-277011A)

Cat. No.: HY-10847

Bioactivity: SB-277011 is a potent and delective dopamine D3 receptor antagonist (pKi values are 8.0, 6.0, 5.0 and <5.2 for D3, D2, 5-HT1D and 5-HT1B respectively); brain penetrant.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



SB-277011 dihydrochloride

(SB-277011A dihydrochloride)

Cat. No.: HY-10847A

Bioactivity: SB-277011 dihydrochloride (SB-277011A dihydrochloride) is a potent, selective, orally bioavailable and brain penetrate **dopamine D$_3$ receptor** antagonist, with **pK$_i$**s of 8.0, 6.0, <5.2 and 5.9 for D $_3$, D $_2$, 5-HT $_{1B}$, and 5-HT $_{1D}$

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



SB269652

Cat. No.: HY-12324

Bioactivity: SB269652 is the first drug-like allosteric modulator of the dopamine D2 receptor (D2R); a new chemical probe that can differentiate D2R monomers from dimers or oligomers depending on the observed pharmacology.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



SCH 23390 hydrochloride

(R-(+)-SCH23390 hydrochloride)

Cat. No.: HY-19545A

Bioactivity: SCH 23390 hydrochloride is a potent **dopamine receptor** D1 antagonist with K_i values of 0.2 and 0.3 nM for the D1 and D5.

Purity: 99.31%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Sertindole

(Lu 23-174)

Cat. No.: HY-14543

Bioactivity: Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Target: Multi-target In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors. Sertindole offers an alternative treatment option for...

Purity: 96.14%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



SKF 38393 hydrochloride

((±)-SKF-38393 hydrochloride; SKF-38393A) Cat. No.: HY-12520A

Bioactivity: SKF 38393 hydrochloride is a selective agonist of the **dopamine D1 receptor (D1DR)** with an IC_{50} of 110 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg, 500 mg



SKF 82958

((±)-SKF 82958; Chloro-AP) Cat. No.: HY-10435

Bioactivity: SKF 82958 is a D1/D5 receptor full agonist. IC50 value: Target: D1/D5 receptor in vitro: Neuropeptide and immediate early gene expression in striatonigral neurons of the normosensitive striatum is induced by mixed D1 receptor SKF-82958, which induces behavioral activity and...

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



SKF-82958 hydrobromide

((±)-SKF 82958 hydrobromide; Chloro-APB hydrobromide) Cat. No.: HY-10435A

Bioactivity: SKF-82958 hydrobromide is a D1/D5 receptor full agonist. IC50 value: Target: D1/D5 receptor in vitro: Neuropeptide and immediate early gene expression in striatonigral neurons of the normosensitive striatum is induced by mixed D1 receptor SKF-82958, which induces behavioral activity and...

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



ST-836

Cat. No.: HY-15238

Bioactivity: ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



ST-836 hydrochloride

Cat. No.: HY-15238A

Bioactivity: ST-836 Hcl is a dopamine receptor ligand; Antiparkinsonian agent.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Sulpiride

Cat. No.: HY-B1019

Bioactivity: Sulpiride is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class, used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Sultopride

(LIN-1418) Cat. No.: HY-42849

Bioactivity: Sultopride is a selective antagonist of **dopamine D2 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg



Sultopride hydrochloride

(LIN-1418 hydrochloride) Cat. No.: HY-42849A

Bioactivity: Sultopride hydrochloride is a selective antagonist of **dopamine D2 receptor**.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Sumanirole maleate

(U-95666E; PNU-95666) Cat. No.: HY-70081A

Bioactivity: Sumanirole maleate(PNU 95666E; U95666E) is a highly selective D2 receptor full agonist with an ED50 of about 46 nM. IC50 value: 46 nM (EC50) Target: D2 receptor Sumanirole was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 25 mg, 50 mg, 100 mg



Talipexole

(B-HT 920) Cat. No.: HY-A0040

Bioactivity: Talipexole (B-HT920) is a dopamine agonist that has been proposed as an antiparkinsonian agent. Target: Dopamine Receptor B-HT920 is a selective alpha 2-adrenoceptor agonist. The effects of B-HT920 have been specified using the alpha-adrenergic antagonists yohimbine and prazosin and the...

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Talipexole dihydrochloride

(B-HT 920 (dihydrochloride))

Cat. No.: HY-A0008

Bioactivity: Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Tetrahydroberberine

(Canadine)

Cat. No.: HY-N0925

Bioactivity: Tetrahydroberberine is an isoquinoline alkaloid isolated from corydalis tuber; has micromolar affinity for dopamine D(2) (pK(i) = 6.08) and 5-HT(1A) (pK(i) = 5.38) receptors but moderate to no affinity for other relevant serotonin receptors (5-HT(1B), 5-HT(1D), 5-HT(3), and 5-HT(4); pK(i) < 5.00).

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Tetrahydropalmatine

(DL-Tetrahydropalmatine)

Cat. No.: HY-N0300

Bioactivity: Tetrahydropalmatine, an active component isolated from corydalis, acts through inhibition of amygdaloid release of **dopamine** to inhibit an epileptic attack in rats.

Purity: 99.07%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Thioridazine hydrochloride

Cat. No.: HY-B0965

Bioactivity: Thioridazine is an antipsychotic drug, used in the treatment of schizophrenia and psychosis, shows D4 selectivity or serotonin antagonism.

Purity: 99.93%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Tiapride hydrochloride

Cat. No.: HY-B1196

Bioactivity: Tiapride hydrochloride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome.

Purity: 99.82%
Clinical Data: Launched
Size: 100 mg



Trifluoperazine dihydrochloride

(TFP; SKF5019)

Cat. No.: HY-B0532A

Bioactivity: Trifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. Target: Dopamine D2 Receptor Trifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. Trifluoperazine inhibited in...

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Triflupromazine hydrochloride

Cat. No.: HY-B0909

Bioactivity: Triflupromazine hydrochloride is an antipsychotic medication, which are Dopamine D1/D2 receptor antagonists.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Trimethobenzamide hydrochloride

(Ro 2-9578)

Cat. No.: HY-12751A

Bioactivity: Trimethobenzamide hydrochloride is a blocker of the D_2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.

Purity: 99.70%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



U91356

Cat. No.: HY-U00227

Bioactivity: U91356 is a **dopamine receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Veralipride

((±)-Veralipride; LIR166)

Cat. No.: HY-101797

Bioactivity: Veralipride is a **D2** receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.

Purity: 99.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Ziprasidone

(CP-88059) Cat. No.: HY-14542

Bioactivity: Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Purity: 98.69%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Ziprasidone D8

(CP-88059 D8) Cat. No.: HY-14542S

Bioactivity: Ziprasidone D8 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Ziprasidone hydrochloride

(CP-88059 hydrochloride) Cat. No.: HY-14542A

Bioactivity: Ziprasidone Hcl(CP-88059 Hcl) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Ziprasidone hydrochloride monohydrate

(CP 88059 (hydrochloride monohydrate)) Cat. No.: HY-17407

Bioactivity: Ziprasidone hydrochloride monohydrate (CP 88059 hydrochloride monohydrate) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity. Target: 5-HT receptor; Dopamine receptor Ziprasidone hydrochloride monohydrate is the salt...

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Zuclopenthixol

((Z)-Clopenthixol) Cat. No.: HY-A0163

Bioactivity: Zuclopenthixol is a thioxanthene derivative which acts as a mixed **dopamine D1/D2 receptor** antagonist.

Purity: 98.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg



EBI2/GPR183



The Epstein-Barr virus (EBV) induced receptor 2 (EBI2; also known as GPR183) is an orphan member of the 7TM receptor family A. EBI2 is a constitutively active seven-transmembrane receptor. EBI2 has been placed in varying 7TM receptor subgroups by different phylogenetic analyses as being a target of peptide or lipid ligands. EBI2 constitutively activates extracellular signal-regulated kinase (ERK) in a pertussis toxin-insensitive manner. EBI2 is up-regulated up to 200-fold in B cells following EBV infection.

EBI2 activation stimulates immune cell migration and has been genetically linked to autoimmune diseases including type 1 diabetes. Small molecule modulators of EBI2 can be useful for probing the function of the receptor and its relevance to human diseases.

EBI2/GPR183 Inhibitors & Modulators

GSK682753A

Cat. No.: HY-101192

Bioactivity: GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (**EBI2**) with an **IC_{50}** of 53.6 nM.

Purity: 98.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



NIBR189

Cat. No.: HY-12336

Bioactivity: NIBR189 is a small molecule antagonist of the Epstein-Barr virus-induced gene 2 (EBI2; GPR183) receptor with IC50 of 16 nM(Binding) and 11 nM (Functional).

Purity: 99.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Endothelin Receptor



Endothelin receptors are G protein-coupled receptors whose activation results in elevation of intracellular-free calcium. There are at least four type known, ETA, ETB1, ETB2 and ETC. ETA is a subtype for vasoconstriction. These receptors are found in the smooth muscle tissue of blood vessels, and binding of endothelin to ETA increases vasoconstriction (contraction of the blood vessel walls) and the retention of sodium, leading to increased blood pressure. ETB1 mediates vasodilation, when endothelin binds to ETB1 receptors, this leads to the release of nitric oxide (also called endothelium-derived relaxing factor), natriuresis and diuresis (the production and elimination of urine) and mechanisms that lower blood pressure. ETB2 mediates vasoconstriction. ETC has yet no clearly defined function. ET receptors are also found in the nervous system where they may mediate neurotransmission and vascular functions.

Endothelin Receptor Inhibitors & Modulators

Ambrisentan
(BSF 208075; LU 208075) Cat. No.: HY-13209

Bioactivity: Ambrisentan is a selective ET type A receptor (**ETAR**) antagonist.

Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Aminaftone
(Aminaftone; Aminaphthone) Cat. No.: HY-19890

Bioactivity: Aminaftone, a derivative of 4-aminobenzoic acid, downregulates **endothelin-1** (**ET-1**) production in vitro by interfering with the transcription of the pre-pro-ET-1 gene.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Aprocitentan
(ACT-132577) Cat. No.: HY-15895

Bioactivity: Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of macitentan, which is dual **ETA/ETB** antagonist designed for tissue targeting.

Purity: 98.13%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Atrasentan
(ABT-627; (+)-A 127722; A-147627) Cat. No.: HY-15403

Bioactivity: Atrasentan is an **endothelin receptor** antagonist with **IC_{50}** of 0.0551 nM for ET_A.

Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg



Atrasentan hydrochloride (ABT-627 (hydrochloride); (+)-A 127722 (hydrochloride); A-147627 (hydrochloride))
Cat. No.: HY-15403A

Bioactivity: Atrasentan (hydrochloride) is an **endothelin receptor** antagonist with **IC_{50}** of 0.0551 nM for ET_A.

Purity: 99.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Atrial Natriuretic Peptide (ANP) (1-28), human, porcine
Cat. No.: HY-P1235

Bioactivity: Atrial Natriuretic Peptide (ANP) (1-28), human, porcine is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. ANP (1-28) inhibits **endothelin-1** secretion in a dose-dependent way.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate
Cat. No.: HY-P1235A

Bioactivity: Atrial Natriuretic Peptide (ANP) (1-28), human, porcine is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. ANP (1-28) inhibits **endothelin-1** secretion in a dose-dependent way.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 500u g, 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), rat
(Atrial natriuretic factor (1-28) (rat)) Cat. No.: HY-P1236

Bioactivity: Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated **endothelin-1** secretion in a concentration-dependent manner.

Purity: 95.52%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), rat TFA
(Atrial natriuretic factor (1-28) (rat) (TFA)) Cat. No.: HY-P1236A

Bioactivity: Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated **endothelin-1** secretion in a concentration-dependent manner.

Purity: 98.74%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Avosentan
(Ro 67-0565; SPP-301) Cat. No.: HY-15195

Bioactivity: Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist.

Purity: 98.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Bosentan

Cat. No.: HY-A0013

Bioactivity: Bosentan is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.

Purity: 99.69%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Bosentan hydrate

Cat. No.: HY-A0013A

Bioactivity: Bosentan hydrate is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g



BQ-123

Cat. No.: HY-12378

Bioactivity: BQ-123 is an ETA endothelin receptor antagonist (Ki values are 1.4 and 1500 nM at ETA and ETB receptors respectively) . 1) Reduces ischemia-induced ventricular arrhythmias in a rat model. 2) BQ-123 prevents LPS-induced preterm birth in mice via the induction of uterine and placental IL-10. 3) The...

Purity: 95.43%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



BQ-788

Cat. No.: HY-15894A

Bioactivity: BQ-788 is a potent, selective **ETB receptor** antagonist with IC_{50} of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC_{50} of 1...

Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg



BQ-788 sodium salt

Cat. No.: HY-15894

Bioactivity: BQ-788 (sodium salt) is a potent and selective **ETB receptor** antagonist, inhibiting ET-1 binding to ETB receptors with an IC_{50} of 1.2 nM in human Girardi heart cells.

Purity: 98.03%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



Endothelin 1 swine, human

Cat. No.: HY-P0202

Bioactivity: Endothelin 1 (swine, human) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ETA and ETB.

Purity: 96.85%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg, 10 mg

Endothelin Mordulator 1

Cat. No.: HY-106182

Bioactivity: Endothelin Mordulator 1 is a **endothelin receptor** modulator, used for the research of endothelin-mediated disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



IRL-1620

Cat. No.: HY-16465

Bioactivity: IRL-1620 is a potent and selective **endothelin receptor** type B (ETB) agonist with a K_i of 16 pM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Macitentan

(ACT-064992)

Cat. No.: HY-14184

Bioactivity: Macitentan is an orally active, non-peptide **endothelin receptor** antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary arterial hypertension.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Macitentan n-butyl analogue

Cat. No.: HY-14184A

Bioactivity: Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin **ETA** and **ETB receptor** antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Purity: 97.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



PD-159020

Cat. No.: HY-101598

Bioactivity: PD-159020 is a non-selective **ETA/ETB** antagonist, with **IC_{50}s** of 30 and 50 nM for hETA and hETB, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Ro 46-2005

Cat. No.: HY-19529

Bioactivity: Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Sitaxsentan

(IPI 1040; TBC-11251)

Cat. No.: HY-76520

Bioactivity: Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure. IC50 value: Target: ETA receptor

Purity: >98%
Clinical Data: Phase 3
Size: 10 mg, 50 mg



Sitaxsentan sodium

(IPI 1040 (sodium); TBC11251 (sodium))

Cat. No.: HY-11103

Bioactivity: Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of **endothelin A receptors**.

Purity: 98.73%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Sparsentan

(RE-021; DARA-a)

Cat. No.: HY-17621

Bioactivity: Sparsentan (RE-021; BMS-346567; PS433540; DARA-a) is a highly potent dual **angiotensin II** and **endothelin A** receptor antagonist with **K_i**s of 0.8 and 9.3 nM, respectively.

Purity: 99.08%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Sulfisoxazole

(Sulfafurazole)

Cat. No.: HY-B0323

Bioactivity: Sulfisoxazole, an endothelin receptor antagonist, is a sulfonamide antibacterial with an oxazole substituent.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Tezosentan

(RO 610612)

Cat. No.: HY-17351

Bioactivity: Tezosentan (RO 610612) is an **endothelin (ET)** receptor antagonist, with **pA_2s** of 9.5, 7.7 for ET_A and ET_B receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



ZD-1611

Cat. No.: HY-19274

Bioactivity: ZD-1611 is a potent, orally active, selective **ETA receptor** antagonist, used for the research of ischemic stroke.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Zibotentan

(ZD4054)

Cat. No.: HY-10088

Bioactivity: Zibotentan (ZD4054) is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). IC50 value: 21 nM Target: ETA receptor Zibotentan is capable of inhibiting or reducing the multitude of effects that are evoked by ET-1 activation of the ETA receptor and...

Purity: 98.13%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GHSR

Growth hormone secretagogue receptor



GHSR (Growth hormone secretagogue receptor) is a member of the G-protein coupled receptor family. GHSR may play a role in energy homeostasis and regulation of body weight. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. One of the important features of GHSR1a displays constitutive activity possessing basal activity in the absence of an agonist, resulting in a high degree of receptor internalization as well as of signaling activity. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity. A range of selective ligands for the GHSR receptor are now available and are being developed for several clinical applications. GHSR agonists have appetite-stimulating and growth hormone-releasing effects, and are likely to be useful for the treatment of muscle wasting and frailty associated with old-age and degenerative diseases. On the other hand, GHSR antagonists have anorectic effects and are likely to be useful for the treatment of obesity.

GHSR Inhibitors & Modulators

Alexamorelin Met 1

((D-Mrp)-Ala-Trp-(D-Phe)) Cat. No.: HY-P0166A

Bioactivity: Alexamorelin Met 1 is one of the metabolites of alexamorelin. The heptapeptide Ala-His-$_{D}$-2-methyl-Trp-Ala-Trp-$_{D}$-Phe-Lys-NH$_{2}$ (Alexamorelin) is a synthetic molecule which inhibits growth hormone secretagogue binding in vitro.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

(D-Mrp)-Ala-Trp-(D-Phe)

Anamorelin

(RC-1291; ONO-7643) Cat. No.: HY-14734

Bioactivity: Anamorelin is a novel **ghrelin receptor** agonist with **EC_{50}** value of 0.74 nM in the FLIPR assay.

Purity: 99.91%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Anamorelin Fumarate

(ONO-7643 Fumarate; RC1291 Fumarate) Cat. No.: HY-14734B

Bioactivity: Anamorelin Fumarate is a novel **ghrelin receptor** agonist with **EC_{50}** value of 0.74 nM in the FLIPR assay.

Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Anamorelin hydrochloride

(RC-1291 hydrochloride; ONO-7643 hydrochloride) Cat. No.: HY-14734A

Bioactivity: Anamorelin hydrochloride is a novel **ghrelin receptor** agonist with **EC_{50}** value of 0.74 nM in the FLIPR assay.

Purity: 99.80%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AZP-531

Cat. No.: HY-P0231

Bioactivity: AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.

Purity: 96.61%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg

Cyclo (RVQSPEHQ)

Capromorelin Tartrate

(CP 424391-18) Cat. No.: HY-15243

Bioactivity: Capromorelin Tartrate is an orally active, potent **growth hormone secretagogue receptor (GHSR)** agonist, with **K_i** of 7 nM for hGHS-R1a.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg



Ibutamoren Mesylate

(MK-677; MK-0677) Cat. No.: HY-50844

Bioactivity: Ibutamoren (Mesylate) is a potent, non-peptide **Growth hormone secretagogue receptor (GHSR)** agonist.

Purity: 96.13%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg



JMV 2959

Cat. No.: HY-U00433

Bioactivity: JMV 2959 is a growth hormone secretagogue receptor type 1a (**$GHS\text{-}R_{1a}$**) antagonist with an **IC_{50}** of 32 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



JMV 2959 hydrochloride

Cat. No.: HY-U00433A

Bioactivity: JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (**$GHS\text{-}R_{1a}$**) antagonist with an **IC_{50}** of 32±3 nM in LLC-PK$_{1}$ cells.

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



ONC212

Cat. No.: HY-111343

Bioactivity: ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer drug and also a selective agonist of **GPR132**.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PF-5190457

Cat. No.: HY-12584

Bioactivity: PF-5190457 is a potent and selective **ghrelin receptor** inverse agonist with a **pK_i** of 8.36.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



TC-G-1008

(GPR39-C3)

Cat. No.: HY-103007

Bioactivity: TC-G-1008 (GPR39-C3) is a potent and orally available **GPR39** agonist with **EC_{50}** values of 0.4 and 0.8 nM for rat and human receptors respectively.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



TM-N1324

Cat. No.: HY-108699

Bioactivity: TM-N1324 is an agonist of G-Protein-Coupled Receptor 39 (**GPR39**) with **EC_{50}**s of 9 nM/5 nM in the presence of Zn^{2+}, and 280 nM/180 nM in the absence of Zn^{2+} for **human/murine GPR39**.

Purity: 98.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Glucagon Receptor

GCGR



Glucagon receptor is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Glucagon Receptor Inhibitors & Modulators

Adomeglivant
(LY2409021)

Cat. No.: HY-19904

Bioactivity: Adomeglivant is a potent and selective glucagon receptor antagonist that is used in clinical trial for type 2 diabetes mellitus.

Purity: 99.84%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Avexitide
(Exendin (9-39))

Cat. No.: HY-P0264

Bioactivity: Avexitide (Exendin (9-39)) is a specific and competitive **glucagon-like peptide-1** receptor antagonist.

Purity: 96.69%
Clinical Data: Phase 4
Size: 10mM x 1mL in Water,
500u g, 1 mg, 5 mg

BETP

Cat. No.: HY-103546

Bioactivity: BETP is an agonist of **glucagon-like peptide-1 (GLP-1) receptor**, with **EC_{50}**s of 0.66 and 0.755 μM for human and rat **GLP-1 receptor**, respectively.

Purity: 99.28%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Dulaglutide
(LY2189265)

Cat. No.: HY-P0120

Bioactivity: Dulaglutide (LY2189265) is a **glucagon-like peptide-1** (**GLP-1**) **receptor** agonist.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Dulaglutide

Exendin-4
(Exenatide)

Cat. No.: HY-13443

Bioactivity: Exendin-4, a 39 amino acid peptide, is a long-acting **glucagon-like** peptide-1 receptor agonist with an **IC_{50}** of 3.22 nM.

Purity: 98.96%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

Exendin-4 Acetate
(Exenatide acetate)

Cat. No.: HY-13443A

Bioactivity: Exendin-4 Acetate, a 39 amino acid peptide, is a long-acting **glucagon-like** peptide-1 receptor agonist with an **IC_{50}** of 3.22 nM.

Purity: 98.69%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Cat. No.: HY-P1229

Bioactivity: FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GLP-1 moiety from Dulaglutide

Cat. No.: HY-P1348

Bioactivity: GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

Purity: 96.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 1

Cat. No.: HY-112185

Bioactivity: GLP-1 receptor agonist 1 is a glucagon-like peptide-1 (GLP-1) receptor agonist extracted from patent WO2018056453A1, Compound 67.

Purity: 99.42%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GLP-1 receptor agonist 2

Cat. No.: HY-112679

Bioactivity: GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor **(GLP-1R)** agonist.

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GLP-1(7-36) Acetate

(Human GLP-1-(7-36)-amide Acetate) Cat. No.: HY-P0054

Bioactivity: GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

Purity: 98.42%
Clinical Data: Phase 2
Size: 500u g, 1 mg, 5 mg, 10 mg

GLP-1(7-37)

Cat. No.: HY-P0055

Bioactivity: GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

Purity: 98.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

GLP-1(7-37) acetate

Cat. No.: HY-P0055A

Bioactivity: GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion [1].

Purity: 98.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

GLP-2(1-33)(human)

(GLP-2 (human); Glucagon-like peptide 2 (human)) Cat. No.: HY-P1024

Bioactivity: GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the **GLP-2 receptor** and stimulate the growth of intestinal epithelium.

Purity: 95.12%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Glucagon

(Porcine glucagon) Cat. No.: HY-P0082

Bioactivity: Glucagon is a peptide hormone that helps regulate the blood sugar (glucose) levels in the body.

Purity: 96.85%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Glucagon receptor antagonists-1

Cat. No.: HY-10036

Bioactivity: Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.

Purity: 90.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Glucagon receptor antagonists-2

Cat. No.: HY-50158

Bioactivity: Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.

Purity: 97.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Glucagon receptor antagonists-3

Cat. No.: HY-50159

Bioactivity: Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Glucagon-Like Peptide (GLP) I (7-36), amide, human

(Human GLP-1-(7-36)-amide) Cat. No.: HY-P0054A

Bioactivity: Glucagon-Like Peptide (GLP) I (7-36), amide, human is a physiological incretin hormone that stimulates insulin secretion.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Glucagon-like peptide 1 (1-37), human

(HuGLP-1) Cat. No.: HY-P1145

Bioactivity: Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the **GLP-1 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg

GRA Ex-25

Cat. No.: HY-50675

Bioactivity: GRA Ex-25 is an inhibitor of **glucagon receptor**, with IC_{50} of 56 and 55 nM for rat and human glucagon receptors, respectively.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Cat. No.: HY-P1231

Bioactivity: GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.

Purity: 99.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFT

Cat. No.: HY-P1228

Bioactivity: HAEGTFT is the first N-terminal 1-7 residues of GLP-1 peptide.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



HAEGTFTSD

Cat. No.: HY-P1226

Bioactivity: HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFTSDVS

Cat. No.: HY-P1224

Bioactivity: HAEGTFTSDVS is the first N-terminal 1-11 residues of GLP-1 peptide.

Purity: 98.31%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFTSDVS

KQMEEEAVRLFIEWLKNGGPSSGAPPPS

Cat. No.: HY-P1223

Bioactivity: KQMEEEAVRLFIEWLKNGGPSSGAPPPS is a Exendin-4 peptide derivative.

Purity: 97.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LGD-6972

Cat. No.: HY-12525

Bioactivity: LGD-6972 is a **glucagon** receptor antagonist.

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Liraglutide

Cat. No.: HY-P0014

Bioactivity: Liraglutide is a **glucagon-like peptide-1** (**GLP-1**) receptor agonist used clinically to treat type 2 diabetes mellitus.

Purity: 99.96%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Lixisenatide

Cat. No.: HY-P0119

Bioactivity: Lixisenatide is a **glucagon-like peptide-1 (GLP-1) receptor** agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

Purity: 98.36%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

MK 0893

Cat. No.: HY-50663

Bioactivity: MK 0893 is a potent and selective **glucagon receptor** antagonist with an IC_{50} of 6.6 nM.

Purity: 99.22%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



NNC-0640

Cat. No.: HY-124622

Bioactivity: NNC-0640 is a potent **human G-protein-coupled glucagon receptor (GCGR)** negative allosteric modulator (NAM) with an **IC_{50}** of 69.2 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg



PF-06291874

(Glucagon receptor antagonists-4)

Cat. No.: HY-19947

Bioactivity: PF-06291874 is a highly potent glucagon receptor antagonist. It displays low in vivo clearance and excellent oral bioavailability in both rats and dogs.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Semaglutide

Cat. No.: HY-114118

Bioactivity: Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 **(GLP-1)** receptor agonist that can be used in the treatment of type 2 diabetes.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Semaglutide

Semaglutide TFA

Cat. No.: HY-114118A

Bioactivity: Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 **(GLP-1)** receptor agonist that can be used in the treatment of type 2 diabetes.

Purity: 98.24%
Clinical Data: Launched
Size: 500u g, 1 mg, 5 mg

Semaglutide

Taspoglutide

(ITM077; R1583; BIM51077)

Cat. No.: HY-P0165

Bioactivity: Taspoglutide is a long-acting glucagon-like peptide 1 (**GLP-1**) receptor agonist developed for treatment of type 2 diabetes, with an **EC_{50}** value of 0.06 nM. Sequence: His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-{Aib}-Arg-NH2.

Purity: 97.17%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg

Tirzepatide

(LY3298176)

Cat. No.: HY-P1731

Bioactivity: Tirzepatide (LY3298176) is a dual **glucose-dependent insulinotropic polypeptide (GIP)** and **glucagon-like peptide-1 (GLP-1) receptor** agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control...

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU0453379

Cat. No.: HY-116819

Bioactivity: VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of **glucagon-like peptide-1R (GLP-1R)** with an **EC_{50}** of 1.3 μM [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



Glucocorticoid Receptor



Glucocorticoid Receptor (GR, or GCR) also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1) is the receptor to which cortisol and other glucocorticoids bind. The GR is expressed in almost every cell in the body and regulates genes controlling the development, metabolism, and immune response. When the glucocorticoid receptor binds to glucocorticoids, its primary mechanism of action is the regulation of gene transcription. The unbound receptor resides in the cytosol of the cell. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex can take either of two paths. The activated GR complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus. Dexamethasone is an agonist, and RU486 and cyproterone acetate are antagonists of the GR. Also, progesterone and DHEA have antagonist effects on the GR.

Glucocorticoid Receptor Inhibitors & Modulators

(20S)-Protopanaxatriol

(20(S)-APPT; g-PPT) Cat. No.: HY-N0835

Bioactivity: (20S)-Protopanaxatriol is a metabolite of ginsenoside, works through the **glucocorticoid receptor (GR)** and **oestrogen receptor (ER)**, and is also a **LXRα** inhibitor.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



(S)-Mapracorat

((S)-ZK-245186; (S)-BOL-303242X) Cat. No.: HY-14864A

Bioactivity: (S)-Mapracorat is a selective and less active glucocorticoid receptor agonist.

Purity: 99.40%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



AL 082D06

(D06; D-06) Cat. No.: HY-15709

Bioactivity: AL 082D06 is a selective, nonsteroidal glucocorticoid receptor (**GR**) antagonist with $\mathbf{K_i}$ of 210 nM.

Purity: 98.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Amcinonide

(CL-34699) Cat. No.: HY-B1197

Bioactivity: Amcinonide inhibit NO release from activated microglia with IC50 3.38 nM. Amcinonide has affinity for the glucocorticoid receptor.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Amebucort

Cat. No.: HY-U00298

Bioactivity: Amebucort is a synthetic glucocorticoid corticosteroid, may used for the research of inflammatory disorders.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



AZD2906

Cat. No.: HY-113854

Bioactivity: AZD2906 is a selective **glucocorticoid receptor (GR)** agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows $\mathbf{IC_{50}}$s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blo...

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AZD5423

Cat. No.: HY-108243

Bioactivity: AZD5423 is an inhaled, potent, selective, and non-steroidal **glucocorticoid receptor (GR)** modulator (SGRM) [1]. AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma [2].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AZD7594

(AZ13189620) Cat. No.: HY-111453

Bioactivity: AZD7594 is a potent selective nonsteroidal **glucocorticoid receptor** modulator, with an $\mathbf{IC_{50}}$ of 0.9 nM.

Purity: 98.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AZD9567

Cat. No.: HY-120012

Bioactivity: AZD9567 (compound 15) is a potent, oral active, non-steroidal and **selective glucocorticoid receptor modulator (SGRM)**, with an $\mathbf{IC_{50}}$ of 3.8 nM. Exhibits excellent efficacy in the streptococcal cell wall (SCW) reactivation model of jo...

Purity: 99.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Beclometasone

(Beclomethasone) Cat. No.: HY-B1540

Bioactivity: Beclometasone (Beclomethasone) is a prototype **glucocorticoid receptor** agonist.

Purity: 92.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 25 mg, 50 mg, 100 mg



Beclometasone dipropionate

Cat. No.: HY-13571A

Bioactivity: Beclometasone dipropionate is a potent glucocorticoid agonist; it is a prodrug of the free form, beclometasone. IC50 Value: 0.2 nM (Inhibiting thymidine incorporation) [1] Target: glucocorticoid receptor in vitro: Cortisol and beclomethasone dipropionate were more potent than salbutamol in inhibiting...

Purity: 99.92%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 250 mg



Betamethasone

Cat. No.: HY-13570

Bioactivity: Betamethasone is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Target: Glucocorticoid Receptor Betamethasone is a potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Unlike other drugs with these...

Purity: 99.24%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Betamethasone acibutate

Cat. No.: HY-121062

Bioactivity: Betamethasone acibutate, derives from Betamethasone, is an acetate ester. Betamethasone acibutate is a glucocorticoid [1].

Purity: >98%

Clinical Data: No Development Reported

Size: 100 mg, 250 mg, 500 mg



Betamethasone dipropionate

(Betamethasone 17,21-dipropionate)

Cat. No.: HY-13571

Bioactivity: Betamethasone dipropionate is a **glucocorticoid** steroid with anti-inflammatory and immunosuppressive abilities.

Purity: 99.12%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 250 mg, 1 g



Betamethasone hydrochloride

Cat. No.: HY-13570A

Bioactivity: Betamethasone (hydrochloride) is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Target: Glucocorticoid Receptor Betamethasone (hydrochloride) is the hydrochloride of betamethasone, which is a potent glucocorticoid steroid with anti-inflammatory and...

Purity: >98%

Clinical Data: Launched

Size: 100 mg, 500 mg



Budesonide

Cat. No.: HY-13580

Bioactivity: Budesonide is a **glucocortical steroid** with potent anti-inflammatory activity.

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Ciclesonide

(RPR251526)

Cat. No.: HY-B0625

Bioactivity: Ciclesonide(RPR251526) is a glucocorticoid used to treat obstructive airway diseases.

Purity: 98.95%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Clobetasol propionate

Cat. No.: HY-13600

Bioactivity: Clobetasol propionate is a anti-inflammatory corticosteroid used to treat various skin disorders.

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Corticosterone (17-Deoxycortisol; 11β,21-Dihydroxyprogesterone; Kendall's compound B)

Cat. No.: HY-B1618

Bioactivity: Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

Purity: 99.70%

Clinical Data: Phase 3

Size: 10mM x 1mL in DMSO, 50 mg



Cortisone (17-Hydroxy-11-dehydrocorticosterone; Kendall's compound E)

Cat. No.: HY-17461

Bioactivity: Cortisone is a 21-carbon steroid hormone. Cortisone is one of the main hormones released by the adrenal gland in response to stress. Target In chemical structure, it is a corticosteroid closely related to cortisol. It is used to treat a variety of ailments and can be administered intravenously,...

Purity: 99.90%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Cortisone acetate
(Cortisone 21-acetate) Cat. No.: HY-17461A

Bioactivity: Cortisone acetate (17-hydroxy-11-dehydrocorticosterone), a 21-carbon steroid hormone, is one of the main hormones released by the adrenal gland in response to stress. IC50 Value: Target: Glucocorticoid Receptor in vitro: Cortisone suppressed this apoptosis at a concentration range of 1-10,000...
Purity: 99.42%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Dagrocorat
(PF-00251802) Cat. No.: HY-16718

Bioactivity: Dagrocorat (PF-00251802) is a novel and dissociated **glucocorticoid receptor** agonist.
Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Deflazacort
Cat. No.: HY-13609

Bioactivity: Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Desisobutyryl-ciclesonide
(CIC-AP; Ciclesonide active principle) Cat. No.: HY-111490

Bioactivity: Desisobutyryl-ciclesonide is the active metabolite of Ciclesonide. Desisobutyryl-ciclesonide has affinity for the **glucocorticoid receptor**.
Purity: 99.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Desonide
Cat. No.: HY-B0248

Bioactivity: Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.
Purity: 99.81%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Dexamethasone
(Hexadecadrol; Prednisolone F) Cat. No.: HY-14648

Bioactivity: Dexamethasone is a **glucocorticoid receptor** agonist.
Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Dexamethasone acetate
(Dexamethasone 21-acetate) Cat. No.: HY-14648A

Bioactivity: Dexamethasone acetate is a **glucocorticoid receptor** agonist.
Purity: 97.68%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Dexamethasone phosphate disodium
(Dexamethasone 21-phosphate disodium salt) Cat. No.: HY-B1829A

Bioactivity: Dexamethasone phosphate disodium is a **glucocorticoid receptor** agonist.
Purity: 99.68%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Exicorilant
(CORT 125281) Cat. No.: HY-117880

Bioactivity: Exicorilant (CORT 125281) is a selective and oral active **glucocorticoid receptor (GR)** antagonist, with a K_i value of 7 nM [1]. Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia [2].
Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Flunisolide
Cat. No.: HY-B1121

Bioactivity: Flunisolide is a corticosteroid often used to treat allergic rhinitis.The principal mechanism of action of Flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.
Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Fluocinolone Acetonide

Cat. No.: HY-B0415

Bioactivity: Fluocinolone Acetonide is a glucocorticoid derivative used topically in the treatment of various skin disorders.

Purity: 98.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Fluocinonide

Cat. No.: HY-B0485

Bioactivity: Fluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders. Target: Glucocorticoid Receptor Fluocinonide is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders...

Purity: 99.42%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Fluticasone propionate

Cat. No.: HY-B0154

Bioactivity: Fluticasone propionate is a high affinity, selective GR (glucocorticoid receptor) agonist which is derived from fluticasone used to treat asthma and allergic rhinitis. Target: Glucocorticoid Receptor Fluticasone propionate is a corticosteroid derived from fluticasone used to treat asthma...

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Fosdagrocorat

(PF-04171327)

Cat. No.: HY-16722

Bioactivity: Fosdagrocorat (PF-04171327) is a dissociated **glucocorticoid receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Glucocorticoid receptor agonist

Cat. No.: HY-14234

Bioactivity: Glucocorticoid receptor agonist is a potent Glucocorticoid receptor agonist. IC50 value: Target:

Purity: 98.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



GW-870086

Cat. No.: HY-103662

Bioactivity: GW-870086 is a potent anti-inflammatory agent, acting as a **glucocorticoid receptor** agonist, with a **pIC_{50}** of 10.1 in A549 cells expressing NF-κB.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Hydrocortisone

(Cortisol)

Cat. No.: HY-N0583

Bioactivity: Hydrocortisone is a steroid hormone or glucocorticoid secreted by the adrenal cortex.

Purity: 99.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Hydrocortisone acetate

(Hydrocortisone 21-acetate; Cortisol 21-acetate)

Cat. No.: HY-B1183

Bioactivity: Hydrocortisone acetate is a corticosteroid, used to decrease swelling, itching, and pain that is caused by minor skin irritations or by hemorrhoids.

Purity: 99.23%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Hydrocortisone cypionate

Cat. No.: HY-U00089

Bioactivity: Hydrocortisone cypionate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg



Hydrocortisone phosphate

(Hydrocortisone 21-phosphate; Cortisol 21-phosphate)

Cat. No.: HY-B1155

Bioactivity: Hydrocortisone phosphate is the pharmaceutical term for cortisol, which is a steroid hormone, in the glucocorticoid class of hormones, increases blood sugar through gluconeogenesis, to suppress the immune system, and to aid in the metabolism of fat, protein, and carbohydrate.

Purity: >98%
Clinical Data: Launched
Size: 50 mg



Loteprednol Etabonate

Cat. No.: HY-17358

Bioactivity: Loteprednol Etabonate is an anti-inflammatory corticosteroid used in optometry and ophthalmology.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Mapracorat

(ZK-245186; BOL-303242X)

Cat. No.: HY-14864

Bioactivity: Mapracorat is a novel non-steroidal selective **glucocorticoid receptor** agonist.

Purity: 99.40%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Meprednisone

Cat. No.: HY-B0243

Bioactivity: Meprednisone is a glucocorticoid and a methylated derivative of prednisone. Target: Glucocorticoid Receptor Meprednisone is a glucocorticoid and a methylated derivative of prednisone. The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in...

Purity: 99.36%
Clinical Data: Launched
Size: 10 mg, 100 mg



Methylprednisolone

(U 7532)

Cat. No.: HY-B0260

Bioactivity: Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Target: Glucocorticoid Receptor Methylprednisolone is typically used for its anti-inflammatory effects. Common uses include arthritis therapy and short-term treatment of bronchial...

Purity: 99.67%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Methylprednisolone succinate

(Methylprednisolone hydrogen succinate)

Cat. No.: HY-B1900

Bioactivity: Methylprednisolone succinate is a synthetic glucocorticoid and widely used as an anti-inflammatory agent.

Purity: 99.14%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Mifepristone

(RU486; RU 38486)

Cat. No.: HY-13683

Bioactivity: Mifepristone is a **progesterone receptor** (**PR**) and **glucocorticoid receptor** (**GR**) antagonist with **IC_{50}**s of 0.2 nM and 2.6 nM in in vitro assay.

Purity: 98.17%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Mometasone furoate

(Sch32088)

Cat. No.: HY-13693

Bioactivity: Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



ORIC-101

Cat. No.: HY-112710

Bioactivity: ORIC-101 is a highly potent and selective **glucocorticoid receptor** antagonist, with an **EC_{50}** of 5.6 nM. Anti-cancer activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Prednisolone

Cat. No.: HY-17463

Bioactivity: Prednisolone is a glucocorticoid with the general properties of the corticosteroids.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Prednisolone disodium phosphate

(Prednisolone 21-phosphate disodium)

Cat. No.: HY-B0645

Bioactivity: Prednisolone disodium phosphate is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Target: Glucocorticoid Receptor Prednisolone irreversibly binds with glucocorticoid receptors (GR) alpha and beta for which they have a high affinity. Prednisolone can activate and...

Purity: 98.37%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Prednisolone Tebutate

Cat. No.: HY-U00098

Bioactivity: Prednisolone tebutate is a synthetic glucocorticoid used as an antiinflammatory and immunosuppressant.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg



Prednisone

(Dehydrocortisone)

Cat. No.: HY-B0214

Bioactivity: Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound. Target: Others Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases (such as...

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Prednisone acetate

(Prednisone 21-acetate)

Cat. No.: HY-B1832

Bioactivity: Prednisone acetate (Prednisone 21-acetate), the acetate salt form of prednisolone, is a **glucocorticoid receptor** agonist with anti-inflammatory and immunomodulating properties [1].

Purity: >98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



Triamcinolone

Cat. No.: HY-B0328

Bioactivity: Triamcinolone is a long-acting synthetic corticosteroid. Target: Glucocorticoid Receptor Dimethyl fumarate is an anti-inflammatory. It is indicated for multiple sclerosis patients with relapsing forms and is also being investigated for the treatment of psoriasis. The mechanism of action of...

Purity: 99.15%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Triamcinolone acetonide

Cat. No.: HY-B0636

Bioactivity: Triamcinolone acetonide is a more potent type of triamcinolone, being about 8 times as effective as prednisone. Target: Glucocorticoid Receptor Triamcinolone acetonide is a synthetic corticosteroid used to treat various skin conditions, to relieve the discomfort of mouth sores, and in...

Purity: 99.08%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Triamcinolone Benetonide

Cat. No.: HY-U00043

Bioactivity: Triamcinolone benetonide is a synthetic glucocorticoid corticosteroid with anti-inflammatory activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



GNRH Receptor

Gonadotropin releasing hormone receptor;GNRHR



GNRH Receptor (Gonadotropin-releasing hormone receptor, GNRHR), also known as the luteinizing hormone releasing hormone receptor (LHRHR), is a member of the seven-transmembrane, G-protein coupled receptor (GPCR) family. It is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes,breast, ovary, and prostate. GNRH Receptor is a 60 kDa G protein-coupled receptor and resides primarily in the pituitary and is responsible for eliciting the actions of LHRH after its release from the hypothalamus. Upon activation, GNRH Receptor stimulates tyrosine phosphatase and elicits the release of LH from the pituitary. Following binding of Gonadotropin releasing hormone (GNRH), GNRH Receptor associates with G-proteins that activate a phosphatidylinositol (PtdIns)-calcium second messenger system. Activation of GNRHR ultimately causes the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH).

GNRH Receptor Inhibitors & Modulators

Abarelix
(R3827; PPI 149)

Cat. No.: HY-13534

Bioactivity: Abarelix is a potent **gonadotrophin-releasing hormone (GnRH)** antagonist, used for prostate cancer treatment.

Purity: 98.11%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Alarelin Acetate
(Alarelin)

Cat. No.: HY-17405

Bioactivity: Alarelin acetate is a synthetic **GnRH** agonist.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Buserelin Acetate

Cat. No.: HY-13581A

Bioactivity: Buserelin (INN) Acetate is a gonadotropin-releasing hormone agonist (GnRH agonist). target: GnRH In vivo: Buserelin treatment reduced the number of neurons along the entire gastrointestinal tract, with increased relative numbers of CRF-immunoreactive submucosal and myenteric neurons in colon...

Purity: 99.98%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Cetrorelix Acetate
(SB-075 acetate; NS-75A)

Cat. No.: HY-P0009A

Bioactivity: Cetrorelix Acetate is a potent gonadotropin-releasing hormone **(GnRH)** receptor antagonist with an IC_{50} of 1.21 nM.

Purity: 98.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Degarelix

Cat. No.: HY-16168A

Bioactivity: Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (**GnRHR**) antagonist.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Elagolix
(NBI-56418)

Cat. No.: HY-14789

Bioactivity: Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).

Purity: 98.06%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Elagolix sodium
(NBI-56418 sodium)

Cat. No.: HY-14369

Bioactivity: Elagolix sodium is a human **GnRH receptor** (**GnRHR**) antagonist with an IC_{50} and K_i of 0.25 and 3.7 nM, respectively.

Purity: 99.20%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Gonadorelin acetate

Cat. No.: HY-12555

Bioactivity: Gonadorelin acetate is a man-made protein that is like a hormone in the body called gonadotropin-releasing hormone (GnRH). Target: GNRH Receptor Gonadorelin acetate is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle...

Purity: 99.97%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Goserelin
(ICI 118630)

Cat. No.: HY-13673

Bioactivity: Goserelin(ICI 118630) is an injectable gonadotropin releasing hormone superagonist (GnRH agonist). IC50 value: Target: GnRH agonist Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders...

Purity: >98%
Clinical Data: Launched
Size: 10 mg



Goserelin acetate
(ICI-118630 acetate)

Cat. No.: HY-13673A

Bioactivity: Goserelin (ICI 118630) acetate is an injectable gonadotropin releasing hormone superagonist (GnRH agonist). IC50 value: Target: GnRH agonist Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri-menopausal women) and prostate, and some benign gynaecological...

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Lecirelin

Cat. No.: HY-P0051

Bioactivity: Lecirelin is a synthetic GnRH (gonadotropin releasing hormone) analogue which shows a great efficacy in the treatment of bovine ovarian follicular cysts.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg

{Glp}-HWSYVLRP

Leuprolide Acetate

(Leuprorelin acetate)

Cat. No.: HY-13665

Bioactivity: Leuprolide acetate is a potent **gonadotropin-releasing hormone** receptor agonist used for the treatment of prostate cancer, endometriosis, uterine fibroids.

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



opigolix

Cat. No.: HY-U00289

Bioactivity: Opigolix is a Gonadotropin-releasing hormone (**GnRH**) receptor antagonist, used for the research of endometriosis and rheumatoid arthritis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Relugolix

(TAK-385)

Cat. No.: HY-16474

Bioactivity: Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013. target: GnRH [1] IC50: 0.33 nM [1] In...

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



GPCR19

G-protein coupled receptor 19



GPCR19 (G-protein coupled receptor 19, GPBAR1) is a protein that in humans is encoded by the GPBAR1 gene. This gene encodes a member of the G protein-coupled receptor (GPCR) superfamily. GPCR19 functions as a cell surface receptor for bile acids. Treatment of cells expressing this GPCR with bile acids induces the production of intracellular cAMP, activation of a MAP kinase signaling pathway, and internalization of the receptor. The receptor is implicated in the suppression of macrophage functions and regulation of energy homeostasis by bile acids. One effect of this receptor is to activate deiodinases which convert the prohormone thyroxine (T4) to the active hormone triiodothyronine (T3). T3 in turn activates the thyroid hormone receptor which increases metabolic rate.

GPCR19 Inhibitors & Modulators

BAR501

Cat. No.: HY-101274

Bioactivity: BAR501 is a potent and selective agonist of **GPBAR1** with an **EC_{50}** of 1 μM.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



BAR502

Cat. No.: HY-101273

Bioactivity: BAR502 is a dual **FXR** and **GPBAR1** agonist with **IC_{50}** values of 2 μM and 0.4 μM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Deoxycholic acid

(Cholanoic Acid; Desoxycholic acid)

Cat. No.: HY-N0593

Bioactivity: Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor **TGR5** that stimulates brown adipose tissue (BAT) thermogenic activity.

Purity: 99.13%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
100 mg, 500 mg

Deoxycholic acid sodium salt

(Sodium deoxycholate)

Cat. No.: HY-N0593A

Bioactivity: Deoxycholic acid sodium salt is specifically responsible for activating the G protein-coupled bile acid receptor **TGR5** that stimulates brown adipose tissue (BAT) thermogenic activity.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg, 500 mg



Hyodeoxycholic acid

(HDCA)

Cat. No.: HY-N0169

Bioactivity: Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a **TGR5 (GPCR19)** agonist, with an **EC_{50}** of 31.6 μM in CHO cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg



INT-767

Cat. No.: HY-12434

Bioactivity: INT-767 is a dual **farnesoid X receptor (FXR)/TGR5** agonist with mean **EC_{50}**s of 30 and 630 nM, respectively [1] [2].

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



INT-777

(S-EMCA)

Cat. No.: HY-15677

Bioactivity: INT-777 is a potent **TGR5** agonist with an **EC_{50}** of 0.82 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



INT-777 R-enantiomer

(S-EMCA R enantiomer)

Cat. No.: HY-15677A

Bioactivity: INT-777 (R-enantiomer) is the R-enantiomer of INT-777, with EC_{50} of 4.79 μM for TGR5, and less potent than INT-777.

Purity:
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg



SB756050

Cat. No.: HY-102016

Bioactivity: SB756050 is a selective **TGR5** agonist currently in phase 1clinical trials for the treatment of type 2 diabetes.

Purity: 99.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



SBI-115

Cat. No.: HY-111534

Bioactivity: SBI-115 is a **TGR5 (GPCR19)** antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 [1].

Purity: 99.51%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



TGR5 Receptor Agonist

Cat. No.: HY-14229

Bioactivity: TGR5 Receptor Agonist, a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



GPR109A

HM74A;PUMA-G;HCA2;HCAR2



GPR109A is a G-protein-coupled receptor for nicotinate but recognizes butyrate with low affinity. GPR109A is expressed in the lumen-facing apical membrane of colonic and intestinal epithelial cells and that the receptor recognizes butyrate as a ligand. The expression of GPR109A is silenced in colon cancer in humans, in a mouse model of intestinal/colon cancer, and in colon cancer cell lines. The tumor-associated silencing of GPR109A involves DNA methylation directly or indirectly. Reexpression of GPR109A in colon cancer cells induces apoptosis, but only in the presence of its ligands butyrate and nicotinate. Butyrate is an inhibitor of histone deacetylases, but apoptosis induced by activation of GPR109A with its ligands in colon cancer cells does not involve inhibition of histone deacetylation. The primary changes in this apoptotic process include down-regulation of Bcl-2, Bcl-xL, and cyclin D1 and up-regulation of death receptor pathway. In addition, GPR109A/butyrate suppresses nuclear factor-kappaB activation in normal and cancer colon cell lines as well as in normal mouse colon. These studies show that GPR109A mediates the tumor-suppressive effects of the bacterial fermentation product butyrate in colon.

GPR109A Inhibitors & Modulators

MK-0354

Cat. No.: HY-13008

Bioactivity: MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.

Purity: 98.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



MK-6892

Cat. No.: HY-10680

Bioactivity: MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor **GPR109A**. K_i and GTPγS EC_{50} of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.

Purity: 98.73%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



GPR119

G protein coupled receptor 119



GPR119 (G protein-coupled receptor 119) is a G protein-coupled receptor that in humans is encoded by the GPR119 gene. GPR119, along with GPR55 and GPR18, have been implicated as novel cannabinoid receptors. GPR119 is expressed predominantly in the pancreas and gastrointestinal tract in rodents and humans, as well as in the brain in rodents. Activation of the receptor has been shown to cause a reduction in food intake and body weight gain in rats. GPR119 has also been shown to regulate incretin and insulin hormone secretion. As a result, new drugs acting on the receptor have been suggested as novel treatments forobesity and diabetes.

GPR119 Inhibitors & Modulators

APD597

(JNJ-38431055)

Cat. No.: HY-15566

Bioactivity: APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119. IC50 value: 46 nM (EC50) [1] Target: hGPR119 The design and synthesis of a second generation GPR119-agonist clinical candidate for the treatment of diabetes is described. APD597 was selected for...

Purity: 99.97%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



APD668

Cat. No.: HY-15565

Bioactivity: APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.

Purity: 99.16%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AR 231453

Cat. No.: HY-15564

Bioactivity: AR231453 is a potent, selective and orally available **GPR119** agonist.

Purity: 99.52%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Firuglipel

Cat. No.: HY-109032

Bioactivity: Firuglipel (DS-8500a) is an orally available, potent and selective **GPR119** agonist.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



GSK1292263

Cat. No.: HY-12066

Bioactivity: GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. IC50 value: Target: GPR119 in vitro: GSK-1292263 is selected from 1538 compounds by using Hypo1, the Fit-Value and Estimate of GSK-1292263 that is aligned in Hypo1 are 8.8 and 7.7 (nM), respectively [1]. in...

Purity: 99.71%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



MBX-2982

Cat. No.: HY-15291

Bioactivity: MBX-2982 is a selective, orally-available G protein-coupled receptor 119 (**GPR119**) agonist.

Purity: 99.39%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



PSN632408

Cat. No.: HY-16673

Bioactivity: PSN632408 is an optimized agonist of GPR119 receptors that shows similar potency to OEA at both recombinant mouse and human GPR119 receptors, exhibiting EC50 values of 5.6 and 7.9 uM, respectively.

Purity: 99.91%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GPR120

G-protein coupled receptor 120



GPR120 (G-protein coupled receptor 120) is a protein that in humans is encoded by the GPR120 gene. GPR120 is a member of the rhodopsin family of G protein-coupled receptors (GPRs). GPR120 has also been shown to mediate the anti-inflammatory and insulin-sensitizing effects of omega 3 fatty acids. Lack of GPR120 is responsible for reduced fat metabolism, thereby leading to obesity.

GPR120 Inhibitors & Modulators

Ginsenoside Rb2
(Ginsenoside C)

Cat. No.: HY-N0040

Bioactivity: Ginsenoside Rb2 is one of the main bioactive components of ginseng extracts. Rb2 can upregulate **GPR120** gene expression.

Purity: 98.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg



GPR120 Agonist 2

Cat. No.: HY-111353

Bioactivity: GPR120 Agonist 2 is a **GPR120** agonist extracted from patent US 20110313003 A1, example 209.

Purity: 98.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



GPR120 modulator 1

Cat. No.: HY-50162

Bioactivity: GPR120 modulator 1 is useful for modulating G protein-coupled receptor 120 (GPR120).

Purity: 98.62%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



GPR120 modulator 2

Cat. No.: HY-50172

Bioactivity: GPR120 modulator 2 is useful for modulating G protein-coupled receptor 120 (GPR120).

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



GPR120-IN-1

Cat. No.: HY-101492

Bioactivity: GPR120-IN-1 is a selective **Gpr120** agonist with a **logEC$_{50}$** of −7.62.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GSK137647A
(GSK 137647)

Cat. No.: HY-19995

Bioactivity: GSK137647A is a selective FFA4 agonist, with pEC50 of 6.3, 6.2, and 6.1 for human, Mouse and Rat FFA4, respectively.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GPR139

G Protein-Coupled Receptor 139



GPR139 (G protein-coupled receptor 139) is a protein that in humans is encoded by the GPR139 gene. GPR139 is an orphan G-protein–coupled receptor expressed in the central nervous system.

The expression pattern of GPR139 has primarily been studied on the mRNA level and showed expression mainly in the central nervous system.

GPR139 is an orphan receptor identified from bioinformatics analysis of the human genome. GPR139 is thus a potential target for the treatment of Parkinson's disease, obesity, eating disorders, and/or diabetes.

The GPR139 is expressed specifically in the brain in areas of relevance for motor control. GPR139 function and signal transduction pathways are elusive, and results in the literature are even contradictory. GPR139 agonists dose-dependently protect primary dopaminergic (DA) neurons against MPP^+ toxicity.

GPR139 Inhibitors & Modulators

JNJ-63533054

Cat. No.: HY-19838

Bioactivity: JNJ-63533054 is a potent and selective agonist of hGPR139 with an EC50 = 16 nM.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



TC-O 9311

Cat. No.: HY-101777

Bioactivity: TC-O 9311 is a potent **orphan G protein-coupled receptor 139 (GPR139)** agonist with an **EC_{50}** of 39 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



GPR40

Free fatty acid receptor 1;FFAR1;FFA1;G-protein-coupled receptor 40



GPR40 (Free fatty acid receptor 1, FFA1) is a class A G-protein coupled receptor that in humans is encoded by the FFAR1 gene. It is strongly expressed in the cells of the pancreas and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis. GPR40 is activated by medium to long chain fatty acids. GPR40 is most strongly activated by eicosatrienoic acid, but has been found to be activated by fatty acids as small as 10 carbons long. For saturated fatty acids the level of activation is dependent on the length of the carbon chain, which is not true for unsaturated fatty acids. It has been found that three hydrophilic residues (arginine-183, asparagine-244, and arginine-258) anchor the carboxylate group of a fatty acid, which activates GPR40.

GPR40 Inhibitors & Modulators

AM-1638

Cat. No.: HY-13467

Bioactivity: AM-1638 is a potent and orally bioavailable **GPR40/FFA1** full agonist with an **EC_{50}** of 0.16 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AM-4668

Cat. No.: HY-12585

Bioactivity: AM-4668 is a **GPR40** agonist for type 2 diabetes. **EC_{50}**s of 3.6 nM and 36 nM for GPR40 in A9 cells (GPR40 IP3 assay) and CHO cells (GPR40 aequorin assay), respectively [1].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg



AMG 837

Cat. No.: HY-13967

Bioactivity: AMG 837 is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



AMG 837 calcium hydrate

Cat. No.: HY-13967B

Bioactivity: AMG 837 calcium hydrate is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



AMG 837 sodium salt

Cat. No.: HY-13967A

Bioactivity: AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. IC50 value: 13 nM (EC50) [1] Target: GPR40 agonist AMG 837 displayed the expected two-fold increase in potency on GPR4...

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



AP5

Cat. No.: HY-112603

Bioactivity: AP5 exhibits potent and selective agonism for the **GPR40 receptor** with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 **EC_{50}** of 0.49±0.28 nM against the GPR40 receptor [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



DC260126

Cat. No.: HY-101906

Bioactivity: DC260126, a small-molecule antagonist of **GPR40**.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



FAA1 agonist-1

Cat. No.: HY-103083

Bioactivity: FAA1 agonist-1 is a potent **free fatty acid receptor 1** (**FFA1/ GPR40**) agonist with a **pEC_{50}** of 7.54.

Purity: 98.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Fasiglifam

(TAK-875)

Cat. No.: HY-10480

Bioactivity: Fasiglifam (TAK-875) is a potent, selective and orally bioavailable **GPR40** agonist with **EC_{50}** of 72 nM.

Purity: 98.94%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



GPR40 Activator 1

Cat. No.: HY-13971

Bioactivity: GPR40 Activator 1 is a potent GPR40 activator for treatment of type 2 diabetes.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



GPR40 Activator 2

Cat. No.: HY-12647

Bioactivity: GPR40 Activator 2 is a potent GPR40 activator from patents WO 2012147516 A1, WO 2012046869A1 and WO 2011078371 A1.

Purity: 99.63%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GPR40 agonist 1

Cat. No.: HY-111359

Bioactivity: GPR40 agonist 1 is a potent and novel **GPR40** full agonist with an $\mathbf{EC_{50}}$ of 2 nM and 17 nM for hGPR40 and rGPR40, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



GPR40 Agonist 2

Cat. No.: HY-U00395

Bioactivity: GPR40 Agonist 2 is a **GPR40** agonist that can be used in the research of diabetes, extracted from patent WO2009054479A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



GPR40/FFAR1 modulator 1

Cat. No.: HY-111763

Bioactivity: GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for **Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1)** [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 250 mg



GW-1100

Cat. No.: HY-50691

Bioactivity: GW-1100 is a selective **GPR40** antagonist with a $\mathbf{pIC_{50}}$ of 6.9.

Purity: 97.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GW9508

Cat. No.: HY-15589

Bioactivity: GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.

Purity: 99.19%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PBI-4050 sodium salt

(Setogepram (sodium salt))

Cat. No.: HY-100775

Bioactivity: PBI-4050 sodium salt acts as an agonist for **GPR40** and as an antagonist or inverse agonist for **GPR84**.

Purity: 99.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



TUG-770

Cat. No.: HY-15697

Bioactivity: TUG-770 is a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist with EC50 of 6 nM for hFFA1. IC50 Value: 6 nM (hFFA1, EC50) [1] Target: GPR40 in vitro: TUG-770 (Compound 22) displayed excellent physicochemical and in vitro ADME properties, with good aqueous solubility, good chemical...

Purity: 98.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GPR55

G protein-coupled receptor 55



GPR55 (G protein-coupled receptor 55) is a G protein-coupled receptor that in humans is encoded by the GPR55 gene. GPR55, along with GPR119 and GPR18, have been implicated as novel cannabinoid receptors. GPR55 is activated by the plant cannabinoids 9-THC and cannabidiol, and the endocannabinoids anandamide, 2-AG, noladin ether in the low nanomolar range. Recent research suggests that lysophosphatidylinositol and its 2-arachidonoyl derivative may be the endogenous ligands for GPR55, and the receptor appears likely to be a possible target for treatment of inflammation and pain as with the other cannabinoid receptors. The physiological role of GPR55 is unclear. GPR55 has been proposed as a new potential drug target for the treatment of diabetes, Parkinson's disease, neuropathic pain, and cancer.

GPR55 Inhibitors & Modulators

Anandamide

Cat. No.: HY-10863

Bioactivity: Anandamide is an immune modulator in the central nervous system acts via not only **cannabinoid receptors** (**CB1** and **CB2**) but also other targets (e.g., **GPR18**/ **GPR55**).

Purity: 99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



CID 16020046

Cat. No.: HY-16697

Bioactivity: CID 16020046 is a potent and selective GPR55(LPI receptor) antagonist; inhibitsGPR55 constitutive activity with IC50 of 0.15 uM.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



GPR84

G protein coupled receptor 84



GPR84 is a G protein-coupled receptor for medium-chain fatty acids. GPR84 is a receptor for free fatty acids and can be potently activated by saturated medium-chain free fatty acids (MCFAs) like decanoic acid, undecanoic acid and lauric acid. GPR84, a receptor for medium-length free fatty acids is upregulated on protein level in LPS activated tolerant $CD14^+$ monocytes and THP-1 cells.

GPR84 is activated by MCFAs with the hydroxyl group at the 2- or 3-position more effectively than nonhydroxylated MCFAs. GPR84 is now considered to be a member of FFA-sensing GPCRs. MCFAs with carbon chain lengths of 9–14 activate GPR84, coupling primarily to a pertussis toxin (PTX)-sensitive $G_{i/o}$ pathway. GPR84 should be a proinflammatory receptor and may be a novel, attractive target for treating chronic low grade inflammation associated-diseases.

GPR84 Inhibitors & Modulators

6-OAU
(GTPL5846)

Cat. No.: HY-12764

Bioactivity: 6-OAU(GTPL5846; 6-n-octylaminouracil) is a surrogate agonist of GPR84; activates human GPR84 in the presence of Gqi5 chimera in HEK293 cells with an EC50 of 105 nM in the PI assay. IC50 value: 105 nM [1] Target: GPR84 agonist in vitro: 6-OAU increased [35S]GTPγS incorporated in Sf9 cell membranes...
Purity: 97.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GPR84 antagonist 8

Cat. No.: HY-112562

Bioactivity: GPR84 antagonist 8 is a selective **GPR84** antagonist.
Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PBI-4050 sodium salt
(Setogepram (sodium salt))

Cat. No.: HY-100775

Bioactivity: PBI-4050 sodium salt acts as an agonist for **GPR40** and as an antagonist or inverse agonist for **GPR84**.
Purity: 99.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Guanylate Cyclase



Guanylatecyclase (guanylylcyclase, GC) is a lyase enzyme. Guanylylcyclase is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylylcyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. The guanylylcyclase activity is modulated by the calcium-binding guanylylcyclase activating proteins (GCAP1 and GCAP2). A key mechanism by which Ca^{2+} modulates phototransduction in rods involves the synthesis of cGMP by guanylylcyclase (GC), regulated by a pair of Ca^{2+}-binding GuanylylCyclase Activating Proteins (GCAP1 and GCAP2).

The second messenger cyclic guanosine monophosphate (cGMP) is generated by the heterodimeric α/β-heme protein soluble guanylatecyclase (sGC) upon activation by its endogenous ligand nitric oxide (NO). NO binds to the reduced prosthetic heme group bound to the β subunit. cGMP is a key mediator of the cardiovascular system and its effects lead to vasodilation, inhibition of smooth muscle proliferation, blockade of leukocyte infiltration and inhibition of platelet aggregation. Impairment of the cytoprotective NO/sGC/cGMP-signalling pathway is associated with the development of serious cardiovascular diseases such as hypertension or heart failure.

Guanylate Cyclase Inhibitors & Modulators

(4-Acetamidocyclohexyl) nitrate
(BM121307) Cat. No.: HY-100295

Bioactivity: BM121307 is a **guanylate cyclase** activator that was in phase I development for the treatment of ischaemic heart disorders. The research has been discontinued.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



BAY 41-2272
Cat. No.: HY-12376

Bioactivity: BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.

Purity: 99.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Cinaciguat
(BAY 58-2667) Cat. No.: HY-14181

Bioactivity: Cinaciguat is an activator of **guanylate cyclase (sGC)**, and used for acute decompensated heart failure.

Purity: 99.40%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Cinaciguat hydrochloride
(BAY 58-2667 hydrochloride) Cat. No.: HY-14181A

Bioactivity: Cinaciguat hydrochloride is a potent soluble **guanylate cyclase** (**GC**) activator with **EC_{50}** of 15 nM in platelets.

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Lificiguat
(YC-1) Cat. No.: HY-14927

Bioactivity: Lificiguat binds to the β subunit of **soluble guanylyl cyclase**(**sGC**) with **K_d** of 0.6-1.1 μM in the presence of CO.

Purity: 99.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Linaclotide
Cat. No.: HY-17584

Bioactivity: Linaclotide is a potent and selective **guanylate cyclase C** agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

Purity: 98.46%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 mg, 10 mg



Nelociguat
(BAY60-4552) Cat. No.: HY-78237

Bioactivity: Nelociguat (BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator.

Purity: 99.73%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Plecanatide acetate
Cat. No.: HY-108741A

Bioactivity: Plecanatide acetate is a **guanylate cyclase-C (GC-C) receptor** agonist, with an **EC_{50}** of 190 nM in T84 cells. Plecanatide acetate shows anti-inflammatory activity in models of murine colitis [1].

Purity: 99.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Praliciguat
(IW-1973) Cat. No.: HY-109039

Bioactivity: Praliciguat (IW-1973) is a potent and orally active **soluble guanylate cyclase** stimulator, enhances NO signaling, acts as a vasodilator. Praliciguat (IW-1973) stimulates sGC in HEK-293 cells with an **EC_{50}** of 197 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 100 mg, 500 mg



Riociguat
(BAY 632521) Cat. No.: HY-14779

Bioactivity: Riociguat is an oral stimulator of soluble guanylate cyclase (**sGC**) used in the treatment of pulmonary hypertension.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Runcaciguat

Cat. No.: HY-109136

Bioactivity: Runcaciguat is an orally active stimulator of **soluble guanylate cyclase**, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg, 100 mg



sGC activator 1

Cat. No.: HY-111516

Bioactivity: sGC activator 1 (Compound (+)-23) is a **soluble guanylate cyclase** (**sGC**) activator with **EC_{50}**s of <5 nM, and 5 nM in CHO and GTM-3 E cells, respectively [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 100 mg



Vericiguat

(BAY1021189)

Cat. No.: HY-16774

Bioactivity: Vericiguat (BAY1021189) is a potent, orally available and soluble **guanylate cyclase** stimulator.

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Histamine Receptor



Histamine Receptors are a class of G protein-coupled receptors with histamine as their endogenous ligand. There are four known histamine receptors: H1 receptor, H2 receptor, H3 receptor, H4 receptor. The H1 receptor is a histamine receptor belonging to the family of Rhodopsin-like G-protein-coupled receptors. This receptor, which is activated by the biogenic amine histamine, is expressed throughout the body, to be specific, in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. H2 receptors are positively coupled to adenylate cyclase via Gs. It is a potent stimulant of cAMP production, which leads to activation of Protein Kinase A. Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act asautoreceptors in presynaptic histaminergic neurons, and also control histamine turnover by feedback inhibition of histamine synthesis and release. The Histamine H4 receptor has been shown to be involved in mediating eosinophil shape change and mast cell chemotaxis.

(±)-Methotrimeprazine (D6)

(dl-Methotrimeprazine D6) Cat. No.: HY-19489S

Bioactivity: (±)-Methotrimeprazine (D6) is the deuterium labeled Methotrimeprazine, which is a D3 dopamine and Histamine H1 receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



(±)-Tazifylline

Cat. No.: HY-U00018

Bioactivity: (±)-Tazifylline is a potent, selective and long-acting **histamine H1 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



ABT-239

Cat. No.: HY-12195

Bioactivity: ABT-239 is a novel, highly efficacious, non-imidazole class of **H3R** antagonist and a transient receptor potential vanilloid type 1 (**TRPV1**) antagonist.

Purity: 98.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Acrivastine

(BW825C) Cat. No.: HY-B1510

Bioactivity: Acrivastine (BW825C) is a short acting **histamine 1** receptor antagonist for the treatment of allergic rhinitis.

Purity: 98.00%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Alcaftadine

(R89674) Cat. No.: HY-17039

Bioactivity: Alcaftadine(R89674) is a H1 histamine receptor antagonist, which is used to prevent eye irritation brought on by allergic conjunctivitis.

Purity: 97.17%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Alimemazine D6

(Trimeprazine D6) Cat. No.: HY-12752S

Bioactivity: Alimemazine D6 is deuterium labeled Alimemazine, which is an antihistamine.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Antazoline hydrochloride

(Phenazoline hydrochloride) Cat. No.: HY-B1067

Bioactivity: Antazoline hydrochloride is a 1st generation antihistamine with also anticholinergic properties used to relieve nasal congestion and in eye drops.

Purity: 99.36%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Antihistamine-1

Cat. No.: HY-100238

Bioactivity: Antihistamine-1 is a **H1-antihistamine** (K_i=6.9 nM) with acceptable blood-brain barrier penetration and also an inhibitor of **CYP2D6** and **hERG channel** with IC_{50}s of 5.4 and 0.8 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Astemizole

(R 43512) Cat. No.: HY-12532

Bioactivity: Astemizole, a second-generation antihistamine drug to diminish allergic symptoms with a long duration of action, is a **histamine H1-receptor** antagonist, with an IC_{50} of 4 nM.
Astemizole also shows potent hERG K+ channel blocking activ...

Purity: >98%
Clinical Data: No Development Reported
Size:



Azatadine

Cat. No.: HY-B0170

Bioactivity: Azatadine is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. Target: Histamine Receptor
Azatadine, a new antihistamine, was evaluated for its efficacy in 20 patients with chronic allergic rhinitis. Eighty percent of patients had symptomatic relief with a twice daily dosage...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Azatadine dimaleate

(Azatadine maleate)

Cat. No.: HY-B0170A

Bioactivity: Azatadine dimaleate is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. Target: Histamine Receptor Azatadine, a new antihistamine, was evaluated for its efficacy in 20 patients with chronic allergic rhinitis. Eighty percent of patients had symptomatic relief with a twice daily...

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Azelastine

Cat. No.: HY-B0462A

Bioactivity: Azelastine is a potent, second-generation, selective, histamine antagonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg



Azelastine hydrochloride

Cat. No.: HY-B0462

Bioactivity: Azelastine HCl is a potent, second-generation, selective, histamine antagonist.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg



Bamirastine

(TAK-427)

Cat. No.: HY-101601

Bioactivity: Bamirastine inhibits ligand binding to recombinant human histamine H_1 receptors (**rhH_1R**) with an **IC_{50}** value of 17.3 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Bavisant

(JNJ-31001074)

Cat. No.: HY-14880

Bioactivity: Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.

Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg



Bavisant dihydrochloride

Cat. No.: HY-14880A

Bioactivity: Bavisant Hcl (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.

Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg



Bavisant dihydrochloride hydrate

(JNJ31001074AAC)

Cat. No.: HY-14880B

Bioactivity: Bavisant Hcl hydrate(JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.

Purity: 99.77%
Clinical Data: Phase 2
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Bepotastine Beslilate

Cat. No.: HY-A0015

Bioactivity: Bepotastine Beslilate (Bepreve) is a histamine H1 receptor anatagonist.

Purity: 99.36%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Betahistine dihydrochloride

Cat. No.: HY-B0524A

Bioactivity: Betahistine Dihydrochloride is a histamine H3 receptors inhibitor used as an antivertigo drug.

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g, 5 g, 10 g



Bilastine

Cat. No.: HY-14447

Bioactivity: Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



BMY-25271

Cat. No.: HY-100191

Bioactivity: BMY-25271 is a **histamine H2 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Brompheniramine maleate

Cat. No.: HY-B0480

Bioactivity: Brompheniramine maleate is a histamine H1 receptors antagonist.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Carbinoxamine maleate salt

Cat. No.: HY-B1589A

Bioactivity: Carbinoxamine maleate salt is a **histamine H1 receptor** antagonist.

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Cetirizine

Cat. No.: HY-17042

Bioactivity: Cetirizine, a second-generation antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria. IC50 value: Target: Histamine H1 receptor Cetirizine crosses the blood-brain barrier only...

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Cetirizine D4 dihydrochloride

Cat. No.: HY-17042AS

Bioactivity: Cetirizine D4 2Hcl is deuterium labeled Cetirizine, which is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Cetirizine D8 dihydrochloride

Cat. No.: HY-17042AS1

Bioactivity: Cetirizine D8 2Hcl is deuterium labeled Cetirizine, which is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Cetirizine dihydrochloride

(P071)

Cat. No.: HY-17042A

Bioactivity: Cetirizine 2Hcl, a second-generation antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria. IC50 value: Target: Histamine H1 receptor Cetirizine crosses the blood-brain barrier only...

Purity: 99.17%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Chlorcyclizine hydrochloride

Cat. No.: HY-112067A

Bioactivity: Chlorcyclizine hydrochloride is a **histamine H1** antagonist.

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Chloropyramine hydrochloride

Cat. No.: HY-B1305

Bioactivity: Chloropyramine hydrochloride is a **histamine receptor H1** antagonist which can also inhibit the biochemical function of **VEGFR-3** and **FAK**.

Purity: 99.30%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg



Chlorpheniramine maleate

(Chlorphenamine maleate)

Cat. No.: HY-B0286A

Bioactivity: Chlorpheniramine maleate is an histamine H1 receptor antagonist with IC50 of 12 nM.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Chlorphenoxamine

Cat. No.: HY-B1607

Bioactivity: Chlorphenoxamine is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent.

Purity: 95.09%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



CI-949

Cat. No.: HY-U00364

Bioactivity: CI-949 is an allergic mediator release inhibitor, which inhibits **histamine**, **leukotriene C_4/D_4 (LTC_4/LTD_4)**, and **thromboxane B_2 (TXB_2)** release with **IC_{50}**s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Cimetidine

(SKF-92334)

Cat. No.: HY-14289

Bioactivity: Cimetidine is a histamine-2 (H2) receptor antagonist.

Purity: 98.0%
Clinical Data: Launched
Size: 1 g, 5 g, 10 g



Cinnarizine

Cat. No.: HY-B1090

Bioactivity: Cinnarizine is an antihistamine and a calcium channel blocker, promote cerebral blood flow, used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Cipralisant

(GT-2331)

Cat. No.: HY-106993

Bioactivity: Cipralisant is a potent and selective **histamine H3 receptor** antagonist in vivo, and an agonist in vitro, with a **pK_i** of 9.9 for histamine H3 receptor and a **K_i** of 0.47 nM for rat histamine H3 receptor; Cipralisant has entered in clinical trials for the treatment of attention-deficit hyperactivity...

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Ciproxifan

(FUB-359)

Cat. No.: HY-14567

Bioactivity: Ciproxifan(FUB-359) is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



Ciproxifan maleate

(FUB 359 maleate)

Cat. No.: HY-15289

Bioactivity: Ciproxifan maleate(FUB-359 maleate) is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Clemastine fumarate

(HS-592 (fumarate); Meclastine (fumarate))

Cat. No.: HY-B0298A

Bioactivity: Clemastine (fumarate) (HS-592 (fumarate)) is a selective histamine H1 receptor antagonist with IC_{50} of 3 nM.

Purity: 99.82%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Clemizole

Cat. No.: HY-30234

Bioactivity: Clemizole is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. The **IC_{50}** of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its **EC_{50}** for viral replication is 8 μM.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Clemizole hydrochloride

Cat. No.: HY-30234A

Bioactivity: Clemizole hydrochloride is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. The **IC_{50}** of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its **EC_{50}** for viral replication is 8 μM.

Purity: 99.32%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CP-66948

Cat. No.: HY-19048

Bioactivity: CP-66948 is a **histamine H2-receptor** antagonist with gastric antisecretory activity and mucosal protective properties.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Cyproheptadine hydrochloride sesquihydrate

Cat. No.: HY-B1165

Bioactivity: Cyproheptadine hydrochloride sesquihydrate is an antihistamine and is an antagonist of serotonin and histamine2.

Purity: 99.20%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Decloxizine

(UCB-1402; NSC289116)

Cat. No.: HY-17582

Bioactivity: Decloxizine(UCB-1402; NSC289116) is a histamine 1 receptor antagonist.

Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg, 500 mg



Decloxizine dihydrochloride

(UCB 1402 dihydrochloride)

Cat. No.: HY-A0075

Bioactivity: Decloxizine dihydrochloride(UCB-1402; NSC289116) is a histamine 1 receptor antagonist.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Desloratadine

(Sch34117)

Cat. No.: HY-B0539

Bioactivity: Desloratadine(Sch34117) is a potent antagonist for human histamine H1 receptor used to treat allergies.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Dexchlorpheniramine maleate

(S-(+)-Chlorpheniramine maleate salt)

Cat. No.: HY-B1062

Bioactivity: Dexchlorpheniramine maleate is an antihistamine, with anticholinergic properties, used to treat allergic conditions.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg



Dimenhydrinate

Cat. No.: HY-B1215

Bioactivity: Dimenhydrinate is an anti-emetic and anti-histamine commonly available over-the-counter as a motion sickness remedy.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Diphenhydramine hydrochloride

Cat. No.: HY-B0303A

Bioactivity: Diphenhydramine HCl (Benadryl), a histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. Target: Histamine H1 receptor Diphenhydramine...

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 250 mg, 500 mg, 5 g



Diphenylpyraline hydrochloride

(4-Diphenylmethoxy-1-methylpiperidine hydrochloride)

Cat. No.: HY-B0970

Bioactivity: Diphenylpyraline Hcl is a first-generation antihistamine with anticholinergic effects, acts as a dopamine reuptake inhibitor, shows to be useful in the treatment of Parkinsonism.

Purity: 99.02%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g



Doxylamine D5 succinate

Cat. No.: HY-A0069S

Bioactivity: Doxylamine D5 succinate is deuterium labeled Doxylamine, which is a first generation antihistamine.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Doxylamine succinate

Cat. No.: HY-A0069

Bioactivity: Doxylamine (succinate) is a first generation antihistamine; can be used by itself as a short-term sedative and in combination with other drugs to provide night-time allergy and cold relief.

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Ebastine

(LAS-W 090; RP64305)

Cat. No.: HY-B0674

Bioactivity: Ebastine(LAS-W 090;RP64305) is a long-acting and selective H1-histamine receptor antagonist. Target: Histamine H1 Receptor Ebastine is a H1 antihistamine with low potential for causing drowsiness. Ebastine (10 mg orally) causes brain histamine H1-receptor occupation of approximately 10%,...

Purity: 99.96%
Clinical Data: Phase 4
Size: 10mM x 1mL in Ethanol, 500 mg, 1 g, 5 g



Ebrotidine

(FI3542)

Cat. No.: HY-15538

Bioactivity: Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection.

Purity: 97.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Epinastine

(WAL801)

Cat. No.: HY-B0640

Bioactivity: Epinastine(WAL801) is an antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Famotidine

(MK-208)

Cat. No.: HY-B0377

Bioactivity: Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Purity: 98.17%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Fenspiride Hydrochloride

Cat. No.: HY-A0027

Bioactivity: Fenspiride HCl is an α adrenergic and H1 histamine receptor antagonist.

Purity: 99.03%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Fexofenadine D6

(MDL-16455 D6)

Cat. No.: HY-B0801S

Bioactivity: Fexofenadine D6 is deuterium labeled is Fexofenadine, which is an antihistamine pharmaceutical drug.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Fexofenadine hydrochloride (MDL-16455 hydrochloride; Terfenidine carboxylate hydrochloride)

Cat. No.: HY-B0801A

Bioactivity: Fexofenadine hydrochloride (MDL-16455 hydrochloride; Terfenidine carboxylate hydrochloride), a **H1R** antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years) [1].

Purity: 99.61%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



FRG8701

Cat. No.: HY-U00238

Bioactivity: FRG-8701 is a new **Histamine H_2-receptor** antagonist with an **IC_{50}** of ranging from 0.25 to 0.43 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



GSK189254A

Cat. No.: HY-14111

Bioactivity: GSK189254A (GSK189254) is a novel, potent and selective histamine **H3** receptor antagonist with **pK_i** values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.

Purity: 98.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



H3 receptor antagonist 1

Cat. No.: HY-U00269

Bioactivity: H3 receptor antagonist 1 is an antagonist of **histamine H3 receptor**, used in the research of neurological disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



H3 receptor-MO-1

Cat. No.: HY-U00339

Bioactivity: H3 receptor-MO-1 is a modulator of **histamine H3 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



H3R-IN-1 Hydrochloride

Cat. No.: HY-112219A

Bioactivity: H3R-IN-1 Hydrochloride is a **histamine receptor 3** (**H3R**) inverse agonist extracted from patent WO2013107336A1, compound example 2.

Purity: 95.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



H4 Receptor antagonist 1

Cat. No.: HY-114025

Bioactivity: H4 Receptor antagonist 1 is a potent and selective **histamine H4 receptor** inverse agonist, with an $\mathbf{IC_{50}}$ of 19 nM.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



H4R antagonist 1

Cat. No.: HY-111501

Bioactivity: H4R antagonist 1 is a potent and highly selective **histamine H4 receptor** (**H4R**) antagonist with an IC_{50} of 27 nM. H4R antagonist 1 does not show any noticeable binding affinity...

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Histamine
(Ergamine)

Cat. No.: HY-B1204

Bioactivity: Histamine is an organic nitrogenous compound involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
100 mg

Histamine phosphate
(Histamine diphosphate)

Cat. No.: HY-A0129

Bioactivity: Histamine diphosphate is a potent agonist of histamine receptors and vasodilator. It can activate nitric oxide synthetase.

Purity: 99.79%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
1 g



Hydroxyzine

Cat. No.: HY-B0548

Bioactivity: Hydroxyzine is a histamine H1-receptor antagonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Hydroxyzine D4 dihydrochloride

Cat. No.: HY-B0548AS

Bioactivity: Hydroxyzine D4 2Hcl is deuterium labeled Hydroxyzine, which is a histamine H1-receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Hydroxyzine dihydrochloride

Cat. No.: HY-B0548A

Bioactivity: Hydroxyzine Dihydrochloride is a histamine H1-receptor antagonist. Target: Histamine H1-Receptor Hydroxyzine inhibits carbachol (10 μM)-induced serotonin release by 34% at 10 μM, by 25% 1 μM and by 17% 0.1 μM in pretreated bladder slices for 60 min [1]. Hydroxyzine (0.1 mM) treatment inhibits the...

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
100 mg, 500 mg



Hydroxyzine pamoate

Cat. No.: HY-B0895

Bioactivity: Hydroxyzine pamoate is a histamine H1-receptor antagonist. Target: Histamine H1-Receptor Hydroxyzine inhibits carbachol (10 μM)-induced serotonin release by 34% at 10 μM, by 25% 1 μM and by 17% 0.1 μM in pretreated bladder slices for 60 min [1]. Hydroxyzine (0.1 mM) treatment inhibits the progression and...

Purity: >98%
Clinical Data: Launched
Size: 100 mg



JNJ-39758979

Cat. No.: HY-101189

Bioactivity: JNJ-39758979 is a selective, high-affinity **histamine H_4 receptor** antagonist with a **K_i** of 12.5 nM.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



JNJ-5207852

Cat. No.: HY-12190

Bioactivity: JNJ-5207852 is a selective and potent **histamine H_3** receptor (H_3R) antagonist, with **pK_is** of 8.9, 9.24 for rat and human H_3R, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



JNJ-7777120

Cat. No.: HY-13508

Bioactivity: JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM, exhibits >1000-fold selectivity over the other histamin receptors.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ketotifen fumarate

(HC 20511 fumarate)

Cat. No.: HY-B0157A

Bioactivity: Ketotifen (fumarate) is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer, which is used to prevent asthma attacks.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 1 g



KP136

(AL136)

Cat. No.: HY-U00168

Bioactivity: KP136 is an orally effective antiallergic agent. The **IC_{50}** is 76.1 μg/mL for **histamine release** and 63 ug/mL for **degranulation**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Lafutidine

(FRG-8813)

Cat. No.: HY-B0160

Bioactivity: Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion.

Purity: 97.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Latrepirdine dihydrochloride

(Dimebolin dihydrochloride)

Cat. No.: HY-14537

Bioactivity: Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and **amyloid-β** (**Aβ**) secretion.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



Levodropropizine

(DF-526; (S)-(-)-Dropropizine)

Cat. No.: HY-B1895

Bioactivity: Levodropropizine (DF-526) is a histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive drug.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Lodoxamide

Cat. No.: HY-14270

Bioactivity: Lodoxamide is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis.

Purity: 98.00%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Lodoxamide tromethamine

(U 42585 E) Cat. No.: HY-16289

Bioactivity: Lodoxamide tromethamine (U 42585 E) is a medication for the treatment of prophylaxis of mast cell-mediated allergic disease.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Loratadine

(SCH 29851; Loratidine) Cat. No.: HY-17043

Bioactivity: Loratadine(SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. IC50 value: 32 uM Target: H1-receptor Loratadine is a non-sedative antihistamine that inhibits histamine-induced activities of IL-6 and IL-8 secretion in endothelial cells.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Mebhydrolin

Cat. No.: HY-B1303A

Bioactivity: Mebhydrolin is a specific **histamine H_1 receptor** antagonist.

Purity: 99.46%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Mebhydrolin napadisylate

(Mebhydroline 1,5-naphthalenedisulfonate salt) Cat. No.: HY-B1303

Bioactivity: Mebhydrolin napadisylate is a specific **histamine H_1 receptor** antagonist.

Purity: 99.53%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Meclizine dihydrochloride

(Meclozine dihydrochloride; NSC28728) Cat. No.: HY-B0349

Bioactivity: Meclizine is a histamine H1 receptor antagonist used to treat nausea and motion sickness Target: Histamine H1 Receptor Meclizine is a histamine H1 receptor antagonist used to treat nausea and motion sickness, possesses anticholinergic, central nervous system depressant, and local anesthetic effects [1]....

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 5 g



Mepyramine maleate

(Pyrilamine maleate) Cat. No.: HY-B1281

Bioactivity: Mepyramine maleate, a first generation antihistamine, is an antagonist of **histamine H1 receptor**, with K_ds of 0.8 nM, 5200 nM and >3000 nM for H1, H2, and H3 receptor, respectively, and a **pK_d** of 9.4 for H1 receptor.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Mequitazine

(LM-209) Cat. No.: HY-B2168

Bioactivity: Mequitazine is a potent, nonsedative and long-acting histamine H_1 antagonist.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Metiamide

(SK&F 92058) Cat. No.: HY-15540

Bioactivity: Metiamide (SK&F 92058) is a histamine H2-receptor antagonist developed from another H2 antagonist, burimamide.

Purity: 97.31%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Mianserin

(Mianserine) Cat. No.: HY-B0188

Bioactivity: Mianserin is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Mianserin hydrochloride

(Org GB 94) Cat. No.: HY-B0188A

Bioactivity: Mianserin hydrochloride is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant. Target: H1 receptor Mianserin is a psychoactive drug of the tetracyclic antidepressant (TeCA) therapeutic family. It is classified as a noradrenergic and specific serotonergic...

Purity: 99.79%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Mizolastine

Cat. No.: HY-B0164

Bioactivity: Mizolastine is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.

Purity: 99.33%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Mizolastine dihydrochloride

Cat. No.: HY-B0164A

Bioactivity: Mizolastine dihydrochloride is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



MK-0249

Cat. No.: HY-U00076

Bioactivity: MK-0249 is a potent **histamine H3 receptor** antagonist, with **K_i** of 1.7 nM for human H3.

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 20 mg



N-Acetylhistamine

(N-Omega-acetylhistamine)

Cat. No.: HY-112175

Bioactivity: N-Acetylhistamine is a histamine metabolite. N-acetylhistamine can be used as a potential biomarker of histidine metabolism for anaphylactoid reactions.

Purity: 98.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg



Nedocromil

(FPL 59002)

Cat. No.: HY-13448

Bioactivity: Nedocromil suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (**LTC_4**), and **prostaglandin D_2** (**PGD_2**).

Purity: 95.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Nedocromil sodium

(FPL 59002KP; Nedocromil disodium salt)

Cat. No.: HY-16344

Bioactivity: Nedocromil sodium suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (**LTC_4**), and **prostaglandin D_2** (**PGD_2**).

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Niperotidine

Cat. No.: HY-15539

Bioactivity: Niperotidine is a **histamine H2-receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Nizatidine

Cat. No.: HY-B0310

Bioactivity: Nizatidine is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.

Purity: 99.49%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Olopatadine hydrochloride

(ALO4943A; KW4679)

Cat. No.: HY-B0426A

Bioactivity: Olopatadine HCl is a histamine blocker used to treat allergic conjunctivitis.

Purity: 99.55%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Osthole

(NSC 31868; Osthol; Ostol)

Cat. No.: HY-N0054

Bioactivity: Osthole is a natural antihistamine alternative. Osthole may be a potential inhibitor of **histamine H_1 receptor** activity.

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 250 mg, 1 g, 5 g



Pemirolast potassium

(TWT-8152; BMY 26517)

Cat. No.: HY-B0538A

Bioactivity: Pemirolast Potassium (BMY 26517) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent. Target: Histamine H1 Receptor Pemirolast potassium (BMY 26517) is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma [1]. Pemirolast...

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Peptide 401

Cat. No.: HY-12537

Bioactivity: Peptide 401, a potent mast cell degranulating factor from bee venom, suppresses the increased vascular permeability due to intradermal injection of various smooth muscle spasmogens (**histamine**, and **5-HT**).

Purity: 98.29%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Perphenazine

Cat. No.: HY-A0077

Bioactivity: Perphenazine is a typical antipsychotic drug, inhibits **5-HT$_{2A}$receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor**, and **Histamine H1 receptor**, with **K$_i$** values of 5.6, 10, 0.765/0.13, 3.4, and 8 ...

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Perphenazine D8 Dihydrochloride

Cat. No.: HY-A0077AS

Bioactivity: Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



PF-3893787 hydrochloride

Cat. No.: HY-19705B

Bioactivity: PF-3893787 hydrochloride is a novel **histamine H4 receptor** antagonist binding affinity (**K$_i$**=2.4 nM) and is also a functional (**K$_i$**=1.56 nM) antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Pheniramine Maleate

Cat. No.: HY-B0971

Bioactivity: Pheniramine Maleate ia an antihistamine and vasoconstrictor.

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Pimethixene

(Pimetixene)

Cat. No.: HY-B1101

Bioactivity: Pimethixene is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene is a highly potent antagonist of 5-HT $_{1A}$, 5-HT $_{2A}$, 5-HT $_{2B}$, 5-HT $_{2C}$, histamine H $_1$, dopamine D $_2$ and D $_{4.4}$ as well as muscari...

Purity: >98%
Clinical Data: Launched
Size: 10 mg



Pimethixene maleate

(Pimetixene maleate)

Cat. No.: HY-B1101A

Bioactivity: Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene maleate is a highly potent antagonist of 5-HT $_{1A}$, 5-HT $_{2A}$, 5-HT $_{2B}$, 5-HT $_{2C}$, histamine H $_1$, dopamine D $_2$ and D $_{4.4}$ as well...

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg



Pirolate

(CP-32387)

Cat. No.: HY-100280

Bioactivity: Pirolate is a **histamine H1** receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Pitolisant

(Tiprolisant)

Cat. No.: HY-12199

Bioactivity: Pitolisant is a potent and selective nonimidazole inverse agonist at the recombinant human **histamine H3 receptor** (**K$_i$**=0.16 nM).

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Pitolisant hydrochloride

(Ciproxidine; BF 2649) Cat. No.: HY-12199B

Bioactivity: Pitolisant hydrochloride is a potent and selective nonimidazole inverse agonist at the recombinant human **histamine H3 receptor** (K_i=0.16 nM).

Purity: 99.22%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Pitolisant oxalate

(Tiprolisant oxalate) Cat. No.: HY-12199A

Bioactivity: Pitolisant oxalate is a potent and selective nonimidazole inverse agonist at the recombinant human **histamine H3 receptor** (K_i=0.16 nM).

Purity: >98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Promethazine hydrochloride

Cat. No.: HY-B0781

Bioactivity: Promethazine Hcl(NSC-231688) is the first-generation antihistamine; strong antagonist of the H1 receptor and moderate mACh receptor antagonist, moderate affinity for 5-HT2A, 5-HT2C, D2 and α1-adrenergic receptors.

Purity: 99.82%
Clinical Data: Launched
Size: 1 g, 5 g



Quinotolast sodium

(FR71021) Cat. No.: HY-U00027

Bioactivity: Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits **histamine**, **LTC_4** and **PGD_2** release in a concentration-dependent manner.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Ranitidine hydrochloride

Cat. No.: HY-B0281A

Bioactivity: Ranitidine is a histamine H2-receptor antagonist that inhibits stomach acid production.

Purity: 99.48%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



ReN-1869 hydrochloride

(NNC-05-1869 hydrochloride) Cat. No.: HY-101724

Bioactivity: ReN 1869 hydrochloride is a novel, selective **histamine H_1 receptor** antagonist, which demonstrates affinity to the histamine H_1 receptor (guinea pig brain) with K_i of 0.19±0.04 μM and the non-selective σ site (guinea pig bra...

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Rocastine

(AHR-11325) Cat. No.: HY-101745

Bioactivity: Rocastine is a selective, nonsedating **H1** antagonist, acting as an antihistamine.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Roxatidine Acetate Hydrochloride

(HOE 760) Cat. No.: HY-B0305A

Bioactivity: Roxatidine Acetate HCl is a specific and competitive histamin H2 receptor antagonist.

Purity: 98.87%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g, 5 g



S 38093

Cat. No.: HY-104003

Bioactivity: S 38093 is a brain-penetrant antagonist of **H3 receptor**, with **K_i** of 8.8, 1.44 and 1.2 μM for rat, mouse and human H3 receptors, respectively.

Purity: 99.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



SUN 1334H

Cat. No.: HY-U00084

Bioactivity: SUN 1334H is a potent, orally active, highly selective **H1 receptor** antagonist, with **K_i** of 9.7 nM.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Toreforant

(JNJ-38518168)

Cat. No.: HY-16756

Bioactivity: Toreforant is a potent and selective histamine H_4 receptor (**H4R**) antagonist, with a K_i at the human receptor of 8.4 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Tripelennamine hydrochloride

Cat. No.: HY-17428

Bioactivity: Tripelennamine Hcl, a H1-receptor antagonist, is a psychoactive drug and member of the pyridine andethylenediamine classes that is used as an antipruritic and first-generation antihistamine. IC50 Value: Target: Histamine H1 receptor Tripelennamine can be used in the treatment of...

Purity: 99.87%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg, 200 mg, 500 mg, 1 g, 5 g



VUF10460

Cat. No.: HY-101420

Bioactivity: VUF10460 is a non-imidazole histamine **H4** receptor agonist; binds to rat H4 receptor with a pK_i of 7.46.

Purity: 98.37%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Wy 49051

Cat. No.: HY-101830

Bioactivity: Wy 49051 is a potent, orally active **H1 receptor** antagonist, with IC_{50} of 44 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Zaltidine

(CP-57361)

Cat. No.: HY-15541

Bioactivity: Zaltidine(CP-57361) is a H2-receptor antagonist, which has the antisecretory action.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg



Imidazoline Receptor



Imidazoline receptors are the primary receptors on which clonidine and other imidazolines act. There are three classes of imidazoline receptors: I1 receptor – mediates the sympatho-inhibitory actions of imidazolines to lower blood pressure, (NISCH or IRAS, imidazoline receptor antisera selected), I2 receptor - an allosteric binding site of monoamine oxidase and is involved in pain modulation and neuroprotection, I3 receptor - regulates insulin secretion from pancreatic beta cells. Activated I1-imidazoline receptors trigger the hydrolysis of phosphatidylcholine into DAG. Elevated DAG levels in turn trigger the synthesis of second messengers arachidonic acid and downstreameicosanoids. In addition, the sodium-hydrogen antiporter is inhibited, and enzymes of catecholamine synthesis are induced. The I1-imidazoline receptor may belong to the neurocytokine receptorfamily, since its signaling pathways are similar to those of interleukins.

Imidazoline Receptor Inhibitors & Modulators

Agmatine sulfate

Cat. No.: HY-101238

Bioactivity: Agmatine sulfate exerts modulatory action at multiple molecular targets, such as neurotransmitter systems, ion channels and nitric oxide synthesis. It is an endogenous agonist at **imidazoline receptor** and a **NO synthase** inhibitor.
Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g



Allantoin

(5-Ureidohydantoin)

Cat. No.: HY-N0543

Bioactivity: Allantoin is a skin conditioning agent that promotes healthy skin, stimulates new and healthy tissue growth.

Purity: 98.36%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg

Moxonidine

(BDF5895)

Cat. No.: HY-B0374

Bioactivity: Moxonidine is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Moxonidine hydrochloride

(BDF5895 hydrochloride)

Cat. No.: HY-B0374A

Bioactivity: Moxonidine Hydrochloride is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Leukotriene Receptor



Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.

Amelubant
(BIIL 284)

Cat. No.: HY-19304

Bioactivity: Amelubant (BIIL 284) is a potent, oral and long acting **LTB_4 receptor** antagonist, negligibly binds to LTB $_4$ receptor, with **K_i**s of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a prodrug of active metabolites B...
Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg

AS-35

Cat. No.: HY-101946

Bioactivity: AS-35 is an orally effective, potent and selective antagonist of **leukotrienes**, antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with **IC_{50}** values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Bunaprolast
(U66858)

Cat. No.: HY-U00170

Bioactivity: Bunaprolast (U66858) is a potent inhibitor of **LTB_4** production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of **lipoxygenase** and **TXB_2** release.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



CI-949

Cat. No.: HY-U00364

Bioactivity: CI-949 is an allergic mediator release inhibitor, which inhibits **histamine**, **leukotriene C_4/D_4 (LTC_4/LTD_4)**, and **thromboxane B_2 (TXB_2)** release with **IC_{50}**s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



CP-105696
(Pfizer 105696)

Cat. No.: HY-19193

Bioactivity: CP-105696 is a potent and selective **Leukotriene B_4** Receptor antagonist, with an **IC_{50}** of 8.42 nM.
Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



CP-96486

Cat. No.: HY-100316

Bioactivity: CP-96486 is a potent and orally active leukotriene D $_4$ (**LTD_4**)/platelet activating factor (**PAF**) receptor antagonist with **K_i**s of 20 and 24 nM, respectively.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Darbufelone mesylate
(CI-1004 mesylate)

Cat. No.: HY-101438A

Bioactivity: Darbufelone mesylate is a dual inhibitor of cellular **$PGF_{2\alpha}$** and **LTB_4** production. Darbufelone potently inhibits **PGHS-2** (**IC_{50}** = 0.19 μM) but is much less potent with **PGHS-1** (**IC_{50}**= 20 μM).
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



DW-1350

Cat. No.: HY-100173

Bioactivity: DW-1350 is a **LTB_4 receptor** antagonist.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gemilukast
(ONO-6950)

Cat. No.: HY-16780

Bioactivity: Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors **($CysLT_1$ and $CysLT_2$)** antagonist, with **IC_{50}s** of 1.7, 25 nM for human CysLT $_1$ and CysLT $_2$, respectively.
Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 100 mg, 500 mg



Iralukast
(CGP 45715A)

Cat. No.: HY-101944

Bioactivity: Iralukast is a cysteinyl-leukotriene antagonist (**CysLT**) with a pK $_i$ of 7.8 for **$CysLT_1$**.
Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



KP496

Cat. No.: HY-U00253

Bioactivity: KP496 is a selective, dual antagonist for **Leukotriene D4 receptor** and **Thromboxane A2 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



LM-1484

Cat. No.: HY-101686

Bioactivity: LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for ^{3}H-LTC4 sites.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



LTD4 antagonist 1

Cat. No.: HY-U00359

Bioactivity: LTD $_4$ antagonist 1 is a potent, orally active antagonist of **leukotriene D_4** (**LTD_4**) with a **K_i** of 0.57 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



LY210073

Cat. No.: HY-U00263

Bioactivity: LY210073 is a **Leukotriene B_4** (**LTB_4**) receptor antagonist with an **IC_{50}** of 6.2 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



LY223982

(CGS23131; SKF107324)

Cat. No.: HY-112737

Bioactivity: LY223982 is a potent and specific inhibitor of **leukotriene B4 receptor**, with an **IC_{50}** of 13.2 nM against [^{3}H]LTB4 binding to LTB4 receptor.

Purity: 100.00%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



MK-571 sodium salt

(L-660711 (sodium salt))

Cat. No.: HY-19989A

Bioactivity: MK-571 sodium salt is a selective, orally active **leukotriene D4 receptor** antagonist, with **K_i**s of 0.22 and 2.1 nM in guinea pig and human lung membranes.

Purity: 99.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Montelukast sodium

(MK0476)

Cat. No.: HY-13315

Bioactivity: Montelukast (sodium) (MK0476) is a potent, selective **$CysLT_1$** receptor antagonist.

Purity: 99.82%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 500 mg



Nedocromil

(FPL 59002)

Cat. No.: HY-13448

Bioactivity: Nedocromil suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (**LTC_4**), and **prostaglandin D_2** (**PGD_2**).

Purity: 95.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Nedocromil sodium

(FPL 59002KP; Nedocromil disodium salt)

Cat. No.: HY-16344

Bioactivity: Nedocromil sodium suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (**LTC_4**), and **prostaglandin D_2** (**PGD_2**).

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

ONO4057

(ONO-LB457)

Cat. No.: HY-U00252

Bioactivity: ONO4057 is a **Leukotriene B_4 receptor** antagonist, with an **IC_{50}** of 0.7±0.3 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Pranlukast
(ONO-1078) Cat. No.: HY-B0290

Bioactivity: Pranlukast is a highly potent, selective and competitive antagonist of peptide **leukotriene**s. Pranlukast inhibits [^{3}H]LTE $_{4}$, [^{3}H]LTD $_{4}$, and [^{3}H]LTC $_{4}$ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 ...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Pranlukast hemihydrate
(ONO-1078 (hemihydrate)) Cat. No.: HY-B0290A

Bioactivity: Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide **leukotriene**s. Pranlukast inhibits [^{3}H]LTE $_{4}$, [^{3}H]LTD $_{4}$, and [^{3}H]LTC $_{4}$ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, ...

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Quinotolast sodium
(FR71021) Cat. No.: HY-U00027

Bioactivity: Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits **histamine**, **LTC$_4$** and **PGD$_2$** release in a concentration-dependent manner.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



RG-12525
(NID 525) Cat. No.: HY-101676

Bioactivity: RG-12525 is a a specific, competitive and orally effective antagonist of the **peptidoleukotrienes**, **LTC4**, **LTD4** and **LTE4**, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with **IC$_{50}$**s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome...

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



RS-601
Cat. No.: HY-U00072

Bioactivity: RS-601 is a novel **leukotriene D4 (LTD4)/thromboxane A2 (TxA2)** dual receptor antagonist, with antiasthmatic activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Tipelukast
(KCA 757; MN 001) Cat. No.: HY-14938

Bioactivity: Tipelukast (KCA 757) is a sulfidopeptide **leukotriene receptor** antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg



YM158 free base
(YM-57158) Cat. No.: HY-U00355

Bioactivity: YM158 free base is a potent and selective **LTD$_4$** and **TXA$_2$ receptor** antagonist with **pA$_2$** values of about 8.87 and 8.81, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Zafirlukast
(ICI 204219) Cat. No.: HY-17492

Bioactivity: Zafirlukast is a potent orally active **leukotriene D$_4$** (**LTD$_4$) receptor** antagonist.

Purity: 99.10%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



LPL Receptor

Lysophospholipid Receptor



LPL Receptor (Lysophospholipid Receptor) group are members of the G protein-coupled receptor family of integral membrane proteins that are important for lipid signaling. In humans, there are eight LPL receptors, each encoded by a separate gene. These LPL receptor genes are also sometimes referred to as "Edg". LPL receptor ligands bind to and activate their cognate receptors located in the cell membrane. Depending on which ligand, receptor, and cell type is involved, the activated receptor can have a range of effects on the cell. These include primary effects of inhibition of adenylyl cyclase and release of calcium from the endoplasmic reticulum, as well as secondary effects of preventingapoptosis and increasing cell proliferation. Type: LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, LPAR6, S1PR1, S1PR2, S1PR3, S1PR4, S1PR5.

AM095

Cat. No.: HY-16039

Bioactivity: AM095 is a selective **LPA_1** receptor antagonist. The **IC_{50}** for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA $_1$-transfected CHO cells is 0.025 and 0.023 μM, respectively.

Purity: 98.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



AM095 free acid

Cat. No.: HY-16040

Bioactivity: AM095 (free acid) is a potent **LPA1** receptor antagonist with **IC_{50}** values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

Purity: 99.28%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



AM966

Cat. No.: HY-15277

Bioactivity: AM966 is a high affinity, selective, oral **LPA_1**-antagonist, inhibits LPA-stimulated intracellular calcium release (**IC_{50}**=17 nM).

Purity: 98.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Amiselimod hydrochloride

(MT-1303 hydrochloride)

Cat. No.: HY-16734A

Bioactivity: Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.

Purity: 99.02%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



AS2717638

Cat. No.: HY-114379

Bioactivity: AS2717638 is an oral active **lysophosphatidic acid receptor 5 (LPA5)** antagonist in rodents. AS2717638 also significantly improves PGE $_2$-, PGF $_{2\alpha}$-, and AMPA-induced allodynia [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



ASP-4058

Cat. No.: HY-111021

Bioactivity: ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 **($S1P_1$ and $S1P_5$)**, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



ASP6432

Cat. No.: HY-120478

Bioactivity: ASP6432 is a potent and selective **type 1 lysophosphatidic acid receptor (LPA1)** antagonist with **IC_{50}**s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



BMS-986020

(AM152)

Cat. No.: HY-100619

Bioactivity: BMS-986020 is an LPA1 antagonist. target: LPA1 BMS-986020 is in Phase 2 clinical development for treating idiopathic pulmonary fibrosis. BMS-986020 selectively inhibits the LPA receptor, which is involved in binding of the signaling molecule lysophosphatidic acid, which in turn is involved in a...

Purity: 99.53%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Cenerimod

(ACT-334441)

Cat. No.: HY-17606

Bioactivity: Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (**S1P1**) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an **EC_{50}** of 2.7 nM.

Purity: 98.43%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Ceralifimod

(ONO-4641)

Cat. No.: HY-12685

Bioactivity: Ceralifimod (ONO-4641) is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with **EC_{50}s** of 27.3, 334 pM for human S1P receptor 1 and 5, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



CYM-5541
(ML249)

Cat. No.: HY-101419

Bioactivity: CYM-5541 (ML249) is an selective and allosteric **$S1P_3$** receptor agonist with an **EC_{50}** between 72 and 132 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Etrasimod
(APD334)

Cat. No.: HY-12789

Bioactivity: Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (**$S1P_1$**) receptor with an **IC_{50}** value of 1.88 nM in CHO cells.

Purity: 99.64%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Fingolimod
(FTY720 free base)

Cat. No.: HY-11063

Bioactivity: Fingolimod is a **sphingosine 1-phosphate** (**S1P**) antagonist with **IC_{50}** of 0.033 nM in K562 and NK cells. Fingolimod also is a **pak1** activator.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Fingolimod hydrochloride
(FTY720)

Cat. No.: HY-12005

Bioactivity: Fingolimod hydrochloride is a **sphingosine 1-phosphate** (**S1P**) antagonist with an **IC_{50}** of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride also is a **pak1** activator.

Purity: 99.76%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 1 g, 5 g



FTY720 (S)-Phosphate
((S)-FTY720P; (S)-FTY720 phosphate)

Cat. No.: HY-15382

Bioactivity: FTY720 (S)-Phosphate is an agonist of **S1P receptor 1 (S1PR1)**, used in the research of acute inflammatory diseases such as acute lung injury.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

GSK2018682

Cat. No.: HY-19511

Bioactivity: GSK2018682 is an agonist for **S1P1** and **S1P5 receptor** with **pEC_{50}**s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.

Purity: 98.23%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Ki16425
(Debio 0719)

Cat. No.: HY-13285

Bioactivity: Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, **LPA1** and **LPA3** with **K_i**s of 0.34 μM and 0.93 μM, respectively.

Purity: 98.67%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



LPA1 antagonist 1

Cat. No.: HY-18076

Bioactivity: LPA1 antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 **(LPA1)** antagonist with an **IC_{50}** of 25 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



LPA2 antagonist 1

Cat. No.: HY-18075

Bioactivity: LPA2 antagonist 1 is a **LPA2** antagonist with an **IC_{50}** of 17 nM.

Purity: 98.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



ONO-7300243

Cat. No.: HY-100882

Bioactivity: ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (**LPA1**) antagonist with **IC_{50}** of 0.16 μM.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Ozanimod
(RPC-1063)

Cat. No.: HY-12288

Bioactivity: Ozanimod is a potent and selective **$S1P_1$** and **$S1P_5$ receptor** agonist with **EC_{50}**s of 410±160 pM and 11±4.3 nM in [^{35}S]-GTPγS binding, respectively.

Purity: 99.81%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PF429242 dihydrochloride

Cat. No.: HY-13447A

Bioactivity: PF429242 dihydrochloride is a reversible and competitive **S1P** inhibitor with an **IC_{50}** of 175 nM.

Purity: 98.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Ponesimod
(ACT-128800)

Cat. No.: HY-10569

Bioactivity: Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator.

Purity: 99.53%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Radioprotectin-1

Cat. No.: HY-114380

Bioactivity: Radioprotectin-1 is a potent and specific nonlipid agonist of **lysophosphatidic acid receptor 2 (LPA_2)**, with an **EC_{50}** value of 25 nM for murine LPA_2 subtype [1].

Purity: 99.44%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



S1p receptor agonist 1

Cat. No.: HY-101265

Bioactivity: S1p receptor agonist 1 is an **S1P** receptor agonist extracted from patent WO 2015039587 A1, compound example 2.

Purity: 98.28%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



S1P1 Agonist III

Cat. No.: HY-12835

Bioactivity: S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.

Purity: 99.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



S1PR1 modulator 1

Cat. No.: HY-126145

Bioactivity: S1PR1 modulator 1 is a selective **S1PR1** inhibitor, with a **pIC_{50}** of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4 [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 250 mg



S1PR1-MO-1

Cat. No.: HY-U00366

Bioactivity: S1PR-MO-1 is the modulator of **sphingosine-1-phosphate receptor**, used for research of hyperproliferative, inflammatory diseases.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



SAR-100842

Cat. No.: HY-100185

Bioactivity: SAR-100842 is a lysophaphatidic acid 1 (**LPA1**/ **Edg-2**) receptor inhibitor.

Purity: 99.69%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg



Siponimod
(BAF-312)

Cat. No.: HY-12355

Bioactivity: Siponimod (BAF-312) is a potent and selective **sphingosine-1-phosphate (S1P)** receptor modulator. It is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (**EC_{50}**s of 0.39, 0.98, >10,000, >1,000, and 750 nM, respectively). Used to treat adult multiple sclerosis.

Purity: 98.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g



TY-52156

Cat. No.: HY-19736

Bioactivity: TY-52156 is a potent and selective **$S1P_3$** receptor antagonist with a **K_i** value of 110 nM [1].

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



W146

(W-146; W 146)

Cat. No.: HY-101395

Bioactivity: W146 is a selective antagonist of sphingosine-1-phosphate receptor 1 (**S1PR1**) with an EC_{50} value of 398 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



mAChR

Muscarinic acetylcholine receptor



mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia.

(+)-Cevimeline hydrochloride hemihydrate

Cat. No.: HY-76772A

Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other...

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



(-)-Cevimeline hydrochloride hemihydrate

Cat. No.: HY-76772B

Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other...

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



AC260584

Cat. No.: HY-100336

Bioactivity: AC260584 is an **M1** muscarinic receptor allosteric agonist with a **pEC$_{50}$** of 7.6.

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Aclidinium Bromide

(LAS 34273; LAS-W 330)

Cat. No.: HY-14144

Bioactivity: Aclidinium Bromide(LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

Purity: 99.54%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Alvameline

(Lu 25-109)

Cat. No.: HY-101586

Bioactivity: Alvameline (Lu25-109) is a partial **M1** agonist and **M2/M3** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Ambutonium bromide

(BL700)

Cat. No.: HY-U00067

Bioactivity: Ambutonium bromide is an acetylcholine antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Anisodamine

(6-Hydroxyhyoscyamine)

Cat. No.: HY-N0584

Bioactivity: Anisodamine is an anticholinergic and α1-adrenergic receptor antagonist used in the treatment of acute circulatory shock, is also a naturally occurring tropane alkaloid found in some plants of the Solanaceae family.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Arecoline hydrobromide

(Arecoline bromide)

Cat. No.: HY-B0489

Bioactivity: Arecoline Hydrobromide is a muscarinic acetylcholine receptor agonist.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g



Atropine

(Tropine tropate; DL-Hyoscyamine)

Cat. No.: HY-B1205

Bioactivity: Atropine is a medication used to treat certain types of nerve agent and pesticide poisonings, some types of slow heart rate, and to decrease saliva production during surgery.

Purity: 99.55%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Atropine methyl bromide

(Methylatropine bromide)

Cat. No.: HY-112076

Bioactivity: Atropine methyl bromide, a **muscarinic receptor (mAChR)** antagonist, is a quaternary ammonium salt of atropine and a mydriatic for dilation of the pupil during ophthalmic examination. It is introduced for relieving pyloric spasm in infants for its highly polar nature. It penetrates less...

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Atropine sulfate
(Sulfatropinol) Cat. No.: HY-B1205A

Bioactivity: Atropine sulfate is a competitive muscarinic acetylcholine receptor antagonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Atropine sulfate monohydrate
(Atropine sulfate hydrate) Cat. No.: HY-B0394

Bioactivity: Atropine sulfate monohydrate is a competitive muscarinic acetylcholine receptor antagonist. Target: mAChR Atropine is a naturally occurring tropane alkaloid extracted from deadly nightshade (Atropa belladonna), Jimson weed (Datura stramonium), mandrake (Mandragora officinarum) and other...

Purity: 99.62%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Batefenterol
(GSK961081; TD-5959) Cat. No.: HY-12980

Bioactivity: Batefenterol (GSK961081;TD-5959) is a novel **muscarinic** receptor antagonist and **β_2-adrenoceptor** agonist; displays high affinity for hM2, hM3 muscarinic and hβ $_2$-adrenoceptor with **K_i** values of 1.4, 1.3 and 3.7 nM, respectively.

Purity: 98.30%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Benzamide Derivative 1
Cat. No.: HY-U00415

Bioactivity: Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Benzetimide hydrochloride
(R4929) Cat. No.: HY-B1547A

Bioactivity: Benzetimide hydrochloride is a muscarinic acetylcholine receptor antagonist.

Purity: 99.44%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Benztropine mesylate (Benzatropine mesylate; Benzotropine mesylate; Benztropine methanesulfonate)
Cat. No.: HY-B0520A

Bioactivity: Benzotropine is a centrally-acting, antimuscarinic agent used as an adjunct in the treatment of Parkinson's disease. Target: mAChR Benzotropine is a centrally-acting, antimuscarinic agent used as an adjunct in the treatment of Parkinson's disease. It may also be used to treat extrapyramidal reactions, such as...

Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g



Beperidium iodide
(SX 810) Cat. No.: HY-100152

Bioactivity: Beperidium iodide shows a competitive antagonistic effect against **acetylcholine receptor** with a **pA2** of 7.93.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Bethanechol
(Carbamyl-β-methylcholine) Cat. No.: HY-B0406

Bioactivity: Bethanechol is a parasympathomimetic choline carbamate that selectively stimulates muscarinic receptors without any effect on nicotinic receptors. Target: muscarinic receptor Hyoscine butylbromide concentration dependently reduced muscle contractions, calcium mobilization, and epithelial secretion...

Purity: >98%
Clinical Data: Launched
Size: 1 g



Bethanechol chloride
(Carbamyl-β-methylcholine chloride) Cat. No.: HY-B0406A

Bioactivity: Bethanechol Chloride is a selective muscarinic receptor agonist without any effect on nicotinic receptors.

Purity: 95.00%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 200 mg, 5 g



Biperiden
(KL 373) Cat. No.: HY-13204A

Bioactivity: Biperiden(KL 373) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. It is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic,...

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Biperiden Hydrochloride

(KL 373 (Hydrochloride)) Cat. No.: HY-13204

Bioactivity: Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. It is used for the adjunctive treatment of all forms of Parkinson's...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



BQCA

Cat. No.: HY-101858

Bioactivity: BQCA a highly selective allosteric modulator of the **M1 mAChR**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



BTM-1086

Cat. No.: HY-U00406

Bioactivity: BTM-1086 is a potent anti-ulcer and gastric secretory inhibiting agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Camylofine

Cat. No.: HY-B1230

Bioactivity: Camylofin is an antimuscarinic, is a smooth muscle relaxant.

Purity: >98%
Clinical Data: Launched
Size: 1 g



Carbamoylcholine chloride

(Carbachol; Carbamylcholine chloride) Cat. No.: HY-B1208

Bioactivity: Carbamoylcholine chloride is used to study responses mediated by nAChR and mAChR, including smooth muscle contraction, gut motility, and neuronal signaling. IC50 value: 10 to 10,000 nM (Ki) Target: nAChR, mAChR Carbamoylcholine is an analog of acetylcholine that activates acetylcholine receptors (AChR)....

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



CDD0102

(CDD0102A) Cat. No.: HY-U00230

Bioactivity: CDD0102 is a potent **M_1 Muscarinic receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Cevimeline

(AF-102B) Cat. No.: HY-70020

Bioactivity: Cevimeline (AF-102B) is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors; used in the treatment of dry mouth associated with sjogren's syndrome.

Purity: 90.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Cevimeline hydrochloride

(AF-102B hydrochloride; SNI-2011 hydrochloride) Cat. No.: HY-70020B

Bioactivity: Cevimeline (Evoxac) Hcl is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors; used in the treatment of dry mouth associated with sjogren's syndrome.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



Cevimeline hydrochloride hemihydrate

Cat. No.: HY-76772

Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



CHF5407

Cat. No.: HY-U00302

Bioactivity: CHF5407 is a **muscarinic M3-receptor** antagonist extracted from patent WO 2008012290 A2, formula Ic.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



Cimetropium Bromide

(DA-3177) Cat. No.: HY-U00106

Bioactivity: Cimetropium Bromide (DA-3177) is a **mAChR** antagonist for long-term treatment of irritable bowel syndrome.

Purity: 95.34%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg



Clidinium bromide

(Ro 2-3773) Cat. No.: HY-B1132

Bioactivity: Clidinium bromide is an anticholinergic (specifically a muscarinic antagonist) drug, may help symptoms of cramping and abdominal/stomach pain by decreasing stomach acid, and slowing the intestines.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Cyclodrine hydrochloride

Cat. No.: HY-U00139

Bioactivity: Cyclodrine hydrochloride is a cholinergic (muscarinic, nicotinic) (**mAChR** and **nAChR**) receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Darenzepine

Cat. No.: HY-100154

Bioactivity: Darenzepine is a **muscarinic receptor** inhibitor extracted from patent US 20170095465 A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Darifenacin

(UK-88525) Cat. No.: HY-A0033

Bioactivity: Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [1] Target: M3 receptor in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response...

Purity: 97.38%
Clinical Data: Launched
Size: 10 mg



Darifenacin hydrobromide

(UK-88525 (hydrobromide)) Cat. No.: HY-A0012

Bioactivity: Darifenacin hydrobromide is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [1] Target: M3 receptor in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response...

Purity: 95.14%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 100 mg



Desfesoterodine

(PNU-200577; (R)-5-Hydroxymethyl Tolterodine) Cat. No.: HY-76569

Bioactivity: Desfesoterodine (PNU-200577; Desfesoterodine) is a potent and selective muscarinic receptor antagonist with a Kb and a pA2 of 0.84 nM and 9.14, respectively.

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Diphenidol hydrochloride

(Difenidol hydrochloride) Cat. No.: HY-A0082

Bioactivity: Diphenidol hydrochloride is a muscarinic antagonist employed as an antiemetic and as an antivertigo agent.

Purity: 99.60%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Diphenmanil methylsulfate

(Diphemanil mesylate) Cat. No.: HY-16171

Bioactivity: Diphemanil methylsulfate is a quaternary ammonium anticholinergic. It binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids as well as saliva and sweat. IC50 value: Target: mAChR Diphemanil Methylsulfate exerts its action by primarily binding the...

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg



DREADD agonist 21

Cat. No.: HY-100234

Bioactivity: DREADD agonist 21 is a potent human muscarinic acetylcholine M3 receptors (**hM3Dq**) agonist($\mathbf{EC_{50}}$=1.7 nM).

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg



Dronedarone
(SR 33589)

Cat. No.: HY-A0016

Bioactivity: Dronedarone (SR 33589) is a newer therapeutic agent with a structural resemblance to amiodarone and a better side effect profile; it is a multichannel blocker with antiadrenergic properties and has been evaluated in both rate and rhythm control strategies in the management of AF.
Purity: 99.49%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Elucaine

Cat. No.: HY-101743

Bioactivity: Elucaine is a **muscarinic acetylcholine receptor** antagonist with anti-ulcerative activity.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



ENS-163 phosphate
(ENS 213-163; Sandoz ENS 163 phosphate; Thiopilocarpine phosphate)

Cat. No.: HY-U00038

Bioactivity: ENS-163 phosphate is a selective **muscarinic M1 receptor** agonist.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Fesoterodine fumarate

Cat. No.: HY-A0030

Bioactivity: Fesoterodine Fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. IC50 value: Target: mAChR Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic...
Purity: 99.52%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg



Flavoxate hydrochloride
(Rec-7-0040; DW61)

Cat. No.: HY-B0549A

Bioactivity: Flavoxate Hydrochloride(DW-61 Hydrochloride) is a muscarinic AChR antagonist used in various urinary syndromes and as an antispasmodic.
Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 1 g



Gallamine Triethiodide

Cat. No.: HY-B0416

Bioactivity: Gallamine Triethiodide is a synthetic nondepolarizing blocking drug.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Glycopyrrolate
(Glycopyrrolate bromide; Glycopyrronium bromide)

Cat. No.: HY-17465

Bioactivity: Glycopyrrolate(Glycopyrronium Br) is a muscarinic competitive antagonist used as an antispasmodic.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Homatropine Bromide
(Homatropine hydrobromide)

Cat. No.: HY-B0547A

Bioactivity: Homatropine Bromide is muscarinic AChR antagonist that is an anticholinergic medication.
Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Homatropine methylbromide
(Homatropine methobromide)

Cat. No.: HY-B1388

Bioactivity: Homatropine Methylbromide is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Imidafenacin
(KRP-197; ONO-8025)

Cat. No.: HY-B0662

Bioactivity: Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors(IC50=4.13 nM).
Purity: 98.38%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Ipratropium bromide

(Sch 1000) Cat. No.: HY-B0241

Bioactivity: Ipratropium Bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Irsogladine

(Dicloguamine) Cat. No.: HY-B0327

Bioactivity: Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.

Purity: 95.13%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Irsogladine maleate

(Dicloguamine maleate; MN1695) Cat. No.: HY-B0327A

Bioactivity: Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



L-Hyoscyamine

(Daturine) Cat. No.: HY-N0471

Bioactivity: L-Hyoscyamine is a chemical compound, a tropane alkaloid it is the levo-isomer to atropine.

Purity: 99.08%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Levetiracetam

(UCB L059) Cat. No.: HY-B0106

Bioactivity: Levetiracetam (UCB L059) is a selective M2 muscarinic acetylcholine receptors (**mAChR**) inhibitor [1]. Antiepileptic agent [1].

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



LY2119620

Cat. No.: HY-15885

Bioactivity: LY2119620 is a high-affinity muscarinic **M_2/M_4 receptor** agonist.

Purity: 99.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



mAChR-IN-1

Cat. No.: HY-12426

Bioactivity: mAChR-IN-1 is a potent muscarinic cholinergic receptor(mAChR) antagonist with IC50 of 17 nM.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



mAChR-IN-1 hydrochloride

Cat. No.: HY-12426A

Bioactivity: mAChR-IN-1 hydrochloride is a potent **muscarinic cholinergic receptor (mAChR)** antagonist, with an **IC_{50}** of 17 nM [1].

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Methacholine chloride

(Acetyl-β-methylcholine chloride) Cat. No.: HY-A0083

Bioactivity: Methacholine chloride is a synthetic choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Methscopolamine bromide

((-)-Scopolamine methyl bromide; Hyoscine methyl bromide) Cat. No.: HY-B0344

Bioactivity: Methscopolamine (Pamine) is a muscarinic acetylcholine receptor blocker. Target: mAChR Methylscopolamine is an oral medication used along with other medications to treat peptic ulcers by reducing stomach acid secretion. With the advent of proton pump inhibitors and antihistamine medications it is...

Purity: 99.44%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Methylbenactyzium Bromide

Cat. No.: HY-B2070

Bioactivity: Methylbenactyzium Bromide is a **muscarinic acetylcholine receptor** (**mAChR**) inhibitor.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Metixene hydrochloride

Cat. No.: HY-120081B

Bioactivity: Metixene hydrochloride is an anticholinergic antiparkinsonian agent, potently inhibits binding of quinuclidinyl benzilate (QNB) to the **muscarinic receptor** in rat brain cortical tissue, with an IC_{50} of 55 nM and a K_d of 15 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



Metixene hydrochloride hydrate

Cat. No.: HY-120081A

Bioactivity: Metixene hydrochloride hydrate is an anticholinergic antiparkinsonian agent, potently inhibits binding of quinuclidinyl benzilate (QNB) to the **muscarinic receptor** in rat brain cortical tissue, with an IC_{50} of 55 nM and a K_d<...

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg



MHP 133

Cat. No.: HY-101653

Bioactivity: MHP 133 is a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with K_i of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



MK-7622

(M1 receptor modulator)

Cat. No.: HY-15618

Bioactivity: MK-7622 is a muscarinic M1 receptor positive allosteric modulator. Target: M1 receptor MK-7622 is useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders.

Purity: 98.37%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Nuvenzepine

Cat. No.: HY-U00119

Bioactivity: Nuvenzepine is an **mAChR** antagonist previously in phase I clinical trials for the treatment of gastrospasm.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Otilonium bromide

(Octylonium bromide; SP63)

Cat. No.: HY-B0499A

Bioactivity: Otilonium Bromide is an antimuscarinic used as a spasmolytic agent.

Purity: 95.07%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Oxitropium Bromide

Cat. No.: HY-U00105

Bioactivity: Oxitropium bromide is an **mAChR** antagonist used as an anticholinergic bronchodilator drug for the treatment of asthma and chronic obstructive pulmonary disease.

Purity: >98%
Clinical Data: Launched
Size: 5 mg



Oxybutynin

Cat. No.: HY-B0267

Bioactivity: Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.

Purity: 98.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Oxybutynin chloride

Cat. No.: HY-B0267A

Bioactivity: Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.

Purity: 98.24%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Pilocarpine Hydrochloride

Cat. No.: HY-B0726

Bioactivity: Pilocarpine Hydrochloride is a selective M3-type muscarinic acetylcholine receptor (**M3 muscarinic receptor**) agonist.

Purity: 99.92%
Clinical Data: Launched
Size: 100 mg, 500 mg



Pilocarpine nitrate

Cat. No.: HY-B1006

Bioactivity: Pilocarpine nitrate is a selective M3-type muscarinic acetylcholine receptor (**M3 muscarinic receptor**) agonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Pimethixene

(Pimetixene)

Cat. No.: HY-B1101

Bioactivity: Pimethixene is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene is a highly potent antagonist of 5-HT $_{1A}$, 5-HT $_{2A}$, 5-HT $_{2B}$, 5-HT $_{2C}$, histamine H $_{1}$, dopamine D $_{2}$ and D $_{4.4}$ as well as muscari...

Purity: >98%
Clinical Data: Launched
Size: 10 mg



Pimethixene maleate

(Pimetixene maleate)

Cat. No.: HY-B1101A

Bioactivity: Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene maleate is a highly potent antagonist of 5-HT $_{1A}$, 5-HT $_{2A}$, 5-HT $_{2B}$, 5-HT $_{2C}$, histamine H $_{1}$, dopamine D $_{2}$ and D $_{4.4}$ as well...

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg



Piperidolate

Cat. No.: HY-B0962A

Bioactivity: Piperidolate is an antimuscarinic, inhibits intestinal cramp induced by acetylcholine (rats and dogs).

Purity: 99.09%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg



Piperidolate hydrochloride

Cat. No.: HY-B0962

Bioactivity: Piperidolate hydrochloride is an antimuscarinic, inhibits intestinal cramp induced by acetylcholine (rats and dogs).

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg



Pirenzepine dihydrochloride

(LS519)

Cat. No.: HY-17037

Bioactivity: Pirenzepine dihydrochloride (LS519) is a selective **M1** muscarinic receptor antagonist.

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Pirmenol hydrochloride

(Cl-845; (±)-Pirmenol hydrochlorid)

Cat. No.: HY-100795A

Bioactivity: Pirmenol hydrochloride inhibits $\mathbf{I_{K.ACh}}$ by blocking **muscarinic receptors**. The $\mathbf{IC_{50}}$ of Pirmenol for inhibition of Carbachol-induced I $_{K.ACh}$ is 0.1 μM.

Purity: 97.20%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Propantheline bromide

Cat. No.: HY-B1188

Bioactivity: Propantheline bromide is an antimuscarinic agent, used for the treatment of hyperhidrosis, cramps or spasms of the stomach, intestines or bladder, and enuresis.

Purity: 95.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Rapacuronium bromide

(Org 9487)

Cat. No.: HY-16423

Bioactivity: Rapacuronium bromide is an allosteric modulator of muscarinic acetylcholine receptor (**mAChR**).

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Revefenacin

(TD-4208; GSK1160724) Cat. No.: HY-15851

Bioactivity: Revefenacin (TD-4208; GSK1160724) is a potent **mAChR** antagonist; has a high affinity on M3 receptor with a K_i of 0.18 nM.

Purity: 99.62%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Rispenzepine

Cat. No.: HY-U00030

Bioactivity: Rispenzepine is a novel antimuscarinic compound with a preferential action at M_1, and M_3 **receptor** subtypes.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Scopolamine

(Hyoscine; Scopine (-)-tropate; Scopine tropate) Cat. No.: HY-N0296

Bioactivity: Scopolamine is a high affinity (nM) **muscarinic** antagonist. **5-HT$_3$** receptor-responses are reversibly inhibited by Scopolamine with an **IC_{50}** of 2.09 μM.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Scopolamine butylbromide (Hyoscine butylbromide;

(-)-Scopolamine butylbromide; Butylscopolamine bromide) Cat. No.: HY-N0340

Bioactivity: Scopolamine butylbromide is a competitive antagonist of muscarinic acetylcholine receptor (mAChR) with an IC50 of 55.3 ± 4.3 nM. Target: mAChR Scopolamine (USAN), also known as levo-duboisine and hyoscine, sold as Scopoderm, is a tropane alkaloid drug with muscarinic antagonist effects. It is among...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Scopolamine hydrobromide ((-)-Scopolamine hydrobromide;

Hyoscine hydrobromide; Scopine hydrobromide) Cat. No.: HY-N0296A

Bioactivity: Scopolamine hydrobromide is a high affinity (nM) **muscarinic** antagonist. **5-HT$_3$** receptor-responses are reversibly inhibited by Scopolamine with an **IC_{50}** of 2.09 μM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Scopolamine N-oxide hydrobromide

(Hyoscine N-oxide hydrobromide) Cat. No.: HY-B2146

Bioactivity: Scopolamine N-oxide hydrobromide is an antagonist of the **muscarinic acetylcholine**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Solifenacin

(YM905 (free base)) Cat. No.: HY-A0034

Bioactivity: Solifenacin (YM905 free base) is a novel **muscarinic receptor** antagonist with **pK_i**s of 7.6, 6.9 and 8.0 for M_1, M_2 and M_3 receptors, respectively.

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg



Solifenacin hydrochloride

(YM905 hydrochloride) Cat. No.: HY-I0230

Bioactivity: Solifenacin Hcl(YM905 Hcl; Vesicare Hcl) is a muscarinic receptor antagonist.

Purity: 99.22%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Solifenacin Succinate

(YM905) Cat. No.: HY-A0002

Bioactivity: Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist. IC50 value: Target: muscarinic receptor Solifenacin succinate (YM905; Vesicare) is a prescription medication used to treat certain bladder problems.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



TAK-071

Cat. No.: HY-122190

Bioactivity: TAK-071 is a novel, potent and highly selective **muscarinic acetylcholine receptor 1 (M1R)** positive allosteric modulator. **EC_{50}** of TAK-071 M1R agonist activities is 520 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Tarafenacin
(SVT-40776) Cat. No.: HY-14825

Bioactivity: Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

Purity: >98%
Clinical Data: Phase 2
Size: 10 mg, 50 mg, 100 mg



Tarafenacin D-tartrate
(SVT-40776 D-tartrate) Cat. No.: HY-14825A

Bioactivity: Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

Purity: 99.70%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



TBPB
Cat. No.: HY-14562

Bioactivity: TBPB is an allosteric M1 mAChR agonist(EC50=289 nM) that regulates amyloid processing and produces antipsychotic-like activity in rats.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Tematropium
(CDDD3602; HGP6) Cat. No.: HY-U00203

Bioactivity: Tematropium (CDDD3602) is a soft anticholinergics.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Temiverine hydrochloride
Cat. No.: HY-U00055

Bioactivity: Temiverine hydrochloride is a synthesized drug that is expected to have anticholinergic action.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Timepidium bromide
(Sesden; SA504) Cat. No.: HY-U00184

Bioactivity: Timepidium bromide (Sesden; SA504) is an anticholinergic agent.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 20 mg



Tiotropium Bromide
(BA679 BR) Cat. No.: HY-17360

Bioactivity: Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.

Purity: 99.61%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tiotropium bromide hydrate
(BA-679 BR hydrate) Cat. No.: HY-B0460

Bioactivity: Tiotropium Bromide hydrate is an anticholinergic and bronchodilator and a muscarinic receptor antagonist. Target: mAChR Tiotropium bromide (Ba 679 BR) is a novel potent and long-lasting muscarinic antagonist that has been developed for the treatment of chronic obstructive airways disease (COPD)....

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Tolterodine ((R)-(+)-Tolterodine; (+)-Tolterodine; (R)-Tolterodine; PNU-200583)
Cat. No.: HY-A0024

Bioactivity: Tolterodine(PNU-200583) is a potent muscarinic receptor antagonists that show selectivity for the urinary bladder over salivary glands in vivo.

Purity: 95.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tolterodine tartrate
(Kabi-2234; PNU-200583E) Cat. No.: HY-90010

Bioactivity: Tolterodine Tartrate(PNU-200583E; Kabi-2234) is a potent muscarinic receptor antagonists that show selectivity for the urinary bladder over salivary glands in vivo. IC50 Value: Target: mAChR in vitro: Carbachol-induced contractions of isolated guinea pig bladder were effectively inhibited by...

Purity: 99.57%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg



Trihexyphenidyl hydrochloride

Cat. No.: HY-B1277

Bioactivity: Trihexyphenidyl hydrochloride is an antiparkinsonian agent of the antimuscarinic class, binds to the M1 muscarinic receptor.

Purity: 99.43%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



Tropicamide

(Ro 1-7683)

Cat. No.: HY-B0321

Bioactivity: Tropicamide is an anticholinergic and a muscarinic receptor subtype M4-preferring antagonist .

Purity: 99.06%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Trospium chloride

Cat. No.: HY-B0461

Bioactivity: Trospium Chloride is a competitive muscarinic cholinergic receptor antagonist.

Purity: 99.14%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Umeclidinium bromide

(GSK573719A)

Cat. No.: HY-12100

Bioactivity: Umeclidinium bromide is a novel **mAChR** antagonist. The affinity (K_i) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.

Purity: 99.72%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Vinconate

(Chanodesethylapovincamine)

Cat. No.: HY-U00316

Bioactivity: Vinconate is an indolonaphthyridine derivative and can stimulate the **muscariic acetylcholine receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



VU 0238429

Cat. No.: HY-12157

Bioactivity: VU 0238429 is positive allosteric modulator of muscarinic acetylcholine receptor subtype 5 **(mAChR5 or M5)**, with an EC_{50} of 1.16 μM.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



VU 0365114

Cat. No.: HY-107651

Bioactivity: VU 0365114 is a **mAChR M_5** positive allosteric modulator, with an EC_{50} of 2.7 μM.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



VU0152100

(VU152100)

Cat. No.: HY-13340

Bioactivity: VU0152100 is a potent and selective allosteric potentiator of M4 mAChR with an EC50 of 380 ± 93 nM.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



VU0357017 hydrochloride

(CID-25010775)

Cat. No.: HY-19752A

Bioactivity: VU0357017 hydrochloride is a highly selective M1 agonists that appear to act at an allosteric site to activate the receptor (EC50 = 477 ± 172 nM; pEC50 = 6.37 ± 0.15). IC50 value: 477 ± 172 nM (EC50) [1] Target: M1 in vitro: VU0357017 is a M1-selective agonists that appear to activate M1 through...

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



VU0467154

Cat. No.: HY-112209

Bioactivity: VU0467154 is a positive allosteric modulator of the **M4 muscarinic acetylcholine receptor (mAChR)**, potentiating the response to ACh with **pEC_{50}**s of 7.75, 6.2 and 6 for rat, human and cynomolgus monkey M4 receptor, respectively.

Purity: 98.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



VU6005806

(AZN-00016130) Cat. No.: HY-128584

Bioactivity: VU6005806 (AZN-00016130) is a potent muscarnic acethylcholine receptor subtype 4 (M_4) positive allosteric modulator (PAM), with **EC_{50}**s of 94 nM, 28 nM, 87 nM and 68 nM for human, rat, dog and cyno M_4, respectively. Used in the research...

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 100 mg



Xanomeline oxalate

(LY246708) Cat. No.: HY-13410

Bioactivity: Xanomeline oxalate (LY246708) is a selective M1 muscarinic receptor agonist. IC50 value: Target: M1 muscarinic receptor in vitro: Xanomeline had high affinity for muscarinic receptors in brain homogenates, but had substantially less or no affinity for a number of other neurotransmitter receptors...

Purity: 98.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



YM-46303

Cat. No.: HY-U00104

Bioactivity: YM-46303 is an **mAChR** antagonist which exhibits the highest affinities for M1 and M3 receptors, and selectivity for M3 over M2 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



YM-58790

Cat. No.: HY-101679

Bioactivity: YM-58790 is a potent antagonist of **M3 muscarinic receptor**, with **K_i** of 15 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



MCHR1 (GPR24)

Melanin concentrating hormone receptor 1



MCHR1 (GPR24), also known as Melanin concentrating hormone receptor 1, belongs to a member of the G protein-coupled receptor family 1, is an integral plasma membrane protein which binds melanin-concentrating hormone, and is one of the melanin-concentrating hormone receptors found in all mammals. MCHR1 can inhibit cAMP accumulation and stimulate intracellular calcium flux, and is probably involved in the neuronal regulation of food consumption. Although structurally similar to somatostatin receptors, this protein does not seem to bind somatostatin. MCHR1 is thought to regulate appetite, and also functions in stress, anxiety and depression.

MCHR1 (GPR24) Inhibitors & Modulators

ALB-127158(a)

Cat. No.: HY-111398

Bioactivity: ALB-127158(a) is a potent and selective melanin concentrating hormone 1 (**MCH_1**) receptor antagonist.

Purity: 99.32%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AZD1979

Cat. No.: HY-U00257

Bioactivity: AZD1979 is a **Melanin-concentrating hormone receptor 1** (**MCHr1**) antagonist with an **IC_{50}** of ~12 nM.

Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg



BMS-819881

Cat. No.: HY-12433

Bioactivity: BMS-819881 is a melaninconcentrating hormone receptor 1 (**MCHR1**) antagonist, which binds rat MCHR1 with a **K_i** of 7 nM. BMS-819881 also is selective and potent for **CYP3A4** activity with an **EC_{50}** of 13 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



MCH-1 antagonist 1

Cat. No.: HY-100331

Bioactivity: MCH-1 antagonist 1 is a potent melanin concentrating hormone (**MCH-1**) antagonist with a **K_i** of 2.6 nM. MCH-1 antagonist 1 also inhibits **CYP3A4** with an **IC_{50}** of 10 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



MCHr1 antagonist 1

Cat. No.: HY-U00353

Bioactivity: MCHr1 antagonist 1 is a selective antagonist of **melanin concentrating hormone-1 (MCH1) receptor**, with a **K_b** of 1 nM and a **K_i** of 4 nM at human MCH1, and may be used to reduce the body mass.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



MCHr1 antagonist 2

Cat. No.: HY-100321

Bioactivity: MCHr1 antagonist 2 is an antagonist of **melanin concentrating hormone receptor 1**, with an **IC_{50}** of 65 nM; MCHr1 antagonist 2 also inhibits **hERG**, with an **IC_{50}** of 4.0 nM in IMR-32 cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Melanin Concentrating Hormone, salmon

(MCH (salmon))

Cat. No.: HY-P1525

Bioactivity: Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G...

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

NGD-4715

Cat. No.: HY-100318

Bioactivity: NGD-4715 is a selective and orally active **melanin-concentrating hormone receptor 1 (MCHR1)** antagonist .

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



SB-568849

Cat. No.: HY-100308

Bioactivity: SB-568849 is a **melanin-concentrating hormone receptor 1** (**MCH R1**) antagonist with a **pK_i** of 7.7.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Melanocortin Receptor

MC Receptor



Melanocortin receptors (MCRs) comprise a family of five, class A, G protein-coupled receptors designated MC1R-MC5R with diverse physiological roles. MCRs are found in chordates and are regarded as having evolved from a single ancestral receptor, possibly corresponding most closely to MC4R. Signaling by MCRs has primarily been observed as occurring through the stimulatory α unit Gs which activates adenylyl cyclase to produce cAMP.

The central nervous melanocortin system is involved in energy homeostasis, regulating food intake and energy expenditure. The brain melanocortin system is defined as the primary neurons that express neuropeptide ligands, and secondary neurons expressing the predominant neural melanocortin receptors (MC3R, MC4R). Mutations in the gene encoding melanocortin receptor agonists, or the genes encoding MC3R or MC4R cause obesity. The other members of the melanocortin receptor family are primarily expressed in the periphery, and are involved in regulating pigmentation (MC1R), adrenal gland function (MC2R), immune function (MC1R/MC3R), and sebaceous gland activity (MC5R).

ACTH (1-17) TFA

(α1-17-ACTH (TFA)) Cat. No.: HY-P1545A

Bioactivity: ACTH (1-17) TFA, an adrenocorticotropin analogue, is a potent **human melanocortin 1 (MC1) receptor** agonist with a K_i of 0.21 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



ACTH 1-17

(α1-17-ACTH) Cat. No.: HY-P1545

Bioactivity: ACTH (1-17), an adrenocorticotropin analogue, is a potent **human melanocortin 1 (MC1) receptor** agonist with a K_i of 0.21 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Adrenocorticotropic Hormone (ACTH) (1-39), rat

(ACTH (1-39) (mouse, rat)) Cat. No.: HY-P1477

Bioactivity: Adrenocorticotropic Hormone (ACTH) (1-39), rat is a potent **melanocortin 2 (MC2) receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Adrenocorticotropic Hormone (ACTH) (1-39), rat TFA

(ACTH (1-39) (mouse, rat) (TFA)) Cat. No.: HY-P1477A

Bioactivity: Adrenocorticotropic Hormone (ACTH) (1-39), rat (TFA) is a potent **melanocortin 2 (MC2) receptor** agonist.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 500u g, 1 mg, 5 mg



Bremelanotide Acetate

(PT-141 Acetate) Cat. No.: HY-18678A

Bioactivity: Bremelanotide Acetate is a melanocortin agonist. IC50 value: Target: melanocortin in vivo: Bremelanotide is a novel drug candidate for the treatment of male and female sexual dysfunction. Bremelanotide has shown promise in effectively treating erectile dysfunction (ED) without the cardiovascular...

Purity: 99.97%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



JNJ-10229570

Cat. No.: HY-107139

Bioactivity: JNJ-10229570 is an antagonist of **melanocortin receptor 1 (MC1R)** and **melanocortin receptor 5 (MC5R)**, which inhibits sebaceous gland differentiation and the production of sebum-specific lipids. JNJ-10229570 inhibits the binding of ^{125}I-NDP-α-MSH to cells expressing human MC1R and MC5R,...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



MC-4R Agonist 1

Cat. No.: HY-U00396

Bioactivity: MC-4R Agonist 1 is an agonist of **human melanocortin-4 receptor (MC-4R)**, used in the research of obesity, diabetes, and sexual dysfunction.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Nonapeptide-1 acetate salt

(Melanostatine-5 acetate salt) Cat. No.: HY-P0097A

Bioactivity: Nonapeptide-1 acetate salt, a peptide hormone, is a potent α-Melanocyte-stimulating hormone **(α-MSH)** antagonist, with an IC_{50} of 11 nM. Reduces synthesis of melanin and helps decrease skin pigmentation to a substantial degree [1].

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



PF-00446687

Cat. No.: HY-10622

Bioactivity: PF-00446687 is a potent, selective **melanocortin-4 receptor** (**MC4R**) agonist with **EC50** of 12±1 nM [1]. Pf-446687 is brain penetrant [2].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Setmelanotide

(RM-493; BIM-22493; IRC-022493) Cat. No.: HY-19870

Bioactivity: Setmelanotide (RM-493;BIM-22493;IRC-022493) is a melanocortin 4 receptor (**MC4R**) agonist with an EC_{50} of 0.27 nM for human MC4R.

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



SNT-207707

Cat. No.: HY-11029

Bioactivity: SNT-207707 is a selective, potent and orally active **melanocortin MC-4** receptor antagonist with an $\mathbf{IC_{50}}$ of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SNT-207858

Cat. No.: HY-11030

Bioactivity: SNT-207858 is a selective and orally available **melanocortin MC-4** receptor antagonist with a 170-fold selectivity vs. MC-3 and a 40-fold selectivity versus MC-5. SNT-207858 has an $\mathbf{IC_{50}}$ of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



β-Melanocyte Stimulating Hormone (MSH), human

(Beta-MSH (1-22) (human))

Cat. No.: HY-P1504

Bioactivity: β-Melanocyte Stimulating Hormone (MSH), human, a 22-residue peptide, acts as an endogenous **melanocortin-4 receptor** (**MC4-R**) agonist [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

β-Melanocyte Stimulating Hormone (MSH), human TFA

(Beta-MSH (1-22) (human) (TFA))

Cat. No.: HY-P1504A

Bioactivity: β-Melanocyte Stimulating Hormone (MSH), human TFA, a 22-residue peptide, acts as an endogenous **melanocortin-4 receptor** (**MC4-R**) agonist [1].

Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



γ-1-Melanocyte Stimulating Hormone (MSH), amide

Cat. No.: HY-P1531

Bioactivity: γ-1-Melanocyte Stimulating Hormone (MSH), amide is a 11-amino acid peptide. γ-1-Melanocyte Stimulating Hormone (MSH) regulates sodium (Na^+) balance and blood pressure through activation of the **melanocortin receptor 3** (**MC3-R**).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Melatonin Receptor



Melatonin Receptor is a G protein-coupled receptor (GPCR) which binds melatonin. Three types of melatonin receptor have been cloned. The MT1 and MT2 receptor subtypes are present in humans and other mammals, while an additional melatonin receptor subtype MT3 has been identified in amphibia and birds. The MT1 subtype's expression in the pars tuberalis of the pituitary gland and suprachiamatic nuclei of the hypothalamus is indicative of melatonin's circadian and reproductive functional involvement. The MT2 subtype's expression in the retina is suggestive of melatonin's effect on the mammalian retina occurring through this receptor. Research suggests that melatonin acts to inhibit the Ca2+-dependent release of dopamine. Melatonin's action in the retina is believed to affect several light-dependent functions, including phagocytosis and photopigment disc shedding.

Melatonin Receptor Inhibitors & Modulators

Melatonin
(N-Acetyl-5-methoxytryptamine) Cat. No.: HY-B0075

Bioactivity: Melatonin is a hormone made by the pineal gland that can activates **melatonin receptor**. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties.

Purity: 98.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Ramelteon
(TAK-375) Cat. No.: HY-A0014

Bioactivity: Ramelteon is a highly potent and selective **melatonin** receptor agonist with K_i values of 14 and 112 pM for human melatonin1 and melatonin2.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg



Ramelteon metabolite M-II
Cat. No.: HY-103005

Bioactivity: Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC_{50}s of 208 pM, 1470 pM for human melatonin receptors (MT_1 or MT_2). Ramelteon is a selective melatonin agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Tasimelteon
(BMS-214778; VEC-162) Cat. No.: HY-14803

Bioactivity: Tasimelteon is a melatonin MT1 and MT2 receptor agonist.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



mGluR

Metabotropic glutamate receptors



mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity.

(1R,2S)-VU0155041

Cat. No.: HY-14417A

Bioactivity: (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial **mGluR4** agonist with an EC_{50} of 2.35 μM.

Purity: 98.42%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



(R)-ADX-47273

Cat. No.: HY-13058B

Bioactivity: (R)-ADX-47273 is a potent **mGluR5** positive allosteric modulator, with an EC_{50} of 168 nM for potentiation .

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



(RS)-MCPG

(alpha-MCPG)

Cat. No.: HY-100371

Bioactivity: (RS)-MCPG is a non-selective group I/group II metabotropic glutamate receptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



(S)-MCPG

((+)-MCPG)

Cat. No.: HY-100406

Bioactivity: (S)-MCPG is the active isomer of (RS)-MCPG (Cat. No. HY-100371), non-selective group I/group II metabotropic glutamate receptor antagonist. In vivo: (S)-MCPG (20.8 μg) injected intraventricularly (i.c.v.) before testing impaired the performance of rats in the spatial version of the Morris...

Purity: 98.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



ADX-47273

Cat. No.: HY-13058

Bioactivity: ADX-47273 is a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5(EC50=170 nM). IC50 value: 170 nM(EC50) [1] [2] Target: positive allosteric modulator (PAM) of mGluR5 in vitro: ADX-47273 increased (9-fold) the response to threshold concentration of glutamate...

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



ADX88178

Cat. No.: HY-18654

Bioactivity: ADX88178 is a potent positive allosteric modulator for metabotropic glutamate receptor 4 (**mGluR4**) with EC_{50} of 4 nM for human mGluR4.

Purity: 98.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



AZD 9272

Cat. No.: HY-110254

Bioactivity: AZD 9272 is a brain penetrant **mGluR5** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



AZD-8529

Cat. No.: HY-107457

Bioactivity: AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of **mGluR2**, with an EC_{50} of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Basimglurant

(RG7090; CTEP Derivative)

Cat. No.: HY-15446

Bioactivity: Basimglurant (RG7090) is a potent, selective and orally available **mGlu5** negative allosteric modulator with a K_d of 1.1 nM.

Purity: 99.56%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BMT-145027

Cat. No.: HY-100728

Bioactivity: BMT-145027 is an **mGluR5** positive allosteric modulator without inherent agonist activity, exhibits an EC_{50} of 47 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



CFMTI

Cat. No.: HY-100402

Bioactivity: CFMTI is a potent and selective metabotropic glutamate receptor (mGluR) 1 allosteric antagonist with IC50 of 2.6 nM. The selectivity of CFMTI to mGluR1 over mGluR5 was >2000-fold. target : mGluR IC 50: 2.6 nM In vitro: The IC50 values of CFMTI against human mGluR5 were 5400 ± 1200 nM,...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



CPPHA

Cat. No.: HY-14612

Bioactivity: CPPHA is a selective positive allosteric modulator of mGluR5 receptor.

Purity: 97.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



CTEP

(RO 4956371; mGluR5 inhibitor)

Cat. No.: HY-15445

Bioactivity: CTEP (RO 4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of **mGlu5 receptor** with **IC_{50}** of 2.2 nM, and shows > 1000-fold selectivity over other mGlu receptors.

Purity: 97.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



DFMTI

(MK5435)

Cat. No.: HY-100404

Bioactivity: DFMTI can completely block the rmGlu1 L757V glutamate response.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Dipraglurant

(ADX48621)

Cat. No.: HY-14859

Bioactivity: Dipraglurant (ADX 48621) is a mGluR5 antagonists with IC50 of 0.021 μM.

Purity: 99.99%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg



E4CPG

Cat. No.: HY-100372

Bioactivity: E4CPG is a novel group I/group II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG .

Purity: 98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Eglumegad

(LY354740; Eglumetad)

Cat. No.: HY-18941

Bioactivity: Eglumegad (LY354740) is a highly potent and selective **group II (mGlu2/3) receptor** agonist with **IC_{50}**s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



FITM

Cat. No.: HY-101845

Bioactivity: FITM is a negative allosteric modulator of **mGlu1** receptor with a **K_i** of 2.5 nM.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Foliglurax monohydrochloride

(PXT002331 (monohydrochloride))

Cat. No.: HY-108703A

Bioactivity: Foliglurax monohydrochloride (PXT002331 monohydrochloride) is a highly selective and potent, brain-penetrant **mGluR4** positive allosteric modulator (PAM), with an **EC_{50}** of 79±19 nM [1]. Antiparkinsonian effect [1].

Purity: 98.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



FPTQ

Cat. No.: HY-100382

Bioactivity: FPTQ is mGluR1 antagonist with IC50 of 6 nM and 1.4 nM for human and mouse mGluR1 respectively. Inhibit [3H] FTIDC target: mGluR1 IC 50: 6 nM [1] In vivo: FPTQ exhibited dose-dependent and plasma concentration- dependent receptor occupancy in the cerebellum and striatum. Compound A inhibit...

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



JNJ-40411813

(ADX-71149)

Cat. No.: HY-15748

Bioactivity: JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM. IC50 value: 147 nM(EC50) Target: mGlu2R JNJ-40411813 displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and...

Purity: 99.69%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



JNJ-42153605

Cat. No.: HY-18162

Bioactivity: JNJ-42153605 is a positive allosteric modulator of the metabotropic glutamate 2 (**mGlu2**) receptor with an **EC_{50}** of 17 nM.

Purity: 98.10%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



JNJ-46778212

(VU 0409551)

Cat. No.: HY-19559

Bioactivity: JNJ-46778212 (VU 0409551) is an **mGlu5** positive allosteric modulator with an **EC_{50}** of 260 nM.

Purity: 99.24%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



JNJ16259685

Cat. No.: HY-100407

Bioactivity: JNJ16259685 is a selective antagonist of **mGlu1 receptor**, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with **IC_{50}** of 19 nM.

Purity: 98.85%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



L-APB

(L-AP 4)

Cat. No.: HY-100781A

Bioactivity: L-APB is a potent and specific agonist for the **group III mGluRs**, with **EC_{50}s** of 0.13, 0.29, 1.0, 249 μM for mGlu $_4$, mGlu $_8$, mGlu $_6$ and mGlu $_7$ receptors, respectively.

Purity: 99.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



L-Cysteinesulfinic acid

Cat. No.: HY-100804

Bioactivity: L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (**mGluR**s) with pEC $_{50}$s of 3.92±0.03, 4.6±0.2, 3.9±0.2, 2.7±0.2, 4.0±0.2, and 3.94±0.08 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



L-Glutamine

(L-Glutamic acid 5-amide)

Cat. No.: HY-N0390

Bioactivity: L-Glutamine is a non-essential amino acid present abundantly throughout the body and is involved in gastrointestinal disorders. Target: mGluR Glutamine (abbreviated as Gln or Q) is one of the 20 amino acids encoded by the standard genetic code. It is not recognized as an essential amino acid, but may...

Purity: 98.0%

Clinical Data: Phase 4

Size: 10mM x 1mL in Water,
100 mg, 500 mg

Lu AF21934

Cat. No.: HY-100366

Bioactivity: Lu AF21934 is a selective and brain-penetrant **mGlu4** receptor positive allosteric modulator with an **IC_{50}** of 500 nM for human mGlu4.

Purity: 98.76%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



LY2794193

Cat. No.: HY-119243

Bioactivity: LY2794193 is a highly potent and selective **mGlu3 receptor** agonist (**hmGlu3** K_i=0.927 nM **EC_{50}**=0.47 nM; **hmGlu2** K_i=412 nM **EC_{50}**=47.5 nM) [1].

Purity: >98%

Clinical Data: No Development Reported

Size: 500 mg, 250 mg



LY2979165

Cat. No.: HY-13239

Bioactivity: LY2979165 is a mGlu2 agonist, which is a novel potent agent that is used as anti-depressants.

Purity: 98.0%

Clinical Data: Phase 1

Size: 10mM x 1mL in water,
1 mg, 5 mg, 10 mg, 50 mg



LY341495

Cat. No.: HY-70059

Bioactivity: LY341495 is a **metabotropic glutamate receptor (mGluR)** antagonist with **IC_{50}**s of 2.9 nM, 10 nM, 170 nM for mGluR-2, mGluR-3, mGluR-8, respectively.

Purity: 99.11%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg



LY404039

Cat. No.: HY-50906

Bioactivity: LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor. IC50 Value:149 nM(Ki for mGlu2); 92 nM(Ki for mGlu3)[1] Target: mGluR1; mGluR2 Metabotropic glutamate (mGlu) receptors have been shown to mediate a number of behaviors including...

Purity: 98.0%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Mavoglurant

(AFQ056)

Cat. No.: HY-15257

Bioactivity: Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5.

Purity: 99.99%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Mavoglurant racemate

(AFQ-056 racemate)

Cat. No.: HY-15257A

Bioactivity: Mavoglurant (racemate) is the racemate of mavoglurant. Mavoglurant is a novel, non-competitive mGlu5 receptor antagonist.

Purity: 98.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg



Methoxy-PEPy

Cat. No.: HY-12510

Bioactivity: Methoxy-PEPy is a potent and highly selective mGlu5 receptor antagonist with IC50 of 1 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



MPEP

Cat. No.: HY-14609A

Bioactivity: MPEP is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



MPEP Hydrochloride

Cat. No.: HY-14609

Bioactivity: MPEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype with IC50 of 36 nM.

Purity: 99.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 50 mg



MSOP

Cat. No.: HY-101226

Bioactivity: MSOP is a selective **group III metabotropic glutamate receptor** antagonist with apparent **K_D** of 51 μM for the L-AP4-sensitive presynaptic mGluR.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg



MTEP hydrochloride

Cat. No.: HY-13206

Bioactivity: MTEP hydrochloride is a potent, selective and non-competitive mGlu5 antagonist with IC50 and Ki of 5 nM and 16 nM, respectively. IC50 Value: 5 nM [1] Target: mGluR5 MTEP occupied mGlu5 receptors in a dose-dependent manner with essentially full receptor occupancy at the highest dose tested...

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 50 mg



O-Phospho-L-serine

(L-Serine O-phosphate; L-SOP)

Cat. No.: HY-15129

Bioactivity: O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the **group III mGluR receptors** (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for **mGluR1** and a potent antagonist for **mGluR2**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 100 mg



PHCCC

Cat. No.: HY-100409

Bioactivity: PHCCC is a Group I metabotropic glutamate receptor antagonist with EC 50 of 6 uM and a positive allosteric modulator of mGluR4. Also as a potent to antagonism for mGluR2 and mGluR8.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Ro 67-7476

Cat. No.: HY-100403

Bioactivity: Ro 67-7476 is a positive allosteric modulator of mGlu1 receptors. Displays no activity at human mGlu1 receptors. Potentiates glutamate-induced calcium release with EC 50 of 60.1 nM.

Purity: 98.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



TCN238

Cat. No.: HY-14419

Bioactivity: TCN238 is a positive allosteric **mGlu4** receptor modulator with an $\mathbf{EC_{50}}$ of 1 μM.

Purity: 99.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Topiramate

(McN 4853; RWJ 17021)

Cat. No.: HY-B0122

Bioactivity: Topiramate is an anticonvulsant that antagonizes GluR5 receptors and acts as a positive allosteric modulator of GABA receptor-mediated currents.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg, 500 mg



trans-ACPD

(Trans-(±)-ACP)

Cat. No.: HY-19434

Bioactivity: trans-ACPD, a metabotropic receptor agonist, produces **calcium** mobilization and an inward current in cultured cerebellar Purkinje neurons.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



VU 0357121

Cat. No.: HY-15393

Bioactivity: VU0357121 is a novel positive and highly selective allosteric modulator (PAM) of mGlu5R with EC50 of 33 nM.

Purity: 99.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



VU 0364439

Cat. No.: HY-15476

Bioactivity: VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



VU0361737

(ML-128)

Cat. No.: HY-14418

Bioactivity: VU 0361737 is a selective positive allosteric modulator (PAM) for mGlu4 receptor with EC50 of 240 nM and 110 nM at human and rat receptors, respectively, displays weak activity at mGlu5 and mGlu8 receptors, is inactive at mGlu1, mGlu2, mGlu3, mGlu6 and mGlu7 receptors. IC50 value: 110 nM (EC50, for rat), 240...

Purity: 99.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



VU0364770

Cat. No.: HY-100588

Bioactivity: VU0364770 is an allosteric of metabotropic glutamate receptor 4 ($\mathbf{mGlu_4}$) modulator, which exhibits a $\mathbf{EC_{50}}$ of 1.1±0.2 μM at human $mGlu_4$.

Purity: 99.54%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



VU0424238

Cat. No.: HY-16617

Bioactivity: VU0424238 is a novel and selective **mGlu5** antagonist with an $\mathbf{IC_{50}}$ value of 11 nM (rat) and an $\mathbf{IC_{50}}$ value of 14 nM (human). VU0424238 has an acceptable CNS penetration [1].

Purity: 99.40%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



VU0650786

Cat. No.: HY-108710

Bioactivity: VU0650786 is a potent and selective CNS penetrant negative allosteric modulator of **metabotropic glutamate receptor subtype 3 (mGlu3)**, with an **IC_{50}** of 392 nM. VU0650786 has antidepressant and anxiolytic activity in rodents [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



VU0652835

Cat. No.: HY-119941

Bioactivity: VU0652835 is a **metabotropic glutamate receptor subtype 5 (mGlu5)** negative allosteric modulator with an **IC_{50}** of 81 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



VU6001376

Cat. No.: HY-112814

Bioactivity: VU6001376 is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 4 **(mGlu4 PAM)** with an **EC_{50}** of 50.1 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 100 mg, 250 mg



VU6005649

Cat. No.: HY-107982

Bioactivity: VU6005649 is a CNS penetrant **$mGlu_{7/8}$ receptor** agonist with **EC_{50}**s of 0.65 μM and 2.6 μM for **$mGlu_7$ receptor** and **$mGlu_8$ receptor**, respectively.

Purity: 98.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



VU6012962

Cat. No.: HY-114403

Bioactivity: VU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (**$mGlu_7$**) negative allosteric modulator (NAM) with an **IC_{50}** of 347 nM [1].

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Xanthurenic acid

Cat. No.: HY-W014666

Bioactivity: Xanthurenic acid is a putative endogenous **Group II metabotropic glutamate receptor** agonist, on sensory transmission in the thalamus.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg



Motilin Receptor

MLNR



Motilin receptor is a G protein-coupled receptor that binds motilin. Motilin in turn is an intestinal peptide that stimulates contraction of gutsmooth muscle. The main function of motilin is to increase the migrating myoelectric complex component of gastrointestinal motility and stimulate the production of pepsin. Motilin is called "housekeeper of the gut" because it improves peristalsis in the small intestine and clears out the gut to prepare for the next meal. A high level of motilin secreted between meals into the blood stimulates the contraction of the fundus and antrum and accelerates gastric emptying. It then contracts the gallbladder and increases the squeeze pressure of the lower esophageal sphincter. Other functions of motilin include increasing the release of pancreatic polypeptide and somatostatin.

Motilin Receptor Inhibitors & Modulators

Camicinal
(GSK962040)

Cat. No.: HY-10922

Bioactivity: Camicinal (GSK962040) is a small molecule, selective motilin receptor agonist with pEC50 of 7.9.

Purity: 97.08%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Camicinal hydrochloride
(GSK962040 (hydrochloride))

Cat. No.: HY-10922A

Bioactivity: Camicinal (GSK962040) hydrochloride is a small molecule, selective motilin receptor agonist with pEC50 of 7.9.

Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg



Motilin (26-47), human, porcine

Cat. No.: HY-P1037

Bioactivity: Motilin(human, porcine) is an endogenous motilin receptor ligand with K_i and EC_{50} of 2.3 nM and 0.3 nM in a Chinese hamster ovary cell line.

Purity: 95.82%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

FVPIFTYGELQRMQEKERNKGQ

Neurokinin Receptor

NK receptor



There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues.

Aprepitant
(MK-0869; MK-869; L-754030) Cat. No.: HY-10052

Bioactivity: Aprepitant (MK-0869) is a selective and high-affinity **neurokinin 1 receptor** antagonist with a K_d of 86 pM.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Befetupitant
(Ro67-5930) Cat. No.: HY-19670

Bioactivity: Befetupitant is a high-affinity, nonpeptide, competitive tachykinin 1 receptor (**NK1R**) antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Fezolinetant
(ESN-364) Cat. No.: HY-19632

Bioactivity: Fezolinetant is an antagonist of the **neurokinin 3 receptor (NK3R)**, used for the treatment of menopausal hot flushes.

Purity: 98.29%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Fosaprepitant
(L-758298) Cat. No.: HY-14407

Bioactivity: Fosaprepitant (L-758298) is a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Fosaprepitant dimeglumine
(MK-0517; L785298) Cat. No.: HY-14407A

Bioactivity: Fosaprepitant dimeglumine(MK-0517) is a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. IC50 Value: Target: NK1 receptor in vitro: Fosaprepitant (also known as MK-0517 and L-758,298) is a water-soluble phosphoryl prodrug for aprepitant, which, when...

Purity: 99.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



GR 159897
Cat. No.: HY-107691

Bioactivity: GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide antagonist at **tachykinin NK_2 receptors**, inhibits binding of [^{3}H]GR100679 to hNK $_2$-CHO cells and rat colon membranes with **pK_i**s of 9.51 and ...

Purity: >98%
Clinical Data: No Development Reported
Size:



Hemokinin 1 mouse
Cat. No.: HY-P1030

Bioactivity: Hemokinin 1 (mouse) is a selective agonist of **neurokinin-1 receptor**, with **K_i** of 0.175 nM and 560 nM for human NK1 receptor and human NK2 receptor, respectively.

Purity: 98.41%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Ibodutant
(MEN 15596) Cat. No.: HY-14770

Bioactivity: Ibodutant (MEN 15596) is a potent and selective **tachykinin NK2 receptor** antagonist with a **pK_i** of 10.1.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Kassinin
Cat. No.: HY-P0250

Bioactivity: Kassinin is a peptide derived from the Kassina frog. It belongs to tachykinin family of neuropeptides. It is secreted as a defense response, and is involved in neuropeptide signalling.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Maropitant
Cat. No.: HY-10053

Bioactivity: Maropitant is a neurokinin (NK1) receptor antagonist. IC50 value: Target: NK1 receptor Maropitant is the first NK1 receptor antagonist developed to treat and prevent emesis in dogs. Treatment with 1 mg/kg Maropitant citrate, significantly reduced the size of ulcerative dermatitis (UD) lesions in...

Purity: 99.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg



Men 10376

(Neurokinin-2 receptor antagonist) Cat. No.: HY-P1276

Bioactivity: Men 10376 is a selective **tachykinin NK-2 receptor** antagonist, with a K_i of 4.4 μM for rat small intestine NK-2 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Men 10376 TFA

(Neurokinin-2 receptor antagonist (TFA)) Cat. No.: HY-P1276A

Bioactivity: Men 10376 TFA is a selective **tachykinin NK-2 receptor** antagonist, with a K_i of 4.4 μM for rat small intestine NK-2 receptor [1].

Purity: 99.76%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



MEN11467

Cat. No.: HY-U00207

Bioactivity: MEN11467 is a selective and orally- effective peptidomimetic **tachykinin NK_1 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Monohydroxy Netupitant D6

Cat. No.: HY-G0012S

Bioactivity: Monohydroxy Netupitant D6 is the deuterium labeled Monohydroxy Netupitant, which is a metabolite of Netupitant.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Netupitant

(CID 6451149) Cat. No.: HY-16346

Bioactivity: Netupitant (CID-6451149) is a highly potent and selective, orally active neurokinin-1 receptor antagonist with Ki of 0.95 nM. IC50 value: 0.95 nM (Ki) [1] Target: NK1 receptor in vitro: Netupitant also dose-dependently inhibited the SP response as expected from an NK1 receptor antagonist....

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Netupitant D6

(CID-6451149 D6) Cat. No.: HY-16346S

Bioactivity: Netupitant D6 is the deuterium labeled Netupitant(CID-6451149), which is a highly potent and selective, orally active neurokinin-1 receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Netupitant metabolite Monohydroxy Netupitant

(Monohydroxy Netupitant) Cat. No.: HY-G0012

Bioactivity: Monohydroxy Netupitant is the metabolite of Netupitant, which is a highly selective NK1 receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Neurokinin A

(α-Neurokinin; Neuromedin L; Substance K) Cat. No.: HY-P0197

Bioactivity: Neurokinin A acts via neurokinin 2 (**NK-2**) receptor.

Purity: 98.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

HKTDSFVGLM-NH_2

Neurokinin A(4-10)

Cat. No.: HY-P0236

Bioactivity: Neurokinin A (4-10) is a **tachykinin NK_2 receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg



Neurokinin A(4-10) TFA

Cat. No.: HY-P0236A

Bioactivity: Neurokinin A (4-10) TFA is a **tachykinin NK_2 receptor** agonist [1].

Purity: 98.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg



Neurokinin antagonist 1

Cat. No.: HY-U00320

Bioactivity: Neurokinin antagonist 1 is a **Neurokinin** antagonist extracted from patent WO1998045262A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Neurokinin B

Cat. No.: HY-P0242

Bioactivity: Neurokinin B belongs to the tachykinin family of peptides. Neurokinin B binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological effect [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Neurokinin B TFA

Cat. No.: HY-P0242A

Bioactivity: Neurokinin B TFA belongs to the tachykinin family of peptides. Neurokinin B binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological effect [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
1 mg, 5 mg, 10 mg, 25 mg



NK-1 Antagonist 1

Cat. No.: HY-106659

Bioactivity: NK-1 Antagonist 1 is an antagonist of **NK-1 receptor**, used in the research of NK-1 related diseases and conditions such as cough, overactive bladder, alcohol dependency and depression.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



NKP608

Cat. No.: HY-18006

Bioactivity: NKP608 is a non-peptidic derivative of 4-aminopiperidine which acts as a selective, specific and potent antagonist at the neurokinin-1 (NK-1) receptor both in vitro(IC50=2.6 nM) and in vivo.

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



Pavinetant

(MLE-4901; AZD2624; AZD4901)

Cat. No.: HY-14432

Bioactivity: Pavinetant (MLE-4901) is a **neurokinin-3 receptor** (**NK3R**) antagonist.

Purity: 99.74%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Physalaemin

Cat. No.: HY-P0255

Bioactivity: Physalaemin, a non-mammalian tachykinin, binds selectively to **neurokinin-1** (**NK1**) **receptor** with high affinity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Rolapitant

(SCH619734)

Cat. No.: HY-14751

Bioactivity: Rolapitant (SCH619734) is a potent, selective and orally active **neurokinin** NK1 receptor antagonist with a K_i of 0.66 nM.

Purity: 98.01%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Saredutant

(SR 48968; SR 48968C)

Cat. No.: HY-106910

Bioactivity: Saredutant is a selective **NK2 receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



SB-222200

Cat. No.: HY-15722

Bioactivity: SB 222200 is a selective, reversible and competitive antagonist of human NK-3 receptor(Ki=4.4 nM) that effectively crosses the blood-brain barrier.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



Scyliorhinin II

Cat. No.: HY-P1588

Bioactivity: Scyliorhinin II is a selective **neurokinin-3 receptor** agonist, with a K_i of 2.5 nM for neurokinin-3 receptor in rat cerebral cortex.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Senktide

Cat. No.: HY-P0187

Bioactivity: Senktide is a tachykinin **NK_3 receptor** agonist.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg



Serlopitant

(VPD-737; MK-0594)

Cat. No.: HY-12114

Bioactivity: Serlopitant is a selective **Neurokinin-1 (NK-1)** receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Substance P

(Neurokinin P)

Cat. No.: HY-P0201

Bioactivity: Substance P is a neuropeptide, acting as a neurotransmitter and as a neuromodulator.The endogenous receptor for substance P is **neurokinin 1 receptor** (**NK1-receptor**, **NK1R**).

Purity: 98.07%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 25 mg

Substance P (1-7)(TFA)

(Substance P (1-7) Trifluoroacetate)

Cat. No.: HY-P1485A

Bioactivity: Substance P (1-7)(TFA) is a fragment of the neuropeptide, substance P (SP). Substance P (1-7)(TFA) gives depressor and bradycardic effects when applied to the nucleus tractus solitarius.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Substance P 1-7

Cat. No.: HY-P1485

Bioactivity: Substance P (7-11) is a fragment of the neuropeptide, substance P (SP). Substance P (7-11) gives depressor and bradycardic effects when applied to the nucleus tractus solitarius.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Substance P 1-9

Cat. No.: HY-P1494

Bioactivity: Substance P (1-9) is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Substance P 7-11

Cat. No.: HY-P1492

Bioactivity: Substance P (7-11) is a C-terminal fragment of Substance P which can cause an increase in the intracellular calcium concentration.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Tachykinin angatonist 1

Cat. No.: HY-U00392

Bioactivity: Tachykinin angatonist 1 is a **neurokinin receptor** antagonist extracted from patent US5968923, compound example 32.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Talnetant

(SB 223412)

Cat. No.: HY-14552

Bioactivity: Talnetant (SB 223412) is a potent and selective NK3 receptor antagonist(ki=1.4 nM, hNK-3-CHO); 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 uM.

Purity: 99.44%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Talnetant hydrochloride

(SB 223412 hydrochloride; SB 223412-A) Cat. No.: HY-14552A

Bioactivity: Talnetant Hcl(SB 223412 Hcl) is a potent and selective NK3 receptor antagonist(ki=1.4 nM, hNK-3-CHO); 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 uM.

Purity: >98%
Clinical Data: Phase 2
Size: 10 mg, 50 mg



Tradipitant

(VLY-686; LY686017) Cat. No.: HY-16732

Bioactivity: Tradipitant is a **neurokinin-1** (**NK-1**) antagonist.

Purity: 99.62%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Vofopitant

(GR 205171) Cat. No.: HY-12142

Bioactivity: Vofopitant is potent **tachykinin NK_1 receptor** antagonist, with **pK_I**s of 10.6, 9.5, and 9.8 for human, rat and ferret NK_1 receptor, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 100 mg



Y1 receptor antagonist 1

Cat. No.: HY-101704

Bioactivity: Y1 receptor antagonist 1, an isomer of H-409/22, is a **neuropeptide Y1 receptor** antagonist.

Purity: 95.03%
Clinical Data: No Development Reported
Size: 1 mg



[bAla8]-Neurokinin A(4-10)

(MEN 10210) Cat. No.: HY-P1031

Bioactivity: [bAla8]-Neurokinin A(4-10) is a **neurokinin 2 (NK2) receptor** agonist.

Purity: 98.17%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



[Nle11]-Substance P

Cat. No.: HY-P1506

Bioactivity: [Nle11]-Substance P is a substance P analog that avoids methionine oxidation problems.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

[Sar9,Met(O2)11]-Substance P

Cat. No.: HY-P1012

Bioactivity: [Sar9,Met(O2)11]-Substance P is a **tachykinin NK_1 receptor** selective agonist.

Purity: 98.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

[Sar9] Substance P

Cat. No.: HY-P1738

Bioactivity: [Sar9] Substance P is a potent and selective **neurokinin (NK)-1 receptor** agonist [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

Neuropeptide Y Receptor

NPY receptor



Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide. These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.

Neuropeptide Y (NPY) is a potent orexigenic neuropeptide, and antagonism of NPY Y1 and NPY Y5 receptors (NPYxR) is considered a potentially important anti-obesity drug target.

Neuropeptide Y (NPY) is widely distributed in the human body and contributes to a vast number of physiological processes. A number of other uses for modulators of NPY receptors have been implied in a range of diseases.

BIIE-0246

(AR-H 053591)

Cat. No.: HY-101986

Bioactivity: BIIE-0246 is a potent and highly selective **non-peptide neuropeptide Y (NPY) Y_2** receptor antagonist, with an **IC_{50}** of 15 nM.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 1 mg



CGP71683 hydrochloride

(CGP71683A)

Cat. No.: HY-107723

Bioactivity: CGP71683 hydrochloride is a competitive **neuropeptide Y5 receptor** antagonist with a **K_i** of 1.3 nM, and shows no obvious activity at Y1 receptor (**K_i**, >4000 nM) and Y2 receptor (**K_i**, 200 nM) in cell membranes.

Purity: 99.63%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



FR252384

Cat. No.: HY-U00335

Bioactivity: FR252384 is a **neuropeptide Y-Y5 receptor** antagonist, with an **IC_{50}** of 2.3 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Galanin (1-16), mouse, porcine, rat

Cat. No.: HY-P1578

Bioactivity: Galanin (1-16), mouse, porcine, rat is an agonist of the hippocampal **galanin receptor**, with a **K_d** of 3 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Galanin (1-16), mouse, porcine, rat TFA

Cat. No.: HY-P1578A

Bioactivity: Galanin (1-16), mouse, porcine, rat (TFA) is an agonist of the hippocampal **galanin receptor**, with a **K_d** of 3 nM.

Purity: 98.08%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg



Galanin (1-30), human

Cat. No.: HY-P1127

Bioactivity: Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of **GalR1 and GalR2 receptors**, with **K_i**s of both 1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Galanin Receptor Ligand M35

Cat. No.: HY-P1840

Bioactivity: Galanin Receptor Ligand M35 is a high-affinity galanin receptor ligand acting as a **galanin receptor** antagonist in the rat spinal cord, rat hippocampus and isolated mouse pancreatic islets. Galanin Receptor Ligand M35 exerts a **K_i** values of 0...

Purity: >98%
Clinical Data: No Development Reported
Size:

Galantide

Cat. No.: HY-P0262

Bioactivity: Galantide is a reversible and non-specific **galanin** receptor antagonist.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

HT-2157

(SNAP 37889)

Cat. No.: HY-100717

Bioactivity: HT-2157 (SNAP 37889) is a selective, high-affinity, competitive antagonists of **galanin-3 receptor** (**Gal_3**).

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



JNJ-31020028

Cat. No.: HY-14450

Bioactivity: JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07, human; pIC50=8.22 rat); >100-fold selective versus human Y1/Y4/Y5 receptors.

Purity: 99.51%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



M40

Cat. No.: HY-P1025

Bioactivity: M40 is a potent, non-selective **galanin receptor** antagonist.

Purity: 98.25%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg, 10 mg

MK-0557

Cat. No.: HY-15411

Bioactivity: MK-0557 is a highly selective, orally available neuropeptide **Y5** receptor antagonist with a K_i of 1.6 nM.

Purity: 98.28%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Neuropeptide Y (13-36), amide, human

(Neuropeptide Y (13-36), human)

Cat. No.: HY-P1480

Bioactivity: Neuropeptide Y (13-36), amide, human is a **neuropeptide Y receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Neuropeptide Y (29-64), amide, human

(Human neuropeptide Y (29-64))

Cat. No.: HY-P0198

Bioactivity: Neuropeptide Y (29-64), amide, human is a biologically active 36-amino acid peptide.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuropeptide Y (29-64), amide, human TFA

Cat. No.: HY-P0198A

Bioactivity: Neuropeptide Y (29-64), amide, human (TFA) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

Purity: 95.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Neuropeptide Y 22-36

Cat. No.: HY-P1818

Bioactivity: Neuropeptide Y (22-36), a 15 amino acid peptide, is a fragment of Neuropeptide Y.

Purity: >98%
Clinical Data: No Development Reported
Size:

SALRHYINLITRQRY-NH_2

Neuropeptide Y(29-64)

Cat. No.: HY-P1601

Bioactivity: Neuropeptide Y(29-64) is a 36 amino acid peptide, a fragment of Neuropeptide Y.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pancreatic Polypeptide, bovine

Cat. No.: HY-P1537

Bioactivity: Pancreatic Polypeptide, bovine, a 36-amino acid, straight chain polypeptide derived primarily from the pancreas, inhibits secretin- and cholecystokinin-stimulated pancreatic secretion; Pancreatic Polypeptide, bovine acts as an agonist of **NPY receptor**, with high affinity at **NPYR4**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Pancreatic Polypeptide, human

(Human pancreatic polypeptide)

Cat. No.: HY-P0199

Bioactivity: Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a **neuropeptide Y** (**NPY**) **Y4**/ **Y5** receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Pancreatic Polypeptide, rat

(Rat pancreatic polypeptide)

Cat. No.: HY-P1532

Bioactivity: Pancreatic Polypeptide, rat is an agonist of **NPY receptor**, with high affinity at **NPYR4**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Peptide YY (PYY), human

Cat. No.: HY-P1514

Bioactivity: Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the **Neuropeptide Y receptors**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

RF9

Cat. No.: HY-107382

Bioactivity: RF9 is a potent and selective **Neuropeptide FF receptor** antagonist, with K_is of 58±5 and 75±9 nM for **hNPFF1R** and **hNPFF2R**, respectively.

Purity: 98.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Velneperit

(S2367)

Cat. No.: HY-14423

Bioactivity: Velneperit (S-2367) is a novel neuropeptide Y (NPY) Y5 receptor antagonist.

Purity: 99.26%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Neurotensin Receptor



Neurotensin receptors are transmembrane receptors that bind the neurotransmitter neurotensin. Two of the receptors encoded by the NTSR1 and NTSR2 genes contain seven transmembrane helices and are G protein coupled. The third receptor has a single transmembrane domain and is encoded by the SORT1 gene. Neurotensin (NTS) is a 13-amino-acid peptide that functions as both a neurotransmitter and a hormone through the activation of the neurotensin receptor NTSR1, a G-protein-coupled receptor (GPCR). In the brain, NTS modulates the activity of dopaminergic systems, opioid-independent analgesia, and the inhibition of food intake; in the gut, NTS regulates a range of digestive processes.

Kinetensin

(Kinetensin (human))

Cat. No.: HY-P1255

Bioactivity: Kinetensin is a **neurotensin**-like peptide isolated from pepsin-treated human plasma.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



ML314

Cat. No.: HY-16639

Bioactivity: ML314 is a potent molecule agonist of NTR1 (EC50 = 1.9 μM); showed good selectivity against NTR2 and GPR35, but did not stimulate Ca2+ mobilization.

Purity: 99.72%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Neurotensin

Cat. No.: HY-P0234

Bioactivity: Neurotensin, a gut tridecapeptide, acts as a potent cellular mitogen for various colorectal and pancreatic cancers which possess high-affinity **neurotensin receptors** (**NTR**).

Purity: 97.32%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Pyr-LYENKPRRPYIL

Opioid Receptor



Opioid receptors are a group of G protein-coupled receptors with opioids as ligands. The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin. Opioid receptors are distributed widely in the brain, and are found in the spinal cord and digestive tract. Opioid receptors are molecules, or sites, within the body that are activated by opioid substances. Opioid receptors inhibit the transmission of impulse in excitatory pathways within the human body system. These pathways include the serotonin, catecholamine, and substance P pathways, which are all implicated in pain perception and feelings of well-being. Opioid receptors are further subclassified into mu, delta, and kappa receptors. All the classes, while exhibiting differing modes of action, share some basic similarities. They all are driven by the potassium pump mechanism, which is found on the plasma membrane of the majority of cells.

ADL-5859

Cat. No.: HY-13044

Bioactivity: ADL5859 is a δ-opioid receptor agonist with Ki of 0.8 nM, selectivity against opioid receptor κ, μ, and weak inhibitory activity at the hERG channel.

Purity: 99.65%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Adrenorphin

(Metorphamide)

Cat. No.: HY-P1087

Bioactivity: Adrenorphin is a opioid octapeptide, acting as a potent agonist of **μ-opioid receptor**, with K_i of 12 nM.

Purity: 95.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Alvimopan

(ADL 8-2698; LY 246736)

Cat. No.: HY-13243

Bioactivity: Alvimopan(LY 246736; ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. IC50 Value: 1.7 nM (Mu-type opioid receptor) [1] Target: mu-opioid receptor in vitro: The dissociation rate of alvimopan from the...

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Alvimopan dihydrate

(ADL 8-2698 dihydrate; LY 246736 dihydrate)

Cat. No.: HY-76657A

Bioactivity: Alvimopan dihydrate (ADL 8-2698 dihydrate; LY 246736 dihydrate) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. IC50 Value: 1.7 nM (Mu-type opioid receptor) [1] Target: mu-opioid receptor in...

Purity: 98.02%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Alvimopan monohydrate

(ADL 8-2698 monohydrate; LY 246736 monohydrate)

Cat. No.: HY-76657

Bioactivity: Alvimopan monohydrate (ADL 8-2698 monohydrate; LY 246736 monohydrate) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.

Purity: 99.18%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



AR-M 1000390 hydrochloride

Cat. No.: HY-101039A

Bioactivity: AR-M 1000390 hydrochloride is an exceptionally selective, potent **δ opioid receptor** agonist with an EC_{50} of 7.2±0.9 nM for δ agonist potency.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Asimadoline

(EMD-61753)

Cat. No.: HY-107384

Bioactivity: Asimadoline is a potent **κ opioid** receptor agonist with IC_{50}s of 5.6 and 1.2 nM for guinea pig and human recombinant κ opioid receptor, respectively.

Purity: 99.36%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Aticaprant

(CERC-501; LY-2456302)

Cat. No.: HY-101718

Bioactivity: Aticaprant (CERC-501) is a potent and centrally-penetrant **kappa opioid** receptor antagonist with a K_i of 0.807 nM.

Purity: 99.24%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg



BAM-22P

(Bovine adrenal medulla-22P)

Cat. No.: HY-P1331

Bioactivity: BAM-22P, a highly potent opioid peptide, is a potent **opioid** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

BAN ORL 24

Cat. No.: HY-13222

Bioactivity: BAN ORL 24 is a potent and selective NOP receptor antagonist. (IC50 values are 0.27, 2500, 6700 and > 10000 nM for NOP, κ-, μ- and δ-receptors respectively).

Purity: 95.07%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Bevenopran

(CB-5945; ADL-5945) Cat. No.: HY-100122

Bioactivity: Bevenopran is a peripheral **μ-opioid receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Cebranopadol

(GRT6005) Cat. No.: HY-15536

Bioactivity: Cebranopadol is an analgesic **NOP** and **opioid receptor** agonist with K_is/ EC_{50}s of 0.9 nM/13 nM, 0.7 nM/1.2 nM, 2.6 nM/17 nM, 18 nM/110 nM for human NOP, MOP, KOP and delta-opioid peptide (DOP) receptor, respectively.

Purity: 98.76%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Cebranopadol ((1α,4α)stereoisomer)

(GRT6005 (1α,4α)stereoisomer) Cat. No.: HY-15536A

Bioactivity: Cebranopadol ((1α,4α)stereoisomer) is a stereoisomer of cebranopadol. Cebranopadol is a potent agonist activity on ORL-1.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg



CYT-1010

Cat. No.: HY-123534

Bioactivity: CYT-1010 is a **mu-opioid receptor** agonist extracted from patent WO2013173730A2, with EC_{50}s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



CYT-1010 hydrochloride

Cat. No.: HY-123534A

Bioactivity: CYT-1010 hydrochloride is a **mu-opioid receptor** agonist extracted from patent WO2013173730A2, with EC_{50}s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



DAMGO

Cat. No.: HY-P0210

Bioactivity: DAMGO is a **μ-opioid receptor** (**μ-OPR**) selective agonist.

Purity: 98.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg



Deltorphin 2

([D-Ala2]-Deltorphin Ⅱ) Cat. No.: HY-P1013

Bioactivity: Deltorphin 2 is a selective peptide agonist for the **δ opioid receptor**.

Purity: 98.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg



Deltorphin I

(Deltorphin 1; Deltorphin C) Cat. No.: HY-P1336

Bioactivity: Deltorphin I is a **δ-opioid receptor** agonist with high affinity and selectivity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Dermorphin

Cat. No.: HY-P0244

Bioactivity: Dermorphin is a natural heptapeptide **μ-opioid receptor** (**MOR**) agonist found in amphibian skin.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg



Dynorphin A (1-10) TFA

Cat. No.: HY-P1594A

Bioactivity: Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds to extracellular loop 2 of the **κ-opioid receptor**. Dynorphin A (1-10) (TFA) also blocks **NMDA**-activated current with an IC_{50} of 42.0 μM.

Purity: 95.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

YGGFLRRIRP

Dynorphin A 1-10

Cat. No.: HY-P1594

Bioactivity: Dynorphin A (1-10) an endogenous opioid neuropeptide, binds to extracellular loop 2 of the **κ-opioid receptor**. Dynorphin A (1-10) also blocks **NMDA**-activated current with an $\mathbf{IC_{50}}$ of 42.0 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

YGGFLRRIRP

Dynorphin B 1-13

Cat. No.: HY-P1337

Bioactivity: Dynorphin B (1-13) acts as an agonist on **opioid κ-receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

YGGFLRRQFKVVT

Endomorphin 1

Cat. No.: HY-P0185

Bioactivity: Endomorphin 1, a high affinity, highly selective agonist of the **μ-opioid receptor**, displays reasonable affinities for kappa $_3$ binding sites, with $\mathbf{K_i}$ value between 20 and 30 nM.

Purity: 98.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg



Endomorphin 2

Cat. No.: HY-P0186

Bioactivity: Endomorphin 2, a high affinity, highly selective agonist of the **μ-opioid receptor**, displays reasonable affinities for kappa $_3$ binding sites, with $\mathbf{K_i}$ value between 20 and 30 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Endomorphin 2 TFA

Cat. No.: HY-P0186A

Bioactivity: Endomorphin 2 TFA, a high affinity, highly selective agonist of the **μ-opioid receptor**, displays reasonable affinities for kappa $_3$ binding sites, with $\mathbf{K_i}$ value between 20 and 30 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg



Gluten Exorphin B5

Cat. No.: HY-P1742

Bioactivity: Gluten Exorphin B5 is an exogenous opioid peptides derived from wheat gluten, acts on **opioid receptor**, increases postprandial plasma insulin level in rats [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



Gluten Exorphin C

Cat. No.: HY-P1596

Bioactivity: Gluten exorphin C is an opioid peptide derived from wheat gluten. Its $\mathbf{IC_{50}}$ values are 40 μM and 13.5 μM for **μ opioid** and **δ opioid** activities in the GPI and MVD assays, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg



Hemorphin-7

Cat. No.: HY-P0318

Bioactivity: Hemorphin-7 is a hemorphin peptide, an endogenous opioid peptide derived from the β-chain of hemoglobin. Hemorphin peptides exhibits antinociceptive and antihypertensive activities, activating opioid receptors and inhibiting angiotensin-converting enzyme (ACE).

Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



JDTic

Cat. No.: HY-10486

Bioactivity: JDTic is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg



JDTic dihydrochloride

Cat. No.: HY-10487

Bioactivity: JDTic (dihydrochloride) is a potent antagonist of **kappa-opioid receptors (KOR)**, blocking the κ-agonist U50, 488-induced antinociception.

Purity: 99.79%
Clinical Data: Phase 1
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



JTC-801

Cat. No.: HY-13274

Bioactivity: JTC-801 is a selective **opioid receptor-like1 (ORL1) receptor** antagonist, binding to ORL1 receptor with a K_i value of 8.2nM.

Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



Kelatorphan

Cat. No.: HY-10827

Bioactivity: Kelatorphan is a full inhibitor of **enkephalin degrading enzymes**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Loperamide hydrochloride

(R-18553 (hydrochloride))

Cat. No.: HY-B0418A

Bioactivity: Loperamide (hydrochloride) (R-18553 (hydrochloride)) is an **opioid receptor** agonist for the treatment of diarrhea.

Purity: 99.69%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



LY-2940094

Cat. No.: HY-114452

Bioactivity: LY-2940094 is a potent, selective and orally available **nociceptin receptor** (**NOP receptor**) antagonist with high affinity (K_i=0.105 nM) and antagonist potency (K_b=0.166 nM). LY-2940094 reduces ethanol self-administration in ani...

Purity: 99.56%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



LY2795050

Cat. No.: HY-15708

Bioactivity: LY2795050 is a novel selective κ-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo. IC50 Value: 0.72 nM (κ-opioid Receptor); 25.8 nM (κ-opioid) [1] Target: κ-opioid Receptor in vitro: LY2795050 displays full antagonist activity and high...

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Matrine

(Matridin-15-one; Vegard; α-Matrine)

Cat. No.: HY-N0164

Bioactivity: Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and u-receptor agonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



MCOPPB triHydrochloride

(MCOPPB 3HCl)

Cat. No.: HY-13101

Bioactivity: MCOPPB 3Hcl is a nociceptin receptor agonist with pKi of 10.07; weaker activity at other opioid receptors. IC50 value: 10.07 (pKi) Target: nociceptin receptor MCOPPB trihydrochloride is a trihydrochloride form of MCOPPB that is a new nonpeptide nociceptin/orphanin FQ peptide (NOP)-receptor...

Purity: 99.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



MT-7716 free base

(W-212393)

Cat. No.: HY-107094A

Bioactivity: MT-7716 free base (W-212393) is a selective non-peptide **nociceptin receptor (NOP)** agonist and promising potential treatment drug for alcohol abuse and relapse prevention [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



MT-7716 hydrochloride

(W-212393 hydrochloride)

Cat. No.: HY-107094

Bioactivity: MT-7716 hydrochloride (W-212393 hydrochloride) is a selective non-peptide **nociceptin receptor (NOP)** agonist and promising potential treatment drug for alcohol abuse and relapse prevention [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 250 mg



N-Desmethylclozapine

(Norclozapine; Desmethylclozapine; Normethylclozapine)

Cat. No.: HY-G0021

Bioactivity: N-Desmethylclozapine is a dengue virus inhibitor, and an agonist of **δ-opioid receptor**.

Purity: 98.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Naloxegol
(NKTR-118; AZ-13337019) Cat. No.: HY-A0118

Bioactivity: Naloxegol (NKTR-118; AZ-13337019) is an **opioid-receptor** antagonist [1].

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Naloxegol oxalate
(NKTR-118 oxalate; AZ-13337019 oxalate) Cat. No.: HY-A0118A

Bioactivity: Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an **opioid-receptor** antagonist [1].

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Naltrindole hydrochloride
Cat. No.: HY-101177

Bioactivity: Naltrindole hydrochloride is a highly potent and selective non-peptide **δ opioid** receptor antagonist with a K_i of 0.02 nM.

Purity: 99.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Neuropeptide AF (93-110), Human
(Neuropeptide AF (human)) Cat. No.: HY-P1246

Bioactivity: Neuropeptide AF (93-110), Human is an **endogenous** antiopioid peptide.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Nociceptin
(Orphanin FQ) Cat. No.: HY-P0183

Bioactivity: Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 25 mg

Nociceptin (1-13), amide
Cat. No.: HY-P1317

Bioactivity: Nociceptin (1-13), amide is a potent **ORL1 (OP4) receptor** agonist with a **pEC_{50}** of 7.9 for mouse vas deferens and a K_i of 0.75 nM for binding to rat forebrain membranes [1] [2].

Purity: >98%
Clinical Data: No Development Reported
Size:

Opioid receptor modulator 1
Cat. No.: HY-U00420

Bioactivity: Opioid receptor modulator 1 is a **opioid receptor** modulator extracted from patent WO2014072809A2, Compound RA11 in EXAMPLE 7.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



ORL1 antagonist 1
Cat. No.: HY-112263

Bioactivity: ORL1 antagonist 1 is an opioid receptor-like 1 (**ORL1**) antagonist with an **IC_{50}** of 61 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PZM21
Cat. No.: HY-101386

Bioactivity: PZM21 is a potent and selective **μ opioid receptor** agonist with an **EC_{50}** of 1.8 nM.

Purity: 99.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Sinomenine hydrochloride
(Cucoline hydrochloride) Cat. No.: HY-15122A

Bioactivity: Sinomenine hydrochloride is a blocker of the **NF-κB** activation and also an activator of **μ-opioid receptor**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



SR17018

Cat. No.: HY-111454

Bioactivity: SR17018 is an **mu-opioid-receptor (MOR)** agonist, binding with GTPγS, with an **EC_{50}** of 97 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Trimebutine

Cat. No.: HY-B0380

Bioactivity: Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.

Purity: >98%
Clinical Data: Launched
Size: 5 g



Trimebutine maleate

Cat. No.: HY-B0380A

Bioactivity: Trimebutine maleate is a drug with antimuscarinic and weak mu opioid agonist effects.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g



Tyr-Gly-Gly-Phe-Met-OH

(Met-Enkephalin; Methionine enkephalin)

Cat. No.: HY-P0073

Bioactivity: Tyr-Gly-Gly-Phe-Met-OH regulates human immune function and inhibits tumor growth via binding to the **opioid receptor**.

Purity: 99.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 25 mg, 50 mg, 100 mg



Valorphin

Cat. No.: HY-P1599

Bioactivity: Valorphin is an endogenous hemoglobin β-chain (33-39) fragment with opioid analgesic activity, binds to rat **mu-opioid receptor**, with an **IC_{50}** of 14 nM; Valorphin also shows anti-tumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Vanilpyruvic acid

(Vanylpyruvic acid)

Cat. No.: HY-101416

Bioactivity: Vanilpyruvic acid is a catecholamine metabolite and precursor to vanillactic acid.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg



ZT 52656A hydrochloride

Cat. No.: HY-101582

Bioactivity: ZT 52656A is a selective **kappa opioid** agonist, used for the prevention or alleviation of pain in the eye.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



[D-Ala2]leucine-enkephalin

Cat. No.: HY-P0098

Bioactivity: [D-Ala2]leucine-enkephalin, a **delta opioid** agonist, is a degradation resistant long-acting Leu-enkephalin.

Purity: 99.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



[Leu5]-Enkephalin

(Leu-enkephalin; Leucine enkephalin; Leucyl-enkephalin)

Cat. No.: HY-P0288

Bioactivity: [Leu5]-Enkephalin is a pentapeptides with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at **opioid receptors**.

Purity: 99.72%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 25 mg



[Leu5]-Enkephalin, amide

(Leu-Enkephalin amide)

Cat. No.: HY-P1470

Bioactivity: [Leu5]-Enkephalin, amide is a **δ opioid receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg



[Met5]-Enkephalin, amide

(5-Methionine-enkephalin amide) Cat. No.: HY-P1467

Bioactivity: [Met5]-Enkephalin, amide is an agonist for **δ opioid receptors** as well as putative **ζ ζ opioid receptors**.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg



β-Casomorphin, bovine

(β-Casomorphin-7 (bovine); Bovine β-casomorphin-7) Cat. No.: HY-P0179

Bioactivity: β-casomorphin, bovine (β-casomorphin-7) is a **opioid** peptide with an **IC_{50}** of 14 μM in an Opioid receptors binding assay.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



β-Casomorphin, human

(Human β-casomorphin 7) Cat. No.: HY-P1481

Bioactivity: β-Casomorphin, human is an opioid peptide, acts as an agonist of **opioid receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



β-Endorphin, human

Cat. No.: HY-P1502

Bioactivity: β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of **opioid receptor**, with preferred affinity for **μ-opioid receptor** and **δ-opioid receptor**; β-Endorphin, human exhibits antinociception activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Orexin Receptor (OX Receptor)

Hypocretin Receptor;HCRT Receptor



Orexin receptors (OX receptor) include orexin 1 receptor and orexin 2 receptor. Orexin receptor type 1 (Ox1R or OX1), is a protein that in humans is encoded by the HCRTR1gene. The orexin 1 receptor (OX1), is a G-protein coupled receptor expressed in the hypothalamus and involved in the regulation of feeding behaviour. OX1 selectively binds the orexin-A neuropeptide. It shares 64% identity with OX2. The OX2 receptors, also known as hypocretin receptor 2, are located primarily in the cerebral cortex, paraventricular hypothalamus, nucleus accumbens, subthalamic and paraventricular thalamus where they are thought to regulate sleep-wakefulness. The OX2 receptor displays equal affinity for Orexin A and Orexin B. The human OX2 receptor gene has been localized to chromosome 6.

Orexin Receptor (OX Receptor) Inhibitors & Modulators

Almorexant
(ACT 078573)

Cat. No.: HY-10805

Bioactivity: Almorexant (ACT 078573) is a potent and competitive dual **orexin 1 receptor** (**OX1**)/ **orexin 2 receptor** (**OX2**) antagonist with **K_i** values of 1.3 and 0.17 nM, respectively.

Purity: 99.17%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Almorexant hydrochloride
(ACT-078573 hydrochloride)

Cat. No.: HY-10805A

Bioactivity: Almorexant hydrochloride (ACT 078573 hydrochloride) is a potent and competitive dual **orexin 1 receptor** (**OX1**)/ **orexin 2 receptor** (**OX2**) antagonist with **K_i** values of 1.3 and 0.17 nM, respectively.

Purity: 99.88%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Filorexant
(MK-6096)

Cat. No.: HY-15653

Bioactivity: Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).

Purity: 98.95%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



GSK1059865

Cat. No.: HY-101534

Bioactivity: GSK1059865 is a potent **orexin 1 receptor** antagonist.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



IPSU

Cat. No.: HY-13796

Bioactivity: IPSU is a selective, orally available and brain penetrant **OX2R** antagonist with a **pK_i** of 7.85.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



Lemborexant
(E-2006)

Cat. No.: HY-16725

Bioactivity: Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia.

Purity: 99.71%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



MK-1064

Cat. No.: HY-19914

Bioactivity: MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia. target: 2-SORA [1] In vivo: MK-1064 promotes sleep and increases both rapid eye movement (REM) and non-REM (NREM) sleep in rats at OX2R occupancies higher than the range observed for dual orexin receptor...

Purity: 99.97%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



MK-3697

Cat. No.: HY-12301

Bioactivity: MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM.

Purity: 99.19%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



Nemorexant
(ACT-541468)

Cat. No.: HY-109095

Bioactivity: Nemorexant (ACT-541468) is a potent **orexin receptor** antagonist extracted from patent WO2015083094A1, compound example 7, has **IC_{50}**s of 2 nM and 3 nM for **Ox_1 receptor** and **Ox_2 receptor**, respectively.

Purity: 99.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Orexin 2 Receptor Agonist

Cat. No.: HY-19320

Bioactivity: Orexin 2 Receptor Agonist is a potent (EC50 on OX2R is 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist.

Purity: 99.72%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Orexin B, human

(Human orexin B) Cat. No.: HY-P1339

Bioactivity: Orexin B, human is an endogenous agonist at **Orexin** receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Orexin B, human TFA

(Human orexin B (TFA)) Cat. No.: HY-P1339A

Bioactivity: Orexin B, human (TFA) is an endogenous agonist at **Orexin** receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

Orexin B, rat, mouse

(Rat orexin B; Orexin B (mouse)) Cat. No.: HY-P1349

Bioactivity: Orexin B, rat, mouse is an endogenous agonist at **Orexin** receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

Purity: 95.54%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

SB-334867

(SB 334867A) Cat. No.: HY-10895

Bioactivity: SB-334867 is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2. IC50 value: 7.2 (pKb) [1] Target: orexin OX1 receptor in vitro: SB-334867-A inhibited the orexin-A (10 nM) and orexin-B (100 nM)-induced calcium responses (pK(B)=7.27+/-0.04 and 7.23+/-0.03 respectively,...

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



SB-334867 free base

(SB334867A free base) Cat. No.: HY-10895A

Bioactivity: SB-334867 free base is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2.

Purity: 99.77%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



SB-408124

Cat. No.: HY-70068

Bioactivity: SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively; exhibits 50-fold selectivity over OX2 receptor.

Purity: 98.27%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 100 mg



SB-408124 Hydrochloride

Cat. No.: HY-76612

Bioactivity: SB408124 Hcl is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively; exhibits 50-fold selectivity over OX2 receptor.

Purity: 98.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



SB-649868

(GSK649868) Cat. No.: HY-10806

Bioactivity: SB-649868 is a potent and selective orally active **orexin** (**OX**) **1** and **OX_2** receptor antagonist (**pK_i** =9.4 and 9.5 at the OX $_1$ and OX $_2$ receptor, respectively).

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



SB-674042

Cat. No.: HY-10898

Bioactivity: SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd = 3.76 nM); exhibits 100-fold selectivity for OX1 over OX2 receptors.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



TCS 1102

Cat. No.: HY-10900

Bioactivity: TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively).

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



TCS-OX2-29

Cat. No.: HY-100452

Bioactivity: TCS-OX2-29 is a potent and selective OX2 receptor antagonist with IC50 of 40 nM. Displays >250-fold selectivity for OX2 over OX1.

Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



Oxytocin Receptor

OXTR



Oxytocin, a hormone involved in numerous physiologic processes, plays a central role in the mechanisms of parturition and lactation. It acts through its receptor, which is a transmembrane receptor belonging to the rhodopsin-type class I G-protein-coupled receptor (GPCR) superfamily, while Gq/phospholipase C (PLC)/inositol 1,4,5-triphosphate (InsP3) is the main pathway via which it exerts its action in the myometrium. The main signaling pathway is the Gq/LPC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. Various peptide and nonpeptide antagonists have been developed as potential tocolytic agents or research tools for the various Oxytocin functions. Many of these oxytocin receptor antagonists are used only as pharmacological tools, while others have tocolytic action.

Oxytocin Receptor Inhibitors & Modulators

Atosiban

(RW22164; RWJ22164)

Cat. No.: HY-17572

Bioactivity: Atosiban(RW22164; Tractocile) is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. IC50 value:...

Purity: 99.09%

Clinical Data: Launched

Size: 5 mg, 10 mg, 50 mg



Carbetocin

Cat. No.: HY-17573

Bioactivity: Carbetocin (Lonactene; Duratocin) is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth; an agonist at peripheral oxytocin receptors.

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Cligosiban

(PF-3274167)

Cat. No.: HY-15023

Bioactivity: Cligosiban, a high oral bioavailability and good brain-penetrant non-peptide **oxytocin receptor** antagonist, shows a high-affinity (K_i=9.5 nM) and an excellent selectivity versus the vasopressin receptors with almost...

Purity: 99.85%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Epelsiban

(GSK 557296)

Cat. No.: HY-105018

Bioactivity: Epelsiban (GSK 557296) is a potent, selective and orally bioavailable **oxytocin receptor** antagonist, with a **pK_i** of 9.9 for human oxytocin receptor.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



L-368,899 hydrochloride

Cat. No.: HY-108677

Bioactivity: L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide **oxytocin receptor** antagonist, with **IC_{50}**s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively, used as a tocolytic agent.

Purity: 98.00%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



L-371,257

Cat. No.: HY-15010

Bioactivity: L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of **oxytocin receptor** (pA2=8.4) with high affinity at both the oxytocin receptor (K_i=19 nM) and **vasopressin V1a receptor** (K_i=3.7 ...

Purity: 99.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg



OT antagonist 1

Cat. No.: HY-103650

Bioactivity: OT antagonist 1 (Compound 4) is a potent, selective **Oxytocin** antagonist with a **K_i** of 50 nM.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



OT antagonist 1 demethyl derivative

Cat. No.: HY-103651

Bioactivity: OT antagonist 1 demethyl derivative is the demethyl derivative of OT antagonist 1. OT antagonist 1 (Compound 4) is a potent, selective **Oxytocin** antagonist with a **K_i** of 50 nM.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



OT antagonist 3

Cat. No.: HY-103649

Bioactivity: OT antagonist 3 is an **oxytocin** (OT) antagonist extracted from patent WO2007017752A1.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



OT-R antagonist 1

(Oxytocin receptor antagonist 1)

Cat. No.: HY-15015

Bioactivity: OT-R antagonist 1 is a new potent and selective nonpeptide low molecular weight OT-R antagonist. OT-R antagonist 1 inhibits oxytocin-evoked intracellular Ca2+ mobilization (IC50 = 8 nM). IC50 value: 8 nM Target: oxytocin receptor in vitro: OT-R antagonist 1 inhibitis IP3-Synthesis, rat OT-R (IC50=0.03 uM)....

Purity: 98.0%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg, 10 mg



OT-R antagonist 2

(Oxytocin receptor antagonist 2) Cat. No.: HY-15015A

Bioactivity: OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist. OT-R antagonist 2 inhibitis IP3-Synthesis, rat OT-R (IC50 = 0.33 μM).

Purity: 99.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Oxytocin

(α-Hypophamine; Oxytocic hormone) Cat. No.: HY-17571

Bioactivity: Oxytocin (α-Hypophamine) is a mammalian neurohypophysial hormone; its actions are mediated by specific, high-affinity oxytocin receptors; ligand of oxytocin receptor.

Purity: 98.68%
Clinical Data: Launched
Size: 5 mg, 10 mg



Oxytocin acetate

(α-Hypophamine acetate; Oxytocic hormone acetate) Cat. No.: HY-17571A

Bioactivity: Oxytocin (α-Hypophamine) acetate is a mammalian neurohypophysial hormone; its actions are mediated by specific, high-affinity oxytocin receptors; ligand of oxytocin receptor.

Purity: 99.79%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Retosiban

(GSK 221149; GSK 221149A) Cat. No.: HY-14778

Bioactivity: Retosiban (GSK221149A) is a potent and selective oxytocin antagonist with a $\mathbf{K_i}$ of 0.65 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



P2Y Receptor



P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose. To date, 12 P2Y receptors have been cloned in humans: P2Y1, P2Y2, P2Y4, P2Y5, P2Y6, P2Y8, P2Y9, P2Y10, P2Y11, P2Y12, P2Y13 and P2Y14. P2Y receptors are present in almost all human tissues where they exert various biological functions based on their G-protein coupling. P2Y2 is a potential drug target for treating cystic fibrosis. P2Y11 is a regulator of immune response, and a common polymorphism carried by almost 20% of North European caucasians give increased risk of myocardial infarction, making P2Y11 an interesting drug target candidate for treatment of myocardial infarction. P2Y12 is the target of the anti-platelet drug clopidogrel and other thienopyridines.

P2Y Receptor Inhibitors & Modulators

AZD1283

Cat. No.: HY-15799

Bioactivity: AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.

Purity: 99.11%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BPTU

(BMS-646786)

Cat. No.: HY-13831

Bioactivity: BPTU is a novel **P2Y1** allosteric antagonist.

Purity: 98.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Clopidogrel

Cat. No.: HY-15283

Bioactivity: Clopidogrel is a well-known and orally active platelet inhibitor that targets **P2Y12** receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Purity: >98%
Clinical Data: Launched
Size: 100 mg



Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate)

Cat. No.: HY-17459

Bioactivity: Clopidogrel is an **antiplatelet** agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.

Purity: 97.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Clopidogrel thiolactone

Cat. No.: HY-15876

Bioactivity: Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Diquafosol tetrasodium

(INS365)

Cat. No.: HY-B0606

Bioactivity: Diquafosol tetrasodium is a **P2Y2** receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



MRS 2578

Cat. No.: HY-13104

Bioactivity: MRS 2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors. IC50 value: 37 nM [1] Target: P2Y6 receptor in vitro: MRS2578 selectively blocks P2Y6 receptor activity versus activity at P2Y1, P2Y2, P2Y4 or P2Y11 receptors....

Purity: 95.67%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



N6-(4-Hydroxybenzyl)adenosine

(Para-topolin riboside)

Cat. No.: HY-18775

Bioactivity: N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM). IC50 value: 6.77-141 μM Target: P2Y12receptor Anti-aggregation activity of N6-(4-Hydroxybenzyl)adenosine could involve an interaction...

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Oral antiplatelet agent 1

Cat. No.: HY-111755

Bioactivity: Oral antiplatelet agent 1 is a potent **antiplatelet** agent with an IC_{50} of 2.94 μM in vitro as well as antithrombotic efficacy in a rat model. P2Y receptor antagonist [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Prasugrel

(PCR 4099)

Cat. No.: HY-15284

Bioactivity: Prasugrel (PCR 4099) is a platelet inhibitor with IC_{50} value of 1.8 μM.

Purity: 98.0%
Clinical Data: Launched
Size: 100 mg, 500 mg



Prasugrel hydrochloride

(PCR 4099 (hydrochloride)) Cat. No.: HY-15284A

Bioactivity: Prasugrel (PCR 4099) hydrochloride is a platelet inhibitor with IC_{50} value of 1.8 μM.

Purity: >98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Prasugrel Maleic acid

(PCR 4099 (Maleic acid)) Cat. No.: HY-15284B

Bioactivity: Prasugrel (PCR 4099) Maleic acid is a platelet inhibitor with IC_{50} value of 1.8 μM.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Suramin

Cat. No.: HY-B0879

Bioactivity: Suramin is a polysulfonated naphthylurea with various biological activities. Suramin is a **DNA topoisomerase II** inhibitor with an **IC_{50}** of 5 μM.

Purity: >98%
Clinical Data: Launched
Size: 50 mg

Suramin sodium salt

(Suramin hexasodium salt; BAY-205; NF-060) Cat. No.: HY-B0879A

Bioactivity: Suramin sodium salt is a polysulfonated naphthylurea with various biological activities. Suramin sodium salt is a **DNA topoisomerase II** inhibitor with an **IC_{50}** of 5 μM.

Purity: 99.93%
Clinical Data: Launched
Size: 50 mg

TAK-024

Cat. No.: HY-100254

Bioactivity: TAK-024 is a **platelet** inhibitor with **IC_{50}**s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Ticagrelor

(AR-C 126532XX; AZD6140) Cat. No.: HY-10064

Bioactivity: Ticagrelor (AZD6140) is a reversible oral **P2Y12** receptor antagonist for the treatment of platelet aggregation.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Prostaglandin Receptor



Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

(+)-Cloprostenol

(D-Cloprostenol) Cat. No.: HY-107381

Bioactivity: (+)-Cloprostenol is a prostaglandin F2α (PGF2α) analogue, and shows selective agonistic activity at the **prostaglandin receptor**.

Purity: 99.13%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg



2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide

Cat. No.: HY-100287

Bioactivity: 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide is a compound that inhibits stress-induced ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Aganepag

(AGN 210937) Cat. No.: HY-19864

Bioactivity: Aganepag is a potent **Prostanoid EP2 receptor** agonist, with an **EC_{50}** of 0.19 nM, and shows no activity at EP4 receptor.

Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



AGN 210676

(Simenepag) Cat. No.: HY-14898

Bioactivity: AGN 210676 is a selective prostaglandin **EP_2** agonist extracted from patent US20070203222A1, Compound example 23, has an **EC_{50}** of 5 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AH 6809

Cat. No.: HY-10418

Bioactivity: AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.

Purity: 99.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Aligeron

Cat. No.: HY-101602

Bioactivity: Aligeron is a non-selective **prostaglandin (PG)** antagonist, and has vasodilatory properties.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



AM211

(AM211 free acid) Cat. No.: HY-13213

Bioactivity: AM211 is a potent, selective and orally bioavailable **prostaglandin D2 (PGD2) receptor type 2 (DP2)** antagonist, with **IC_{50}**s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AMG-009

Cat. No.: HY-19499

Bioactivity: AMG-009 is a potent antagonist of **prostaglandin D2**, with **IC_{50}** of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Asapiprant

(S-555739) Cat. No.: HY-16763

Bioactivity: Asapiprant is a potent and selective **DP_1 receptor** antagonist with a **K_i** of 0.44 nM.

Purity: 99.67%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



AZ-1355

Cat. No.: HY-101692

Bioactivity: AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I_2/thromboxane A_2 ratio in vitro.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



AZD1981

Cat. No.: HY-15950

Bioactivity: AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4). IC50 value: Target: GPR44 antagonist in vitro: AZD1981 produced a concentration-dependent displacement of the [3H]PGD2-specific binding with a mean pIC50 of 8.4 ±...

Purity: 99.26%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BAY-1316957

Cat. No.: HY-111539

Bioactivity: BAY-1316957 is a highly potent and selective **EP4 receptor** antagonist with an **IC_{50}** of 15.3 nM. Good oral bioavailability [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 100 mg



Benorilate

(Salipran)

Cat. No.: HY-107795

Bioactivity: Benorylate (Benoral) is the esterification product of paracetamol and acetylsalicylic acid. It has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit **prostaglandin (PG)** synthesis.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



BI-671800

Cat. No.: HY-114141

Bioactivity: BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells **(DP2/CRTH2)**, with **IC_{50}** values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cel...

Purity: 99.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Bimatoprost

(AGN 192024)

Cat. No.: HY-B0191

Bioactivity: Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.

Purity: 96.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg



Bunaprolast

(U66858)

Cat. No.: HY-U00170

Bioactivity: Bunaprolast (U66858) is a potent inhibitor of **LTB_4** production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of **lipoxygenase** and **TXB_2** release.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



BW 245C

Cat. No.: HY-101987

Bioactivity: BW 245C is a **prostanoid DP-receptor (DP1)** agonist, used to treat stroke.

Purity: 99.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg



Carbacyclin

(Carbaprostacyclin; Carba-PGI2)

Cat. No.: HY-112322

Bioactivity: Carbacyclin is a PGI2 analogue, acts as a **prostacyclin (PGI2) receptor** agonist and vasodilator, and potently inhibits platelet aggregation.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 1 mg



CAY10471 Racemate

(TM30089 Racemate)

Cat. No.: HY-13706

Bioactivity: CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective **prostaglandin D2 receptor CRTH2** antagonist, with a **K_i** of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (K_i >10000 nM) or PGD2 receptor DP (K_i 1...

Purity: 99.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



CAY10595

Cat. No.: HY-118180

Bioactivity: CAY10595 is a potent **CRTH2/DP2** receptor antagonist that binds to the human receptor with a **K_i** of 10 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



CGS 15435

Cat. No.: HY-100283

Bioactivity: CGS 15435, a potent thromboxane (**TxA_2**) synthetase inhibitor with an **IC_{50}** of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI_2 synthetase and lipoxygenase enzymes.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



CI-949

Cat. No.: HY-U00364

Bioactivity: CI-949 is an allergic mediator release inhibitor, which inhibits **histamine**, **leukotriene C_4/D_4 (LTC_4/LTD_4)**, and **thromboxane B_2 (TXB_2)** release with **IC_{50}**s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



CJ-42794

(CJ-042794)

Cat. No.: HY-10797

Bioactivity: CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3).

Purity: 99.31%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Cloprostenol sodium salt

(ICI 80996 sodium salt)

Cat. No.: HY-108415

Bioactivity: Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent [1], and is a **PGF2α receptor** agonist [2].

Purity: 99.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CRTh2 antagonist 1

Cat. No.: HY-112265

Bioactivity: CRTh2 antagonist 1 is a **CRTh2** antagonist with an **IC_{50}** of 89 nM

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CRTH2-IN-1

(Ramatroban analog)

Cat. No.: HY-U00423

Bioactivity: CRTH2-IN-1 (Ramatroban analog) is a selective **prostaglandin D2 receptor DP2** (**CRTH2**) antagonist with an IC_{50} of 6 nM in a human DP2 binding assay.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Darbufelone mesylate

(CI-1004 mesylate)

Cat. No.: HY-101438A

Bioactivity: Darbufelone mesylate is a dual inhibitor of cellular **$PGF_{2\alpha}$** and **LTB_4** production. Darbufelone potently inhibits **PGHS-2** (**IC_{50}** = 0.19 μM) but is much less potent with **PGHS-1** (**IC_{50}**= 20 μM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Dinoprost

(Prostaglandin F2a; PGF2α)

Cat. No.: HY-12956

Bioactivity: Dinoprost(Prostaglandin F2α) is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Dinoprost tromethamine salt (Prostaglandin F2a tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM)

Cat. No.: HY-12956A

Bioactivity: Dinoprost tromethamine salt is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



E7046

Cat. No.: HY-103088

Bioactivity: E7046 is an orally bioavailable and specific **EP4** antagonist, with **IC_{50}** of 13.5 nM and K_i of 23.14 nM, exhibiting anti-tumor activities.

Purity: 99.60%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



EP1-antanoist-1

Cat. No.: HY-101695

Bioactivity: EP1-antanoist-1 is a **EP1** antagonist with a **pK_i** of 7.54 and an **pIC_{50}** of 8.5.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Etersalate

(Eterylate; Etherylate)

Cat. No.: HY-101606

Bioactivity: Etersalate inhibits platelet function and decreases **thromboxane A2** (**TXA2**) levels.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Ethamsylate

Cat. No.: HY-B1074

Bioactivity: Ethamsylate is a haemostatic drug, also inhibits biosynthesis and action of those prostaglandins.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Evatanepag

(CP-533536 free acid)

Cat. No.: HY-14839

Bioactivity: Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Fevipiprant

(NVP-QAW039; QAW039)

Cat. No.: HY-16768

Bioactivity: Fevipiprant(QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood. IC50:0.44 nM(PGD2-induced...

Purity: 98.73%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



Ginsenoside Ro **(Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V)**

Cat. No.: HY-N0607

Bioactivity: Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a **Ca^{2+}**-antagonistic antiplatelet effect with an IC_{50} of 155 μM. Ginsenoside Ro reduces the production of **TXA_2** more than it reduces the activities...

Purity: 98.69%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Grapiprant

(CJ-023423; RQ-00000007; AAT-007)

Cat. No.: HY-16781

Bioactivity: Grapiprant is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Target: prostaglandin receptor in vitro: Grapiprant is a novel pharmacologically active ingredient, acts as a selective EP4 receptor antagonist whose physiological ligand is...

Purity: 99.68%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



GSK-269984A

Cat. No.: HY-14467

Bioactivity: GSK-269984A is a **Prostaglandin E2 Receptor 1 (EP1)** antagonist with a **pIC_{50}** of 7.9.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



GSK726701A

Cat. No.: HY-112152

Bioactivity: GSK726701A is a novel **prostaglandin E2 receptor 4 (EP4)** partial agonist with a **pEC_{50}** of 7.4.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



GW627368

Cat. No.: HY-16963

Bioactivity: GW627368(GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor(Ki= 100 nM) with additional human TP receptor affinity(Ki= 150 nM).

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg



Iloprost

(Ciloprost; ZK 36374) Cat. No.: HY-A0096

Bioactivity: Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.

Purity: 99.06%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



KF 13218

Cat. No.: HY-U00231

Bioactivity: KF 13218 is a potent, selective and long lasting **thromboxane B2** (**TXB2**) synthase inhibitor with an IC_{50} value of 5.3±1.3 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



KP496

Cat. No.: HY-U00253

Bioactivity: KP496 is a selective, dual antagonist for **Leukotriene D4 receptor** and **Thromboxane A2 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



KW-8232 free base

Cat. No.: HY-100304

Bioactivity: KW-8232 free base is an anti-osteoporotic agent, and can reduces the biosynthesis of **PGE2**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



L 888607

Cat. No.: HY-111271

Bioactivity: L 888607 is a potent, and selective **CRTH2** (also known as DP $_2$) agonist with a K_i of 0.8 nM.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



L 888607 Racemate

Cat. No.: HY-111271A

Bioactivity: L 888607 Racemate is a selective prostaglandin D $_2$ receptor subtype 1 **(DP1)** antagonist, with K_i**s** of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Laropiprant

(MK-0524) Cat. No.: HY-50175

Bioactivity: Laropiprant is a potent, selective **DP receptor** antagonist with K_i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.

Purity: 99.21%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Latanoprost

(PHXA41) Cat. No.: HY-B0577

Bioactivity: Latanoprost is an agonist for the **FP prostanoid receptor**, and lowers intraocular-pressure (IOP).

Purity: 96.81%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



LCB-2853

Cat. No.: HY-101700

Bioactivity: LCB-2853 is an antagonist of **thromboxane A2 (TXA2) receptor**, with antiplatelet and antithrombotic activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



MF498

Cat. No.: HY-10794

Bioactivity: MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, displayed strong binding affinity for the EP4 receptor with Ki of 0.7 nM.

Purity: 98.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg



Misoprostol

(SC-29333)

Cat. No.: HY-B0610

Bioactivity: Misoprostol(SC29333) is a synthetic prostaglandin E1 (PGE1) analog that is used to prevent gastric ulcers, to treat missed miscarriage, to induce labor, and to induce abortion.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



MK-2894

Cat. No.: HY-10413

Bioactivity: MK-2894 is a highly potent and selective second generation EP4 antagonist.

Purity: 98.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



MK-2894 sodium salt

Cat. No.: HY-10414

Bioactivity: MK-2894 sodium salt is a highly potent and selective second generation EP4 antagonist.

Purity: 98.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



MK-447

Cat. No.: HY-100297

Bioactivity: MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH_2, and other **prostaglandins**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



MK-7246

Cat. No.: HY-15853

Bioactivity: MK-7246 is a potent and selective **CRTH2** antagonist with a K_i of 2.5±0.5 nM.

Purity: 98.16%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



MK-7246 S enantiomer

Cat. No.: HY-15853A

Bioactivity: MK-7246 S enantiomer is the less active enantiomer of MK-7246. MK-7246 is a potent and selective CRTH2 antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



MK-8318

Cat. No.: HY-112604

Bioactivity: MK-8318 is a potent and selective **CRTh2 receptor** antagonist with a K_i of 5.0 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



MRE-269

(ACT-333679)

Cat. No.: HY-79593

Bioactivity: MRE-269 is an active metabolite of selexipag, and acts as a selective **IP receptor** agonist.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Nedocromil

(FPL 59002)

Cat. No.: HY-13448

Bioactivity: Nedocromil suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (**LTC_4**), and **prostaglandin D_2** (**PGD_2**).

Purity: 95.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Nedocromil sodium

(FPL 59002KP; Nedocromil disodium salt)

Cat. No.: HY-16344

Bioactivity: Nedocromil sodium suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (**LTC_4**), and **prostaglandin D_2** (**PGD_2**).

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

OBE022

Cat. No.: HY-112284

Bioactivity: OBE022 is an oral and selective prostaglandin F $_{2\alpha}$ (**PGF$_{2\alpha}$**) receptor antagonist, with **K$_i$s** of 1 nM, 26 nM for human and rat FP receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



ONO-AE3-208

(AE 3-208)

Cat. No.: HY-50901

Bioactivity: ONO-AE3-208 is an **EP4** antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.

Purity: 98.65%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

p-Hydroxycinnamic acid

Cat. No.: HY-N2391

Bioactivity: p-Hydroxycinnamic acid, a common dietary phenol, could **inhibit platelet** activity, with **IC$_{50}$s** of 371 μM, 126 μM for thromboxane B $_2$ production and lipopolysaccharide-induced prostaglandin E $_2$ generation, respectively.

Purity: 99.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg



PF-04418948

Cat. No.: HY-18966

Bioactivity: PF-04418948 is an orally active, potent and selective **prostaglandin EP2 receptor** antagonist with an **IC$_{50}$** of 16 nM.

Purity: 99.60%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Prostaglandin E1

(PGE1)

Cat. No.: HY-B0131

Bioactivity: Prostaglandin E1 (PGE1) is a potent vasodilator and activates the **prostaglandin E1 (EP)** receptor.

Purity: 98.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Prostaglandin E2

(Dinoprostone)

Cat. No.: HY-101952

Bioactivity: Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.

Purity: 98.01%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Quinotolast sodium

(FR71021)

Cat. No.: HY-U00027

Bioactivity: Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits **histamine**, **LTC$_4$** and **PGD$_2$** release in a concentration-dependent manner.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Ralinepag

(APD811)

Cat. No.: HY-16751

Bioactivity: Ralinepag is a potent, orally bioavailable and non-prostanoid **prostacyclin (IP) receptor** agonist, with **EC$_{50}$**s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.

Purity: 98.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ramatroban

(BAY u3405)

Cat. No.: HY-B0745

Bioactivity: Ramatroban is a selective **thromboxane A$_2$** (**TxA$_2$**, **IC$_{50}$**=14 nM) antagonist, which also antagonizes **CRTH2** (**IC$_{50}$**=113 nM) by inhibiting **PGD$_2$** binding.

Purity: 99.16%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Rebamipide

(OPC12759; Proamipide)

Cat. No.: HY-B0360

Bioactivity: Rebamipide is an inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger.

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



RO1138452

(CAY10441) Cat. No.: HY-108912

Bioactivity: RO1138452 is a potent and selective **IP** (**prostacyclin**) **receptor** antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, **pK_i** is 9.3±0.1; in a recombinant IP receptor system, **pK_i** is 8.7±0.06.

Purity: 98.21%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



RS-601

Cat. No.: HY-U00072

Bioactivity: RS-601 is a novel **leukotriene D4 (LTD4)/thromboxane A2 (TxA2)** dual receptor antagonist, with antiasthmatic activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Selexipag

(NS-304; ACT-293987) Cat. No.: HY-14870

Bioactivity: Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (**PGI_2**) receptor (IP receptor).

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Seratrodast

(AA 2414) Cat. No.: HY-B0774

Bioactivity: Seratrodast(AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist.

Purity: 98.12%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Setipiprant

(ACT-129968; KYTH-105) Cat. No.: HY-16635

Bioactivity: Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.

Purity: 98.17%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Taprenepag

(CP-544326) Cat. No.: HY-14899

Bioactivity: CP-544326 is a potent and selective **prostaglandin E2 receptor** agonist with an **EC_{50}** of 2.8 nM.

Purity: 99.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Taprenepag isopropyl

(PF-04217329) Cat. No.: HY-19998

Bioactivity: Taprenepag isopropyl is a highly selective **EP_2 receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Terbogrel

(BIBV 308SE) Cat. No.: HY-19189

Bioactivity: Terbogrel is an orally available **thromboxane A2 receptor** antagonist and a **thromboxane A2 synthase** inhibitor, with both **IC_{50}**s of about 10 nM.

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 20 mg



Terutroban

(S-18886) Cat. No.: HY-16991

Bioactivity: Terutroban is a **thromboxane-prostaglandin receptor** antagonist.

Purity: 99.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



TG4-155

Cat. No.: HY-18971

Bioactivity: TG4-155 is a potent, brain-permeant and selective **EP2 receptor** antagonist with a **K_i** of 9.9 nM [1] [2]. TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1 [1]. TG4-155 has an EP2 Schild K_B of 2.4 nM ...

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



TG6-10-1

Cat. No.: HY-16978

Bioactivity: TG6-10-1 is an **EP2** antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors [1].

Purity: 99.28%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Tiaprost

(Iliren)

Cat. No.: HY-111478

Bioactivity: Tiaprost is a prostaglandin $F_{2\alpha}$ (**$PGF_{2\alpha}$**) analogue.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg



Timapiprant

(OC000459)

Cat. No.: HY-15342

Bioactivity: Timapiprant (OC000459) is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM.

Purity: 95.12%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Travoprost

(Fluprostenol isopropyl ester; AL6221; Flu-Ipr)

Cat. No.: HY-B0584

Bioactivity: Travoprost is used to treat glaucoma and ocular hypertension.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Treprostinil

(LRX-15)

Cat. No.: HY-100441

Bioactivity: Treprostinil (LRX-15) is a potent **DP1** and **EP2** agonist with **EC_{50}** values of 0.6±0.1 and 6.2±1.2 nM, respectively.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg



Treprostinil sodium

(UT-15)

Cat. No.: HY-16504

Bioactivity: Treprostinil sodium is a potent **DP1** and **EP2** agonist with **EC_{50}** values of 0.6±0.1 and 6.2±1.2 nM, respectively.

Purity: 98.49%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg



YM158 free base

(YM-57158)

Cat. No.: HY-U00355

Bioactivity: YM158 free base is a potent and selective **LTD_4** and **TXA_2 receptor** antagonist with **pA_2** values of about 8.87 and 8.81, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Protease-Activated Receptor (PAR)

Thrombin receptors



Protease activated receptors (PARs) are a family of four G-protein-coupled receptors (PAR1, PAR2, PAR3, and PAR4) that are self-activated by tethered peptide ligands exposed by proteolytic cleavage of the extracellular amino terminus. PAR1, PAR3, and PAR4 are activated by thrombin, whereas PAR2 and, to a lesser degree, PAR4, are activated by trypsin.

PAR1 is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces. PAR1 antagonism might be explored as a treatment for influenza, including that caused by highly pathogenic H5N1 and H1N1 viruses.

PAR2 receptors have been implicated in numerous physiological processes necessitating therapeutic intervention, especially pain and inflammation and syndromes with a strong inflammatory component, including colitis, gastritis, pancreatitis, asthma and pulmonary disease, and arthritis.

AC-55541

Cat. No.: HY-14350

Bioactivity: AC-55541 is a novel small-molecule protease-activated receptor 2(PAR2) agonist; activated PAR2 signaling in cellular proliferation assays, phosphatidylinositol hydrolysis assays, and Ca(2+) mobilization assays, with potencies ranging from 200 to 1000 nM. IC50 value: 200-1000 nM(EC50) [1] Target: PAR2...

Purity: 99.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



AZ3451

Cat. No.: HY-112558

Bioactivity: AZ3451 is a potent **protease-activated receptor-2 (PAR2)** antagonist with IC_{50} of 23 nM.

Purity: 99.33%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



BMS-986120

Cat. No.: HY-19837

Bioactivity: BMS-986120 is an antagonist of the Platelet Protease-Activated Receptor-4 (**PAR4**), with **IC_{50}s** of 9.5, 2.1 nM in human and monkey blood, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

GB-88

Cat. No.: HY-120261

Bioactivity: GB-88 is an oral, selective non-peptide antagonist of **PAR2**, inhibits **PAR2** activated Ca^{2+} release with an **IC_{50}** of 2 μM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



I-191

Cat. No.: HY-117793

Bioactivity: I-191 is a potent **protease-activated receptor 2 (PAR2)** antagonist [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



PAR-4 Agonist Peptide, amide

(PAR-4-AP; AY-NH2)

Cat. No.: HY-P1309

Bioactivity: PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2) is a proteinase-activated receptor-4 (**PAR-4**) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



PAR-4 Agonist Peptide, amide TFA

(PAR-4-AP (TFA); AY-NH2 (TFA))

Cat. No.: HY-P1309A

Bioactivity: PAR-4 Agonist Peptide, amide TFA (PAR-4-AP TFA; AY-NH2 TFA) is a proteinase-activated receptor-4 (**PAR-4**) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist [1].

Purity: 99.93%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Protease-Activated Receptor-2 Activating Peptide

Cat. No.: HY-P1308

Bioactivity: Protease-Activated Receptor-2 Activating Peptide is an agonist of Protease-Activated Receptor-2 (**PAR-2**).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Protease-Activated Receptor-2, amide

Cat. No.: HY-P0283

Bioactivity: Protease-Activated Receptor-2, amide (SLIGKV-NH_2) is a highly potent protease-activated receptor-2 (PAR2) activating peptide.

Purity: 98.33%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg



Protease-Activated Receptor-4

Cat. No.: HY-P0297

Bioactivity: Protease-Activated Receptor-4 is the agonist of **proteinase-activated receptor-4 (PAR4)**.

Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



TFLLR-NH2

Cat. No.: HY-P0226

Bioactivity: TFLLR-NH2 is a selective **PAR1** agonist with an $\mathbf{EC_{50}}$ of 1.9 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



TFLLR-NH2(TFA)

Cat. No.: HY-P0226A

Bioactivity: TFLLR-NH2 (TFA) is a selective **PAR1** agonist with an $\mathbf{EC_{50}}$ of 1.9 μM.

Purity: 99.29%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Thrombin Receptor Activator for Peptide 5 TRAP-5

Cat. No.: HY-P1536

Bioactivity: Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or **Proteinase Activated Receptor 1** (1-5), used in the research of coronary heart disease (CHD).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



TRAP-6 (PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6)

Cat. No.: HY-P0078

Bioactivity: TRAP-6 is a protease-activated receptor 1 **(PAR1)** agonist.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Vorapaxar (SCH 530348)

Cat. No.: HY-10119

Bioactivity: Vorapaxar is a **protease-activated receptor (PAR-1)** antagonist that inhibits thrombin-induced platelet activation.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Ras



Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

1A-116

Cat. No.: HY-104064

Bioactivity: 1A-116 is a specific **Rac1** inhibitor.

Purity: 99.28%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



6H05

Cat. No.: HY-12408

Bioactivity: 6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras [1]. 6H05 can...

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



6H05 TFA

Cat. No.: HY-12408A

Bioactivity: 6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras [1]. 6H05 can...

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg



AMG-510

Cat. No.: HY-114277

Bioactivity: AMG-510 is a potent **KRAS G12C** covalent inhibitor [1].

Purity: 99.01%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AMG-510 racemate

Cat. No.: HY-114277A

Bioactivity: AMG-510 racemate is the racemate of AMG-510. AMG-510 is a potent **KRAS G12C** covalent inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Antineoplaston A10

Cat. No.: HY-128553

Bioactivity: Antineoplaston A10, a naturally occurring substance in human body, is a **Ras** inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



ARS-1323

Cat. No.: HY-U00416

Bioactivity: ARS-1323 is a novel inhibitor of **mutant K-ras G12C** extracted from patent WO 2015054572 A1.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg



ARS-1620

Cat. No.: HY-U00418

Bioactivity: ARS-1620 is an atropisomeric selective **KRAS^{G12C}** inhibitor with desirable pharmacokinetics.

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



ARS-1630

Cat. No.: HY-U00417

Bioactivity: ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of **mutant K-ras G12C** extracted from patent WO 2015054572 A1.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



ARS-853

Cat. No.: HY-19706

Bioactivity: ARS-853 is a selective, covalent **KRAS^{G12C}** inhibitor with an **IC_{50}** of 2.5 μM.

Purity: 98.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg



BQU57

Cat. No.: HY-12875

Bioactivity: BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 μM in H2122 and 1.3 μM in H358.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CASIN

Cat. No.: HY-12874

Bioactivity: CASIN is a selective GTPase Cdc42 inhibitor with IC50 of 2 uM.

Purity: 98.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CCG-1423

Cat. No.: HY-13991

Bioactivity: CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



CCG-203971

Cat. No.: HY-108361

Bioactivity: CCG-203971 is a second-generation **RhoA**/myocardin-related transcription factor A (**MRTF-A**) inhibitor. CCG-203971 potently targets RhoA/C-activated serum response element (SRE)-luciferase (IC_{50}=6.2 μM).

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg



CID-1067700

Cat. No.: HY-13452

Bioactivity: CID-1067700 is a pan **GTPase** inhibitor, and competitively inhibits Ras-related in brain 7 (**Rab7**) with a K_i of 13 nM.

Purity: 98.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Digeranyl bisphosphonate

(DGBP)

Cat. No.: HY-U00145

Bioactivity: Digeranyl bisphosphonate is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.

Purity: 98.0%
Clinical Data: No Development Reported
Size:



EHop-016

Cat. No.: HY-12810

Bioactivity: EHop-016 is a novel potent and selective inhibitor of Rac GTPase; inhibits Rac1 activity in MDA-MB-435 cells with an IC50 of 1.1 uM.

Purity: 99.36%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



EHT 1864

Cat. No.: HY-16659

Bioactivity: EHT 1864 is a small molecule inhibitor of Rac1 signaling; modulate γ-Secretase-mediated APP processing.

Purity: 99.60%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GGTI298

Cat. No.: HY-100876

Bioactivity: GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC_{50} values of 3 and > 20 μM in vivo, respectively.

Purity: 96.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



GGTI298 Trifluoroacetate

Cat. No.: HY-15871

Bioactivity: GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (**GGTase I**) inhibitor, which can inhibit **Rap1A** with IC_{50} of 3 μM; little effect on **Ha-Ras** with IC_{50} of >20 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



K-Ras G12C-IN-1

Cat. No.: HY-18604

Bioactivity: K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1. IC50 value: Target: K-ras G12C inhibitor

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



K-Ras G12C-IN-2

Cat. No.: HY-18605

Bioactivity: K-Ras G12C-IN-2 is a novel and irreversible inhibitor of **G12C mutant K-Ras** protein.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



K-Ras G12C-IN-3

Cat. No.: HY-18606

Bioactivity: K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



K-Ras(G12C) inhibitor 12

Cat. No.: HY-18707

Bioactivity: K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor, the half-maximum effective concentration (EC50) for K-Ras(G12C) inhibitor 12 in H1792 cells is 0.32 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



K-Ras-IN-1

Cat. No.: HY-18674

Bioactivity: K-Ras-IN-1 is a K-Ras inhibitor, by binding to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure.(the detailed information refer to the reference)

Purity: 98.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Kobe0065

Cat. No.: HY-15716

Bioactivity: Kobe0065 is a novel and effective inhibitor of **Ras-Raf interaction**, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.

Purity: 99.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



kobe2602

Cat. No.: HY-15717

Bioactivity: kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 149 ± 55 μM.

Purity: 89.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 250 mg



KRas G12C inhibitor 1

Cat. No.: HY-112491

Bioactivity: KRas G12C inhibitor 1 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



KRas G12C inhibitor 2

Cat. No.: HY-112492

Bioactivity: KRas G12C inhibitor 2 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



KRas G12C inhibitor 3

Cat. No.: HY-112493

Bioactivity: KRas G12C inhibitor 3 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



KRas G12C inhibitor 4

Cat. No.: HY-112494

Bioactivity: KRas G12C inhibitor 1 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



KRAS G12C inhibitor 5

Cat. No.: HY-114168

Bioactivity: KRAS G12C inhibitor 5 is a **KRas G12C** inhibitor extracted from patent WO2017201161A1, Compound example 147 [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



MBQ-167

Cat. No.: HY-112842

Bioactivity: MBQ-167 is a dual **Rac/Cdc42** inhibitor, with **IC_{50}s** of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.

Purity: 99.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



ML-098

(CID-7345532)

Cat. No.: HY-19800

Bioactivity: ML-098 (CID-7345532) is an activator of the GTP-binding protein **Rab7** with an **EC_{50}** of 77.6 nM.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



ML141

(CID-2950007)

Cat. No.: HY-12755

Bioactivity: ML141(CID-2950007) is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase(IC50=200 nM) with low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).

Purity: 99.21%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



MRTX-1257

Cat. No.: HY-114436

Bioactivity: MRTX-1257 is a selective, irreversible, covalent and oral active **KRAS G12C** inhibitor, with an **IC_{50}** of 900 pM for KRAS dependent ERK phosphorylation in H358 cells [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



NSC 23766

Cat. No.: HY-15723

Bioactivity: NSC 23766 is a specific inhibitor of the binding and activation of **Rac GTPase**, used for cancer treatment.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



NSC 23766 trihydrochloride

Cat. No.: HY-15723A

Bioactivity: NSC 23766 trihydrochloride is an inhibitor of **Rac1** activation.

Purity: 99.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



Oncrasin-1

Cat. No.: HY-16662

Bioactivity: Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.

Purity: 98.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Pan-RAS-IN-1

Cat. No.: HY-101295

Bioactivity: Pan-RAS-IN-1 is a **pan-Ras** inhibitor that disrupts the interaction of Ras proteins and their effectors.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



RBC8

Cat. No.: HY-12873

Bioactivity: RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Rho-Kinase-IN-1

Cat. No.: HY-100270

Bioactivity: Rho-Kinase-IN-1 is a **rho kinase** inhibitor extracted from US 20090325960 A1, compound 1.008.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Rhosin

Cat. No.: HY-12646A

Bioactivity: Rhosin is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 uM Kd; does not interfere with the binding of Cdc42 or Rac1.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Rhosin hydrochloride

Cat. No.: HY-12646

Bioactivity: Rhosin hydrochloride is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 uM Kd; does not interfere with the binding of Cdc42 or Rac1. IC50 value: 0.4 uM(binding Kd) [1] Target: RhoA inhibitor Rhosin is specific to the interaction between RhoA and its GEFs including LARG, DBL, LBC, p115...

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Salirasib (S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS)

Cat. No.: HY-14754

Bioactivity: Salirasib is a **Ras** inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.

Purity: 98.72%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Y16

Cat. No.: HY-12649

Bioactivity: Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

Purity: 97.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



ZCL278

Cat. No.: HY-13963

Bioactivity: ZCL278 is a selective **Cdc42** modulator that directly binds to Cdc42 and inhibits its functions with K_d of 11.4 μM for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR) experiment.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



RGS Protein

Regulators of G-protein Signaling;Regulator of G-protein Signaling



RGS (Regulators of G protein signaling) are protein structural domains that activate GTPases for heterotrimeric G-protein alpha-subunits. RGS proteins are multi-functional, GTPase-accelerating proteins that promote GTP hydrolysis by the alpha subunit of heterotrimeric G proteins, thereby inactivating the G protein and rapidly switching off G protein-coupled receptor signaling pathways. Upon activation by GPCRs, heterotrimeric G proteins exchange GDP for GTP, are released from the receptor, and dissociate into free, active GTP-bound alpha subunit and beta-gamma dimer, both of which activate downstream effectors. The response is terminated upon GTP hydrolysis by the alpha subunit, which can then bind the beta-gamma dimer and the receptor. RGS proteins markedly reduce the lifespan of GTP-bound alpha subunits by stabilising the G protein transition state. All RGS proteins contain an RGS-box (or RGS domain), which is required for activity. Some small RGS proteins such as RGS1 and RGS4 are little more than an RGS domain, while others also contain additional domains that confer further functionality.

RGS Protein Inhibitors & Modulators

CCG 203769

Cat. No.: HY-U00431

Bioactivity: CCG-203769 is a selective G protein signaling (**RGS4**) inhibitor, which blocks the RGS4-Gα $_{o}$ protein-protein interaction in vitro with an **IC_{50}** of 17 nM.

Purity: 99.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



CCG-63802

Cat. No.: HY-70074

Bioactivity: CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4. CCG-63802 inhibits GTPase accelerating protein activity of RGS4 and blocks its...

Purity: 95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



CCG-63808

Cat. No.: HY-70075

Bioactivity: CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.

Purity: 97.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Sigma Receptor



Sigma receptor is a non-opioid receptor that binds diverse classes of psychotropic drugs. Sigma receptors are subdivided into two subtypes, sigma-1 and sigma-2. The sigma-1 receptor is a 25-kDa protein possessing one putative transmembrane domain and an endoplasmic reticulum retention signal. Sigma-1 receptors are highly expressed in deeper laminae of the cortex, olfactory bulb, nuclei of mesencephalon, hypothalamus, and Purkinje cells in the brain. Sigma-1 receptors are predominantly localized at the endoplasmic reticulum of both neurons and oligodendrocytes. From behavioral studies, sigma-1 receptors were shown to be involved in higher-ordered brain functions including memory and drug dependence. The sigma-2 receptor (σ2R) is a sigma receptor subtype which preferentially binds to siramesine and PB28. PGRMC1 was recently identified as the sigma-2 receptor. Unlike sigma-1 receptor, it has not yet been cloned. Activation of the receptor can cause apoptosis. A pharmacophore model based on benzooxazolone derivatives has been developed.

Sigma Receptor Inhibitors & Modulators

4-IBP

Cat. No.: HY-100155

Bioactivity: 4-IBP is a selective σ1 agonist with a high level of affinity for the σ1 receptor (Ki = 1.7 nM) and a moderate affinity for the σ2 receptor (Ki = 25.2 nM) .

Purity: 98.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AVex-73 hydrochloride

(AE-37 hydrochloride)

Cat. No.: HY-101864

Bioactivity: AVex-73 hydrochloride is a **Sigma-1 Receptor** agonist with an **IC_{50}** of 860 nM.

Purity: 99.72%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BD-1047 dihydrobromide

Cat. No.: HY-16996A

Bioactivity: BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.

Purity: 98.18%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



BD1063 dhydrochloride

Cat. No.: HY-18101A

Bioactivity: BD1063 dhydrochloride is a potent and selective **sigma 1 receptor** antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg



Cutamesine

(SA4503; AGY 94806)

Cat. No.: HY-14813

Bioactivity: Cutamesine (SA4503; AGY-94806) is a selective sigma 1 receptor(σ1R) agonist; high affinity for the sigma 1 receptor subtype labeled by (+)-[3H]pentazocine (IC50= 17.4±1.9 nM); 100-fold less affinity for the sigma 2 receptor.

Purity: >98%
Clinical Data: Phase 2
Size: 10 mg, 50 mg



Cutamesine dihydrochloride

(SA4503 (dihydrochloride); AGY94806 dihydrochloride)

Cat. No.: HY-13510

Bioactivity: Cutamesine dihydrochloride (SA4503 dihydrochloride) is a potent **Sigma 1** receptor agonist with an **IC_{50}** of 17.4 nM in guinea pig brain membranes.

Purity: 98.74%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Dimemorfan phosphate

Cat. No.: HY-B2215

Bioactivity: Dimemorfan phosphate is a **sigma 1 receptor** agonist, used as a potent antitussive.

Purity: 98.42%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Ditolylguanidine

(1,3-Di-o-tolylguanidine; DTG)

Cat. No.: HY-14218

Bioactivity: Ditolylguanidine (1,3-Di-o-tolylguanidine; DTG) is an agonist of **sigma receptor (σ1/σ2 receptor)** [1].

Purity: 99.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g



E1R

Cat. No.: HY-116463

Bioactivity: E1R is a positive allosteric modulator of **sigma-1 receptors** with cognition-enhancing activity [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Noscapine

((S,R)-Noscapine)

Cat. No.: HY-13716

Bioactivity: Noscapine is an orally administrable drug used worldwide for cough suppression, primarily mediated by its σ-receptor agonist activity, and possess anticancer activity. Target: σ-receptor in vitro: Noscapine is a phthalideisoquinoline alkaloid from opium, is a recently discovered anticancer drug...

Purity: 97.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



PRE-084 hydrochloride

Cat. No.: HY-18100A

Bioactivity: PRE-084 hydrochloride is a high affinity, selective σ1 agonist, has an IC50 of 44 nM in the sigma receptor assay.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Roluperidone

(CYR-101; MIN-101; MT-210)

Cat. No.: HY-19469

Bioactivity: Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for **5-HT$_{2A}$** and **sigma-2** receptors (**K$_i$** of 7.53 nM and 8.19 nM for 5-HT $_{2A}$ and sigma-2, respectively).

Purity: 98.26%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



S1RA

(E-52862)

Cat. No.: HY-18099

Bioactivity: S1RA(E-52862) is a potent and selective sigma-1 receptor(σ1R, Ki=17 nM) antagonist, showed good selectivity against σ2R (Ki > 1000 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



S1RA hydrochloride

(E-52862 hydrochloride)

Cat. No.: HY-18099A

Bioactivity: S1RA Hcl(E-52862 Hcl) is a potent and selective sigma-1 receptor(σ1R, Ki=17 nM) antagonist, showed good selectivity against σ2R (Ki > 1000 nM).

Purity: 99.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Sigma-2 receptor antagonist 1

Cat. No.: HY-111669

Bioactivity: Sigma-2 receptor antagonist 1 is a **sigma-2 (σ-2) receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Sigma-LIGAND-1

Cat. No.: HY-101626

Bioactivity: Sigma-LIGAND-1 is a selective **sigma receptor** ligand, has receptor **IC$_{50}$**s of 16 nM at the DTG site, 19 nM at the PPP site, and a **K$_i$** of 4000 nM at the dopamine D2 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Siramesine

(Lu 28-179)

Cat. No.: HY-14221

Bioactivity: Siramesine(Lu 28-179) is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



Siramesine hydrochloride

(Lu 28-179 hydrochloride)

Cat. No.: HY-14221A

Bioactivity: Siramesine(Lu 28-179) Hcl is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



UNC0642

Cat. No.: HY-13980

Bioactivity: UNC0642 is a potent and selective **G9a/GLP** inhibitor, with an **IC$_{50}$** of less than 2.5 nM.

Purity: 99.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Somatostatin Receptor

SSTRs;SSTR



Somatostatin receptor is a family of G protein-coupled seven transmembrane receptors. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biological effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. Include SSTR1, SSTR2, SSTR3, SSTR4, SSTR5. SSTR1 is expressed in highest levels in jejunum and stomach. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney. SSTR3 is functionally coupled to adenylyl cyclase. SSTR4 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in fetal and adult brain and lung. SSTR5 is a member of the superfamily of receptors having seven transmembrane segments.

CYN 154806

Cat. No.: HY-P1202

Bioactivity: CYN 154806, a cyclic octapeptide, is a potent and **selective somatostatin sst2** receptor antagonist, with **pIC$_{50}$** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively [1] [2].

Purity: >98%
Clinical Data: No Development Reported
Size:



CYN 154806 TFA

Cat. No.: HY-P1202A

Bioactivity: CYN 154806 (TFA), a cyclic octapeptide, is a potent and **selective somatostatin sst2** receptor antagonist, with **pIC$_{50}$** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 recept...

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg



MK-4256

Cat. No.: HY-13466

Bioactivity: MK-4256 is a potent and selective **SSTR3** antagonist with **IC$_{50}$**s of 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively.

Purity: 98.63%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Octreotide

(SMS 201-995)

Cat. No.: HY-P0036

Bioactivity: Octreotide is a somatostatin analog that binds to the **somatostatin receptor**, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.

Purity: 99.15%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Octreotide acetate

(SMS 201-995 (acetate))

Cat. No.: HY-17365

Bioactivity: Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits **growth hormone**, **glucagon**, and **insulin** more potently.

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Pasireotide

(SOM 230; SOM 320)

Cat. No.: HY-16381

Bioactivity: Pasireotide(SOM 230) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9 respectively). IC50 value: 8.2/9.0/9.1/<7.0/9.9(pKi, sst1/2/3/4/5) [1] in vitro:...

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg



Pasireotide ditrifluoroacetate

(SOM230 ditrifluoroacetate; Pasireotide TFA salt)

Cat. No.: HY-79135

Bioactivity: Pasireotide (ditrifluoroacetate) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human **somatostatin receptors** (subtypes sst1/2/3/4/5, **pK$_i$**=8.2/9.0/9.1/<7.0/9.9, respectively).

Purity: 95.06%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



Pasireotide L-aspartate salt

(SOM230 L-aspartate)

Cat. No.: HY-79136

Bioactivity: Pasireotide(SOM 230) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9 respectively). IC50 value: 8.2/9.0/9.1/<7.0/9.9(pKi, sst1/2/3/4/5) [1] in vitro:...

Purity: 99.44%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg



SSTR5 antagonist 1

Cat. No.: HY-102037

Bioactivity: SSTR5 antagonist 1 is a potent, selective, and orally available somatostatin receptor subtype 5 (**SSTR5**) antagonist with **IC$_{50}$**s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively. (Compound 25a) [1]

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



SSTR5 antagonist 2

Cat. No.: HY-114191

Bioactivity: SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and **selective somatostatin (receptor) subtype 5 (SSTR5)** antagonist and has potential to treat type 2 diabetes mellitus (T2DM) [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



SSTR5 antagonist 2 TFA

Cat. No.: HY-114191A

Bioactivity: SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and **selective somatostatin (receptor) subtype 5 (SSTR5)** antagonist and has potential to treat type 2 diabetes mellitus (T2DM) [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg



Vapreotide acetate

(RC-160 acetate; BMY-41606 acetate) Cat. No.: HY-P0061A

Bioactivity: Vapreotide acetate is a synthetic analog of somatostatin for the treatment of variceal bleeding; also exhibits antitumor activity. Sequence: Phe-Cys-Tyr-Trp-Lys-Val-Cys-Trp-NH2(Disulfide bridge: Cys2-Cys7).

Purity: 99.61%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 50 mg

TSH Receptor

Thyrotropin receptor;Thyroid-stimulating hormone Receptor



The thyrotropin receptor (TSHR), one of the primary antigens in autoimmune thyroid disease, is a target of both antigen-specific T cells and antibodies in patients with this condition. Autoantibodies to the TSHR (TSHR-Ab) act as thyroid stimulating factor (TSH) agonists in autoimmune hyperthyroidism (Robert Graves disease) but as TSH antagonists in autoimmune hypothyroidism (Hashimoto thyroiditis). The TSHR antigen is primarily expressed in the epithelial cells of the thyroid follicles, but TSHR mRNA and protein have been reported in a variety of cell types, some of which show evidence of receptor activity. TSH receptor (TSHR) plays an important role in the pathogenesis of thyroid disease, a TSHR antagonist could be a novel treatment.

TSH, acting through the TSH receptor, is the major stimulator of thyroid cell growth, differentiation and function.

TSH Receptor Inhibitors & Modulators

ML-109

Cat. No.: HY-114116

Bioactivity: ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC_{50} of 40 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



ML224

(NCGC00242364; ANTAG3) Cat. No.: HY-12381

Bioactivity: ML224(NCGC00242364; ANTAG3) is a selective TSHR inverse agonist; inhibits TSH-stimulated cAMP production with an IC50 = 2.3 μM.

Purity: 99.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Org41841

Cat. No.: HY-100271

Bioactivity: Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (**LHCGR**) and thyroid-stimulating hormone receptor (**TSHR**) with **EC_{50}**s of 0.2 and 7.7 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Urotensin Receptor

UT receptor



Urotensin receptor (UT) is a G-protein coupled receptor which binds the peptide hormoneurotensin. The urotensin-II (UT) receptor is a Gq/11-protein-coupled receptor that mediates complex hemodynamic effects and influences neuromuscular physiology. The UT receptor displays greatest expression levels in the peripheral vasculature, heart and kidney, although they are found elsewhere, notably the central nervous system, at lower levels. The UT receptor produces potent but variable vasoconstrictor effects in some vascular beds, yet mediates vasodilation in others; it has also been implicated in osmoregulation.

Urotensin Receptor Inhibitors & Modulators

Palosuran
(ACT-058362) **Cat. No.:** HY-10655

Bioactivity: Palosuran (ACT-058362) is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Vasopressin Receptor



Vasopressin receptors are a family of tissue-specific G protein-coupled receptors, which classified into V1, V2 and V3 subtypes. These three subtypes differ in localization, function and signal transduction mechanisms. Although all three of these proteins are G-protein coupled receptors (GPCRs), activation of AVPR1A and AVPR1B stimulate phospholipase C, while activation of AVPR2 stimulates adenylate cyclase. These three receptors for vasopressin have unique tissue distributions. AVPR1A are expressed in vascular smooth muscle cells, hepatocytes, platelets, brain cells, and uterus cells. AVPR1B are expressed in cells of the anterior pituitary and throughout the brain, especially in the pyramidal neurons of the hippocampal CA2 field. AVPR2 are expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, in fetal lung tissue and lung cancer, the last two being associated with alternative splicing. AVPR2 is also expressed in the liver where stimulation releases a variety of clotting factors into the bloodstream.

Balovaptan
(RG7314)

Cat. No.: HY-109024

Bioactivity: Balovaptan is a highly potent and selective brain-penetrant **vasopressin 1a (hV1a) receptor** antagonist, with K_is of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors, and is used for the research of autism.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Conivaptan hydrochloride
(YM 087)

Cat. No.: HY-18347A

Bioactivity: Conivaptan (hydrochloride) is a non-peptide antagonist of **vasopressin receptor**, with K_i values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Fuscoside
(OPC-21268)

Cat. No.: HY-15009

Bioactivity: Fuscoside (OPC-21268) is an orally effective, nonpeptide, **vasopressin V1** receptor antagonist with an **IC_{50}** of 0.4 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



L-371,257

Cat. No.: HY-15010

Bioactivity: L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of **oxytocin receptor** (pA2=8.4) with high affinity at both the oxytocin receptor (**K_i**=19 nM) and **vasopressin V1a receptor** (**K_i**=3.7 ...

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg



Lixivaptan
(VPA-985; WAY-VPA 985)

Cat. No.: HY-14185

Bioactivity: Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective **vasopressin receptor** V2 antagonist, with **IC_{50}** values of 1.2 and 2.3 nM for human and rat V2, respectively.

Purity: 99.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Mozavaptan
(OPC-31260; OPC31260I)

Cat. No.: HY-18346

Bioactivity: Mozavaptan (OPC31260) is a orally effective, nonpeptide **vasopressin** V2 receptor antagonist with an **IC_{50}** of 14 nM.

Purity: 98.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



RG7713
(RO5028442)

Cat. No.: HY-12981

Bioactivity: RG7713 (RO5028442) is a highly potent and selective **Brain-Penetrant Vasopressin 1a** (**V1a**) receptor antagonist with **K_i**s of 1 nM (**hV1a**) and 39 nM (**mV1a**).

Purity: 99.49%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Terlipressin

Cat. No.: HY-12554

Bioactivity: Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells. Terlipressin can result in splanchnic vasoconstriction augmenting systemic arterial blood pressure with beneficial circulatory and renal effects that would be expected to also ameliorate the key...

Purity: 99.07%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tolvaptan
(OPC-41061)

Cat. No.: HY-17000

Bioactivity: Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation. IC50 value: 1.28 uM (inhibition of AVP-induced platelet aggregation) Target: vasopressin receptor 2 Tolvaptan (OPC-41061) is a...

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



WAY-151932
(VNA-932; WAY-VNA 932)

Cat. No.: HY-19381

Bioactivity: WAY-151932 is a **vasopressin V_2-receptor** agonist with **IC_{50}** of 80.3 nM and 778 nM in human-V_2 binding and V_{1a} binding assay.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg